PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32355810-0 2020 PIM1 inhibitor synergizes the anti-tumor effect of osimertinib via STAT3 dephosphorylation in EGFR-mutant non-small cell lung cancer. osimertinib 51-62 epidermal growth factor receptor Homo sapiens 94-98 32355810-10 2020 It was more efficient in suppressing EGFR activation and phosphorylation of STAT3 compared with osimertinib treatment alone. osimertinib 96-107 epidermal growth factor receptor Homo sapiens 37-41 32274079-0 2020 The impact of age and performance status on the efficacy of osimertinib in patients with EGFR T790M-positive non-small cell lung cancer. osimertinib 60-71 epidermal growth factor receptor Homo sapiens 89-93 31839416-1 2020 OBJECTIVES: The 3rd generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR TKI) osimertinib has shown promising efficacy both in EGFR-mutant, T790M positive non-small cell lung cancer (NSCLC) patients who have become resistant to 1st or 2nd generation EGFR TKIs and patients with sensitizing EGFR mutations as the first line therapy. osimertinib 101-112 epidermal growth factor receptor Homo sapiens 91-95 31839416-1 2020 OBJECTIVES: The 3rd generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR TKI) osimertinib has shown promising efficacy both in EGFR-mutant, T790M positive non-small cell lung cancer (NSCLC) patients who have become resistant to 1st or 2nd generation EGFR TKIs and patients with sensitizing EGFR mutations as the first line therapy. osimertinib 101-112 epidermal growth factor receptor Homo sapiens 150-154 31839416-1 2020 OBJECTIVES: The 3rd generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR TKI) osimertinib has shown promising efficacy both in EGFR-mutant, T790M positive non-small cell lung cancer (NSCLC) patients who have become resistant to 1st or 2nd generation EGFR TKIs and patients with sensitizing EGFR mutations as the first line therapy. osimertinib 101-112 epidermal growth factor receptor Homo sapiens 150-154 31839416-1 2020 OBJECTIVES: The 3rd generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR TKI) osimertinib has shown promising efficacy both in EGFR-mutant, T790M positive non-small cell lung cancer (NSCLC) patients who have become resistant to 1st or 2nd generation EGFR TKIs and patients with sensitizing EGFR mutations as the first line therapy. osimertinib 101-112 epidermal growth factor receptor Homo sapiens 150-154 31839416-8 2020 Some other putative resistance mechanisms to osimertinib, such as the recurrent EGFR V834 L mutation, were also identified. osimertinib 45-56 epidermal growth factor receptor Homo sapiens 80-84 31926441-0 2020 Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 40-44 31926441-2 2020 In vitro and preclinical animal studies have shown that osimertinib exerts antitumor activity against EGFR exon 20 mutation positive NSCLC. osimertinib 56-67 epidermal growth factor receptor Homo sapiens 102-106 31926441-3 2020 We report on a cohort of advanced stage NSCLC patients who harbor an EGFR exon 20 mutation and received osimertinib treatment. osimertinib 104-115 epidermal growth factor receptor Homo sapiens 69-73 31926441-13 2020 CONCLUSION: Osimertinib has limited antitumor activity in patients with EGFR exon 20 mutated NSCLC, with an ORR of 5 %. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 72-76 31809241-0 2020 Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 29-61 32070867-2 2020 AZD9291 is a third-generation EGFR-TKI and approved to treat NSCLC patients harboring EGFR T790M mutation and common targetable activating EGFR mutations, but it has a limited effect for wtEGFR NSCLC. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 30-34 32070867-2 2020 AZD9291 is a third-generation EGFR-TKI and approved to treat NSCLC patients harboring EGFR T790M mutation and common targetable activating EGFR mutations, but it has a limited effect for wtEGFR NSCLC. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 86-90 32070867-2 2020 AZD9291 is a third-generation EGFR-TKI and approved to treat NSCLC patients harboring EGFR T790M mutation and common targetable activating EGFR mutations, but it has a limited effect for wtEGFR NSCLC. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 86-90 31809241-1 2020 PURPOSE: In this phase I study (BLOOM), osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was evaluated in patients with leptomeningeal metastases (LMs) from EGFR-mutated (EGFRm) advanced non-small-cell lung cancer (NSCLC) whose disease had progressed on previous EGFR-TKI therapy. osimertinib 40-51 epidermal growth factor receptor Homo sapiens 72-104 31809241-1 2020 PURPOSE: In this phase I study (BLOOM), osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was evaluated in patients with leptomeningeal metastases (LMs) from EGFR-mutated (EGFRm) advanced non-small-cell lung cancer (NSCLC) whose disease had progressed on previous EGFR-TKI therapy. osimertinib 40-51 epidermal growth factor receptor Homo sapiens 106-110 31809241-1 2020 PURPOSE: In this phase I study (BLOOM), osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was evaluated in patients with leptomeningeal metastases (LMs) from EGFR-mutated (EGFRm) advanced non-small-cell lung cancer (NSCLC) whose disease had progressed on previous EGFR-TKI therapy. osimertinib 40-51 epidermal growth factor receptor Homo sapiens 213-217 31809241-1 2020 PURPOSE: In this phase I study (BLOOM), osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was evaluated in patients with leptomeningeal metastases (LMs) from EGFR-mutated (EGFRm) advanced non-small-cell lung cancer (NSCLC) whose disease had progressed on previous EGFR-TKI therapy. osimertinib 40-51 epidermal growth factor receptor Homo sapiens 213-217 32042433-3 2020 We report a rare case of primary resistance to osimertinib, although liquid biopsy revealed EGFR T790M positivity. osimertinib 47-58 epidermal growth factor receptor Homo sapiens 92-96 32067121-0 2020 EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients. osimertinib 45-56 epidermal growth factor receptor Homo sapiens 0-4 32067121-1 2020 BACKGROUND: Despite the impressive anti-tumor activity of osimertinib in epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer (NSCLC) patients, 30-40% of patients still show limited response. osimertinib 58-69 epidermal growth factor receptor Homo sapiens 73-105 32067121-1 2020 BACKGROUND: Despite the impressive anti-tumor activity of osimertinib in epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer (NSCLC) patients, 30-40% of patients still show limited response. osimertinib 58-69 epidermal growth factor receptor Homo sapiens 107-111 31825714-0 2020 Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 76-80 31825714-2 2020 Here, we report the efficacy and safety of osimertinib in patients with NSCLC harboring uncommon EGFR mutations. osimertinib 43-54 epidermal growth factor receptor Homo sapiens 97-101 31825714-16 2020 CONCLUSION: Osimertinib demonstrated favorable activity with manageable toxicity in patients with NSCLC harboring uncommon EGFR mutations. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 123-127 32042433-6 2020 Osimertinib was initiated when liquid biopsy showed EGFR T790M positivity. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 52-56 31671073-1 2020 EGFR-mutated lung adenocarcinoma patients treated with gefitinib and osimertinib show a therapeutic benefit limited by the appearance of secondary mutations, such as EGFRT790M and EGFRC797S. osimertinib 69-80 epidermal growth factor receptor Homo sapiens 0-4 31671073-2 2020 It is generally assumed that these secondary mutations render EGFR completely unresponsive to the inhibitors, but contrary to this, we uncovered here that gefitinib and osimertinib increased STAT3 phosphorylation (p-STAT3) in EGFRT790M and EGFRC797S tumoral cells. osimertinib 169-180 epidermal growth factor receptor Homo sapiens 62-66 31863283-0 2020 Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib. osimertinib 47-58 epidermal growth factor receptor Homo sapiens 62-66 31810534-0 2020 First-line osimertinib treatment in patients with lung squamous cell carcinoma harboring active epidermal growth factor receptor mutations. osimertinib 11-22 epidermal growth factor receptor Homo sapiens 96-128 31955357-10 2020 The most common EGFR-TKIs used as 2L monotherapy in patients who received 1L EGFR-TKI were afatinib and osimertinib (n = 7 for both). osimertinib 104-115 epidermal growth factor receptor Homo sapiens 16-20 31769875-0 2020 Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. osimertinib 94-105 epidermal growth factor receptor Homo sapiens 0-32 31769875-1 2020 BACKGROUND: This study assesses different technologies for detecting epidermal growth factor receptor (EGFR) mutations from circulating tumor DNA in patients with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) from the AURA3 study (NCT02151981), and it evaluates clinical responses to osimertinib and platinum-pemetrexed according to the plasma T790M status. osimertinib 302-313 epidermal growth factor receptor Homo sapiens 163-167 31929495-13 2020 Because molecular biology of the surgical specimen showed epidermal growth factor receptor (EGFR)-activating mutations, he was treated with osimertinib for 2 months. osimertinib 140-151 epidermal growth factor receptor Homo sapiens 58-90 31751012-2 2020 A phase 3 trial compared first-line osimertinib with other EGFR-TKIs in patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). osimertinib 36-47 epidermal growth factor receptor Homo sapiens 86-90 31751012-10 2020 CONCLUSIONS: Among patients with previously untreated advanced NSCLC with an EGFR mutation, those who received osimertinib had longer overall survival than those who received a comparator EGFR-TKI. osimertinib 111-122 epidermal growth factor receptor Homo sapiens 77-81 32005071-0 2020 Erratum to clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation. osimertinib 41-52 epidermal growth factor receptor Homo sapiens 111-115 31999837-1 2020 BACKGROUND: The major clinical obstacle that limits the long-term benefits of treatment with osimertinib (AZD9291) in patients with epidermal growth factor receptor-mutant non-small cell lung cancer is the development of acquired resistance. osimertinib 93-104 epidermal growth factor receptor Homo sapiens 132-164 31999837-1 2020 BACKGROUND: The major clinical obstacle that limits the long-term benefits of treatment with osimertinib (AZD9291) in patients with epidermal growth factor receptor-mutant non-small cell lung cancer is the development of acquired resistance. osimertinib 106-113 epidermal growth factor receptor Homo sapiens 132-164 32022929-2 2020 No prospective data have been available for the efficacy of osimertinib in patients with non-small cell lung cancer (NSCLC) who develop resistance to first- or second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and who test positive for the TKI resistance-conferring T790M mutation of EGFR by liquid biopsy. osimertinib 60-71 epidermal growth factor receptor Homo sapiens 178-210 32022929-2 2020 No prospective data have been available for the efficacy of osimertinib in patients with non-small cell lung cancer (NSCLC) who develop resistance to first- or second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and who test positive for the TKI resistance-conferring T790M mutation of EGFR by liquid biopsy. osimertinib 60-71 epidermal growth factor receptor Homo sapiens 212-216 33271494-3 2020 This phase III clinical trial showed that the use of adjuvant osimertinib in stage IB-IIIA NSCLC patients harboring EGFR mutations had a clinically meaningful benefit. osimertinib 62-73 epidermal growth factor receptor Homo sapiens 116-120 33276288-3 2020 Osimertinib is a TKI that was fast-tracked by the United States Food and Drug Administration in 2015 and subsequently approved for the treatment of metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 159-191 31882494-1 2020 Osimertinib is an oral, irreversible epidermal growth factor receptor inhibitor that is associated with various pulmonary manifestations including transient asymptomatic pulmonary opacities (TAPOs) and pneumonitis. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 37-69 32706102-1 2020 INTRODUCTION: Osimertinib is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated efficacy in the treatment of EGFR-mutant non-small-cell lung cancer (NSCLC) in prospective clinical trials. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 62-94 32706102-1 2020 INTRODUCTION: Osimertinib is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated efficacy in the treatment of EGFR-mutant non-small-cell lung cancer (NSCLC) in prospective clinical trials. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 96-100 32706102-1 2020 INTRODUCTION: Osimertinib is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated efficacy in the treatment of EGFR-mutant non-small-cell lung cancer (NSCLC) in prospective clinical trials. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 179-183 32706102-2 2020 MATERIAL AND METHODS: This retrospective analysis evaluated the outcomes of 32 pretreated patients with EGFR T790M mutation who received osimertinib in clinical practice at seven centers in Poland within the Expanded Drug Access Program. osimertinib 137-148 epidermal growth factor receptor Homo sapiens 104-108 32706102-13 2020 CONCLUSION: These results confirm the value of osimertinib in patients with previously treated EGFR T790M-mutant NSCLC. osimertinib 47-58 epidermal growth factor receptor Homo sapiens 95-99 31838405-1 2020 BACKGROUND: In the FLAURA trial, osimertinib demonstrated superior progression-free survival and a favorable toxicity profile to erlotinib or gefitinib as initial therapy in patients with EGFR-mutated advanced non-small-cell lung cancer. osimertinib 33-44 epidermal growth factor receptor Homo sapiens 188-192 31929495-13 2020 Because molecular biology of the surgical specimen showed epidermal growth factor receptor (EGFR)-activating mutations, he was treated with osimertinib for 2 months. osimertinib 140-151 epidermal growth factor receptor Homo sapiens 92-96 33148913-5 2020 In comparison with PC-9 cells, PC-9 BIMi2- / - cells were less sensitive to apoptosis mediated by EGFR-TKIs such as gefitinib and osimertinib. osimertinib 130-141 epidermal growth factor receptor Homo sapiens 98-102 31864554-0 2020 Capmatinib and Osimertinib Combination Therapy for EGFR-Mutant Lung Adenocarcinoma. osimertinib 15-26 epidermal growth factor receptor Homo sapiens 51-55 31786475-2 2020 This study aimed to investigate the incidence of acquired T790M mutation and their outcome to subsequent osimertinib in patients of advanced NSCLC harboring uncommon EGFR mutations. osimertinib 105-116 epidermal growth factor receptor Homo sapiens 166-170 31557536-0 2020 Exon-16-skipping HER2 as a novel mechanism of osimertinib-resistance in EGFR L858R/T790M-positive non-small-cell lung cancer. osimertinib 46-57 epidermal growth factor receptor Homo sapiens 72-76 31557536-1 2020 BACKGROUND: Osimertinib is the current recommended treatment for EGFR T790M-positive NSCLC following EGFR-TKI therapy. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 65-69 31557536-1 2020 BACKGROUND: Osimertinib is the current recommended treatment for EGFR T790M-positive NSCLC following EGFR-TKI therapy. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 101-105 31557536-3 2020 We had a patient suffering from EGFR L858R/T790M-positive NSCLC who initially responded to osimertinib therapy but eventually developed resistance. osimertinib 91-102 epidermal growth factor receptor Homo sapiens 32-36 31557536-13 2020 We also found mutant EGFR and HER2D16 cooperated to activate downstream signaling for osimertinib-resistance. osimertinib 86-97 epidermal growth factor receptor Homo sapiens 21-25 31786475-11 2020 CONCLUSIONS: Uncommon EGFR mutation showed a significantly lower incidence of acquired T790M mutation and benefited significantly less from subsequent osimertinib treatment than common EGFR mutations in patients with advanced NSCLC. osimertinib 151-162 epidermal growth factor receptor Homo sapiens 22-26 31640894-0 2020 Response to the combination of dabrafenib, trametinib and osimertinib in a patient with EGFR-mutant NSCLC harboring an acquired BRAFV600E mutation. osimertinib 58-69 epidermal growth factor receptor Homo sapiens 88-92 32650965-0 2020 ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort. osimertinib 61-72 epidermal growth factor receptor Homo sapiens 76-108 31494653-4 2020 RESULTS: An EGFR T790M mutation was detected in 32 non-small cell lung carcinoma patients, of whom 21 (65.6%) underwent osimertinib treatment after detection of the mutation. osimertinib 120-131 epidermal growth factor receptor Homo sapiens 12-16 31494653-9 2020 CONCLUSIONS: Non-small cell lung carcinoma patients in whom an EGFR T790M mutation was detected in plasma samples demonstrated a poorer response to osimertinib than those in whom the mutation was detected in tissue specimens. osimertinib 148-159 epidermal growth factor receptor Homo sapiens 63-67 32650965-1 2020 PURPOSE: Osimertinib has proven efficacy in EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) patients; however, its benefits have not been evaluated in a real-world setting. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 44-48 32650965-2 2020 METHODS: ASTRIS is a single-arm, open-label, multinational study to evaluate the efficacy and safety of osimertinib for the treatment of EGFR T790M mutation-positive NSCLC. osimertinib 104-115 epidermal growth factor receptor Homo sapiens 137-141 31758670-1 2020 BACKGROUND: Osimertinib (AZD9291) is a third-generation EGFR-tyrosine kinase inhibitor (TKI) that selectively inhibits the activating EGFR mutation and T790M mutation, and is currently used globally to treat EGFR-mutant non-small cell lung cancer (NSCLC). osimertinib 25-32 epidermal growth factor receptor Homo sapiens 56-60 31758670-1 2020 BACKGROUND: Osimertinib (AZD9291) is a third-generation EGFR-tyrosine kinase inhibitor (TKI) that selectively inhibits the activating EGFR mutation and T790M mutation, and is currently used globally to treat EGFR-mutant non-small cell lung cancer (NSCLC). osimertinib 25-32 epidermal growth factor receptor Homo sapiens 134-138 31758670-0 2020 Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation. osimertinib 83-94 epidermal growth factor receptor Homo sapiens 130-134 31758670-1 2020 BACKGROUND: Osimertinib (AZD9291) is a third-generation EGFR-tyrosine kinase inhibitor (TKI) that selectively inhibits the activating EGFR mutation and T790M mutation, and is currently used globally to treat EGFR-mutant non-small cell lung cancer (NSCLC). osimertinib 25-32 epidermal growth factor receptor Homo sapiens 134-138 31758670-1 2020 BACKGROUND: Osimertinib (AZD9291) is a third-generation EGFR-tyrosine kinase inhibitor (TKI) that selectively inhibits the activating EGFR mutation and T790M mutation, and is currently used globally to treat EGFR-mutant non-small cell lung cancer (NSCLC). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 56-60 31758670-3 2020 METHODS: We established osimertinib-resistant cells (PC9/T790M/AZDR and H1975/AZDR) derived from EGFR-mutant NSCLC cells harboring T790M mutation, and investigated the mechanism of acquired resistance to osimertinib by whole-exome sequencing and multiple phospho-receptor tyrosine kinase (RTK) array. osimertinib 24-35 epidermal growth factor receptor Homo sapiens 97-101 31758670-1 2020 BACKGROUND: Osimertinib (AZD9291) is a third-generation EGFR-tyrosine kinase inhibitor (TKI) that selectively inhibits the activating EGFR mutation and T790M mutation, and is currently used globally to treat EGFR-mutant non-small cell lung cancer (NSCLC). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 134-138 31758670-4 2020 A tumor specimen from an EGFR-mutant NSCLC patient with acquired resistance to osimertinib was also subjected to immunohistochemical analysis. osimertinib 79-90 epidermal growth factor receptor Homo sapiens 25-29 31758670-1 2020 BACKGROUND: Osimertinib (AZD9291) is a third-generation EGFR-tyrosine kinase inhibitor (TKI) that selectively inhibits the activating EGFR mutation and T790M mutation, and is currently used globally to treat EGFR-mutant non-small cell lung cancer (NSCLC). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 134-138 31758670-8 2020 Immunohistochemical analysis revealed that the expression level of phosphorylated IGF1R was higher in the tumor specimen from the EGFR-mutant NSCLC patient with acquired resistance to osimertinib than in the specimen collected prior to the treatment. osimertinib 184-195 epidermal growth factor receptor Homo sapiens 130-134 31758670-9 2020 CONCLUSIONS: IGF1R activation could occur following treatment with osimertinib in EGFR-mutant NSCLC with T790M mutation, and might be one of the mechanisms underlying osimertinib resistance. osimertinib 67-78 epidermal growth factor receptor Homo sapiens 82-86 31562701-1 2019 INTRODUCTION: The third-generation epidermal growth factor receptor (EGFR) inhibitor osimertinib is a promising therapeutic option for patients with advanced non-small-cell lung cancer (NSCLC) in second-line or first-line treatment because of its applications in selectively inhibiting EGFR T790M and EGFR-tyrosine kinase inhibitor sensitizing mutations. osimertinib 85-96 epidermal growth factor receptor Homo sapiens 35-67 31171828-8 2019 We discovered that, AZD9291, a potent and selective EGFR inhibitor, disrupted the interaction of EZH2-EED, leading to impairment of PRC2 activity and downregulation of EZH2 protein. osimertinib 20-27 epidermal growth factor receptor Homo sapiens 52-56 31562701-1 2019 INTRODUCTION: The third-generation epidermal growth factor receptor (EGFR) inhibitor osimertinib is a promising therapeutic option for patients with advanced non-small-cell lung cancer (NSCLC) in second-line or first-line treatment because of its applications in selectively inhibiting EGFR T790M and EGFR-tyrosine kinase inhibitor sensitizing mutations. osimertinib 85-96 epidermal growth factor receptor Homo sapiens 69-73 31562701-1 2019 INTRODUCTION: The third-generation epidermal growth factor receptor (EGFR) inhibitor osimertinib is a promising therapeutic option for patients with advanced non-small-cell lung cancer (NSCLC) in second-line or first-line treatment because of its applications in selectively inhibiting EGFR T790M and EGFR-tyrosine kinase inhibitor sensitizing mutations. osimertinib 85-96 epidermal growth factor receptor Homo sapiens 286-290 31562701-1 2019 INTRODUCTION: The third-generation epidermal growth factor receptor (EGFR) inhibitor osimertinib is a promising therapeutic option for patients with advanced non-small-cell lung cancer (NSCLC) in second-line or first-line treatment because of its applications in selectively inhibiting EGFR T790M and EGFR-tyrosine kinase inhibitor sensitizing mutations. osimertinib 85-96 epidermal growth factor receptor Homo sapiens 286-290 32010579-3 2019 Methods: Parallel somatic mutation and DNA methylation profiling was performed on a total of 85 longitudinal plasma samples obtained from 8 stage IV osimertinib-treated EGFR T790M-positive lung adenocarcinoma patients. osimertinib 149-160 epidermal growth factor receptor Homo sapiens 169-173 31560541-4 2019 In this work, we optimized compound 2 by scaffold hopping and exploiting the potent inhibitory activity of various warhead groups to obtain a clinical candidate, 78 (DBPR112), which not only displayed a potent inhibitory activity against EGFRL858R/T790M double mutations but also exhibited tenfold potency better than the third-generation inhibitor, osimertinib, against EGFR and HER2 exon 20 insertion mutations. osimertinib 350-361 epidermal growth factor receptor Homo sapiens 238-242 32010579-2 2019 In this study, we aimed to evaluate the potential of parallel serial assessment of somatic mutation and methylation profile in monitoring the response to osimertinib of epidermal growth factor receptor (EGFR) T790M-positive advanced lung adenocarcinoma patients. osimertinib 154-165 epidermal growth factor receptor Homo sapiens 169-201 32010579-2 2019 In this study, we aimed to evaluate the potential of parallel serial assessment of somatic mutation and methylation profile in monitoring the response to osimertinib of epidermal growth factor receptor (EGFR) T790M-positive advanced lung adenocarcinoma patients. osimertinib 154-165 epidermal growth factor receptor Homo sapiens 203-207 31832192-3 2019 Recent studies suggest that a key mechanism of acquired resistance to third-generation EGFR-TKIs (such as osimertinib) may be MET amplification and/or protein overactivation, especially when they are used as a first-line treatment. osimertinib 106-117 epidermal growth factor receptor Homo sapiens 87-91 31607559-0 2019 Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China. osimertinib 22-33 epidermal growth factor receptor Homo sapiens 78-82 31832192-4 2019 Therefore, in patients resistant to first-generation EGFR-TKIs caused by MET amplification and/or protein overactivation, the combination of osimertinib with MET or MEK inhibitors may be considered. osimertinib 141-152 epidermal growth factor receptor Homo sapiens 53-57 31865717-0 2019 Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation. osimertinib 30-41 epidermal growth factor receptor Homo sapiens 100-104 31865717-15 2019 CONCLUSIONS: Whether EGFR+ with T790M mutation was positive or negative, osimertinib is an effective drug and can improve quality of life and prolong the survival for NSCLC patient with EGFR mutation to progress LM. osimertinib 73-84 epidermal growth factor receptor Homo sapiens 21-25 31865717-15 2019 CONCLUSIONS: Whether EGFR+ with T790M mutation was positive or negative, osimertinib is an effective drug and can improve quality of life and prolong the survival for NSCLC patient with EGFR mutation to progress LM. osimertinib 73-84 epidermal growth factor receptor Homo sapiens 186-190 31769726-0 2019 Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma. osimertinib 56-67 epidermal growth factor receptor Homo sapiens 25-29 31769726-3 2019 We report the case of a young female with heavily pretreated EGFR-mutated GBM, for whom we initiated osimertinib, an oral, third-generation tyrosine kinase inhibitor that irreversibly inhibits EGFR and has significant brain penetration. osimertinib 101-112 epidermal growth factor receptor Homo sapiens 61-65 33906716-9 2019 The non-small cell lung cancer (NSCLC) in this case maintained EGFR activating mutation and lost EGFR T790M mutation was a genetic change after osimertinib treatment. osimertinib 144-155 epidermal growth factor receptor Homo sapiens 97-101 31930052-2 2019 We explored in vitro and in vivo the effect of the epidermal growth factor receptor (EGFR) inhibitor, osimertinib, alone and in combination with dihydroartemisinin (DHA) in HNSCC. osimertinib 102-113 epidermal growth factor receptor Homo sapiens 51-83 31930052-2 2019 We explored in vitro and in vivo the effect of the epidermal growth factor receptor (EGFR) inhibitor, osimertinib, alone and in combination with dihydroartemisinin (DHA) in HNSCC. osimertinib 102-113 epidermal growth factor receptor Homo sapiens 85-89 31769726-3 2019 We report the case of a young female with heavily pretreated EGFR-mutated GBM, for whom we initiated osimertinib, an oral, third-generation tyrosine kinase inhibitor that irreversibly inhibits EGFR and has significant brain penetration. osimertinib 101-112 epidermal growth factor receptor Homo sapiens 193-197 31793440-4 2019 Osimertinib, a third-generation irreversible EGFR-TKI with good potential to cross the BBB, has shown significant clinical activity and acceptable safety profile in patients with EGFR-positive NSCLC brain and leptomeningeal metastases. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 45-49 31446643-2 2019 Here, we introduce an effective approach for overcoming resistance to the EGFR-TKI, AZD9291, in NSCLC cells using SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met)-targeting antibody-drug conjugate (ADC) consisting of an anti-c-Met monoclonal antibody (c-Met mAb) conjugated to a microtubule inhibitor. osimertinib 84-91 epidermal growth factor receptor Homo sapiens 74-78 31454149-8 2019 AZD9291 is effective to treat NSCLC patients with EGFR-sensitivity mutation and T790 M resistance mutation, but the clinical efficacy in patients with wild-type EGFR remains modest. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 50-54 31454149-9 2019 We showed that DYRK1A repression could enhance the anti-cancer effect of AZD9291 by inducing apoptosis and suppressing cell proliferation in EGFR wild-type NSCLC cells. osimertinib 73-80 epidermal growth factor receptor Homo sapiens 141-145 31454149-12 2019 Collectively, targeting DYRK1A might be an attractive target for AZD9291 sensitization in EGFR wild-type NSCLC patients. osimertinib 65-72 epidermal growth factor receptor Homo sapiens 90-94 31793440-4 2019 Osimertinib, a third-generation irreversible EGFR-TKI with good potential to cross the BBB, has shown significant clinical activity and acceptable safety profile in patients with EGFR-positive NSCLC brain and leptomeningeal metastases. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 179-183 31793440-7 2019 These data have supported osimertinib to be recognized as a "preferred" first-line treatment for EGFR-positive metastatic NSCLC by the National Comprehensive Cancer Network (NCCN). osimertinib 26-37 epidermal growth factor receptor Homo sapiens 97-101 31568888-5 2019 Osimertinib, a third-generation, central nervous system active EGFR-TKI which potently and selectively inhibits both EGFR-TKI sensitizing (EGFRm) and the most common EGFR T790 M resistance mutations, has shown superior efficacy versus first-generation EGFR-TKIs (gefitinib / erlotinib). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 63-67 31903227-0 2019 Impact of clinical features of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients on osimertinib efficacy. osimertinib 126-137 epidermal growth factor receptor Homo sapiens 31-63 31903227-0 2019 Impact of clinical features of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients on osimertinib efficacy. osimertinib 126-137 epidermal growth factor receptor Homo sapiens 65-69 31254668-1 2019 INTRODUCTION: Osimertinib is an effective third-generation tyrosine kinase inhibitor (TKI) for EGFR-mutant lung cancers. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 95-99 31254668-3 2019 We characterized a novel EGFR mutation in exon 20 that was acquired while on osimertinib. osimertinib 77-88 epidermal growth factor receptor Homo sapiens 25-29 31254668-4 2019 METHODS: A 79-year-old woman had disease progression during third-line treatment with osimertinib for an EGFR L858R/T790M-mutant lung cancer. osimertinib 86-97 epidermal growth factor receptor Homo sapiens 105-109 31568888-5 2019 Osimertinib, a third-generation, central nervous system active EGFR-TKI which potently and selectively inhibits both EGFR-TKI sensitizing (EGFRm) and the most common EGFR T790 M resistance mutations, has shown superior efficacy versus first-generation EGFR-TKIs (gefitinib / erlotinib). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 117-121 31600593-0 2019 Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study. osimertinib 25-36 epidermal growth factor receptor Homo sapiens 40-44 31600593-1 2019 OBJECTIVES: The understanding of histo-molecular mechanisms associated with resistance to osimertinib is a critical step to define the optimal treatment strategy in advanced EGFR-mutated Non-Small-Cell-Lung-Cancer (NSCLC). osimertinib 90-101 epidermal growth factor receptor Homo sapiens 174-178 31568888-5 2019 Osimertinib, a third-generation, central nervous system active EGFR-TKI which potently and selectively inhibits both EGFR-TKI sensitizing (EGFRm) and the most common EGFR T790 M resistance mutations, has shown superior efficacy versus first-generation EGFR-TKIs (gefitinib / erlotinib). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 117-121 31600593-2 2019 MATERIALS AND METHODS: We performed a multicentric retrospective analysis on a cohort of consecutive patients treated with osimertinib for an advanced EGFR-mutated NSCLC and collected histo-molecular data from plasma and tumor samples at the time of progression. osimertinib 123-134 epidermal growth factor receptor Homo sapiens 151-155 31600593-15 2019 CONCLUSION: We confirmed the efficacy of osimertinib in patients with advanced EGFR mutation positive NSCLC. osimertinib 41-52 epidermal growth factor receptor Homo sapiens 79-83 31568888-5 2019 Osimertinib, a third-generation, central nervous system active EGFR-TKI which potently and selectively inhibits both EGFR-TKI sensitizing (EGFRm) and the most common EGFR T790 M resistance mutations, has shown superior efficacy versus first-generation EGFR-TKIs (gefitinib / erlotinib). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 117-121 31568888-6 2019 Osimertinib is now a treatment option for patients with advanced NSCLC harboring EGFRm in the first-line setting, and treatment of choice for patients with T790 M positive NSCLC following disease progression on first-line EGFR-TKIs. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 81-85 31921341-1 2019 Osimertinib is a first-line treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harbouring EGFR mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 120-124 31857949-5 2019 The need to overcome this resistance mechanism led to the development of third-generation EGFR TKIs, of which osimertinib is the only one to date with regulatory approval. osimertinib 110-121 epidermal growth factor receptor Homo sapiens 90-94 31857953-5 2019 However, newly developed TKIs with improved penetration such as osimertinib for EGFR and alectinib, ceritinib, brigatinib, or lorlatinib for ALK have demonstrated significant intracranial activity that should contribute to improved overall survival. osimertinib 64-75 epidermal growth factor receptor Homo sapiens 80-84 31671561-3 2019 Gefitinib, erlotinib, afatinib, and osimertinib are TK inhibitors (TKIs) that specifically target EGFR and are currently approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as first line treatment for sensitive EGFR-mutant patients. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 98-102 31671561-3 2019 Gefitinib, erlotinib, afatinib, and osimertinib are TK inhibitors (TKIs) that specifically target EGFR and are currently approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as first line treatment for sensitive EGFR-mutant patients. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 250-254 31921341-4 2019 We herein describe a case of a 53-year-old patient with metastatic EGFR-mutated NSCLC, who developed pneumonitis after osimertinib treatment and was successfully rechallenged with 40 mg daily osimertinib, with CNS response. osimertinib 119-130 epidermal growth factor receptor Homo sapiens 67-71 31921341-4 2019 We herein describe a case of a 53-year-old patient with metastatic EGFR-mutated NSCLC, who developed pneumonitis after osimertinib treatment and was successfully rechallenged with 40 mg daily osimertinib, with CNS response. osimertinib 192-203 epidermal growth factor receptor Homo sapiens 67-71 31632838-0 2019 Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort. osimertinib 18-29 epidermal growth factor receptor Homo sapiens 40-44 31728437-2 2019 We present a patient with adenocarcinoma of the lung harboring an uncommon EGFR Exon 21 mutation treated with osimertinib as second-line therapy. osimertinib 110-121 epidermal growth factor receptor Homo sapiens 75-79 31632838-2 2019 Here, we report the detection of EGFR L792 mutations, a non-covalent mechanism of osimertinib resistance, using Guardant360 cfDNA testing in a patient with metastatic EGFR-mutant non-small cell lung cancer (NSCLC) whose disease progressed on osimertinib. osimertinib 82-93 epidermal growth factor receptor Homo sapiens 33-37 31632838-2 2019 Here, we report the detection of EGFR L792 mutations, a non-covalent mechanism of osimertinib resistance, using Guardant360 cfDNA testing in a patient with metastatic EGFR-mutant non-small cell lung cancer (NSCLC) whose disease progressed on osimertinib. osimertinib 82-93 epidermal growth factor receptor Homo sapiens 167-171 31632838-2 2019 Here, we report the detection of EGFR L792 mutations, a non-covalent mechanism of osimertinib resistance, using Guardant360 cfDNA testing in a patient with metastatic EGFR-mutant non-small cell lung cancer (NSCLC) whose disease progressed on osimertinib. osimertinib 242-253 epidermal growth factor receptor Homo sapiens 33-37 31632838-4 2019 In vitro functional assays demonstrated that the EGFR L858R/T790M/L792F/H mutations conferred intermediate-level resistance to osimertinib. osimertinib 127-138 epidermal growth factor receptor Homo sapiens 49-53 31642175-2 2019 In preclinical and clinical studies, the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib has demonstrated activity in the central nervous system (CNS), and studies are ongoing. osimertinib 124-135 epidermal growth factor receptor Homo sapiens 58-90 31762748-0 2019 The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance. osimertinib 69-80 epidermal growth factor receptor Homo sapiens 18-22 31645848-0 2019 Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 29-33 31645848-5 2019 Previous reports showing successful treatment of EGFR exon 20 insertion-positive lung adenocarcinoma with the standard osimertinib dose of 80 mg are limited. osimertinib 119-130 epidermal growth factor receptor Homo sapiens 49-53 31645848-6 2019 The present case demonstrated that osimertinib could be a possible treatment option for EGFR exon 20 insertion-positive lung adenocarcinoma. osimertinib 35-46 epidermal growth factor receptor Homo sapiens 88-92 31581247-10 2019 CONCLUSIONS: Osimertinib seemed to be the most preferable first-line treatment in advanced EGFR-mutated NSCLC. osimertinib 13-24 epidermal growth factor receptor Homo sapiens 91-95 31591158-11 2019 Subgroup analyses by the two most common EGFR mutation types indicated that osimertinib was associated with the best progression free survival in patients with the exon 19 deletion, and gefitinib plus pemetrexed based chemotherapy was associated with the best progression free survival in patients with the Leu858Arg mutation. osimertinib 76-87 epidermal growth factor receptor Homo sapiens 41-45 31591158-12 2019 CONCLUSIONS: These results indicate that osimertinib and gefitinib plus pemetrexed based chemotherapy were associated with the best progression free survival and overall survival benefits for patients with advanced EGFR mutated NSCLC, compared with other first line treatments. osimertinib 41-52 epidermal growth factor receptor Homo sapiens 215-219 31857889-0 2019 Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 36-68 31857889-0 2019 Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 69-73 31642175-2 2019 In preclinical and clinical studies, the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib has demonstrated activity in the central nervous system (CNS), and studies are ongoing. osimertinib 124-135 epidermal growth factor receptor Homo sapiens 92-96 31642175-3 2019 We report here a case of osimertinib used at 160 mg once daily in a heavily pretreated patient with EGFR exon 20 T790M-negative advanced NSCLC with LM to achieve a partial response, including shrinkage of the LM, for up to 12 months until further progression. osimertinib 25-36 epidermal growth factor receptor Homo sapiens 100-104 31564718-0 2019 Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. osimertinib 25-36 epidermal growth factor receptor Homo sapiens 40-44 31564718-1 2019 Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung cancer (NSCLC) with EGFR oncogene addiction. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 49-81 31564718-1 2019 Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung cancer (NSCLC) with EGFR oncogene addiction. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 83-87 31564718-1 2019 Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung cancer (NSCLC) with EGFR oncogene addiction. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 144-148 31564718-1 2019 Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung cancer (NSCLC) with EGFR oncogene addiction. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 144-148 31564718-1 2019 Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung cancer (NSCLC) with EGFR oncogene addiction. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 144-148 31564718-3 2019 On account of the high degree of tumour heterogeneity and adaptive cellular signalling pathways in NSCLC, the acquired osimertinib resistance is highly heterogeneous, encompassing EGFR-dependent as well as EGFR-independent mechanisms. osimertinib 119-130 epidermal growth factor receptor Homo sapiens 180-184 31564718-3 2019 On account of the high degree of tumour heterogeneity and adaptive cellular signalling pathways in NSCLC, the acquired osimertinib resistance is highly heterogeneous, encompassing EGFR-dependent as well as EGFR-independent mechanisms. osimertinib 119-130 epidermal growth factor receptor Homo sapiens 206-210 31564718-5 2019 This review summarises the molecular mechanisms of resistance to osimertinib in patients with advanced EGFR-mutated NSCLC, including MET/HER2 amplification, activation of the RAS-mitogen-activated protein kinase (MAPK) or RAS-phosphatidylinositol 3-kinase (PI3K) pathways, novel fusion events and histological/phenotypic transformation, as well as discussing the current evidence regarding potential new approaches to counteract osimertinib resistance. osimertinib 65-76 epidermal growth factor receptor Homo sapiens 103-107 31411906-7 2019 The third-generation EGFR TKI, osimertinib has been approved for patients whose tumor has become resistant through the secondary T790M resistant EGFR mutation. osimertinib 31-42 epidermal growth factor receptor Homo sapiens 21-25 31411906-7 2019 The third-generation EGFR TKI, osimertinib has been approved for patients whose tumor has become resistant through the secondary T790M resistant EGFR mutation. osimertinib 31-42 epidermal growth factor receptor Homo sapiens 145-149 31470227-9 2019 Accordingly, the third-generation EGFR-TKI osimertinib effectively inhibited gefitinib-resistant tumors in vivo. osimertinib 43-54 epidermal growth factor receptor Homo sapiens 34-38 31651902-0 2019 Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 55-59 31651902-6 2019 CONCLUSIONS: Osimertinib showed greater treatment benefit for patients with NSCLC with EGFR mutation than EGFR-TKIs/chemotherapy, especially for T790M mutation-positive patients. osimertinib 13-24 epidermal growth factor receptor Homo sapiens 87-91 31502118-0 2019 Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion. osimertinib 69-80 epidermal growth factor receptor Homo sapiens 124-128 31414729-0 2019 Plasma next generation sequencing and droplet digital PCR-based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequent-line osimertinib. osimertinib 194-205 epidermal growth factor receptor Homo sapiens 77-109 31414729-0 2019 Plasma next generation sequencing and droplet digital PCR-based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequent-line osimertinib. osimertinib 194-205 epidermal growth factor receptor Homo sapiens 111-115 31502118-1 2019 BACKGROUND: Osimertinib is a new third-generation, epidermal growth factor receptor-tyrosine kinase inhibitor highly selective for the epidermal growth factor receptor with both activating and T790M mutations. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 51-83 31502118-1 2019 BACKGROUND: Osimertinib is a new third-generation, epidermal growth factor receptor-tyrosine kinase inhibitor highly selective for the epidermal growth factor receptor with both activating and T790M mutations. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 135-167 31502118-2 2019 A recent phase III trial showed a statistically significant progression-free survival benefit with osimertinib vs. gefitinib or erlotinib as first-line treatment for EGFR-mutated non-small cell lung cancer, and preliminary data are available on resistance mechanisms to first-line osimertinib therapy. osimertinib 99-110 epidermal growth factor receptor Homo sapiens 166-170 31502118-3 2019 OBJECTIVE: The objective of this study was to examine potential in vitro mechanisms of acquired resistance to osimertinib in a cell model carrying an EGFR exon 19 deletion. osimertinib 110-121 epidermal growth factor receptor Homo sapiens 150-154 31754333-0 2019 Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 33-37 31754333-5 2019 Results: Osimertinib plus pterostilbene yielded synergistic effects in all EGFR-mutation positive NSCLC cell lines investigated. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 75-79 31754333-8 2019 Conclusion: The results of this study indicate that pterostilbene may be used to abrogate the activated resistance pathways of single osimertinib treatment in EGFR-mutation positive NSCLC. osimertinib 134-145 epidermal growth factor receptor Homo sapiens 159-163 31571928-0 2019 Treatment Response To Osimertinib In EGFR-Mutated Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Series. osimertinib 22-33 epidermal growth factor receptor Homo sapiens 37-41 31571928-6 2019 Recent related studies and our cases indicate that osimertinib has a positive effect on LM from EGFR-mutant NSCLC, regardless of T790M status. osimertinib 51-62 epidermal growth factor receptor Homo sapiens 96-100 31754333-3 2019 In the present study, we treated EGFR-mutation positive cell lines with the combination of osimertinib plus a natural compound, pterostilbene, which has been reported to abrogate Src and STAT3 activation. osimertinib 91-102 epidermal growth factor receptor Homo sapiens 33-37 31108249-9 2019 Third-generation EGFR TKI osimertinib was highly potent against EGFR exon 20 insertion-mutant cells (IC50, 14.7-62.7 nM), including EGFR H773insH, and spared wild-type EGFR cells. osimertinib 26-37 epidermal growth factor receptor Homo sapiens 64-68 31370698-0 2019 Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study. osimertinib 24-35 epidermal growth factor receptor Homo sapiens 53-57 31370698-7 2019 Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. osimertinib 32-43 epidermal growth factor receptor Homo sapiens 100-104 31108249-0 2019 Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations. osimertinib 24-35 epidermal growth factor receptor Homo sapiens 51-55 31108249-5 2019 EGFR exon 20 insertion-mutant structures and couplings with osimertinib, a third-generation EGFR TKI, were modeled and compared. osimertinib 60-71 epidermal growth factor receptor Homo sapiens 0-4 31108249-9 2019 Third-generation EGFR TKI osimertinib was highly potent against EGFR exon 20 insertion-mutant cells (IC50, 14.7-62.7 nM), including EGFR H773insH, and spared wild-type EGFR cells. osimertinib 26-37 epidermal growth factor receptor Homo sapiens 17-21 31632761-0 2019 Impact of performance status and age on osimertinib efficacy in patients with EGFR-mutant T790M-positive non-small-cell lung cancer. osimertinib 40-51 epidermal growth factor receptor Homo sapiens 78-82 31108249-9 2019 Third-generation EGFR TKI osimertinib was highly potent against EGFR exon 20 insertion-mutant cells (IC50, 14.7-62.7 nM), including EGFR H773insH, and spared wild-type EGFR cells. osimertinib 26-37 epidermal growth factor receptor Homo sapiens 64-68 31632766-0 2019 Impact of clinical features on the efficacy of osimertinib treatment in epidermal growth factor receptor mutant non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors due to T790M mutation. osimertinib 47-58 epidermal growth factor receptor Homo sapiens 72-104 31108249-9 2019 Third-generation EGFR TKI osimertinib was highly potent against EGFR exon 20 insertion-mutant cells (IC50, 14.7-62.7 nM), including EGFR H773insH, and spared wild-type EGFR cells. osimertinib 26-37 epidermal growth factor receptor Homo sapiens 64-68 31592498-8 2019 EGFR-targeted therapy with osimertinib 80 mg daily was initiated. osimertinib 27-38 epidermal growth factor receptor Homo sapiens 0-4 31442277-0 2019 Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study. osimertinib 28-39 epidermal growth factor receptor Homo sapiens 68-72 31442277-1 2019 Osimertinib showed encouraging efficacy in patients with advanced EGFR T790M-positive NSCLC in previous randomized controlled trials. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 66-70 31592498-11 2019 This is an illustrative case of NSCLC-PM with EGFR exon 19 deletion mutation, wherein osimertinib, a third-generation EGFR-tyrosine kinase inhibitor, eradicated the sellar metastasis and prevented the need for radiotherapy. osimertinib 86-97 epidermal growth factor receptor Homo sapiens 46-50 31592498-11 2019 This is an illustrative case of NSCLC-PM with EGFR exon 19 deletion mutation, wherein osimertinib, a third-generation EGFR-tyrosine kinase inhibitor, eradicated the sellar metastasis and prevented the need for radiotherapy. osimertinib 86-97 epidermal growth factor receptor Homo sapiens 118-122 31558282-9 2019 A recent clinical trial has demonstrated that EGFRs harboring some of these less common mutations also appear to be sensitive to the third-generation EGFR TKI, osimertinib. osimertinib 160-171 epidermal growth factor receptor Homo sapiens 46-50 31164318-0 2019 Response to First-Line Osimertinib Treatment in Non-Small-Cell Lung Cancer With Coexisting G719A and Primary T790M Epidermal Growth Factor Receptor Mutations. osimertinib 23-34 epidermal growth factor receptor Homo sapiens 115-147 30920616-0 2019 Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 30-34 30920616-1 2019 BACKGROUND: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is effective against EGFR T790M mutation-positive non-small-cell lung cancer (NSCLC) in patients who have good performance status (PS). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 46-78 30920616-1 2019 BACKGROUND: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is effective against EGFR T790M mutation-positive non-small-cell lung cancer (NSCLC) in patients who have good performance status (PS). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 80-84 30920616-1 2019 BACKGROUND: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is effective against EGFR T790M mutation-positive non-small-cell lung cancer (NSCLC) in patients who have good performance status (PS). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 144-148 30920616-3 2019 METHODS: We retrospectively evaluated the efficacy and safety of osimertinib in patients with EGFR T790M mutation-positive NSCLC who had Eastern Cooperative Oncology Group PS scores of 2-4 and who were administered 80 mg of osimertinib once daily between March 2016 and February 2017. osimertinib 65-76 epidermal growth factor receptor Homo sapiens 94-98 30920616-11 2019 CONCLUSIONS: Osimertinib therapy demonstrates promising efficacy and acceptable safety in patients with EGFR T790M mutation-positive NSCLC who have poor PS. osimertinib 13-24 epidermal growth factor receptor Homo sapiens 104-108 31289574-1 2019 Currently, osimertinib (AZD9291) is the only third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor approved by the Food and Drug Administration for the treatment of non-small cell lung cancer (NSCLC) with EGFR T790M mutations. osimertinib 24-31 epidermal growth factor receptor Homo sapiens 62-94 31261881-1 2019 Herein a novel series of histone deacetylases (HDACs) and epidermal growth factor receptor (EGFR) dual inhibitors were designed and synthesized based on the structure of the approved EGFR inhibitor osimertinib (AZD9291). osimertinib 211-218 epidermal growth factor receptor Homo sapiens 58-90 31261881-1 2019 Herein a novel series of histone deacetylases (HDACs) and epidermal growth factor receptor (EGFR) dual inhibitors were designed and synthesized based on the structure of the approved EGFR inhibitor osimertinib (AZD9291). osimertinib 211-218 epidermal growth factor receptor Homo sapiens 92-96 31261881-1 2019 Herein a novel series of histone deacetylases (HDACs) and epidermal growth factor receptor (EGFR) dual inhibitors were designed and synthesized based on the structure of the approved EGFR inhibitor osimertinib (AZD9291). osimertinib 211-218 epidermal growth factor receptor Homo sapiens 183-187 31229973-0 2019 Successful osimertinib treatment in a patient who exhibited intramedullary spinal cord metastases of lung adenocarcinoma with an acquired EGFR T790M mutation. osimertinib 11-22 epidermal growth factor receptor Homo sapiens 138-142 31229973-2 2019 We describe a 52-year-old man with ISCMs secondary to lung adenocarcinoma who acquired the T790M mutation of the epidermal growth factor receptor (EGFR) after previous use of a first-generation EGFR tyrosine kinase inhibitor (TKI); he was successfully treated with osimertinib. osimertinib 265-276 epidermal growth factor receptor Homo sapiens 113-145 31229973-2 2019 We describe a 52-year-old man with ISCMs secondary to lung adenocarcinoma who acquired the T790M mutation of the epidermal growth factor receptor (EGFR) after previous use of a first-generation EGFR tyrosine kinase inhibitor (TKI); he was successfully treated with osimertinib. osimertinib 265-276 epidermal growth factor receptor Homo sapiens 147-151 30993382-1 2019 The T790M mutation is recognized as a typical mechanism of acquired resistance to first generation of epithermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib in non-small cell lung cancer (NSCLC) patients who are commonly treated by third generation of EGFR-TKI AZD9291 (osimertinib). osimertinib 297-304 epidermal growth factor receptor Homo sapiens 164-168 30993382-1 2019 The T790M mutation is recognized as a typical mechanism of acquired resistance to first generation of epithermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib in non-small cell lung cancer (NSCLC) patients who are commonly treated by third generation of EGFR-TKI AZD9291 (osimertinib). osimertinib 297-304 epidermal growth factor receptor Homo sapiens 288-292 30993382-1 2019 The T790M mutation is recognized as a typical mechanism of acquired resistance to first generation of epithermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib in non-small cell lung cancer (NSCLC) patients who are commonly treated by third generation of EGFR-TKI AZD9291 (osimertinib). osimertinib 306-317 epidermal growth factor receptor Homo sapiens 164-168 30993382-1 2019 The T790M mutation is recognized as a typical mechanism of acquired resistance to first generation of epithermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib in non-small cell lung cancer (NSCLC) patients who are commonly treated by third generation of EGFR-TKI AZD9291 (osimertinib). osimertinib 306-317 epidermal growth factor receptor Homo sapiens 288-292 30943730-0 2019 Osimertinib in the treatment of leptomeningeal disease in T790M-negative, epidermal growth factor receptor-mutated non-small cell lung cancer: a case report. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 74-106 30943730-2 2019 Osimertinib is a third generation EGFR-tyrosine kinase inhibitor (TKI) with preclinical and early clinical studies showing activity against LMC resistant to previous TKI treatments and acquired T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 34-38 30943730-3 2019 We report a case of osimertinib in the treatment of LMC in a T790M-negative, EGFR-mutated NSCLC with significant clinical benefit and no toxicity. osimertinib 20-31 epidermal growth factor receptor Homo sapiens 77-81 30943730-4 2019 Osimertinib is a potentially effective treatment for LMC associated with EGFR-mutated NSCLC regardless of T790M status and a well-tolerated treatment for poor performance status patients. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 73-77 31124059-1 2019 BACKGROUND: The third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) osimertinib has become the standard treatment for patients with pretreated EGFR-mutated non-small cell lung cancer (NSCLC) who acquire the T790M resistance mutation. osimertinib 105-116 epidermal growth factor receptor Homo sapiens 33-65 31124059-1 2019 BACKGROUND: The third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) osimertinib has become the standard treatment for patients with pretreated EGFR-mutated non-small cell lung cancer (NSCLC) who acquire the T790M resistance mutation. osimertinib 105-116 epidermal growth factor receptor Homo sapiens 67-71 31124059-1 2019 BACKGROUND: The third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) osimertinib has become the standard treatment for patients with pretreated EGFR-mutated non-small cell lung cancer (NSCLC) who acquire the T790M resistance mutation. osimertinib 105-116 epidermal growth factor receptor Homo sapiens 180-184 31319998-11 2019 After subsequent treatment with osimertinib, SCC transformation was observed with the disappearance of the EGFR p.T790 M mutation and acquired copy number loss in PTEN. osimertinib 32-43 epidermal growth factor receptor Homo sapiens 107-111 31555510-8 2019 Luminespib downregulated the expression of the several proteins involved in osimertinib-resistance and the combination of this compound plus osimertinib caused an important decrease of expression of several of these proteins, such as Stat3, Yap, Akt, EGFR and Met. osimertinib 141-152 epidermal growth factor receptor Homo sapiens 251-255 31637005-5 2019 In this study, we found that EGFR TKIs, including gefitinib and AZD9291, impaired lysosome-dependent degradation of SQSTM1, thus compromising their anti-cancer efficiency. osimertinib 64-71 epidermal growth factor receptor Homo sapiens 29-33 31092401-4 2019 Remarkably, osimertinib, an ATP-competitive covalent EGFR inhibitor, uniquely and significantly enhances the binding of JBJ-04-125-02 for mutant EGFR. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 53-57 31092401-4 2019 Remarkably, osimertinib, an ATP-competitive covalent EGFR inhibitor, uniquely and significantly enhances the binding of JBJ-04-125-02 for mutant EGFR. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 145-149 31092401-8 2019 Here, we identify a mutant EGFR allosteric inhibitor that is effective as a single agent and in combination with the EGFR TKI osimertinib.This article is highlighted in the In This Issue feature, p. 813. osimertinib 126-137 epidermal growth factor receptor Homo sapiens 27-31 31290421-1 2019 Osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR)-tyrosine-kinase inhibitor (TKI), is useful in the treatment of non-small cell lung cancer who show resistance to first-generation EGFR-TKIs and harbor T790M mutation. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 42-74 31290421-1 2019 Osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR)-tyrosine-kinase inhibitor (TKI), is useful in the treatment of non-small cell lung cancer who show resistance to first-generation EGFR-TKIs and harbor T790M mutation. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 76-80 31290421-1 2019 Osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR)-tyrosine-kinase inhibitor (TKI), is useful in the treatment of non-small cell lung cancer who show resistance to first-generation EGFR-TKIs and harbor T790M mutation. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 212-216 31097094-1 2019 BACKGROUND: Osimertinib is a tyrosine kinase inhibitor (TKI) that is an essential agent for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 109-141 31097094-1 2019 BACKGROUND: Osimertinib is a tyrosine kinase inhibitor (TKI) that is an essential agent for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 143-147 31097094-16 2019 CONCLUSIONS: Re-administration of osimertinib for EGFR-mutant NSCLC yielded modest activity with tolerable toxicity. osimertinib 34-45 epidermal growth factor receptor Homo sapiens 50-54 31088573-12 2019 CONCLUSIONS: Osimertinib seems to be a suitable therapy for treatment-naive patients with sensitizing and resistant compound EGFR mutations. osimertinib 13-24 epidermal growth factor receptor Homo sapiens 125-129 31122294-0 2019 The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma. osimertinib 36-43 epidermal growth factor receptor Homo sapiens 21-25 31122294-4 2019 The third-generation EGFR-targeted drug, AZD9291, is a novel and irreversible inhibitor. osimertinib 41-48 epidermal growth factor receptor Homo sapiens 21-25 31122294-12 2019 In contrast to erlotinib, AZD9291 continuously and efficiently inhibited the EGFR/ERK signaling in GBM cells. osimertinib 26-33 epidermal growth factor receptor Homo sapiens 77-81 30831205-11 2019 Combined inhibition of EGFR and MEK (with osimertinib and trametinib) or BRAF (with a pan-RAF inhibitor) are potential therapeutic strategies that should be explored. osimertinib 42-53 epidermal growth factor receptor Homo sapiens 23-27 30763730-1 2019 INTRODUCTION: Osimertinib is a third-generation EGFR-tyrosine kinase inhibitor (TKI). osimertinib 14-25 epidermal growth factor receptor Homo sapiens 48-52 30736738-0 2019 Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report. osimertinib 107-114 epidermal growth factor receptor Homo sapiens 79-83 30623574-8 2019 AZD-9291 was more effective than Erlotinib in inhibiting phospho-EGFR, and downstream phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) and phopho-signal transducer and activator of transcription 3 (p-STAT3) pathway signaling. osimertinib 0-8 epidermal growth factor receptor Homo sapiens 65-69 30623574-10 2019 Our findings highlight EGFR-TKIs, Tarceva, and AZD-9291, attenuate HDM-induced inflammatory IL-6 and IL-8 cytokines via EGFR signaling axis pathway, but not AMPK signaling pathway. osimertinib 47-55 epidermal growth factor receptor Homo sapiens 120-124 30885336-0 2019 Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study. osimertinib 27-38 epidermal growth factor receptor Homo sapiens 42-46 30885336-1 2019 INTRODUCTION: Osimertinib is an EGFR tyrosine kinase inhibitor (TKI) with antitumor activity in non-small cell lung cancer (NSCLC) with EGFR T790 M mutations. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 32-36 30885336-1 2019 INTRODUCTION: Osimertinib is an EGFR tyrosine kinase inhibitor (TKI) with antitumor activity in non-small cell lung cancer (NSCLC) with EGFR T790 M mutations. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 136-140 30883029-1 2019 BACKGROUND: Osimertinib (AZD9291), a third-generation EGFR-tyrosine kinase inhibitor, can effectively prolong survival in non-small cell lung cancer (NSCLC) patients with EGFR mutations, particularly T790M mutations; however, acquired resistance to AZD9291 is inevitable, thus exploration of the targets of resistance is urgent. osimertinib 25-32 epidermal growth factor receptor Homo sapiens 54-58 30883029-1 2019 BACKGROUND: Osimertinib (AZD9291), a third-generation EGFR-tyrosine kinase inhibitor, can effectively prolong survival in non-small cell lung cancer (NSCLC) patients with EGFR mutations, particularly T790M mutations; however, acquired resistance to AZD9291 is inevitable, thus exploration of the targets of resistance is urgent. osimertinib 25-32 epidermal growth factor receptor Homo sapiens 171-175 30512189-1 2019 BACKGROUND: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is selective for both EGFR-TKI-sensitizing and T790M (threonine-to-methionine substitution at codon 790)-resistance mutations. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 46-78 30512189-1 2019 BACKGROUND: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is selective for both EGFR-TKI-sensitizing and T790M (threonine-to-methionine substitution at codon 790)-resistance mutations. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 80-84 30512189-1 2019 BACKGROUND: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is selective for both EGFR-TKI-sensitizing and T790M (threonine-to-methionine substitution at codon 790)-resistance mutations. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 145-149 30502627-1 2019 Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been approved for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 44-76 30502627-1 2019 Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been approved for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 78-82 30502627-1 2019 Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been approved for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 160-164 30502627-1 2019 Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been approved for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). osimertinib 13-20 epidermal growth factor receptor Homo sapiens 44-76 30502627-1 2019 Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been approved for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). osimertinib 13-20 epidermal growth factor receptor Homo sapiens 78-82 30502627-1 2019 Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been approved for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). osimertinib 13-20 epidermal growth factor receptor Homo sapiens 160-164 30471155-1 2019 BACKGROUND: The cobas epidermal growth factor receptor (EGFR) Mutation Test v2 designed for cell-free DNA (cfDNA) is approved as a companion diagnostic for osimertinib therapy. osimertinib 157-168 epidermal growth factor receptor Homo sapiens 23-55 30471155-1 2019 BACKGROUND: The cobas epidermal growth factor receptor (EGFR) Mutation Test v2 designed for cell-free DNA (cfDNA) is approved as a companion diagnostic for osimertinib therapy. osimertinib 157-168 epidermal growth factor receptor Homo sapiens 57-61 30856555-1 2019 The third-generation EGFR inhibitor, osimertinib (AZD9291), selectively and irreversibly inhibits EGFR activating and T790 M mutants while sparing wild-type EGFR. osimertinib 50-57 epidermal growth factor receptor Homo sapiens 21-25 30856555-1 2019 The third-generation EGFR inhibitor, osimertinib (AZD9291), selectively and irreversibly inhibits EGFR activating and T790 M mutants while sparing wild-type EGFR. osimertinib 50-57 epidermal growth factor receptor Homo sapiens 98-102 30856555-1 2019 The third-generation EGFR inhibitor, osimertinib (AZD9291), selectively and irreversibly inhibits EGFR activating and T790 M mutants while sparing wild-type EGFR. osimertinib 50-57 epidermal growth factor receptor Homo sapiens 98-102 30736738-3 2019 CASE PRESENTATION: Here we reported a NSCLC patient with EGFR sensitive mutation of deletion within EGFR exon 19, who had been resistant to icotinib and AZD9291 successively after a period of 18 months response duration. osimertinib 153-160 epidermal growth factor receptor Homo sapiens 57-61 30736738-3 2019 CASE PRESENTATION: Here we reported a NSCLC patient with EGFR sensitive mutation of deletion within EGFR exon 19, who had been resistant to icotinib and AZD9291 successively after a period of 18 months response duration. osimertinib 153-160 epidermal growth factor receptor Homo sapiens 100-104 30521113-0 2019 Overcoming T790M mutant small cell lung cancer with the third-generation EGFR-TKI osimertinib. osimertinib 82-93 epidermal growth factor receptor Homo sapiens 73-77 30463991-0 2019 Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Cells. osimertinib 73-84 epidermal growth factor receptor Homo sapiens 98-102 30463991-1 2019 Osimertinib (AZD9291) has an efficacy superior to that of standard EGFR-tyrosine kinase inhibitors for the first-line treatment of patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 145-149 30463991-1 2019 Osimertinib (AZD9291) has an efficacy superior to that of standard EGFR-tyrosine kinase inhibitors for the first-line treatment of patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC). osimertinib 13-20 epidermal growth factor receptor Homo sapiens 145-149 30463991-4 2019 However, the acquired resistance mechanisms when osimertinib is initially used for EGFR-mutant NSCLC remain unclear. osimertinib 49-60 epidermal growth factor receptor Homo sapiens 83-87 30463991-5 2019 In this study, we experimentally established acquired osimertinib-resistant cell lines from EGFR-mutant NSCLC cell lines and investigated the molecular profiles of resistant cells to uncover the mechanisms of acquired resistance. osimertinib 54-65 epidermal growth factor receptor Homo sapiens 92-96 30642450-0 2019 Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M. osimertinib 63-74 epidermal growth factor receptor Homo sapiens 133-137 30642450-1 2019 BACKGROUND: Osimertinib demonstrates superior efficacy in patients with non-small cell lung cancer (NSCLC) who acquired EGFR T790M mutation as resistant mechanism to upfront EGFR tyrosine kinase inhibitors (TKIs). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 120-124 30642450-1 2019 BACKGROUND: Osimertinib demonstrates superior efficacy in patients with non-small cell lung cancer (NSCLC) who acquired EGFR T790M mutation as resistant mechanism to upfront EGFR tyrosine kinase inhibitors (TKIs). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 174-178 30642450-4 2019 The aim of this study is to investigate the prevalence of T790 M loss after progression to osimertinib in Chinese patients with NSCLC harboring EGFR T790 M mutation and to compare their clinical outcomes and characteristics when stratified by T790 M mutational status at osimertinib resistance. osimertinib 91-102 epidermal growth factor receptor Homo sapiens 144-148 30521113-5 2019 Unexpectedly, this SCLC patient maintained a sensitive response to the third-generation EGFR-TKI osimertinib. osimertinib 97-108 epidermal growth factor receptor Homo sapiens 88-92 30521113-6 2019 This special case may indicate that osimertinib represents an effective target drug for SCLC patients who harbor an EGFR T790M mutation. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 116-120 30539501-3 2019 For EGFR T790M-positive patients who progress on EGFR TKI therapy, osimertinib is an effective treatment option. osimertinib 67-78 epidermal growth factor receptor Homo sapiens 4-8 30539501-3 2019 For EGFR T790M-positive patients who progress on EGFR TKI therapy, osimertinib is an effective treatment option. osimertinib 67-78 epidermal growth factor receptor Homo sapiens 49-53 30539501-7 2019 EGFR T790M-positive patients subsequently received osimertinib. osimertinib 51-62 epidermal growth factor receptor Homo sapiens 0-4 30539501-14 2019 Osimertinib confers high response rates after afatinib failure in EGFR T790M-positive patients and its use in sequence potentially allows extended chemotherapy-free treatment. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 66-70 30322949-9 2019 After 2 months of osimertinib withdrawal, this complex was dissociated, and the EGFR signal, but not the GRB2/SOS1 signal, was activated. osimertinib 18-29 epidermal growth factor receptor Homo sapiens 80-84 30145802-1 2019 AZD9291, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is highly selective against EGFR T790M-mutant non-small cell lung cancer (NSCLC). osimertinib 0-7 epidermal growth factor receptor Homo sapiens 88-92 30145802-1 2019 AZD9291, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is highly selective against EGFR T790M-mutant non-small cell lung cancer (NSCLC). osimertinib 0-7 epidermal growth factor receptor Homo sapiens 127-131 30145802-5 2019 AZD9291-induced cell death was enhanced by Akt knockdown, and the levels of both EGFR and phosphorylated EGFR were decreased by AZD9291. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 81-85 30145802-5 2019 AZD9291-induced cell death was enhanced by Akt knockdown, and the levels of both EGFR and phosphorylated EGFR were decreased by AZD9291. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 105-109 30145802-5 2019 AZD9291-induced cell death was enhanced by Akt knockdown, and the levels of both EGFR and phosphorylated EGFR were decreased by AZD9291. osimertinib 128-135 epidermal growth factor receptor Homo sapiens 81-85 30145802-5 2019 AZD9291-induced cell death was enhanced by Akt knockdown, and the levels of both EGFR and phosphorylated EGFR were decreased by AZD9291. osimertinib 128-135 epidermal growth factor receptor Homo sapiens 105-109 30145802-7 2019 Thus, AZD9291 was found to induce autophagy, decrease in EGFR levels, and show a strong inhibitory effect on NSCLC both in vitro and in vivo. osimertinib 6-13 epidermal growth factor receptor Homo sapiens 57-61 30322949-0 2019 KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR. osimertinib 67-78 epidermal growth factor receptor Homo sapiens 9-13 30322949-0 2019 KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR. osimertinib 67-78 epidermal growth factor receptor Homo sapiens 152-156 30322949-1 2019 The critical T790M mutation in EGFR, which mediates resistance to first- and second-generation EGFR tyrosine kinase inhibitors (TKI; gefitinib, erlotinib, and afatinib), has facilitated the development of third-generation mutation-selective EGFR TKIs (rociletinib and osimertinib). osimertinib 268-279 epidermal growth factor receptor Homo sapiens 31-35 30322949-1 2019 The critical T790M mutation in EGFR, which mediates resistance to first- and second-generation EGFR tyrosine kinase inhibitors (TKI; gefitinib, erlotinib, and afatinib), has facilitated the development of third-generation mutation-selective EGFR TKIs (rociletinib and osimertinib). osimertinib 268-279 epidermal growth factor receptor Homo sapiens 95-99 30322949-10 2019 Concomitant inhibition of MAPK kinase and EGFR could overcome osimertinib resistance. osimertinib 62-73 epidermal growth factor receptor Homo sapiens 42-46 30322949-8 2019 Phospho-EGFR (Y1068) and growth factor receptor-bound protein 2 (GRB2)/son of sevenless homolog 1 (SOS1) complex was found to mediate osimertinib resistance in OsiR1 cells with sustained KRAS activation. osimertinib 134-145 epidermal growth factor receptor Homo sapiens 8-12 30111817-11 2019 Our study not only revealed a common mechanism of EMT in both gefitinib and AZD9291 resistance beyond EGFR mutations per se, but also provides a new strategy to overcome it. osimertinib 76-83 epidermal growth factor receptor Homo sapiens 102-106 30171779-1 2018 AIM: We report on two Phase 1, open-label, single-arm studies assessing the effect of osimertinib on simvastatin (CYP3A substrate) and rosuvastatin (breast cancer resistance protein substrate [BCRP] substrate) exposure in patients with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer who have progressed after treatment with an EGFR tyrosine kinase inhibitor, to determine, upon coadministration, whether osimertinib could affect the exposure of these agents. osimertinib 86-97 epidermal growth factor receptor Homo sapiens 245-277 30365094-0 2019 Osimertinib (AZD9291) increases radio-sensitivity in EGFR T790M non-small cell lung cancer. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 53-57 30365094-1 2019 Osimertinib (AZD9291) is a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated significant clinical benefits in patients with EGFR-sensitizing mutations or the T790M mutation. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 44-76 30365094-1 2019 Osimertinib (AZD9291) is a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated significant clinical benefits in patients with EGFR-sensitizing mutations or the T790M mutation. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 78-82 30365094-1 2019 Osimertinib (AZD9291) is a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated significant clinical benefits in patients with EGFR-sensitizing mutations or the T790M mutation. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 179-183 30520383-4 2019 CONCLUSION: To date, in the light of the data from the FLAURA study, osimertinib represents the best first-line option in NSCLC patients with EGFR activating mutations; EGFR-TKI plus chemotherapy combination therapies, even though interesting, must still be considered investigational. osimertinib 69-80 epidermal growth factor receptor Homo sapiens 142-146 30591099-5 2018 In addition, the third-generation TKI drugs Osimertinib (AZD9291) and Rociletinib (CO-1686) have been developed to further benefit patients with primary TKI resistance caused by T790M mutation of EGFR. osimertinib 57-64 epidermal growth factor receptor Homo sapiens 196-200 30240852-10 2019 CONCLUSION: In this Asian population, first-line osimertinib demonstrated a clinically meaningful improvement in PFS over an SoC EGFR TKI, with a safety profile consistent with that for the overall FLAURA study population. osimertinib 49-60 epidermal growth factor receptor Homo sapiens 129-133 30171779-1 2018 AIM: We report on two Phase 1, open-label, single-arm studies assessing the effect of osimertinib on simvastatin (CYP3A substrate) and rosuvastatin (breast cancer resistance protein substrate [BCRP] substrate) exposure in patients with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer who have progressed after treatment with an EGFR tyrosine kinase inhibitor, to determine, upon coadministration, whether osimertinib could affect the exposure of these agents. osimertinib 86-97 epidermal growth factor receptor Homo sapiens 279-283 30291293-0 2018 Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer. osimertinib 92-103 epidermal growth factor receptor Homo sapiens 107-111 29660496-9 2018 However, in H1975 cells, which harbor the TKI-resistant EGFRL858R/T790M mutant, osimertinib, but not erlotinib, could significantly inhibit phosphorylation of EGFR-pY-1197, STAT5A-pY694 and CAV1-pY14, suggesting these sites also predict response in TKI-resistant cells. osimertinib 80-91 epidermal growth factor receptor Homo sapiens 56-60 30291293-6 2018 When ANKRD1 was silenced in the EGFR-TKIs-resistant cell lines, afatinib and osimertinib could induce apoptosis of the cell lines. osimertinib 77-88 epidermal growth factor receptor Homo sapiens 32-36 30291293-7 2018 Imatinib could inhibit ANKRD1 expression, resulting in restoration of the sensitivity to afatinib and osimertinib of EGFR-TKI-resistant cells. osimertinib 102-113 epidermal growth factor receptor Homo sapiens 117-121 30358214-0 2018 Circulating tumor cells predict prognosis following secondline AZD 9291 treatment in EGFR-T790M mutant non-small cell lung cancer patients. osimertinib 63-71 epidermal growth factor receptor Homo sapiens 85-89 30615755-3 2018 According to clinical test and in vivo experimental data, the efficiencies of gefitinib and erlotinib are only 37% and 12% compared to AZD9291, and 0.300 mug of EGFR inactivation requires 0.484 mug of AZD9291, 0.815 mug of gefitinib and 1.348 mug of erlotinib. osimertinib 201-208 epidermal growth factor receptor Homo sapiens 161-165 29797219-0 2018 Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial-mesenchymal transition phenotype. osimertinib 44-51 epidermal growth factor receptor Homo sapiens 8-12 29797219-0 2018 Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial-mesenchymal transition phenotype. osimertinib 44-51 epidermal growth factor receptor Homo sapiens 58-62 29797219-1 2018 PURPOSE: AZD9291 is an irreversible, small-molecule inhibitor which has potency against mutant EGFR- and T790M-resistant mutation. osimertinib 9-16 epidermal growth factor receptor Homo sapiens 95-99 29797219-12 2018 CONCLUSIONS: Loss of EGFR could be proposed as a potential acquired resistance mechanism of AZD9291 in EGFR-mutant NSCLC cells with an EMT phenotype. osimertinib 92-99 epidermal growth factor receptor Homo sapiens 21-25 29797219-12 2018 CONCLUSIONS: Loss of EGFR could be proposed as a potential acquired resistance mechanism of AZD9291 in EGFR-mutant NSCLC cells with an EMT phenotype. osimertinib 92-99 epidermal growth factor receptor Homo sapiens 103-107 29907952-1 2018 The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib (AZD9291) has shown significant clinical efficacy against the EGFR T790M mutation in non-small cell lung cancer (NSCLC) patients. osimertinib 106-113 epidermal growth factor receptor Homo sapiens 21-53 29907952-1 2018 The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib (AZD9291) has shown significant clinical efficacy against the EGFR T790M mutation in non-small cell lung cancer (NSCLC) patients. osimertinib 106-113 epidermal growth factor receptor Homo sapiens 55-59 29907952-1 2018 The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib (AZD9291) has shown significant clinical efficacy against the EGFR T790M mutation in non-small cell lung cancer (NSCLC) patients. osimertinib 106-113 epidermal growth factor receptor Homo sapiens 167-171 29802850-4 2018 The third-generation TKIs such as AZD9291, HM61713, CO-1686 and WZ4002 can overcome T790M through covalent binding to the EGFR kinase through Cys 797, but ultimately lose their efficacy upon emergence of the C797S mutation that abolishes the covalent bonding. osimertinib 34-41 epidermal growth factor receptor Homo sapiens 122-126 29506987-1 2018 Purpose: The third-generation EGFR tyrosine kinase inhibitor osimertinib is approved to treat patients with EGFR T790M-positive non-small cell lung cancer (NSCLC) who have developed resistance to earlier-generation drugs. osimertinib 61-72 epidermal growth factor receptor Homo sapiens 30-34 29506987-2 2018 Acquired EGFR C797S mutation has been reported to mediate osimertinib resistance in some patients. osimertinib 58-69 epidermal growth factor receptor Homo sapiens 9-13 29506987-6 2018 Further analysis of the 12 matched pretreatment samples confirmed that these EGFR mutations were acquired during osimertinib treatment. osimertinib 113-124 epidermal growth factor receptor Homo sapiens 77-81 29506987-8 2018 Besides C797 mutations, novel secondary mutations of EGFR L718 and L792 residues confer osimertinib resistance, both in vitro and in vivo, and are of great clinical and pharmaceutical relevance. osimertinib 88-99 epidermal growth factor receptor Homo sapiens 53-57 30358214-1 2018 PURPOSE: AZD9291 has been developed as third-generation epithermal growth factor receptor (EGFR)- tyrosine kinase inhibitor (TKI) with activities against T790M mutation. osimertinib 9-16 epidermal growth factor receptor Homo sapiens 56-89 30358214-1 2018 PURPOSE: AZD9291 has been developed as third-generation epithermal growth factor receptor (EGFR)- tyrosine kinase inhibitor (TKI) with activities against T790M mutation. osimertinib 9-16 epidermal growth factor receptor Homo sapiens 91-95 30358214-3 2018 METHODS: Enrolled patients confirmed with EGFR T790M mutation received AZD9291 80 mg orally once daily as second-line treatment. osimertinib 71-78 epidermal growth factor receptor Homo sapiens 42-46 29641535-1 2018 AZD9291 (osimertinib) is approved for standard care in patients with EGFR T790M-positive non-small cell lung cancer (NSCLC) after prior EGFR TKI progression. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 69-73 29910645-3 2018 However, resistance inevitably develops, and the third-generation tki osimertinib has been approved to target the gatekeeper EGFR mutation T790M, which is responsible for resistance in 60% of cases. osimertinib 70-81 epidermal growth factor receptor Homo sapiens 125-129 29910649-9 2018 Conclusions: The treatment algorithm for EGFR mutation is changing with the proven efficacy of osimertinib for the acquired T790M mutation. osimertinib 95-106 epidermal growth factor receptor Homo sapiens 41-45 32700141-0 2018 Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 58-62 32700141-1 2018 INTRODUCTION: The osimertinib (AZD9291) US Expanded Access Program (EAP) provided compassionate access to osimertinib prior to US Food and Drug Administration (FDA) approval for patients with advanced/metastatic epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer (NSCLC) following progression on tyrosine kinase inhibitors (TKIs) targeting EGFR. osimertinib 18-29 epidermal growth factor receptor Homo sapiens 212-244 32700141-1 2018 INTRODUCTION: The osimertinib (AZD9291) US Expanded Access Program (EAP) provided compassionate access to osimertinib prior to US Food and Drug Administration (FDA) approval for patients with advanced/metastatic epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer (NSCLC) following progression on tyrosine kinase inhibitors (TKIs) targeting EGFR. osimertinib 18-29 epidermal growth factor receptor Homo sapiens 246-250 32700141-1 2018 INTRODUCTION: The osimertinib (AZD9291) US Expanded Access Program (EAP) provided compassionate access to osimertinib prior to US Food and Drug Administration (FDA) approval for patients with advanced/metastatic epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer (NSCLC) following progression on tyrosine kinase inhibitors (TKIs) targeting EGFR. osimertinib 18-29 epidermal growth factor receptor Homo sapiens 371-375 29673089-0 2018 Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report. osimertinib 128-135 epidermal growth factor receptor Homo sapiens 44-48 29874151-1 2018 AIM: This study aims to develop new nanoformulations of EGFR T790M targeted inhibitor AZD9291 and paclitaxel (PTX) for combination therapy of lung cancer. osimertinib 86-93 epidermal growth factor receptor Homo sapiens 56-60 29998228-6 2018 Osimertinib mesylate (formerly AZD-9291) is a potent third-generation TKI which irreversibly inhibits mutated EGFR alleles, including T790M. osimertinib 31-39 epidermal growth factor receptor Homo sapiens 110-114 29730192-1 2018 A series of novel 2,4-diarylaminopyrimidine derivatives of AZD9291 were discovered as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors. osimertinib 59-66 epidermal growth factor receptor Homo sapiens 115-147 29730192-1 2018 A series of novel 2,4-diarylaminopyrimidine derivatives of AZD9291 were discovered as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors. osimertinib 59-66 epidermal growth factor receptor Homo sapiens 149-153 29730192-6 2018 Docking study performed for 8a with ATP binding site of EGFR-TK showed the similar binding mode to that of AZD9291. osimertinib 107-114 epidermal growth factor receptor Homo sapiens 56-60 29789021-8 2018 AZD9291 was found to be an excellent treatment option and yielded the longest survival for T790M+ patients in all groups who had progressed on EGFR-TKIs; for other treatments, the prognosis of T790M- patient subgroups varied. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 143-147 29425688-1 2018 Given the successful identification of epidermal growth factor receptor EGFR T790M, the third-generation EGFR tyrosine kinase inhibitor (TKI), osimertinib (OSI, AZD9291), was developed to target EGFR T790M mutation. osimertinib 161-168 epidermal growth factor receptor Homo sapiens 105-109 29425688-1 2018 Given the successful identification of epidermal growth factor receptor EGFR T790M, the third-generation EGFR tyrosine kinase inhibitor (TKI), osimertinib (OSI, AZD9291), was developed to target EGFR T790M mutation. osimertinib 161-168 epidermal growth factor receptor Homo sapiens 105-109 29641535-1 2018 AZD9291 (osimertinib) is approved for standard care in patients with EGFR T790M-positive non-small cell lung cancer (NSCLC) after prior EGFR TKI progression. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 136-140 29641535-2 2018 Furthermore, AZD9291 is now being evaluated as a first-line treatment for NSCLC patients with activation EGFR mutations. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 105-109 29641535-5 2018 AZD9291-resistant cells (PC9/AZDR) were established using EGFR inhibitor-naive PC9 cells. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 58-62 29641535-7 2018 Resistance to AZD9291 developed through aberrant activation of ERK signaling by an EGFR-independent mechanism. osimertinib 14-21 epidermal growth factor receptor Homo sapiens 83-87 29641535-12 2018 Thus, co-targeting EGFR and MEK may be an effective strategy to overcome resistance to AZD9291. osimertinib 87-94 epidermal growth factor receptor Homo sapiens 19-23 28765329-0 2017 Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation. osimertinib 34-41 epidermal growth factor receptor Homo sapiens 62-66 29212784-3 2018 Irreversible inhibitors (e.g., osimertinib/AZD9291) inhibit T790M-EGFR, but several mechanisms, including a third-site mutation, C797S, confer renewed resistance. osimertinib 43-50 epidermal growth factor receptor Homo sapiens 66-70 29568384-2 2018 Though WZ4002/CO-1686/AZD9291 are effective in overcoming EGFR T790M by targeting Cys797 via covalent bonding, their efficacy is again limited due to the emergence of C797S mutation. osimertinib 22-29 epidermal growth factor receptor Homo sapiens 58-62 29332537-1 2018 AZD9291 is a novel, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), which is administered orally. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 33-65 29332537-1 2018 AZD9291 is a novel, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), which is administered orally. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 67-71 29332537-5 2018 In PC-9-IR cells, AZD9291 remarkably decreases phosphorylation levels of EGFR, extracellular regulated protein kinase (ERK), and protein kinase B (AKT). osimertinib 18-25 epidermal growth factor receptor Homo sapiens 73-77 29332537-7 2018 Our findings suggest a potential therapeutic effect of AZD9291 as a radiation sensitizer in lung cancer cells with an acquired EGFR T790M mutation, providing a rationale for a clinical trial using the combination of AZD9291 and radiation in NSCLCs harboring acquired T790M mutation. osimertinib 55-62 epidermal growth factor receptor Homo sapiens 127-131 28730963-1 2018 BACKGROUND: Osimertinib (OSI), also known as AZD9291, is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been approved for the treatment of non-small cell lung cancer (NSCLC) patients. osimertinib 45-52 epidermal growth factor receptor Homo sapiens 76-108 28730963-1 2018 BACKGROUND: Osimertinib (OSI), also known as AZD9291, is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been approved for the treatment of non-small cell lung cancer (NSCLC) patients. osimertinib 45-52 epidermal growth factor receptor Homo sapiens 110-114 28880013-0 2017 Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 61-65 28880013-1 2017 Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been approved for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). osimertinib 13-20 epidermal growth factor receptor Homo sapiens 44-76 28880013-1 2017 Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been approved for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). osimertinib 13-20 epidermal growth factor receptor Homo sapiens 78-82 28880013-1 2017 Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been approved for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). osimertinib 13-20 epidermal growth factor receptor Homo sapiens 160-164 28765329-1 2017 Purpose: The mechanisms accounting for anticancer activity of AZD9291 (osimertinib or TAGRISSO), an approved third-generation EGFR inhibitor, in EGFR-mutant non-small cell lung cancer (NSCLC) cells and particularly for the subsequent development of acquired resistance are unclear and thus are the focus of this study.Experimental Design: AZD9219-resistant cell lines were established by exposing sensitive cell lines to AZD9291. osimertinib 62-69 epidermal growth factor receptor Homo sapiens 126-130 28765329-1 2017 Purpose: The mechanisms accounting for anticancer activity of AZD9291 (osimertinib or TAGRISSO), an approved third-generation EGFR inhibitor, in EGFR-mutant non-small cell lung cancer (NSCLC) cells and particularly for the subsequent development of acquired resistance are unclear and thus are the focus of this study.Experimental Design: AZD9219-resistant cell lines were established by exposing sensitive cell lines to AZD9291. osimertinib 62-69 epidermal growth factor receptor Homo sapiens 145-149 28765329-6 2017 Gene knockdown were achieved with siRNA or shRNA.Results: AZD9291 potently induced apoptosis in EGFR-mutant NSCLC cell lines, in which ERK phosphorylation was suppressed accompanied with Bim elevation and Mcl-1 reduction likely due to enhanced Mcl-1 degradation and increased Bim stability. osimertinib 58-65 epidermal growth factor receptor Homo sapiens 96-100 28765329-9 2017 The combination of a MEK inhibitor with AZD9291 restores the sensitivity of AZD9291-resistant cells including those with C797S mutation to undergo apoptosis and growth regression in vitro and in vivoConclusions: Modulation of MEK/ERK-dependent Bim and Mcl-1 degradation critically mediates sensitivity and resistance of EGFR-mutant NSCLC cells to AZD9291 and hence is an effective strategy to overcome acquired resistance to AZD9291. osimertinib 40-47 epidermal growth factor receptor Homo sapiens 320-324 28765329-9 2017 The combination of a MEK inhibitor with AZD9291 restores the sensitivity of AZD9291-resistant cells including those with C797S mutation to undergo apoptosis and growth regression in vitro and in vivoConclusions: Modulation of MEK/ERK-dependent Bim and Mcl-1 degradation critically mediates sensitivity and resistance of EGFR-mutant NSCLC cells to AZD9291 and hence is an effective strategy to overcome acquired resistance to AZD9291. osimertinib 76-83 epidermal growth factor receptor Homo sapiens 320-324 28765329-9 2017 The combination of a MEK inhibitor with AZD9291 restores the sensitivity of AZD9291-resistant cells including those with C797S mutation to undergo apoptosis and growth regression in vitro and in vivoConclusions: Modulation of MEK/ERK-dependent Bim and Mcl-1 degradation critically mediates sensitivity and resistance of EGFR-mutant NSCLC cells to AZD9291 and hence is an effective strategy to overcome acquired resistance to AZD9291. osimertinib 76-83 epidermal growth factor receptor Homo sapiens 320-324 28765329-9 2017 The combination of a MEK inhibitor with AZD9291 restores the sensitivity of AZD9291-resistant cells including those with C797S mutation to undergo apoptosis and growth regression in vitro and in vivoConclusions: Modulation of MEK/ERK-dependent Bim and Mcl-1 degradation critically mediates sensitivity and resistance of EGFR-mutant NSCLC cells to AZD9291 and hence is an effective strategy to overcome acquired resistance to AZD9291. osimertinib 76-83 epidermal growth factor receptor Homo sapiens 320-324 29086838-10 2017 CONCLUSIONS: The accuracy and efficiency of RD-Metabolizer was further illustrated by a metabolism prediction case of AZD9291, which is a mutant-selective EGFR inhibitor. osimertinib 118-125 epidermal growth factor receptor Homo sapiens 155-159 28341106-0 2017 The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. osimertinib 45-52 epidermal growth factor receptor Homo sapiens 105-109 28341106-2 2017 The AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients (APPLE) trial is a randomized, open-label, multicenter, 3-arm, phase II study in advanced, epidermal growth factor receptor (EGFR)-mutant and EGFR tyrosine kinase inhibitor (TKI)-naive non-small-cell lung cancer (NSCLC) patients, to evaluate the best strategy for sequencing gefitinib and osimertinib treatment. osimertinib 4-11 epidermal growth factor receptor Homo sapiens 64-68 28341106-2 2017 The AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients (APPLE) trial is a randomized, open-label, multicenter, 3-arm, phase II study in advanced, epidermal growth factor receptor (EGFR)-mutant and EGFR tyrosine kinase inhibitor (TKI)-naive non-small-cell lung cancer (NSCLC) patients, to evaluate the best strategy for sequencing gefitinib and osimertinib treatment. osimertinib 4-11 epidermal growth factor receptor Homo sapiens 216-220 28341106-2 2017 The AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients (APPLE) trial is a randomized, open-label, multicenter, 3-arm, phase II study in advanced, epidermal growth factor receptor (EGFR)-mutant and EGFR tyrosine kinase inhibitor (TKI)-naive non-small-cell lung cancer (NSCLC) patients, to evaluate the best strategy for sequencing gefitinib and osimertinib treatment. osimertinib 4-11 epidermal growth factor receptor Homo sapiens 216-220 28808573-1 2017 Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for EGFR-T790M-positive non-small cell lung cancer. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 44-76 28808573-1 2017 Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for EGFR-T790M-positive non-small cell lung cancer. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 78-82 28808573-1 2017 Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for EGFR-T790M-positive non-small cell lung cancer. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 123-127 28219203-3 2017 Now, with the continuously emerging of new types of EGFR-TKIs and ever-increasing publication of clinical trial results on afatinib, AZD9291 and other TKIs, we have more first-line choices for patients with EGFR mutations. osimertinib 133-140 epidermal growth factor receptor Homo sapiens 207-211 28422737-7 2017 The clones were also highly sensitive to the 3rd-generation EGFR TKI AZD9291, which is cytotoxic to lung cancer cells with EGFR T790M. osimertinib 69-76 epidermal growth factor receptor Homo sapiens 60-64 28422737-7 2017 The clones were also highly sensitive to the 3rd-generation EGFR TKI AZD9291, which is cytotoxic to lung cancer cells with EGFR T790M. osimertinib 69-76 epidermal growth factor receptor Homo sapiens 123-127 28237877-1 2017 Osimertinib (OSI), also known as AZD9291, is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has been approved for the treatment of non-small cell lung cancer (NSCLC) patients harboring EGFR T790M mutation. osimertinib 33-40 epidermal growth factor receptor Homo sapiens 64-96 28237877-1 2017 Osimertinib (OSI), also known as AZD9291, is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has been approved for the treatment of non-small cell lung cancer (NSCLC) patients harboring EGFR T790M mutation. osimertinib 33-40 epidermal growth factor receptor Homo sapiens 98-102 28237877-1 2017 Osimertinib (OSI), also known as AZD9291, is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has been approved for the treatment of non-small cell lung cancer (NSCLC) patients harboring EGFR T790M mutation. osimertinib 33-40 epidermal growth factor receptor Homo sapiens 228-232 28061471-1 2017 AZD9291, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), benefits patients with T790M mutant non-small-cell lung cancer who fail treatment with first-generation EGFR TKIs. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 28-60 28061471-1 2017 AZD9291, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), benefits patients with T790M mutant non-small-cell lung cancer who fail treatment with first-generation EGFR TKIs. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 62-66 28061471-1 2017 AZD9291, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), benefits patients with T790M mutant non-small-cell lung cancer who fail treatment with first-generation EGFR TKIs. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 205-209 28061471-3 2017 We reported an advanced lung adenocarcinoma female with EGFR exon19 deletion treated on AZD9291 after failure of erlotinib and chemotherapy. osimertinib 88-95 epidermal growth factor receptor Homo sapiens 56-60 28577957-1 2017 OBJECTIVES: Reliable epidermal growth factor receptor (EGFR) mutation testing techniques are required to identify eligible patients with EGFR mutation/T790M positive advanced non-small cell lung cancer (NSCLC), for treatment with osimertinib (AZD9291), an oral, potent, irreversible EGFR tyrosine kinase inhibitor (TKI) selective for EGFR-TKI-sensitizing and T790M resistance mutations over wild-type EGFR. osimertinib 243-250 epidermal growth factor receptor Homo sapiens 21-53 28577957-1 2017 OBJECTIVES: Reliable epidermal growth factor receptor (EGFR) mutation testing techniques are required to identify eligible patients with EGFR mutation/T790M positive advanced non-small cell lung cancer (NSCLC), for treatment with osimertinib (AZD9291), an oral, potent, irreversible EGFR tyrosine kinase inhibitor (TKI) selective for EGFR-TKI-sensitizing and T790M resistance mutations over wild-type EGFR. osimertinib 243-250 epidermal growth factor receptor Homo sapiens 55-59 28577957-1 2017 OBJECTIVES: Reliable epidermal growth factor receptor (EGFR) mutation testing techniques are required to identify eligible patients with EGFR mutation/T790M positive advanced non-small cell lung cancer (NSCLC), for treatment with osimertinib (AZD9291), an oral, potent, irreversible EGFR tyrosine kinase inhibitor (TKI) selective for EGFR-TKI-sensitizing and T790M resistance mutations over wild-type EGFR. osimertinib 243-250 epidermal growth factor receptor Homo sapiens 137-141 28577957-1 2017 OBJECTIVES: Reliable epidermal growth factor receptor (EGFR) mutation testing techniques are required to identify eligible patients with EGFR mutation/T790M positive advanced non-small cell lung cancer (NSCLC), for treatment with osimertinib (AZD9291), an oral, potent, irreversible EGFR tyrosine kinase inhibitor (TKI) selective for EGFR-TKI-sensitizing and T790M resistance mutations over wild-type EGFR. osimertinib 243-250 epidermal growth factor receptor Homo sapiens 137-141 28577957-1 2017 OBJECTIVES: Reliable epidermal growth factor receptor (EGFR) mutation testing techniques are required to identify eligible patients with EGFR mutation/T790M positive advanced non-small cell lung cancer (NSCLC), for treatment with osimertinib (AZD9291), an oral, potent, irreversible EGFR tyrosine kinase inhibitor (TKI) selective for EGFR-TKI-sensitizing and T790M resistance mutations over wild-type EGFR. osimertinib 243-250 epidermal growth factor receptor Homo sapiens 137-141 28577957-1 2017 OBJECTIVES: Reliable epidermal growth factor receptor (EGFR) mutation testing techniques are required to identify eligible patients with EGFR mutation/T790M positive advanced non-small cell lung cancer (NSCLC), for treatment with osimertinib (AZD9291), an oral, potent, irreversible EGFR tyrosine kinase inhibitor (TKI) selective for EGFR-TKI-sensitizing and T790M resistance mutations over wild-type EGFR. osimertinib 243-250 epidermal growth factor receptor Homo sapiens 137-141 27923714-1 2017 INTRODUCTION: AZD9291 (osimertinib) is designed for acquired T790M mutation after first- and second-generation EGFR) tyrosine kinase inhibitors have been used. osimertinib 14-21 epidermal growth factor receptor Homo sapiens 111-115 27861144-3 2016 Osimertinib (AZD9291) is a novel EGFR tyrosine kinase inhibitor (TKI) that is potent and selective for sensitising (EGFRm) and T790M resistance mutations. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 33-37 27840244-1 2017 The third-generation tyrosine kinase inhibitors (TKI), AZD9291 (osimertinib) and CO-1686 (rociletinib) of epidermal growth factor receptor (EGFR) are highly active against T790M positive non-small cell lung cancer (NSCLC). osimertinib 55-62 epidermal growth factor receptor Homo sapiens 140-144 28029074-7 2017 In this review, we discuss the molecular heterogeneity of EGFR and provide rational preclinical and clinical guidelines for testing AZD9291, a third generation, irreversible EGFR-TKI with both a high affinity for EGFRvIII and excellent brain penetration. osimertinib 132-139 epidermal growth factor receptor Homo sapiens 174-178 27885838-2 2017 Osimertinib (AZD9291) has been developed as 3rd generation EGFR-TKI with activities against sensitizing mutations and T790 M resistance mutation, which account for about 50% of the mechanisms of acquired resistance to 1st or 2nd generation EGFR-TKIs. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 59-63 27885838-2 2017 Osimertinib (AZD9291) has been developed as 3rd generation EGFR-TKI with activities against sensitizing mutations and T790 M resistance mutation, which account for about 50% of the mechanisms of acquired resistance to 1st or 2nd generation EGFR-TKIs. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 240-244 27641462-2 2016 Osimertinib (AZD9291, Tagrisso ) is a third-generation, irreversible EGFR TKI, active in case of T790M mutation. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 69-73 27835594-1 2016 Osimertinib (OSI, also known as AZD9291) is the newest FDA-approved epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutation. osimertinib 32-39 epidermal growth factor receptor Homo sapiens 68-100 27835594-1 2016 Osimertinib (OSI, also known as AZD9291) is the newest FDA-approved epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutation. osimertinib 32-39 epidermal growth factor receptor Homo sapiens 102-106 27835594-1 2016 Osimertinib (OSI, also known as AZD9291) is the newest FDA-approved epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutation. osimertinib 32-39 epidermal growth factor receptor Homo sapiens 187-191 27770386-4 2016 AZD9291 (osimertinib; Tagrisso) is the first and only FDA approved third-generation EGFR TKI for T790M-positive advanced NSCLC patients. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 84-88 27770386-7 2016 To overcome the acquired resistance to AZD9291, EAI045 was discovered and recently reported to be an allosteric EGFR inhibitor that overcomes T790M- and C797S-mediated resistance. osimertinib 39-46 epidermal growth factor receptor Homo sapiens 112-116 27751847-1 2016 BACKGROUND: Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR Thr790Met resistance mutation. osimertinib 25-32 epidermal growth factor receptor Homo sapiens 67-71 27751847-1 2016 BACKGROUND: Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR Thr790Met resistance mutation. osimertinib 25-32 epidermal growth factor receptor Homo sapiens 112-116 27751847-1 2016 BACKGROUND: Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR Thr790Met resistance mutation. osimertinib 25-32 epidermal growth factor receptor Homo sapiens 112-116 27612423-8 2016 Third generation EGFR kinase inhibitor (AZD9291) inhibits the growth of L858R/T790M-EGFR driven cells and also induces EGFR degradation. osimertinib 40-47 epidermal growth factor receptor Homo sapiens 17-21 27612423-8 2016 Third generation EGFR kinase inhibitor (AZD9291) inhibits the growth of L858R/T790M-EGFR driven cells and also induces EGFR degradation. osimertinib 40-47 epidermal growth factor receptor Homo sapiens 84-88 27612423-8 2016 Third generation EGFR kinase inhibitor (AZD9291) inhibits the growth of L858R/T790M-EGFR driven cells and also induces EGFR degradation. osimertinib 40-47 epidermal growth factor receptor Homo sapiens 84-88 27257132-0 2016 L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC. osimertinib 58-65 epidermal growth factor receptor Homo sapiens 69-73 27450722-1 2016 The 3rd generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs; e.g., AZD9291), which selectively and irreversibly inhibit EGFR activating and T790M mutants, represent very promising therapeutic options for patients with non-small cell lung cancer (NSCLC) that has become resistant to 1st generation EGFR-TKIs due to T790M mutation. osimertinib 97-104 epidermal growth factor receptor Homo sapiens 80-84 27450722-1 2016 The 3rd generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs; e.g., AZD9291), which selectively and irreversibly inhibit EGFR activating and T790M mutants, represent very promising therapeutic options for patients with non-small cell lung cancer (NSCLC) that has become resistant to 1st generation EGFR-TKIs due to T790M mutation. osimertinib 97-104 epidermal growth factor receptor Homo sapiens 150-154 27450722-1 2016 The 3rd generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs; e.g., AZD9291), which selectively and irreversibly inhibit EGFR activating and T790M mutants, represent very promising therapeutic options for patients with non-small cell lung cancer (NSCLC) that has become resistant to 1st generation EGFR-TKIs due to T790M mutation. osimertinib 97-104 epidermal growth factor receptor Homo sapiens 150-154 27450722-4 2016 The current study has demonstrated that Met amplification and hyperactivation is a resistance mechanism to both 1st and 3rd generation EGFR-TKIs since both erlotinib- and AZD9291-resistant HCC827 cell lines possessed amplified Met gene and hyperactivated Met, and were cross-resistant to AZD9291 or erlotinib. osimertinib 171-178 epidermal growth factor receptor Homo sapiens 135-139 27450722-4 2016 The current study has demonstrated that Met amplification and hyperactivation is a resistance mechanism to both 1st and 3rd generation EGFR-TKIs since both erlotinib- and AZD9291-resistant HCC827 cell lines possessed amplified Met gene and hyperactivated Met, and were cross-resistant to AZD9291 or erlotinib. osimertinib 288-295 epidermal growth factor receptor Homo sapiens 135-139 27450722-6 2016 Hence, we suggest that Met inhibition is also an effective strategy to overcome resistance of certain EGFR-mutated NSCLCs with Met amplification to AZD9291, warranting the further clinical validation of our findings. osimertinib 148-155 epidermal growth factor receptor Homo sapiens 102-106 27252416-1 2016 PURPOSE: To identify novel mechanisms of resistance to third-generation EGFR inhibitors in patients with lung adenocarcinoma that progressed under therapy with either AZD9291 or rociletinib (CO-1686). osimertinib 167-174 epidermal growth factor receptor Homo sapiens 72-76 27649127-0 2016 Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 42-46 27469903-0 2016 Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma. osimertinib 103-110 epidermal growth factor receptor Homo sapiens 75-79 27177916-4 2016 Osimertinib (AZD9291) is a novel mono-anilino-pyrimidine third-generation EGFR TKI targeting both sensitizing and T790M EGFR-mutation which showed promising results in T790M-positive NSCLC. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 74-78 27660466-3 2016 Osimertinib (AZD9291, Tagrisso ), an oral, third-generation EGFR TKI, has been designed to target the EGFR T790M mutation, while sparing wild-type EGFR. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 60-64 27660466-3 2016 Osimertinib (AZD9291, Tagrisso ), an oral, third-generation EGFR TKI, has been designed to target the EGFR T790M mutation, while sparing wild-type EGFR. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 102-106 27660466-3 2016 Osimertinib (AZD9291, Tagrisso ), an oral, third-generation EGFR TKI, has been designed to target the EGFR T790M mutation, while sparing wild-type EGFR. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 102-106 27177916-4 2016 Osimertinib (AZD9291) is a novel mono-anilino-pyrimidine third-generation EGFR TKI targeting both sensitizing and T790M EGFR-mutation which showed promising results in T790M-positive NSCLC. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 120-124 27044261-0 2016 AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 68-72 27044261-3 2016 Although AZD9291 is selective for both T790 M and activating EGFR mutations over wild-type EGFR, it is highly active when T790 M is present, especially EGFR(L858R/T790M), and modestly active when T790 M is absent. osimertinib 9-16 epidermal growth factor receptor Homo sapiens 61-65 27044261-3 2016 Although AZD9291 is selective for both T790 M and activating EGFR mutations over wild-type EGFR, it is highly active when T790 M is present, especially EGFR(L858R/T790M), and modestly active when T790 M is absent. osimertinib 9-16 epidermal growth factor receptor Homo sapiens 91-95 27044261-3 2016 Although AZD9291 is selective for both T790 M and activating EGFR mutations over wild-type EGFR, it is highly active when T790 M is present, especially EGFR(L858R/T790M), and modestly active when T790 M is absent. osimertinib 9-16 epidermal growth factor receptor Homo sapiens 91-95 27044261-4 2016 The aim of this study was to elucidate the underlying mechanism of the high sensitivity of NSCLC cells harboring EGFR(L858R/T790M) to AZD9291. osimertinib 134-141 epidermal growth factor receptor Homo sapiens 113-117 27044261-5 2016 In H1975 cells harboring EGFR(L858R/T790M), AZD9291 potently inhibited cellular growth and EGFR signaling pathways together with depletion of mutant EGFR protein. osimertinib 44-51 epidermal growth factor receptor Homo sapiens 25-29 27044261-5 2016 In H1975 cells harboring EGFR(L858R/T790M), AZD9291 potently inhibited cellular growth and EGFR signaling pathways together with depletion of mutant EGFR protein. osimertinib 44-51 epidermal growth factor receptor Homo sapiens 91-95 27044261-5 2016 In H1975 cells harboring EGFR(L858R/T790M), AZD9291 potently inhibited cellular growth and EGFR signaling pathways together with depletion of mutant EGFR protein. osimertinib 44-51 epidermal growth factor receptor Homo sapiens 91-95 27044261-10 2016 Taken together, our results provide a potential mechanism for the sensitivity of EGFR(L858R/T790M) cells to AZD9291 and suggest that AZD9291 may be effective in cases of T790 M-positive EGFR resistance. osimertinib 133-140 epidermal growth factor receptor Homo sapiens 81-85 27044261-6 2016 AZD9291-induced depletion of EGFR(L858R/T790M) protein was abrogated through inhibition of the proteasome with MG132. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 29-33 27044261-9 2016 Moreover, oral administration of AZD9291 as a single agent induced tumor regression in vivo in a H1975 tumor xenograft model and reduced EGFR(L858R/T790M) protein levels in xenograft tumors. osimertinib 33-40 epidermal growth factor receptor Homo sapiens 137-141 27044261-10 2016 Taken together, our results provide a potential mechanism for the sensitivity of EGFR(L858R/T790M) cells to AZD9291 and suggest that AZD9291 may be effective in cases of T790 M-positive EGFR resistance. osimertinib 108-115 epidermal growth factor receptor Homo sapiens 81-85 27393503-0 2016 Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment. osimertinib 87-94 epidermal growth factor receptor Homo sapiens 20-24 27393503-1 2016 AZD9291, a T790M specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has demonstrated impressive response rates in tumours harbouring the EGFR T790M resistance mutation. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 26-58 27393503-1 2016 AZD9291, a T790M specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has demonstrated impressive response rates in tumours harbouring the EGFR T790M resistance mutation. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 60-64 27393503-1 2016 AZD9291, a T790M specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has demonstrated impressive response rates in tumours harbouring the EGFR T790M resistance mutation. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 168-172 27393503-2 2016 Emergence of resistance to AZD9291 has been shown to occur through several different mechanisms including the development of new mutations (e.g. C797S) in the EGFR tyrosine kinase domain. osimertinib 27-34 epidermal growth factor receptor Homo sapiens 159-163 27393503-6 2016 In the first patient, both EGFR T790M and L858R became undetectable in the plasma within 1 month after treatment with AZD9291. osimertinib 118-125 epidermal growth factor receptor Homo sapiens 27-31 27448564-3 2016 AZD9291 (osimertinib, tagrisso) has been approved for treatment of the metastatic EGFR T790M mutation-positive non-small cell lung cancer. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 82-86 26902828-1 2016 PURPOSE: Osimertinib (AZD9291) 80 mg once daily is approved by the US FDA for the treatment of patients with metastatic EGFR T790M-positive NSCLC whose disease has previously progressed on EGFR-TKI therapy. osimertinib 22-29 epidermal growth factor receptor Homo sapiens 120-124 27071706-6 2016 Osimertinib (AZD9291, TAGRISSO) was recently approved by FDA for metastatic EGFR T790M mutation-positive NSCLC. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 76-80 26845230-1 2016 Mutant selective epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as rociletinib and AZD9291, are effective for tumors with T790M secondary mutation that become refractory to first-generation EGFR-TKI. osimertinib 114-121 epidermal growth factor receptor Homo sapiens 78-82 26845230-1 2016 Mutant selective epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as rociletinib and AZD9291, are effective for tumors with T790M secondary mutation that become refractory to first-generation EGFR-TKI. osimertinib 114-121 epidermal growth factor receptor Homo sapiens 221-225 26902828-1 2016 PURPOSE: Osimertinib (AZD9291) 80 mg once daily is approved by the US FDA for the treatment of patients with metastatic EGFR T790M-positive NSCLC whose disease has previously progressed on EGFR-TKI therapy. osimertinib 22-29 epidermal growth factor receptor Homo sapiens 189-193 26958497-0 2016 AZD9291 in TKI EGFR resistance in non-small cell lung cancer and the new concept of phase I trials. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 15-19 26749488-2 2016 Several third-generation EGFR-mutant selective TKI, such as AZD9291 (AstraZeneca), Rociletinib (Clovis), or HM61713 (Hanmi) have been developed. osimertinib 60-67 epidermal growth factor receptor Homo sapiens 25-29 26729184-1 2016 Osimertinib (Tagrisso( ), AZD9291) is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by AstraZeneca for the treatment of advanced non-small cell lung cancer (NSCLC). osimertinib 26-33 epidermal growth factor receptor Homo sapiens 124-128 26958497-8 2016 To date, however, only AZD9291, an oral, potent, irreversible EGFR TKI that is selective for EGFR tyrosine kinase inhibitor-sensitizing mutations and the T790M resistance mutation has shown to be not only highly active but also fairly tolerable in a large cohort of patients. osimertinib 23-30 epidermal growth factor receptor Homo sapiens 62-66 26958497-8 2016 To date, however, only AZD9291, an oral, potent, irreversible EGFR TKI that is selective for EGFR tyrosine kinase inhibitor-sensitizing mutations and the T790M resistance mutation has shown to be not only highly active but also fairly tolerable in a large cohort of patients. osimertinib 23-30 epidermal growth factor receptor Homo sapiens 93-97 26958499-0 2016 AZD9291 in epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 11-43 26958499-3 2016 AZD9291 is a third generation irreversible EGFR TKI with activity against the activating EGFR mutation, the T790M acquired resistance mutation, and relative sparing of the wild-type EGFR. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 43-47 26958499-3 2016 AZD9291 is a third generation irreversible EGFR TKI with activity against the activating EGFR mutation, the T790M acquired resistance mutation, and relative sparing of the wild-type EGFR. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 89-93 26958499-3 2016 AZD9291 is a third generation irreversible EGFR TKI with activity against the activating EGFR mutation, the T790M acquired resistance mutation, and relative sparing of the wild-type EGFR. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 89-93 26958499-4 2016 AZD9291 was investigated in a phase I trial with expansion cohorts in patients with disease progression after EGFR TKI. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 110-114 26716903-0 2016 High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells. osimertinib 49-56 epidermal growth factor receptor Homo sapiens 34-38 26716903-0 2016 High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells. osimertinib 49-56 epidermal growth factor receptor Homo sapiens 103-107 26716903-6 2016 Moreover, treatment with a higher dose of AZD9291, also associated with inhibited phosphorylation of EGFR downstream molecule S6, regressed LMC refractory to the aforementioned EGFR-TKI treatments. osimertinib 42-49 epidermal growth factor receptor Homo sapiens 101-105 26716903-6 2016 Moreover, treatment with a higher dose of AZD9291, also associated with inhibited phosphorylation of EGFR downstream molecule S6, regressed LMC refractory to the aforementioned EGFR-TKI treatments. osimertinib 42-49 epidermal growth factor receptor Homo sapiens 177-181 26716903-7 2016 These observations suggest that the third generation EGFR-TKI AZD9291 may be an effective treatment for first or second generation EGFR-TKI resistant LMC caused by EGFR-mutant lung cancer. osimertinib 62-69 epidermal growth factor receptor Homo sapiens 53-57 26716903-7 2016 These observations suggest that the third generation EGFR-TKI AZD9291 may be an effective treatment for first or second generation EGFR-TKI resistant LMC caused by EGFR-mutant lung cancer. osimertinib 62-69 epidermal growth factor receptor Homo sapiens 131-135 26716903-7 2016 These observations suggest that the third generation EGFR-TKI AZD9291 may be an effective treatment for first or second generation EGFR-TKI resistant LMC caused by EGFR-mutant lung cancer. osimertinib 62-69 epidermal growth factor receptor Homo sapiens 131-135 26744526-7 2016 ALW-II-41-27 was also effective in decreasing viability of cells with acquired resistance to the third-generation EGFR TKI AZD9291. osimertinib 123-130 epidermal growth factor receptor Homo sapiens 114-118 26775573-5 2016 Third generation EGFR inhibitors (rociletinib, AZD9291) are effective for patients who develop a resistance mutation such as T790M resistance mutation; they obtained temporary authorization for use in France in 2015. osimertinib 47-54 epidermal growth factor receptor Homo sapiens 17-21 26798593-6 2015 Two new studies have shown that two covalent pyrimidine inhibitors-AZD9291 and rociletinib of EGFR-T790M (i.e., third generation EGFR TKIs) shown remarkable clinical activity in patients with acquired resistance to erlotinib, gefitinib and afatinib when the tumor carries EGFR-T790M in conjunction with an activating mutation. osimertinib 67-74 epidermal growth factor receptor Homo sapiens 94-98 26762749-0 2016 Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment. osimertinib 90-97 epidermal growth factor receptor Homo sapiens 56-60 26612314-0 2016 Rapid clearance of circulating tumor DNA during treatment with AZD9291 of a lung cancer patient presenting the resistance EGFR T790M mutation. osimertinib 63-70 epidermal growth factor receptor Homo sapiens 122-126 27486808-1 2016 BACKGROUND: Osimertinib (AZD9291, Tagrisso) is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). osimertinib 25-32 epidermal growth factor receptor Homo sapiens 87-119 27486808-1 2016 BACKGROUND: Osimertinib (AZD9291, Tagrisso) is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). osimertinib 25-32 epidermal growth factor receptor Homo sapiens 121-125 26522274-0 2015 Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed. osimertinib 43-50 epidermal growth factor receptor Homo sapiens 54-86 26522274-4 2015 One such agent is AstraZeneca"s "breakthrough" AZD9291 molecule that shows a 200-fold selectivity for T790M/L858R over wild type EGFR. osimertinib 47-54 epidermal growth factor receptor Homo sapiens 129-133 26522274-5 2015 Our X-ray crystal structure reveals the binding mode of AZD9291 to the kinase domain of wild type EGFR. osimertinib 56-63 epidermal growth factor receptor Homo sapiens 98-102 26494259-0 2015 EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. osimertinib 151-158 epidermal growth factor receptor Homo sapiens 0-4 26494259-3 2015 Plasma samples were collected from patients entering the ongoing AURA trial (NCT01802632), investigating the safety, tolerability, and efficacy of AZD9291 in patients with EGFR-sensitizing mutation-positive NSCLC. osimertinib 147-154 epidermal growth factor receptor Homo sapiens 172-176 26798593-6 2015 Two new studies have shown that two covalent pyrimidine inhibitors-AZD9291 and rociletinib of EGFR-T790M (i.e., third generation EGFR TKIs) shown remarkable clinical activity in patients with acquired resistance to erlotinib, gefitinib and afatinib when the tumor carries EGFR-T790M in conjunction with an activating mutation. osimertinib 67-74 epidermal growth factor receptor Homo sapiens 129-133 26798593-6 2015 Two new studies have shown that two covalent pyrimidine inhibitors-AZD9291 and rociletinib of EGFR-T790M (i.e., third generation EGFR TKIs) shown remarkable clinical activity in patients with acquired resistance to erlotinib, gefitinib and afatinib when the tumor carries EGFR-T790M in conjunction with an activating mutation. osimertinib 67-74 epidermal growth factor receptor Homo sapiens 129-133 26450446-0 2015 AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 11-15 26450446-3 2015 AZD9291 is an oral, irreversible, mutant-selective EGF receptor (EGFR) tyrosine kinase inhibitor (TKI) developed to have potency against EGFR mutations, including T790M mutation, while sparing wild-type EGFR. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 51-63 26450446-3 2015 AZD9291 is an oral, irreversible, mutant-selective EGF receptor (EGFR) tyrosine kinase inhibitor (TKI) developed to have potency against EGFR mutations, including T790M mutation, while sparing wild-type EGFR. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 65-69 26450446-3 2015 AZD9291 is an oral, irreversible, mutant-selective EGF receptor (EGFR) tyrosine kinase inhibitor (TKI) developed to have potency against EGFR mutations, including T790M mutation, while sparing wild-type EGFR. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 137-141 26450446-3 2015 AZD9291 is an oral, irreversible, mutant-selective EGF receptor (EGFR) tyrosine kinase inhibitor (TKI) developed to have potency against EGFR mutations, including T790M mutation, while sparing wild-type EGFR. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 137-141 26450446-4 2015 A Phase I trial of AZD9291 in EGFR-mutant NSCLC patients, demonstrated high activity, essentially among T790M-mutant tumors, with a manageable tolerability profile. osimertinib 19-26 epidermal growth factor receptor Homo sapiens 30-34 26450446-5 2015 Ongoing Phase III trials are evaluating AZD9291 in EGFR-mutant patients as first-line treatment compared with erlotinib and gefitinib; and as second-line treatment compared with chemotherapy after progression on EGFR TKI in T790M-mutant tumors. osimertinib 40-47 epidermal growth factor receptor Homo sapiens 51-55 26629426-5 2015 Two EGFR TKIs targeting T790M, AZD9291 and rociletinib, are new active treatment options for NSCLC but differ in adverse effect profiles. osimertinib 31-38 epidermal growth factor receptor Homo sapiens 4-8 26269204-0 2015 EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. osimertinib 54-61 epidermal growth factor receptor Homo sapiens 0-4 26269204-0 2015 EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. osimertinib 54-61 epidermal growth factor receptor Homo sapiens 65-69 26269204-1 2015 BACKGROUND: AZD9291 is an oral, irreversible, mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKI), which specifically targets both sensitizing and resistant T790M mutations. osimertinib 12-19 epidermal growth factor receptor Homo sapiens 63-95 26269204-1 2015 BACKGROUND: AZD9291 is an oral, irreversible, mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKI), which specifically targets both sensitizing and resistant T790M mutations. osimertinib 12-19 epidermal growth factor receptor Homo sapiens 97-101 26269204-1 2015 BACKGROUND: AZD9291 is an oral, irreversible, mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKI), which specifically targets both sensitizing and resistant T790M mutations. osimertinib 12-19 epidermal growth factor receptor Homo sapiens 131-135 26269204-4 2015 Mutations at the EGFR C797 codon, located within the kinase-binding site, were very recently reported to be a potential mechanism of resistance to AZD9291 in T790M-positive patients. osimertinib 147-154 epidermal growth factor receptor Homo sapiens 17-21 26370354-8 2015 Third-generation EGFR-mutant-selective TKIs, such as AZD9291 or rociletininb, which target Thr790Met-mutant tumours, the most common mechanism of EGFR TKI resistance, have entered clinical trials, and exciting, albeit preliminary, efficacy data have been reported. osimertinib 53-60 epidermal growth factor receptor Homo sapiens 17-21 26473643-0 2015 Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor. osimertinib 37-44 epidermal growth factor receptor Homo sapiens 81-85 26473643-1 2015 INTRODUCTION: AZD9291, a third-generation and mutation-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is active against patients with EGFR-mutant non-small-cell lung cancer (NSCLC) who failed prior treatment with EGFR TKIs. osimertinib 14-21 epidermal growth factor receptor Homo sapiens 65-97 26473643-1 2015 INTRODUCTION: AZD9291, a third-generation and mutation-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is active against patients with EGFR-mutant non-small-cell lung cancer (NSCLC) who failed prior treatment with EGFR TKIs. osimertinib 14-21 epidermal growth factor receptor Homo sapiens 99-103 26473643-1 2015 INTRODUCTION: AZD9291, a third-generation and mutation-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is active against patients with EGFR-mutant non-small-cell lung cancer (NSCLC) who failed prior treatment with EGFR TKIs. osimertinib 14-21 epidermal growth factor receptor Homo sapiens 170-174 26473643-1 2015 INTRODUCTION: AZD9291, a third-generation and mutation-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is active against patients with EGFR-mutant non-small-cell lung cancer (NSCLC) who failed prior treatment with EGFR TKIs. osimertinib 14-21 epidermal growth factor receptor Homo sapiens 170-174 26473643-3 2015 In this study, we identified the mechanisms of acquired resistance to AZD9291 in EGFR-mutant NSCLC. osimertinib 70-77 epidermal growth factor receptor Homo sapiens 81-85 26473643-4 2015 METHODS: Four NSCLC patients with both an EGFR exon 19 deletion and the EGFR mutation after developing acquired resistance to first-generation EGFR TKIs received AZD9291 at doses of 20 to 80 mg/day in a phase I trial (NCT01802632). osimertinib 162-169 epidermal growth factor receptor Homo sapiens 72-76 26473643-4 2015 METHODS: Four NSCLC patients with both an EGFR exon 19 deletion and the EGFR mutation after developing acquired resistance to first-generation EGFR TKIs received AZD9291 at doses of 20 to 80 mg/day in a phase I trial (NCT01802632). osimertinib 162-169 epidermal growth factor receptor Homo sapiens 72-76 26473643-8 2015 EGFR-mutant clones depopulated AZD9291-resistant tumors to below 1% (baseline, 14%-36%) in three patients with progression: one with the loss of EGFR-double mutant clones and two accompanied by transformation to small-cell carcinoma and focal fibroblast growth factor receptor 1 (FGFR1) amplification, respectively. osimertinib 31-38 epidermal growth factor receptor Homo sapiens 0-4 26473643-9 2015 EGFR-mutant clones remained and the EGFR ligand was overexpressed in one patient with focal progression to AZD9291. osimertinib 107-114 epidermal growth factor receptor Homo sapiens 36-40 26473643-10 2015 CONCLUSION: Acquired resistance mechanisms of AZD9291 in patients with EGFR-mutant NSCLC who failed treatment with first-generation EGFR TKIs include the loss of EGFR-mutant clones plus alternative pathway activation or histologic transformation and EGFR ligand-dependent activation. osimertinib 46-53 epidermal growth factor receptor Homo sapiens 71-75 26473643-10 2015 CONCLUSION: Acquired resistance mechanisms of AZD9291 in patients with EGFR-mutant NSCLC who failed treatment with first-generation EGFR TKIs include the loss of EGFR-mutant clones plus alternative pathway activation or histologic transformation and EGFR ligand-dependent activation. osimertinib 46-53 epidermal growth factor receptor Homo sapiens 132-136 26473643-10 2015 CONCLUSION: Acquired resistance mechanisms of AZD9291 in patients with EGFR-mutant NSCLC who failed treatment with first-generation EGFR TKIs include the loss of EGFR-mutant clones plus alternative pathway activation or histologic transformation and EGFR ligand-dependent activation. osimertinib 46-53 epidermal growth factor receptor Homo sapiens 132-136 26473643-10 2015 CONCLUSION: Acquired resistance mechanisms of AZD9291 in patients with EGFR-mutant NSCLC who failed treatment with first-generation EGFR TKIs include the loss of EGFR-mutant clones plus alternative pathway activation or histologic transformation and EGFR ligand-dependent activation. osimertinib 46-53 epidermal growth factor receptor Homo sapiens 132-136 25948633-1 2015 PURPOSE: Mutant selective irreversible pyrimidine-based EGFR kinase inhibitors, including WZ4002, CO-1686, and AZD9291, are effective in preclinical models and in lung cancer patients harboring the EGFR T790M gefitinib/erlotinib resistance mutation. osimertinib 111-118 epidermal growth factor receptor Homo sapiens 56-60 25948633-1 2015 PURPOSE: Mutant selective irreversible pyrimidine-based EGFR kinase inhibitors, including WZ4002, CO-1686, and AZD9291, are effective in preclinical models and in lung cancer patients harboring the EGFR T790M gefitinib/erlotinib resistance mutation. osimertinib 111-118 epidermal growth factor receptor Homo sapiens 198-202 25948633-7 2015 EGFR L718Q, L844V, and C797S cause resistance to both WZ4002 and CO-1686 while, in contrast, only EGFR C797S leads to AZD9291 resistance. osimertinib 118-125 epidermal growth factor receptor Homo sapiens 0-4 25948633-7 2015 EGFR L718Q, L844V, and C797S cause resistance to both WZ4002 and CO-1686 while, in contrast, only EGFR C797S leads to AZD9291 resistance. osimertinib 118-125 epidermal growth factor receptor Homo sapiens 98-102 26370354-8 2015 Third-generation EGFR-mutant-selective TKIs, such as AZD9291 or rociletininb, which target Thr790Met-mutant tumours, the most common mechanism of EGFR TKI resistance, have entered clinical trials, and exciting, albeit preliminary, efficacy data have been reported. osimertinib 53-60 epidermal growth factor receptor Homo sapiens 146-150 25870145-0 2015 Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. osimertinib 59-66 epidermal growth factor receptor Homo sapiens 44-48 25870145-3 2015 We describe the detection of heterogeneous mechanisms of resistance within populations of EGFR-mutant cells (PC9 and/or NCI-H1975) with acquired resistance to current and newly developed EGFR tyrosine kinase inhibitors, including AZD9291. osimertinib 230-237 epidermal growth factor receptor Homo sapiens 90-94 25939061-0 2015 Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. osimertinib 52-59 epidermal growth factor receptor Homo sapiens 9-13 25939061-0 2015 Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. osimertinib 52-59 epidermal growth factor receptor Homo sapiens 100-104 25939061-1 2015 Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291. osimertinib 212-219 epidermal growth factor receptor Homo sapiens 140-172 25939061-1 2015 Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291. osimertinib 212-219 epidermal growth factor receptor Homo sapiens 174-178 25939061-2 2015 We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291. osimertinib 209-216 epidermal growth factor receptor Homo sapiens 154-158 25923549-0 2015 AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 11-15 25979928-6 2015 More recently, drugs that target EGFR T790M (e.g., rociletinib, AZD9291, and others) have entered clinical trials, with impressive results observed in phase I clinical trials. osimertinib 64-71 epidermal growth factor receptor Homo sapiens 33-37 25923549-2 2015 In preclinical models, the EGFR inhibitor AZD9291 has been shown to be effective against both EGFR tyrosine kinase inhibitor-sensitizing and T790M resistance mutations. osimertinib 42-49 epidermal growth factor receptor Homo sapiens 27-31 25923549-2 2015 In preclinical models, the EGFR inhibitor AZD9291 has been shown to be effective against both EGFR tyrosine kinase inhibitor-sensitizing and T790M resistance mutations. osimertinib 42-49 epidermal growth factor receptor Homo sapiens 94-98 25923549-3 2015 METHODS: We administered AZD9291 at doses of 20 to 240 mg once daily in patients with advanced lung cancer who had radiologically documented disease progression after previous treatment with EGFR tyrosine kinase inhibitors. osimertinib 25-32 epidermal growth factor receptor Homo sapiens 191-195 25923549-15 2015 CONCLUSIONS: AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 77-81 25923549-15 2015 CONCLUSIONS: AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 155-159 25936890-9 2015 EGFR inhibitors specifically targeting T790M resistance mutations (AZD9291, CO-1686, HM61713) are in the early stages of development. osimertinib 67-74 epidermal growth factor receptor Homo sapiens 0-4 25806323-0 2014 Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer. osimertinib 57-64 epidermal growth factor receptor Homo sapiens 42-46 25611025-7 2015 Third-generation EGFR-TKIs, AZD9291, CO-1686, and HM61713, inhibit both EGFR activating and resistance mutations, while sparing wild-type EGFR. osimertinib 28-35 epidermal growth factor receptor Homo sapiens 17-21 25611025-7 2015 Third-generation EGFR-TKIs, AZD9291, CO-1686, and HM61713, inhibit both EGFR activating and resistance mutations, while sparing wild-type EGFR. osimertinib 28-35 epidermal growth factor receptor Homo sapiens 72-76 25611025-7 2015 Third-generation EGFR-TKIs, AZD9291, CO-1686, and HM61713, inhibit both EGFR activating and resistance mutations, while sparing wild-type EGFR. osimertinib 28-35 epidermal growth factor receptor Homo sapiens 72-76 25477325-6 2015 Using a panel of erlotinib/afatinib-resistant cells, including a novel patient-derived cell line (VP-2), we found that AZD9291 was more potent than A+C at inhibiting cell growth and EGFR signaling in this setting. osimertinib 119-126 epidermal growth factor receptor Homo sapiens 182-186 25806323-0 2014 Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer. osimertinib 57-64 epidermal growth factor receptor Homo sapiens 82-86 25806323-6 2014 AZD9291, as a mono-anilino-pyrimidine compound, is a novel, irreversible EGFR-TKI, has proved to be more effective against both EGFR-TKI sensitizing and resistance T790M mutations in preclinical models. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 73-77 25806323-6 2014 AZD9291, as a mono-anilino-pyrimidine compound, is a novel, irreversible EGFR-TKI, has proved to be more effective against both EGFR-TKI sensitizing and resistance T790M mutations in preclinical models. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 128-132 25806323-7 2014 This phase I clinical study showed that AZD9291 has robust efficacy and is well tolerated in EGFR mutant NSCLC patients with acquired resistance to EGFR-TKIs. osimertinib 40-47 epidermal growth factor receptor Homo sapiens 93-97 25806323-7 2014 This phase I clinical study showed that AZD9291 has robust efficacy and is well tolerated in EGFR mutant NSCLC patients with acquired resistance to EGFR-TKIs. osimertinib 40-47 epidermal growth factor receptor Homo sapiens 148-152 25296354-9 2014 Ongoing preclinical efforts for treating resistance have started to translate into patient care (including clinical trials of the covalent EGFR-T790M TKIs AZD9291 and CO-1686) and hold promise to further boost the median survival of patients with EGFR mutated NSCLC. osimertinib 155-162 epidermal growth factor receptor Homo sapiens 139-143 25296354-9 2014 Ongoing preclinical efforts for treating resistance have started to translate into patient care (including clinical trials of the covalent EGFR-T790M TKIs AZD9291 and CO-1686) and hold promise to further boost the median survival of patients with EGFR mutated NSCLC. osimertinib 155-162 epidermal growth factor receptor Homo sapiens 247-251 24893891-0 2014 AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 25-29 25271963-0 2014 Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. osimertinib 52-59 epidermal growth factor receptor Homo sapiens 36-40 25271963-5 2014 We describe herein the evolution of an early, mutant selective lead to the clinical candidate AZD9291, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor. osimertinib 94-101 epidermal growth factor receptor Homo sapiens 137-141 24893891-0 2014 AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 74-78 24893891-3 2014 AZD9291 is a novel oral, potent, and selective third-generation irreversible inhibitor of both EGFRm(+) sensitizing and T790M resistance mutants that spares wild-type EGFR. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 95-99 24893891-7 2014 SIGNIFICANCE: We report the development of a novel structurally distinct third-generation EGFR TKI, AZD9291, that irreversibly and selectively targets both sensitizing and resistant T790M(+) mutant EGFR while harboring less activity toward wild-type EGFR. osimertinib 100-107 epidermal growth factor receptor Homo sapiens 90-94 24893891-7 2014 SIGNIFICANCE: We report the development of a novel structurally distinct third-generation EGFR TKI, AZD9291, that irreversibly and selectively targets both sensitizing and resistant T790M(+) mutant EGFR while harboring less activity toward wild-type EGFR. osimertinib 100-107 epidermal growth factor receptor Homo sapiens 198-202 25027951-8 2014 Mutant-selective EGFR inhibitors (AZD9291, CO-1686, HM61713) that specifically target the T790M resistance mutation are in early development. osimertinib 34-41 epidermal growth factor receptor Homo sapiens 17-21 24893891-7 2014 SIGNIFICANCE: We report the development of a novel structurally distinct third-generation EGFR TKI, AZD9291, that irreversibly and selectively targets both sensitizing and resistant T790M(+) mutant EGFR while harboring less activity toward wild-type EGFR. osimertinib 100-107 epidermal growth factor receptor Homo sapiens 198-202 33971844-1 2021 BACKGROUND: Osimertinib is a third generation tyrosine kinase inhibitor (TKI) that targets the epidermal growth factor receptor (EGFR) in lung cancer. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 95-127 25841416-4 2014 This article compares and contrasts the discovery and development of gefitinib-the first EGFR tyrosine kinase inhibitor and AZD9291, an irreversible inhibitor of both sensitizing and resistant mutated EGFR. osimertinib 124-131 epidermal growth factor receptor Homo sapiens 201-205 33971844-1 2021 BACKGROUND: Osimertinib is a third generation tyrosine kinase inhibitor (TKI) that targets the epidermal growth factor receptor (EGFR) in lung cancer. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 129-133 33813328-10 2021 CONCLUSION: This is the first randomised study to investigate the efficacy and safety of the combination of osimertinib and cytotoxic chemotherapy for EGFR-mutated NSCLC. osimertinib 108-119 epidermal growth factor receptor Homo sapiens 151-155 33819860-8 2021 Osimertinib similarly increased ecto-CRT expression in association with apoptosis induction in five EGFR-mutated NSCLC cell lines. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 100-104 33819860-9 2021 Furthermore, the plasma concentration of soluble CRT in 16 NSCLC patients treated with single-agent pemetrexed or docetaxel and in nine EGFR-mutated NSCLC patients treated with osimertinib was increased after treatment onset. osimertinib 177-188 epidermal growth factor receptor Homo sapiens 136-140 33809064-2 2021 Third-generation EGFR-TKIs, such as osimertinib and rociletinib (CO-1686), was developed to target such resistance mutations. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 17-21 33819860-0 2021 Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non-small cell lung cancer. osimertinib 51-62 epidermal growth factor receptor Homo sapiens 42-46 33819860-3 2021 MATERIALS AND METHODS: We investigated the ability of seven cytotoxic chemotherapeutic agents and the third-generation EGFR-TKI osimertinib to induce translocation of the DAMP calreticulin to the cell surface in multiple NSCLC cell lines. osimertinib 128-139 epidermal growth factor receptor Homo sapiens 119-123 33816581-1 2021 Cardiac arrest occurred in an 85-year-old female administered osimertinib for advanced lung cancer expressing epidermal growth factor receptor (EGFR) mutations. osimertinib 62-73 epidermal growth factor receptor Homo sapiens 110-142 33816581-1 2021 Cardiac arrest occurred in an 85-year-old female administered osimertinib for advanced lung cancer expressing epidermal growth factor receptor (EGFR) mutations. osimertinib 62-73 epidermal growth factor receptor Homo sapiens 144-148 34544302-7 2022 RESULTS: Of the 782 patients who received first-line (1L) therapy with first-/second-generation EGFR TKIs in the cohort A, erlotinib was the most common (58%), and osimertinib was the most widely prescribed second-line (2L) therapy (52%). osimertinib 164-175 epidermal growth factor receptor Homo sapiens 96-100 33796513-9 2021 In this case, the need for intense daily radiation treatment with its associated toxicities was negated, and as such we propose that osimertinib may be a promising treatment for choroidal metastasis secondary to EGFR-mutated lung adenocarcinoma. osimertinib 133-144 epidermal growth factor receptor Homo sapiens 212-216 32798009-0 2020 Osimertinib for the Treatment of EGFR Mutation-Positive Lung Adenocarcinoma Complicated With Dermatomyositis. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 33-37 33034420-0 2020 Lung adenocarcinoma in a patient with a cis EGFR L858R-K860I doublet mutation identified using NGS-based profiling test: Negative diagnosis on initial companion test and successful treatment with osimertinib. osimertinib 196-207 epidermal growth factor receptor Homo sapiens 44-48 33034420-8 2020 The patient was then successfully treated with a third-generation EGFR-tyrosine kinase inhibitor, osimertinib. osimertinib 98-109 epidermal growth factor receptor Homo sapiens 66-70 33034420-13 2020 WHAT THIS STUDY ADDS: Osimertinib was effective in an NSCLC patient with EGFR L858R and K860I mutations. osimertinib 22-33 epidermal growth factor receptor Homo sapiens 73-77 32796633-3 2020 We report a case of an 80-year-old Japanese woman with lung adenocarcinoma harboring an EGFR-sensitizing mutation who was treated with osimertinib as the first-line treatment. osimertinib 135-146 epidermal growth factor receptor Homo sapiens 88-92 34839016-1 2022 BACKGROUND: While osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the standard treatment in patients with advanced non-small cell lung cancer (NSCLC) with sensitising EGFR and acquired T790M mutations, progression inevitably occurs. osimertinib 18-29 epidermal growth factor receptor Homo sapiens 50-82 34839016-1 2022 BACKGROUND: While osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the standard treatment in patients with advanced non-small cell lung cancer (NSCLC) with sensitising EGFR and acquired T790M mutations, progression inevitably occurs. osimertinib 18-29 epidermal growth factor receptor Homo sapiens 84-88 34839016-1 2022 BACKGROUND: While osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the standard treatment in patients with advanced non-small cell lung cancer (NSCLC) with sensitising EGFR and acquired T790M mutations, progression inevitably occurs. osimertinib 18-29 epidermal growth factor receptor Homo sapiens 226-230 34839016-3 2022 PATIENTS AND METHODS: BOOSTER is an open-label randomised phase II trial investigating the efficacy and safety of combined osimertinib 80 mg daily and bevacizumab 15 mg/kg every 3 weeks, versus osimertinib alone, in patients with EGFR-mutant advanced NSCLC and acquired T790M mutations after failure on previous EGFR TKI therapy. osimertinib 123-134 epidermal growth factor receptor Homo sapiens 230-234 34918542-8 2022 In one of the studies (called the FLAURA study), the third-generation EGFR TKI osimertinib improved overall survival (the length of time that patients survived, from first dose of treatment to death) when compared to first-generation EGFR TKIs. osimertinib 79-90 epidermal growth factor receptor Homo sapiens 70-74 34648945-11 2022 Kinase activity of the BRAF protein isolated from X12CL was inhibited by treatment with the EGFR TKIs gefitinib and osimertinib, and expression of BRAFG469V in non-EGFR-expressing NR6 cells promoted growth in low serum, which was also sensitive to EGFR TKIs. osimertinib 116-127 epidermal growth factor receptor Homo sapiens 92-96 34958168-1 2022 BACKGROUND: Osimertinib is the standard first-line treatment for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 114-146 34958168-1 2022 BACKGROUND: Osimertinib is the standard first-line treatment for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 148-152 34962076-0 2022 Combined targeting of EGFR and BRAF triggers regression of osimertinib resistance by using osimertinib and vemurafenib concurrently in a patient with heterogeneity between different lesions. osimertinib 59-70 epidermal growth factor receptor Homo sapiens 22-26 34323489-1 2022 The pyrimidine core-containing compound Osimertinib is the only epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) from the third generation that has been approved by the U.S. Food and Drug Administration to target threonine 790 methionine (T790M) resistance while sparing the wild-type epidermal growth factor receptor (WT EGFR). osimertinib 40-51 epidermal growth factor receptor Homo sapiens 124-128 34323489-1 2022 The pyrimidine core-containing compound Osimertinib is the only epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) from the third generation that has been approved by the U.S. Food and Drug Administration to target threonine 790 methionine (T790M) resistance while sparing the wild-type epidermal growth factor receptor (WT EGFR). osimertinib 40-51 epidermal growth factor receptor Homo sapiens 306-338 34323489-1 2022 The pyrimidine core-containing compound Osimertinib is the only epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) from the third generation that has been approved by the U.S. Food and Drug Administration to target threonine 790 methionine (T790M) resistance while sparing the wild-type epidermal growth factor receptor (WT EGFR). osimertinib 40-51 epidermal growth factor receptor Homo sapiens 343-347 34323489-3 2022 A tertiary cystein 797 to serine 797 (C797S) mutation in the EGFR kinase domain has hampered Osimertinib treatment in patients with advanced EGFR-mutated non-small-cell lung cancer (NSCLC). osimertinib 93-104 epidermal growth factor receptor Homo sapiens 61-65 34323489-3 2022 A tertiary cystein 797 to serine 797 (C797S) mutation in the EGFR kinase domain has hampered Osimertinib treatment in patients with advanced EGFR-mutated non-small-cell lung cancer (NSCLC). osimertinib 93-104 epidermal growth factor receptor Homo sapiens 141-145 34861243-6 2022 Notably, Dic was shown to synergistically improve the chemo-sensitivity of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)-resistant lung cancer cells to gefitinib and osimertinib. osimertinib 190-201 epidermal growth factor receptor Homo sapiens 135-139 33813328-1 2021 BACKGROUND: Osimertinib is now a standard treatment for patients with previously untreated EGFR-mutated advanced non-small cell lung cancer (NSCLC). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 91-95 33813328-3 2021 PATIENTS AND METHODS: We conducted an open-label randomised phase 2 study to evaluate osimertinib and carboplatin-pemetrexed combination in comparison with osimertinib monotherapy in EGFR mutation-positive NSCLC patients who experienced disease progression associated with the emergence of the T790M resistance mutation of EGFR during first-line EGFR-TKI therapy. osimertinib 86-97 epidermal growth factor receptor Homo sapiens 183-187 33589348-2 2021 AIMS: Multiple studies have shown conflicting results on the correlation between the EGFR T790M quantitative level and survival outcomes in osimertinib-treated patients. osimertinib 140-151 epidermal growth factor receptor Homo sapiens 85-89 32890631-0 2020 Osimertinib in CNS progressive EGFR-mutant lung cancer: Do we need to detect T790M? osimertinib 0-11 epidermal growth factor receptor Homo sapiens 31-35 34794818-3 2022 The third-generation EGFR tyrosine kinase inhibitors (TKIs) Rociletinib and Osimertinib (AZD9291) achieved remarkable clinical efficacy. osimertinib 89-96 epidermal growth factor receptor Homo sapiens 21-25 34599981-1 2022 Osimertinib, as the third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), is a first-line molecularly targeted drug for non-small cell lung cancer (NSCLC). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 70-74 34599981-6 2022 A PAR2 inhibitor facilitated osimertinib to attenuate EGFR transactivation, ERK phosphorylation, EMT and PD-L1 expression which were associated to osimertinib resistance. osimertinib 29-40 epidermal growth factor receptor Homo sapiens 54-58 34706132-1 2022 Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for lung adenocarcinoma (LUAD) harboring activating mutations, but patients ultimately develop acquired resistance. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 94-98 34921211-6 2021 Moreover, only osimertinib/trametinib combination treatment, but not monotherapy with either of these drugs, leads to robust tumor shrinkage in EGFR-driven xenograft models harboring BRAFV600E mutations. osimertinib 15-26 epidermal growth factor receptor Homo sapiens 144-148 34865963-5 2022 The introduction of the 3G EGFR-TKI, osimertinib, provides an opportunity to overcome T790M-mediated resistance to 1G, and 2G EGFR-TKIs. osimertinib 37-48 epidermal growth factor receptor Homo sapiens 27-31 34865963-5 2022 The introduction of the 3G EGFR-TKI, osimertinib, provides an opportunity to overcome T790M-mediated resistance to 1G, and 2G EGFR-TKIs. osimertinib 37-48 epidermal growth factor receptor Homo sapiens 126-130 34865963-6 2022 Additionally, with the use of osimertinib, fewer T790M mutations are being detected as T790M is not a reported resistance mechanism to 3G EGFR-TKIs. osimertinib 30-41 epidermal growth factor receptor Homo sapiens 138-142 34844838-7 2022 In addition, MEOX2/GLI1 was shown to be involved in the increased proliferation of tumour cells and resistance capacity to cisplatin, EGFR-TKIs (erlotinib and AZD9291 "osimertinib"), AZD8542-SMO, and AZD6244-MEKK1/2. osimertinib 168-179 epidermal growth factor receptor Homo sapiens 134-138 34758637-0 2022 First-line osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status. osimertinib 11-22 epidermal growth factor receptor Homo sapiens 26-30 34643820-0 2022 Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 154-158 34643820-1 2022 BACKGROUND: Osimertinib is effective in patients with T790M mutation-positive advanced non-small-cell lung cancer (NSCLC) resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 135-167 34643820-1 2022 BACKGROUND: Osimertinib is effective in patients with T790M mutation-positive advanced non-small-cell lung cancer (NSCLC) resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 169-173 34643820-11 2022 Patients negative for activating EGFR mutations after osimertinib administration had longer median PFS than those positive for these mutations. osimertinib 54-65 epidermal growth factor receptor Homo sapiens 33-37 34643820-12 2022 CONCLUSION: Osimertinib was sufficiently effective in EGFR-TKI-resistant, poor PS patients with T790M mutation-positive advanced NSCLC. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 54-58 34969538-1 2022 INTRODUCTION: The third-generation tyrosine kinase inhibitor (TKI) osimertinib is recommended as a first-line treatment in advanced non-small cell lung cancer harboring an activating mutation of Epidermal Growth Factor Receptor (EGFR). osimertinib 67-78 epidermal growth factor receptor Homo sapiens 195-227 34969538-1 2022 INTRODUCTION: The third-generation tyrosine kinase inhibitor (TKI) osimertinib is recommended as a first-line treatment in advanced non-small cell lung cancer harboring an activating mutation of Epidermal Growth Factor Receptor (EGFR). osimertinib 67-78 epidermal growth factor receptor Homo sapiens 229-233 34894319-0 2022 Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice. osimertinib 42-53 epidermal growth factor receptor Homo sapiens 77-81 34974477-1 2022 Osimertinib is the most reliable epidermal growth factor receptor-tyrosine kinase (EGFR-TKI) and is recommended as the first-line EGFR-TKI. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 83-87 34974477-1 2022 Osimertinib is the most reliable epidermal growth factor receptor-tyrosine kinase (EGFR-TKI) and is recommended as the first-line EGFR-TKI. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 130-134 34979367-4 2022 In quest for finding newer moieties, we have developed a pharmacophore model utilizing drugs like lazertinib, osimertinib, nazartinib, avitinib, afatininb, and talazoparib that are known to inhibit EGFR along with their downstream signaling. osimertinib 110-121 epidermal growth factor receptor Homo sapiens 198-202 34987382-1 2021 Osimertinib shows strong clinical activity in first- and second-line treatment of nonsmall-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, especially EGFR T790M. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 130-162 34987382-1 2021 Osimertinib shows strong clinical activity in first- and second-line treatment of nonsmall-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, especially EGFR T790M. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 164-168 34987382-1 2021 Osimertinib shows strong clinical activity in first- and second-line treatment of nonsmall-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, especially EGFR T790M. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 192-196 34486915-0 2021 Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study. osimertinib 23-34 epidermal growth factor receptor Homo sapiens 47-51 34944068-6 2021 Cells driven by EGFR-D770>GY were insensitive to erlotinib and osimertinib, displayed sensitivity to poziotinib and dacomitinib and were uniquely sensitive to afatinib and dacomitinib in comparison with other more typical EGFR exon 20 insertion mutations using proliferation and biochemical assays. osimertinib 63-74 epidermal growth factor receptor Homo sapiens 16-20 34911336-1 2022 Third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, have demonstrated efficacy in patients with EGFR-mutant non-small cell lung cancer; however, almost all patients will eventually relapse. osimertinib 65-76 epidermal growth factor receptor Homo sapiens 17-21 34911336-1 2022 Third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, have demonstrated efficacy in patients with EGFR-mutant non-small cell lung cancer; however, almost all patients will eventually relapse. osimertinib 65-76 epidermal growth factor receptor Homo sapiens 122-126 34301748-1 2021 On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved osimertinib as adjuvant therapy in patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations, as detected by an FDA-approved test. osimertinib 75-86 epidermal growth factor receptor Homo sapiens 177-209 34301748-1 2021 On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved osimertinib as adjuvant therapy in patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations, as detected by an FDA-approved test. osimertinib 75-86 epidermal growth factor receptor Homo sapiens 211-215 34534838-1 2021 To resolve the problem of drug resistance caused by epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer, we used the principle of collocation to design and synthesize a series of aminopyrimidine derivatives with 4,5,6,7-tetrahydrothieno (3,2-c)pyridine side chains (according to the binding mode of AZD9291 to EGFRT790M) for use as EGFRL858R/T790M kinase inhibitors. osimertinib 327-334 epidermal growth factor receptor Homo sapiens 52-84 34808132-0 2021 Targeting ROR1 in combination with osimertinib in EGFR mutant lung cancer cells. osimertinib 35-46 epidermal growth factor receptor Homo sapiens 50-54 34808132-1 2021 Lung cancer that exhibits epidermal growth factor receptor (EGFR) gene mutation is sensitive to EGFR-tyrosine kinase inhibitors (TKIs), such as osimertinib. osimertinib 144-155 epidermal growth factor receptor Homo sapiens 26-58 34808132-1 2021 Lung cancer that exhibits epidermal growth factor receptor (EGFR) gene mutation is sensitive to EGFR-tyrosine kinase inhibitors (TKIs), such as osimertinib. osimertinib 144-155 epidermal growth factor receptor Homo sapiens 60-64 34808132-1 2021 Lung cancer that exhibits epidermal growth factor receptor (EGFR) gene mutation is sensitive to EGFR-tyrosine kinase inhibitors (TKIs), such as osimertinib. osimertinib 144-155 epidermal growth factor receptor Homo sapiens 96-100 34808132-7 2021 In conclusion, targeting ROR1 in combination with osimertinib in EGFR mutant lung cancer may be a novel therapeutic option. osimertinib 50-61 epidermal growth factor receptor Homo sapiens 65-69 34907286-6 2021 The integrative analysis confirmed that the average expression of EGFR ligands (AREG, EREG, HBEGF, TGFA, and EPGN) is associated with osimertinib sensitivity. osimertinib 134-145 epidermal growth factor receptor Homo sapiens 66-70 34846235-0 2021 Cost-effectiveness of osimertinib in the treatment of advanced EGFR-mutated non-small cell lung cancer: a systematic review. osimertinib 22-33 epidermal growth factor receptor Homo sapiens 63-67 34846235-2 2021 Although targeted tyrosine kinase inhibitors (TKIs) have reconstructed the care of these patients, the resistance of TKIs to the secondary EGFR-T790M mutation in advanced or metastatic NSCLC, led to the introduction of the third generation of them, like osimertinib. osimertinib 254-265 epidermal growth factor receptor Homo sapiens 139-143 34846235-10 2021 Therefore, further studies in those countries are needed to evaluate the cost-effectiveness of osimertinib for sensitizing EGFR mutation without T790M and required T790M in advanced or metastatic NSCLC. osimertinib 95-106 epidermal growth factor receptor Homo sapiens 123-127 34950579-10 2021 In EGFR-mutant patients, osimertinib showed the greatest benefit in iPFS (HR=0.32, 95%CI 0.15-0.69) compared to conventional chemotherapy, while gefitinib + chemotherapy showed the greatest overall PFS benefit (HR=0.26, 95%CI 0.10-0.70). osimertinib 25-36 epidermal growth factor receptor Homo sapiens 3-7 34865626-1 2021 BACKGROUND: The study aimed to compare the efficacy of osimertinib plus cranial radiotherapy (RT) with osimertinib alone in advanced non-small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations and brain metastases (BMs). osimertinib 103-114 epidermal growth factor receptor Homo sapiens 187-219 34865626-1 2021 BACKGROUND: The study aimed to compare the efficacy of osimertinib plus cranial radiotherapy (RT) with osimertinib alone in advanced non-small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations and brain metastases (BMs). osimertinib 103-114 epidermal growth factor receptor Homo sapiens 221-225 34926262-3 2021 Here, we report a case of acquired EGFR L858R/L718Q mutation with advanced NSCLC that resistant to osimertinib, which was successfully overcome using dacomitinib. osimertinib 99-110 epidermal growth factor receptor Homo sapiens 35-39 34926262-13 2021 The acquired EGFR L718Q mutation in subsequent resistance to osimertinib could be overcome using dacomitinib, indicating a promising treatment option in the clinic. osimertinib 61-72 epidermal growth factor receptor Homo sapiens 13-17 34635007-3 2021 AZD3759 and osimertinib are both BBB-penetrating EGFR inhibitors. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 49-53 34612594-0 2021 Possibility of brigatinib-based therapy, or chemotherapy plus anti-angiogenic treatment after resistance of osimertinib harboring EGFR T790M-cis-C797S mutations in lung adenocarcinoma patients. osimertinib 108-119 epidermal growth factor receptor Homo sapiens 130-134 34612594-1 2021 BACKGROUND: There was no standard treatment for patients who acquired resistance to osimertinib mediated by epidermal growth factor receptor (EGFR) T790M-cis-C797S. osimertinib 84-95 epidermal growth factor receptor Homo sapiens 108-140 34612594-1 2021 BACKGROUND: There was no standard treatment for patients who acquired resistance to osimertinib mediated by epidermal growth factor receptor (EGFR) T790M-cis-C797S. osimertinib 84-95 epidermal growth factor receptor Homo sapiens 142-146 34634633-0 2021 Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies. osimertinib 34-45 epidermal growth factor receptor Homo sapiens 49-53 34749119-0 2021 Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 49-81 34749119-1 2021 BACKGROUND: Osimertinib is the standard of care in the initial treatment for advanced epidermal growth factor receptor (EGFR) mutation-positive lung cancer. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 86-118 34749119-1 2021 BACKGROUND: Osimertinib is the standard of care in the initial treatment for advanced epidermal growth factor receptor (EGFR) mutation-positive lung cancer. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 120-124 34749119-3 2021 METHODS: We performed a retrospective multicentre cohort study for 538 EGFR mutation-positive patients, who received osimertinib as the initial treatment between August 2018 and December 2019. osimertinib 117-128 epidermal growth factor receptor Homo sapiens 71-75 34763195-1 2021 AIM OF THE STUDY: The AZENT (NCT02841579) study aimed to assess the efficacy and safety of first-line osimertinib in patients with epidermal growth factor receptor(EGFR)mutation-positive advanced non-small-cell lung cancer (NSCLC) and with a coexisting low allelic fraction of Thr790Met. osimertinib 102-113 epidermal growth factor receptor Homo sapiens 131-163 34763195-1 2021 AIM OF THE STUDY: The AZENT (NCT02841579) study aimed to assess the efficacy and safety of first-line osimertinib in patients with epidermal growth factor receptor(EGFR)mutation-positive advanced non-small-cell lung cancer (NSCLC) and with a coexisting low allelic fraction of Thr790Met. osimertinib 102-113 epidermal growth factor receptor Homo sapiens 164-168 34763195-16 2021 CONCLUSION: Despite early study termination, osimertinib first-line therapy yields an overall PFS of 23.1 months in EGFR-mutant patients harbouring a coexisting low allelic fraction of EGFR Thr790Met mutation. osimertinib 45-56 epidermal growth factor receptor Homo sapiens 116-120 34763195-16 2021 CONCLUSION: Despite early study termination, osimertinib first-line therapy yields an overall PFS of 23.1 months in EGFR-mutant patients harbouring a coexisting low allelic fraction of EGFR Thr790Met mutation. osimertinib 45-56 epidermal growth factor receptor Homo sapiens 185-189 34723634-11 2021 To date, the study has shown that osimertinib could be beneficial for patients with resectable EGFR-mutated NSCLC. osimertinib 34-45 epidermal growth factor receptor Homo sapiens 95-99 34920242-1 2021 INTRODUCTION: After the development of acquired resistance to osimertinib, the standard-of-care treatment for advanced EGFR-mutated NSCLC is chemotherapy. osimertinib 62-73 epidermal growth factor receptor Homo sapiens 119-123 34525256-0 2021 Clinical Outcomes of Patients Taking First-generation EGFR-TKIs May Predict the Benefits Afforded by Osimertinib in EGFR T790M-mutant NSCLC Patients. osimertinib 101-112 epidermal growth factor receptor Homo sapiens 54-58 34525256-0 2021 Clinical Outcomes of Patients Taking First-generation EGFR-TKIs May Predict the Benefits Afforded by Osimertinib in EGFR T790M-mutant NSCLC Patients. osimertinib 101-112 epidermal growth factor receptor Homo sapiens 116-120 34525256-2 2021 The association between the clinical outcomes of patients on first-line EGFR-TKIs and the efficacy of osimertinib as second-line treatment has not been previously assessed. osimertinib 102-113 epidermal growth factor receptor Homo sapiens 72-76 34525256-4 2021 PATIENTS AND METHODS: We retrospectively analyzed 67 patients with EGFR mutations on osimertinib after treatment with first-generation EGFR-TKIs. osimertinib 85-96 epidermal growth factor receptor Homo sapiens 67-71 34525256-4 2021 PATIENTS AND METHODS: We retrospectively analyzed 67 patients with EGFR mutations on osimertinib after treatment with first-generation EGFR-TKIs. osimertinib 85-96 epidermal growth factor receptor Homo sapiens 135-139 34525256-7 2021 Correlation analysis showed that the female sex and isolated (not multiple) progression on first-line EGFR-TKIs were correlated with a superior response to osimertinib. osimertinib 156-167 epidermal growth factor receptor Homo sapiens 102-106 34525256-9 2021 Univariate analysis indicated that the treatment response, PFS, and progression when on first-line EGFR-TKIs affected the PFS on osimertinib. osimertinib 129-140 epidermal growth factor receptor Homo sapiens 99-103 34525256-10 2021 Multivariate analysis showed that progression when on first-line EGFR-TKIs was independently prognostic of a response to osimertinib. osimertinib 121-132 epidermal growth factor receptor Homo sapiens 65-69 34525256-12 2021 A low frequency of the EGFR T790M allele in plasma tended to predict an inferior efficacy of osimertinib and shorter PFS. osimertinib 93-104 epidermal growth factor receptor Homo sapiens 23-27 34525256-13 2021 CONCLUSION: We found that patients who benefited from first-line EGFR-TKIs may experience prolonged PFS and a higher response rate when subsequently given osimertinib. osimertinib 155-166 epidermal growth factor receptor Homo sapiens 65-69 34525256-14 2021 A low plasma frequency of the EGFR T790M allele may predict poor osimertinib efficacy and shorter PFS. osimertinib 65-76 epidermal growth factor receptor Homo sapiens 30-34 34723634-15 2021 Based on the results from ADAURA, osimertinib has been approved for the treatment of resectable EGFR-mutated NSCLC after tumor removal. osimertinib 34-45 epidermal growth factor receptor Homo sapiens 96-100 34419684-1 2021 BACKGROUND: Osimertinib has been reported to be effective against central nervous system (CNS) metastasis from activating epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 122-154 34419684-1 2021 BACKGROUND: Osimertinib has been reported to be effective against central nervous system (CNS) metastasis from activating epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 156-160 34419684-3 2021 PURPOSE: This study aimed to evaluate the efficacy of osimertinib against radiotherapy-naive CNS metastasis from sensitizing EGFR mutation-positive NSCLC. osimertinib 54-65 epidermal growth factor receptor Homo sapiens 125-129 34419684-19 2021 The primary endpoint was met, and the results demonstrated the efficacy of osimertinib in patients with CNS metastasis harboring EGFR T790M mutations especially for EGFR-sensitizing mutation of exon 19 deletion. osimertinib 75-86 epidermal growth factor receptor Homo sapiens 129-133 34419684-19 2021 The primary endpoint was met, and the results demonstrated the efficacy of osimertinib in patients with CNS metastasis harboring EGFR T790M mutations especially for EGFR-sensitizing mutation of exon 19 deletion. osimertinib 75-86 epidermal growth factor receptor Homo sapiens 165-169 34649106-18 2021 CONCLUSION: Sequential afatinib and osimertinib demonstrated encouraging activity in patients with EGFR mutation-positive NSCLC and acquired T790M. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 99-103 34739853-3 2021 However, the phase 3 ADAURA trial has recently shown that the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimertinib, reduces the risk of disease recurrence by 80% versus placebo in the adjuvant setting for patients with stage IB-IIIA EGFR mutation-positive NSCLC following complete tumor resection with or without adjuvant chemotherapy, according to physician and patient choice. osimertinib 135-146 epidermal growth factor receptor Homo sapiens 62-94 34739853-3 2021 However, the phase 3 ADAURA trial has recently shown that the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimertinib, reduces the risk of disease recurrence by 80% versus placebo in the adjuvant setting for patients with stage IB-IIIA EGFR mutation-positive NSCLC following complete tumor resection with or without adjuvant chemotherapy, according to physician and patient choice. osimertinib 135-146 epidermal growth factor receptor Homo sapiens 96-100 34739853-3 2021 However, the phase 3 ADAURA trial has recently shown that the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimertinib, reduces the risk of disease recurrence by 80% versus placebo in the adjuvant setting for patients with stage IB-IIIA EGFR mutation-positive NSCLC following complete tumor resection with or without adjuvant chemotherapy, according to physician and patient choice. osimertinib 135-146 epidermal growth factor receptor Homo sapiens 265-269 34808485-0 2021 A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer. osimertinib 22-33 epidermal growth factor receptor Homo sapiens 37-41 34808485-1 2021 OBJECTIVES: Several preclinical data proposed a potential efficacy of osimertinib, a third-generation EGFR tyrosine kinase inhibitor, for EGFR exon 20 insertion (EGFR ex20ins)-positive non-small cell lung cancer (NSCLC). osimertinib 70-81 epidermal growth factor receptor Homo sapiens 138-142 34808485-1 2021 OBJECTIVES: Several preclinical data proposed a potential efficacy of osimertinib, a third-generation EGFR tyrosine kinase inhibitor, for EGFR exon 20 insertion (EGFR ex20ins)-positive non-small cell lung cancer (NSCLC). osimertinib 70-81 epidermal growth factor receptor Homo sapiens 162-166 34808485-4 2021 In this study, we performed a prospective, single-arm, multi-center, open-label, non-randomized phase I/II study to evaluate efficacy of osimertinib for EGFR ex20ins-positive NSCLC. osimertinib 137-148 epidermal growth factor receptor Homo sapiens 153-157 34808485-10 2021 Interestingly, the exploratory study demonstrated statistically significant positive correlation between plasma osimertinib concentration/in vitro IC50 ratio and PFS (R = 0.9912, P = 0.0001), highlighting the mutation type-specific concentration-dependent efficacy of osimertinib for EGFR ex20ins-positive NSCLC. osimertinib 268-279 epidermal growth factor receptor Homo sapiens 284-288 34635799-0 2021 Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib. osimertinib 139-150 epidermal growth factor receptor Homo sapiens 112-116 34635799-1 2021 Emergence of acquired resistance to osimertinib (AZD9291), the first-approved third-generation EGFR inhibitor that selectively and irreversibly inhibits the activating EGFR mutations and the resistant T790M mutation, is a giant and urgent clinical challenge. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 95-99 34635799-1 2021 Emergence of acquired resistance to osimertinib (AZD9291), the first-approved third-generation EGFR inhibitor that selectively and irreversibly inhibits the activating EGFR mutations and the resistant T790M mutation, is a giant and urgent clinical challenge. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 168-172 34635799-1 2021 Emergence of acquired resistance to osimertinib (AZD9291), the first-approved third-generation EGFR inhibitor that selectively and irreversibly inhibits the activating EGFR mutations and the resistant T790M mutation, is a giant and urgent clinical challenge. osimertinib 49-56 epidermal growth factor receptor Homo sapiens 95-99 34635799-1 2021 Emergence of acquired resistance to osimertinib (AZD9291), the first-approved third-generation EGFR inhibitor that selectively and irreversibly inhibits the activating EGFR mutations and the resistant T790M mutation, is a giant and urgent clinical challenge. osimertinib 49-56 epidermal growth factor receptor Homo sapiens 168-172 34635799-2 2021 Fully understanding the biology underlying the response of EGFR mutant non-small cell lung cancer (NSCLC) to osimertinib is the foundation for development of mechanism-driven strategies to overcome acquired resistance to osimertinib or other third-generation EGFR inhibitors. osimertinib 109-120 epidermal growth factor receptor Homo sapiens 59-63 34635799-2 2021 Fully understanding the biology underlying the response of EGFR mutant non-small cell lung cancer (NSCLC) to osimertinib is the foundation for development of mechanism-driven strategies to overcome acquired resistance to osimertinib or other third-generation EGFR inhibitors. osimertinib 109-120 epidermal growth factor receptor Homo sapiens 259-263 34635799-3 2021 This study focused on tackling this important issue by elucidating the critical role of sterol regulatory element-binding protein 1 (SREBP1) degradation in conferring the response of EGFR mutant NSCLC cells to osimertinib and by validating the strategy via directly targeting SREBP1 for overcoming osimertinib acquired resistance. osimertinib 210-221 epidermal growth factor receptor Homo sapiens 183-187 34635799-4 2021 Osimertinib facilitated degradation of the mature form of SREBP1 (mSREBP1) in a GSK3/FBXW7-dependent manner and reduced protein levels of its regulated genes in EGFR-mutant NSCLC cells/tumors accompanied with suppression of lipogenesis. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 161-165 34635799-7 2021 Collectively, we have demonstrated a novel connection between osimertinib and SREBP1 degradation and its impact on the response of EGFR mutant NSCLC cells to osimertinib and suggested an effective strategy for overcoming acquired resistance to osimertinib, and possibly other EGFR inhibitors, via targeting SREBP1. osimertinib 62-73 epidermal growth factor receptor Homo sapiens 131-135 34635799-7 2021 Collectively, we have demonstrated a novel connection between osimertinib and SREBP1 degradation and its impact on the response of EGFR mutant NSCLC cells to osimertinib and suggested an effective strategy for overcoming acquired resistance to osimertinib, and possibly other EGFR inhibitors, via targeting SREBP1. osimertinib 62-73 epidermal growth factor receptor Homo sapiens 276-280 34635799-7 2021 Collectively, we have demonstrated a novel connection between osimertinib and SREBP1 degradation and its impact on the response of EGFR mutant NSCLC cells to osimertinib and suggested an effective strategy for overcoming acquired resistance to osimertinib, and possibly other EGFR inhibitors, via targeting SREBP1. osimertinib 158-169 epidermal growth factor receptor Homo sapiens 131-135 34704378-3 2021 In total, 76 patients with EGFR T790M mutation who received osimertinib after re-biopsy or liquid biopsy were enrolled for the analysis. osimertinib 60-71 epidermal growth factor receptor Homo sapiens 27-31 34704378-5 2021 A significant difference was observed in the disease control rate between those who received osimertinib treatment after chemotherapy (group A) and those who received osimertinib immediately following EGFR-TKI therapy (group B) (34 (94.4%) vs. 31 (77.5%), p = 0.036). osimertinib 167-178 epidermal growth factor receptor Homo sapiens 201-205 34704378-8 2021 Osimertinib treatment following first/second generation EGFR-TKI treatment or chemotherapy resulted in improved survival benefit. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 56-60 34727807-0 2021 Carcinomatosis under control by osimertinib in EGFR and TP53 mutated lung adenocarcinoma. osimertinib 32-43 epidermal growth factor receptor Homo sapiens 47-51 34848786-1 2021 Osimertinib is a standard of care therapy for previously untreated epidermal growth factor receptor mutation-positive non-small cell lung cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 67-99 34215931-1 2021 OBJECTIVES: The study was designed to investigate the safety of ramucirumab administered in combination with erlotinib or osimertinib for patients with untreated EGFR-mutated non-small cell lung cancer (NSCLC) and asymptomatic brain metastases, a patient subgroup in which these regimens have remained untested. osimertinib 122-133 epidermal growth factor receptor Homo sapiens 162-166 34885115-0 2021 The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells. osimertinib 44-55 epidermal growth factor receptor Homo sapiens 70-74 34885115-1 2021 BACKGROUND: The third-generation epidermal growth factor receptor (EGFR) inhibitor, Osimertinib, is used to treat non-small cell lung cancer (NSCLC) patients with tyrosine kinase inhibitor (TKI) resistance caused by acquired EGFR T790M mutation. osimertinib 84-95 epidermal growth factor receptor Homo sapiens 33-65 34885115-1 2021 BACKGROUND: The third-generation epidermal growth factor receptor (EGFR) inhibitor, Osimertinib, is used to treat non-small cell lung cancer (NSCLC) patients with tyrosine kinase inhibitor (TKI) resistance caused by acquired EGFR T790M mutation. osimertinib 84-95 epidermal growth factor receptor Homo sapiens 67-71 34885115-1 2021 BACKGROUND: The third-generation epidermal growth factor receptor (EGFR) inhibitor, Osimertinib, is used to treat non-small cell lung cancer (NSCLC) patients with tyrosine kinase inhibitor (TKI) resistance caused by acquired EGFR T790M mutation. osimertinib 84-95 epidermal growth factor receptor Homo sapiens 225-229 34885115-14 2021 RESULT: ERK2 expression correlated with EGFR expression and higher ERK2 level was associated with worse prognosis of patients and Osimertinib resistance. osimertinib 130-141 epidermal growth factor receptor Homo sapiens 40-44 34816394-1 2021 Osimertinib (OB) is a third-generation irreversible tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR), overexpressed in non-small cell lung cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 92-124 34816394-1 2021 Osimertinib (OB) is a third-generation irreversible tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR), overexpressed in non-small cell lung cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 126-130 34807331-0 2022 First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study. osimertinib 11-22 epidermal growth factor receptor Homo sapiens 65-69 34807331-1 2022 OBJECTIVE: The clinical outcomes of poor performance status (PS) patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who are treated with osimertinib as a first-line treatment have not been sufficiently evaluated. osimertinib 183-194 epidermal growth factor receptor Homo sapiens 79-111 34807331-1 2022 OBJECTIVE: The clinical outcomes of poor performance status (PS) patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who are treated with osimertinib as a first-line treatment have not been sufficiently evaluated. osimertinib 183-194 epidermal growth factor receptor Homo sapiens 113-117 34807331-2 2022 This study aimed to assess the efficacy and safety of osimertinib in chemotherapy-naive and poor PS (2 or more) patients with NSCLC harboring sensitive EGFR mutations. osimertinib 54-65 epidermal growth factor receptor Homo sapiens 152-156 34807331-3 2022 MATERIALS AND METHODS: We assessed the clinical effects of osimertinib as a first-line treatment for patients with poor PS NSCLC with an exon 19 deletion or exon 21 L858R mutation in EGFR. osimertinib 59-70 epidermal growth factor receptor Homo sapiens 183-187 34807331-10 2022 CONCLUSION: Considering the findings of this study, osimertinib appears to be an effective and safe treatment option for patients with poor PS and advanced NSCLC harboring sensitive EGFR mutations. osimertinib 52-63 epidermal growth factor receptor Homo sapiens 182-186 34723634-0 2021 A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer. osimertinib 59-70 epidermal growth factor receptor Homo sapiens 119-123 34723634-2 2021 Osimertinib (TAGRISSO ) is a medication used to treat a type of NSCLC with a change (mutation) in the EGFR gene, known as EGFR-mutated NSCLC. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 102-106 34723634-2 2021 Osimertinib (TAGRISSO ) is a medication used to treat a type of NSCLC with a change (mutation) in the EGFR gene, known as EGFR-mutated NSCLC. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 122-126 34723634-2 2021 Osimertinib (TAGRISSO ) is a medication used to treat a type of NSCLC with a change (mutation) in the EGFR gene, known as EGFR-mutated NSCLC. osimertinib 13-21 epidermal growth factor receptor Homo sapiens 102-106 34723634-2 2021 Osimertinib (TAGRISSO ) is a medication used to treat a type of NSCLC with a change (mutation) in the EGFR gene, known as EGFR-mutated NSCLC. osimertinib 13-21 epidermal growth factor receptor Homo sapiens 122-126 34798865-11 2021 Multivariate logistic regression analysis at 3 months from the start of EGFR-TKI treatment revealed that oligo-residual disease (P < 0.001), the lack of residual central nervous system metastases (P = 0.032), and initial treatment with osimertinib (P = 0.028) were independent predictors of PD limited to residual disease sites. osimertinib 236-247 epidermal growth factor receptor Homo sapiens 72-76 34849025-1 2021 Background: The clinical outcomes of elderly patients with EGFR-mutated non-small cell lung cancer (NSCLC) who are treated with osimertinib have not been sufficiently evaluated. osimertinib 128-139 epidermal growth factor receptor Homo sapiens 59-63 34849025-2 2021 This study aimed to assess the efficacy and safety of osimertinib in elderly chemotherapy-naive patients with NSCLC harboring sensitive EGFR mutations. osimertinib 54-65 epidermal growth factor receptor Homo sapiens 136-140 34849025-3 2021 Patients and Methods: We assessed the clinical effects of osimertinib as a first-line treatment for elderly NSCLC patients (>=75 years of age) with an exon 19 deletion or exon 21 L858R mutation in EGFR. osimertinib 58-69 epidermal growth factor receptor Homo sapiens 197-201 34849025-11 2021 Conclusion: Considering the findings of this study and despite an observed discordance between PFS and TTF, osimertinib appears to be an effective and safe treatment option in elderly patients with advanced NSCLC harboring sensitive EGFR mutations. osimertinib 108-119 epidermal growth factor receptor Homo sapiens 233-237 34806395-7 2021 In Japan, osimertinib treatment after failure of EGFR-TKI treatments requires the T790M mutation in the tumor, blood or body fluid, so BE treatment was started as second-line treatment. osimertinib 10-21 epidermal growth factor receptor Homo sapiens 49-53 34831415-6 2021 After the role of EGFR T790M mutation in acquired drug resistance was reported, osimertinib, a third-generation irreversible EGFR-TKI, was designed to overcome the resistance conferred by T790M mutation. osimertinib 80-91 epidermal growth factor receptor Homo sapiens 18-22 34831415-6 2021 After the role of EGFR T790M mutation in acquired drug resistance was reported, osimertinib, a third-generation irreversible EGFR-TKI, was designed to overcome the resistance conferred by T790M mutation. osimertinib 80-91 epidermal growth factor receptor Homo sapiens 125-129 34871271-2 2021 Osimertinib is a promising option for NSCLC with LM harboring epidermal growth factor receptor (EGFR) mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 96-100 34740861-0 2022 Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. osimertinib 57-68 epidermal growth factor receptor Homo sapiens 102-106 34849025-0 2021 A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer. osimertinib 37-48 epidermal growth factor receptor Homo sapiens 87-91 34802213-0 2021 (Osimertinib Re-challenge for EGFR-mutant NSCLC after : Osimertinib-induced Interstitial Lung Disease: A Case Report). osimertinib 1-12 epidermal growth factor receptor Homo sapiens 30-34 34802213-2 2021 We report a case of a 64-year-old male with stage IV adeno-non-small cell lung cancer (NSCLC) harboring an exon 19 deletion in the epidermal growth factor receptor (EGFR) treated with osimertinib 80 mg/d for first-line targeted therapy. osimertinib 184-195 epidermal growth factor receptor Homo sapiens 131-163 34802213-2 2021 We report a case of a 64-year-old male with stage IV adeno-non-small cell lung cancer (NSCLC) harboring an exon 19 deletion in the epidermal growth factor receptor (EGFR) treated with osimertinib 80 mg/d for first-line targeted therapy. osimertinib 184-195 epidermal growth factor receptor Homo sapiens 165-169 34389237-0 2021 Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD). osimertinib 185-196 epidermal growth factor receptor Homo sapiens 60-64 34389237-1 2021 INTRODUCTION: Osimertinib, a third-generation, irreversible, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), selectively inhibits both EGFR-TKI sensitizing (EGFRm) and EGFR T790M resistance mutations and has demonstrated efficacy in non-small cell lung cancer (NSCLC) CNS metastases. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 121-125 34389237-1 2021 INTRODUCTION: Osimertinib, a third-generation, irreversible, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), selectively inhibits both EGFR-TKI sensitizing (EGFRm) and EGFR T790M resistance mutations and has demonstrated efficacy in non-small cell lung cancer (NSCLC) CNS metastases. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 191-195 34602008-1 2021 AIM: To evaluate the cost-effectiveness of first-line treatments such as erlotinib, gefitinib, afatinib, dacomitinib, and osimertinib, for patients diagnosed with stage IIIB/IV NSCLC harbouring EGFR mutations. osimertinib 122-133 epidermal growth factor receptor Homo sapiens 194-198 34278827-0 2021 Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 80-84 34278827-1 2021 Osimertinib is a third-generation, irreversible oral EGFR-tyrosine kinase inhibitor), that potently inhibits EGFR-tyrosine kinase inhibitor-sensitizing mutations and T790M resistance mutations together with efficacy in CNS metastases in patients with non-small-cell lung cancer (NSCLC). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 53-57 34278827-1 2021 Osimertinib is a third-generation, irreversible oral EGFR-tyrosine kinase inhibitor), that potently inhibits EGFR-tyrosine kinase inhibitor-sensitizing mutations and T790M resistance mutations together with efficacy in CNS metastases in patients with non-small-cell lung cancer (NSCLC). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 109-113 34558640-3 2021 Osimertinib is a representative of the 3rd-generation EGFR-TKIs that target T790M mutation, and has satisfactory efficacy in the treatment of T790M-positive NSCLC with disease progression following use of 1st- or 2nd-generation EGFR-TKIs. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 54-58 34558640-3 2021 Osimertinib is a representative of the 3rd-generation EGFR-TKIs that target T790M mutation, and has satisfactory efficacy in the treatment of T790M-positive NSCLC with disease progression following use of 1st- or 2nd-generation EGFR-TKIs. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 228-232 34849493-1 2021 Introduction: With the approval of first-line osimertinib treatment in stage IV EGFR-mutated NSCLC, detection of resistance mechanisms will become increasingly important-and complex. osimertinib 46-57 epidermal growth factor receptor Homo sapiens 80-84 34994592-0 2021 Patient With Stage IV NSCLC and CNS Metastasis With EGFR Exon 18-25 Kinase Domain Duplication With Response to Osimertinib as a First-Line Therapy. osimertinib 111-122 epidermal growth factor receptor Homo sapiens 52-56 34994604-0 2021 Standard-Dose Osimertinib in EGFR-Mutated Non-Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 29-33 34994604-3 2021 This study reports on outcomes of patients with EGFR-mutated non-small-cell lung cancer who developed LMD and were subsequently treated with osimertinib. osimertinib 141-152 epidermal growth factor receptor Homo sapiens 48-52 34994624-0 2021 Divergent RET- and BRAF-Mediated Resistance to Osimertinib in EGFR-Mutant NSCLC: A Case Report. osimertinib 47-58 epidermal growth factor receptor Homo sapiens 62-66 34694530-0 2021 Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC. osimertinib 15-26 epidermal growth factor receptor Homo sapiens 62-66 34245854-0 2021 Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis. osimertinib 104-115 epidermal growth factor receptor Homo sapiens 88-92 34245854-1 2021 The promising therapeutic efficacy of the third generation EGFR inhibitor, osimertinib (AZD9291), for the treatment of patients with EGFR-mutant non-small cell lung cancer (NSCLC) has been demonstrated in the clinic both as first-line and second line therapy. osimertinib 75-86 epidermal growth factor receptor Homo sapiens 59-63 34245854-1 2021 The promising therapeutic efficacy of the third generation EGFR inhibitor, osimertinib (AZD9291), for the treatment of patients with EGFR-mutant non-small cell lung cancer (NSCLC) has been demonstrated in the clinic both as first-line and second line therapy. osimertinib 75-86 epidermal growth factor receptor Homo sapiens 133-137 34245854-1 2021 The promising therapeutic efficacy of the third generation EGFR inhibitor, osimertinib (AZD9291), for the treatment of patients with EGFR-mutant non-small cell lung cancer (NSCLC) has been demonstrated in the clinic both as first-line and second line therapy. osimertinib 88-95 epidermal growth factor receptor Homo sapiens 59-63 34245854-1 2021 The promising therapeutic efficacy of the third generation EGFR inhibitor, osimertinib (AZD9291), for the treatment of patients with EGFR-mutant non-small cell lung cancer (NSCLC) has been demonstrated in the clinic both as first-line and second line therapy. osimertinib 88-95 epidermal growth factor receptor Homo sapiens 133-137 34702733-1 2021 According to a preclinical report, the investigational tyrosine kinase inhibitor BDTX-1535 may mitigate resistance to osimertinib, the standard of care for EGFR-mutant non-small cell lung cancer. osimertinib 118-129 epidermal growth factor receptor Homo sapiens 156-160 34770832-2 2021 The similarity search of icotinib, almonertinib, and olmutinib against a database of 154 EGFR ligands revealed the highest similarity scores with erlotinib (0.9333), osimertinib (0.9487), and WZ4003 (0.8421), respectively. osimertinib 166-177 epidermal growth factor receptor Homo sapiens 89-93 34887192-1 2022 INTRODUCTION: Osimertinib is a standard first-line treatment for non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor gene (EGFR). osimertinib 14-25 epidermal growth factor receptor Homo sapiens 127-159 34887192-1 2022 INTRODUCTION: Osimertinib is a standard first-line treatment for non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor gene (EGFR). osimertinib 14-25 epidermal growth factor receptor Homo sapiens 166-170 34656143-10 2021 Pharmacologic inhibition of EZH1/2 in combination with osimertinib prevented relapse with squamous-features in an EGFR-mutant patient-derived xenograft model, and inhibition of EZH1/2 or PI3K/AKT signaling re-sensitized resistant squamous-like tumors to osimertinib. osimertinib 55-66 epidermal growth factor receptor Homo sapiens 114-118 34734065-2 2021 AZD9291 has been developed as a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) with activity against T790M mutation. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 49-81 34734065-2 2021 AZD9291 has been developed as a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) with activity against T790M mutation. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 83-87 34638461-5 2021 Herein, we employed stable isotope labeling by amino acids in cell culture (SILAC) quantitative mass spectrometry-based proteomics to investigate potential immune escape molecular mechanisms in osimertinib resistant EGFR mutant lung adenocarcinoma by interrogating the alterations in the human leukocyte antigen (HLA) Class I-presented immunopeptidome, Class I-interactome, and the whole cell proteome between isogenic osimertinib-sensitive and -resistant human lung adenocarcinoma cells. osimertinib 194-205 epidermal growth factor receptor Homo sapiens 216-220 34605320-1 2022 INTRODUCTION: Osimertinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 74-106 34593465-3 2021 PATIENTS AND METHODS: We retrospectively investigated the survival time of patients diagnosed with EGFR-mutated advanced or recurrent NSCLC who had received afatinib, a second-generation EGFR-TKI, or osimertinib, a third-generation EGFR-TKI, as the first-line treatment. osimertinib 200-211 epidermal growth factor receptor Homo sapiens 232-236 34605320-3 2022 CASE REPORT: We report a previously healthy 56-year-old woman who developed elevated serum creatine kinase levels during osimertinib monotherapy for epidermal growth factor receptor mutation-positive lung adenocarcinoma. osimertinib 121-132 epidermal growth factor receptor Homo sapiens 149-181 34364740-1 2021 Osimertinib is used as a first-line treatment for metastatic non-small cell lung cancer with positive epidermal growth factor receptor mutations based on the results of the FLAURA trial. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 102-134 34364740-2 2021 However, as with any other epidermal growth factor receptor tyrosine kinase inhibitor, resistance also develops for osimertinib. osimertinib 116-127 epidermal growth factor receptor Homo sapiens 27-59 34365179-1 2021 OBJECTIVES: The ADAURA demonstrated the efficacy of osimertinib as adjuvant therapy in patients with resected stage IB-IIIA adenocarcinoma harboring epidermal growth factor receptor (EGFR) mutations. osimertinib 52-63 epidermal growth factor receptor Homo sapiens 149-181 34183449-2 2021 PD-L1 expression may also impact therapeutic outcomes of epidermal growth factor receptor (EGFR)-targeted therapy (e.g., with osimertinib/AZD9291) against EGFR mutant non-small cell lung cancers (NSCLCs) and can even be altered during the treatment albeit with largely undefined mechanisms. osimertinib 126-137 epidermal growth factor receptor Homo sapiens 57-89 34183449-2 2021 PD-L1 expression may also impact therapeutic outcomes of epidermal growth factor receptor (EGFR)-targeted therapy (e.g., with osimertinib/AZD9291) against EGFR mutant non-small cell lung cancers (NSCLCs) and can even be altered during the treatment albeit with largely undefined mechanisms. osimertinib 126-137 epidermal growth factor receptor Homo sapiens 91-95 34183449-2 2021 PD-L1 expression may also impact therapeutic outcomes of epidermal growth factor receptor (EGFR)-targeted therapy (e.g., with osimertinib/AZD9291) against EGFR mutant non-small cell lung cancers (NSCLCs) and can even be altered during the treatment albeit with largely undefined mechanisms. osimertinib 126-137 epidermal growth factor receptor Homo sapiens 155-159 34183449-2 2021 PD-L1 expression may also impact therapeutic outcomes of epidermal growth factor receptor (EGFR)-targeted therapy (e.g., with osimertinib/AZD9291) against EGFR mutant non-small cell lung cancers (NSCLCs) and can even be altered during the treatment albeit with largely undefined mechanisms. osimertinib 138-145 epidermal growth factor receptor Homo sapiens 57-89 34183449-2 2021 PD-L1 expression may also impact therapeutic outcomes of epidermal growth factor receptor (EGFR)-targeted therapy (e.g., with osimertinib/AZD9291) against EGFR mutant non-small cell lung cancers (NSCLCs) and can even be altered during the treatment albeit with largely undefined mechanisms. osimertinib 138-145 epidermal growth factor receptor Homo sapiens 91-95 34183449-2 2021 PD-L1 expression may also impact therapeutic outcomes of epidermal growth factor receptor (EGFR)-targeted therapy (e.g., with osimertinib/AZD9291) against EGFR mutant non-small cell lung cancers (NSCLCs) and can even be altered during the treatment albeit with largely undefined mechanisms. osimertinib 138-145 epidermal growth factor receptor Homo sapiens 155-159 34183449-3 2021 This study primarily focuses on elucidating the mechanism by which osimertinib induces PD-L1 degradation in addition to validating osimertinib"s effect on decreasing PD-L1 expression in EGFR mutant NSCLC cells and tumors. osimertinib 131-142 epidermal growth factor receptor Homo sapiens 186-190 34858779-10 2021 The response of Osimertinib in 74 EGFR p.T790M-positive patients detected by dPCR, including 26 determined as negative by ARMS-PCR, were evaluated to have an ORR of 44.59% and a DCR of 90.54%. osimertinib 16-27 epidermal growth factor receptor Homo sapiens 34-38 34858779-11 2021 Conclusions: dPCR is a sensitive and accurate tool for ctDNA-based EGFR p.T790M detection due to its significantly improved sensitivity without compromising specificity, and dPCR is equivalent to ARMS-PCR as a companion diagnostic tool while benefiting more patients under Osimertinib treatment. osimertinib 273-284 epidermal growth factor receptor Homo sapiens 67-71 34638411-4 2021 In the case of first-line treatment by first (erlotinib, gefitinib)- or second-generation (afatinib) TKIs, osimertinib is approved in second-line treatment for patients with T790M EGFR mutation. osimertinib 107-118 epidermal growth factor receptor Homo sapiens 180-184 34660285-0 2021 Machine Learning-Based CT Radiomics Analysis for Prognostic Prediction in Metastatic Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation Receiving Third-Generation EGFR-TKI Osimertinib Treatment. osimertinib 182-193 epidermal growth factor receptor Homo sapiens 126-130 34660285-0 2021 Machine Learning-Based CT Radiomics Analysis for Prognostic Prediction in Metastatic Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation Receiving Third-Generation EGFR-TKI Osimertinib Treatment. osimertinib 182-193 epidermal growth factor receptor Homo sapiens 173-177 34660285-1 2021 Background and Purpose: As a third-generation EGFR tyrosine kinase inhibitor (TKI), osimertinib is approved for treating advanced non-small cell lung cancer (NSCLC) patients with EGFR-T790M mutation after progression on first- or second-generation EGFR-TKIs such as gefitinib, erlotinib and afatinib. osimertinib 84-95 epidermal growth factor receptor Homo sapiens 179-183 34660285-1 2021 Background and Purpose: As a third-generation EGFR tyrosine kinase inhibitor (TKI), osimertinib is approved for treating advanced non-small cell lung cancer (NSCLC) patients with EGFR-T790M mutation after progression on first- or second-generation EGFR-TKIs such as gefitinib, erlotinib and afatinib. osimertinib 84-95 epidermal growth factor receptor Homo sapiens 248-252 34660285-2 2021 We aim at exploring the feasibility and effectiveness of using radiomic features from chest CT scan to predict the prognosis of metastatic non-small cell lung cancer (NSCLC) patients with EGFR-T790M mutation receiving second-line osimertinib therapy. osimertinib 230-241 epidermal growth factor receptor Homo sapiens 188-192 34585625-0 2021 Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib. osimertinib 129-140 epidermal growth factor receptor Homo sapiens 76-80 34585625-1 2021 INTRODUCTION: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved as first-line therapy for advanced EGFR-mutated non-small cell lung cancer (NSCLC). osimertinib 14-25 epidermal growth factor receptor Homo sapiens 48-80 34585625-1 2021 INTRODUCTION: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved as first-line therapy for advanced EGFR-mutated non-small cell lung cancer (NSCLC). osimertinib 14-25 epidermal growth factor receptor Homo sapiens 82-86 34585625-1 2021 INTRODUCTION: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved as first-line therapy for advanced EGFR-mutated non-small cell lung cancer (NSCLC). osimertinib 14-25 epidermal growth factor receptor Homo sapiens 164-168 34585625-3 2021 METHODS: In this multicentric study, we retrospectively analyzed 92 patients with EGFR-mutated NSCLC treated with osimertinib. osimertinib 114-125 epidermal growth factor receptor Homo sapiens 82-86 34621884-0 2021 Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F compound mutation benefits from both afatinib and osimertinib: A case report. osimertinib 127-138 epidermal growth factor receptor Homo sapiens 32-64 34621884-9 2021 CONCLUSION: Our case revealed that both afatinib and the osimertinib + bevacizumab combination demonstrated clinical efficacy in NSCLC harboring an EGFR L833F-L861Q compound mutation. osimertinib 57-68 epidermal growth factor receptor Homo sapiens 148-152 34303194-1 2021 AZD9291 (osimertinib) is the third-generation EGFR-TKI treat for EGFR mutated NSCLC patients. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 46-50 34303194-1 2021 AZD9291 (osimertinib) is the third-generation EGFR-TKI treat for EGFR mutated NSCLC patients. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 65-69 34303194-1 2021 AZD9291 (osimertinib) is the third-generation EGFR-TKI treat for EGFR mutated NSCLC patients. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 46-50 34303194-1 2021 AZD9291 (osimertinib) is the third-generation EGFR-TKI treat for EGFR mutated NSCLC patients. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 65-69 34303194-7 2021 Enhancing IGFBP7 expression in EGFR-mutated non-small cell lung cancer (NSCLC) cells using lentiviruses infection reduced their sensitivity to AZD9291. osimertinib 143-150 epidermal growth factor receptor Homo sapiens 31-35 34536138-0 2021 A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study. osimertinib 39-50 epidermal growth factor receptor Homo sapiens 123-127 34536138-1 2021 PURPOSE: Osimertinib is the standard treatment for advanced non-small cell lung cancer (NSCLC) patients with T790M mutation after the failure of first-/second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI). osimertinib 9-20 epidermal growth factor receptor Homo sapiens 231-235 34536138-7 2021 Notably, the PFS of the prior EGFR-TKI was independently related to ORR (OR, 95% CI 0.98, 0.96-1.00, p = 0.030), PFS (HR, 95% CI 0.98, 0.97-1.00, p = 0.009) and OS (HR, 95% CI 0.96, 0.93-0.98, p < 0.001) of osimertinib treatment. osimertinib 207-218 epidermal growth factor receptor Homo sapiens 30-34 34536138-11 2021 CONCLUSION: PFS of the prior EGFR-TKI treatment, performance status score and bone metastasis were independent prognosticators of the osimertinib treatment. osimertinib 134-145 epidermal growth factor receptor Homo sapiens 29-33 34365179-1 2021 OBJECTIVES: The ADAURA demonstrated the efficacy of osimertinib as adjuvant therapy in patients with resected stage IB-IIIA adenocarcinoma harboring epidermal growth factor receptor (EGFR) mutations. osimertinib 52-63 epidermal growth factor receptor Homo sapiens 183-187 34289988-0 2021 Targeting c-Myc to overcome acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR tyrosine kinase inhibitor, osimertinib. osimertinib 131-142 epidermal growth factor receptor Homo sapiens 51-55 34289988-1 2021 Osimertinib (AZD9291 or TAGRISSOTM) is a promising and approved third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for treating patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR-activating mutations or the resistant T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 81-113 34289988-1 2021 Osimertinib (AZD9291 or TAGRISSOTM) is a promising and approved third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for treating patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR-activating mutations or the resistant T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 115-119 34289988-1 2021 Osimertinib (AZD9291 or TAGRISSOTM) is a promising and approved third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for treating patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR-activating mutations or the resistant T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 234-238 34289988-1 2021 Osimertinib (AZD9291 or TAGRISSOTM) is a promising and approved third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for treating patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR-activating mutations or the resistant T790M mutation. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 81-113 34289988-1 2021 Osimertinib (AZD9291 or TAGRISSOTM) is a promising and approved third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for treating patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR-activating mutations or the resistant T790M mutation. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 115-119 34289988-1 2021 Osimertinib (AZD9291 or TAGRISSOTM) is a promising and approved third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for treating patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR-activating mutations or the resistant T790M mutation. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 234-238 34289988-5 2021 Osimertinib rapidly and sustainably decreased c-Myc levels primarily via enhancing protein degradation in EGFR-mutant (EGFRm) NSCLC cell lines and xenograft tumors. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 106-110 34217707-3 2021 Consequently, mutant selective third-generation EGFR TKIs represented by AZD9291 (Osimertinib) have been developed to offer more effective therapeutic treatment, but the clinical application is limited by the acquired resistance and the high costs. osimertinib 73-80 epidermal growth factor receptor Homo sapiens 48-52 34217707-3 2021 Consequently, mutant selective third-generation EGFR TKIs represented by AZD9291 (Osimertinib) have been developed to offer more effective therapeutic treatment, but the clinical application is limited by the acquired resistance and the high costs. osimertinib 82-93 epidermal growth factor receptor Homo sapiens 48-52 34575554-1 2021 Osimertinib has become a standard of care in the first-line treatment of advanced-stage non-small-cell lung cancer (NSCLC) harboring exon 19 and 21 activating mutations in the EGFR gene. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 176-180 34575554-3 2021 Acquired resistance mechanisms to osimertinib in EGFR-driven NSCLC include MET amplification, EGFR C797S mutation, neuroendocrine differentiation, small-cell lung carcinoma histologic transformation, PD-L1 and KRAS amplifications and ESR1-AKAP12 and MKRN1-BRAF translocations, as well as BRAF V600 mutation. osimertinib 34-45 epidermal growth factor receptor Homo sapiens 49-53 34575554-3 2021 Acquired resistance mechanisms to osimertinib in EGFR-driven NSCLC include MET amplification, EGFR C797S mutation, neuroendocrine differentiation, small-cell lung carcinoma histologic transformation, PD-L1 and KRAS amplifications and ESR1-AKAP12 and MKRN1-BRAF translocations, as well as BRAF V600 mutation. osimertinib 34-45 epidermal growth factor receptor Homo sapiens 94-98 34575554-5 2021 In this review, we discuss the rationale for EGFR/BRAF/MEK co-inhibition in the light of a clinical case of EGFR-mutant NSCLC developing a BRAF V600 mutation as an acquired resistance mechanism to osimertinib and responding to the association of osimertinib plus dabrafenib and trametinib. osimertinib 197-208 epidermal growth factor receptor Homo sapiens 45-49 34575554-5 2021 In this review, we discuss the rationale for EGFR/BRAF/MEK co-inhibition in the light of a clinical case of EGFR-mutant NSCLC developing a BRAF V600 mutation as an acquired resistance mechanism to osimertinib and responding to the association of osimertinib plus dabrafenib and trametinib. osimertinib 197-208 epidermal growth factor receptor Homo sapiens 108-112 34568058-0 2021 A Phase I Trial of Dasatinib and Osimertinib in TKI Naive Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer. osimertinib 33-44 epidermal growth factor receptor Homo sapiens 81-85 34568058-1 2021 Background: Osimertinib is an effective first-line therapy option for EGFR-mutant NSCLC, but virtually all patients develop resistance. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 70-74 34568058-4 2021 Method: This is a single-arm phase I/II trial of osimertinib and dasatinib in TKI-naive advanced EGFR-mutant NSCLC (NCT02954523). osimertinib 49-60 epidermal growth factor receptor Homo sapiens 97-101 34491978-1 2021 BACKGROUND Osimertinib is an oral third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) approved as first-line therapy for advanced non-small cell lung cancer (NSCLC) with positive EGFR mutation. osimertinib 11-22 epidermal growth factor receptor Homo sapiens 51-83 34491978-1 2021 BACKGROUND Osimertinib is an oral third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) approved as first-line therapy for advanced non-small cell lung cancer (NSCLC) with positive EGFR mutation. osimertinib 11-22 epidermal growth factor receptor Homo sapiens 85-89 34491978-1 2021 BACKGROUND Osimertinib is an oral third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) approved as first-line therapy for advanced non-small cell lung cancer (NSCLC) with positive EGFR mutation. osimertinib 11-22 epidermal growth factor receptor Homo sapiens 216-220 34161878-5 2021 Both pyrimidine analogues 4a and 4b displayed outstanding inhibitory activity against EGFRWT and its two mutated isoforms EGFRL858R and EGFRT790M in comparing to erlotinib and osimertinib as reference drugs. osimertinib 176-187 epidermal growth factor receptor Homo sapiens 86-92 34161879-2 2021 Among the derivatives synthesized, 10c (IC50 = 5.192 nM), 10j (IC50 = 10.35 nM), and 10o (IC50 = 0.3524 nM) exhibited higher potencies against EGFRT790/M/L858R compared to the known EGFR inhibitor AZD-9291 (IC50 = 20.80 nM). osimertinib 197-205 epidermal growth factor receptor Homo sapiens 182-186 34145929-0 2021 MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma. osimertinib 80-91 epidermal growth factor receptor Homo sapiens 49-53 34145929-2 2021 However, due to acquired resistance to EGFR-TKIs, even patients on third-generation osimertinib, have a poor prognosis. osimertinib 84-95 epidermal growth factor receptor Homo sapiens 39-43 34145929-5 2021 We found that after a long-term exposure to gefitinib, the first-generation EGFR-TKI, lung cancer cells harboring the EGFR-TKI-sensitive mutations became resistant to both gefitinib and osimertinib. osimertinib 186-197 epidermal growth factor receptor Homo sapiens 76-80 34258882-2 2021 This study aimed to evaluate the efficacy of sequential afatinib and osimertinib treatment in patients with NSCLC harboring EGFR mutations. osimertinib 69-80 epidermal growth factor receptor Homo sapiens 124-128 34107727-1 2021 The GioTag study assessed how drugs called afatinib and osimertinib affected people with non-small cell lung cancer (NSCLC) who had mutations in the epidermal growth factor receptor (EGFR) gene. osimertinib 56-67 epidermal growth factor receptor Homo sapiens 149-181 34107727-1 2021 The GioTag study assessed how drugs called afatinib and osimertinib affected people with non-small cell lung cancer (NSCLC) who had mutations in the epidermal growth factor receptor (EGFR) gene. osimertinib 56-67 epidermal growth factor receptor Homo sapiens 183-187 34107727-9 2021 This study showed that afatinib followed by osimertinib treatment was effective in patients with NSCLC with EGFR mutations developing T790M resistance mutations on initial afatinib treatment. osimertinib 44-55 epidermal growth factor receptor Homo sapiens 108-112 34410991-0 2021 Acquired EGFR C797G Mutation Detected by Liquid Biopsy as Resistance Mechanism After Treatment With Osimertinib: A Case Report. osimertinib 100-111 epidermal growth factor receptor Homo sapiens 9-13 34410991-1 2021 BACKGROUND: Osimertinib is a third-generation EGFR-tyrosine kinase inhibitor approved for the treatment of T790M-positive non-small-cell lung cancer. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 46-50 34410991-7 2021 CONCLUSION: Our case report revealed a rare EGFR-dependent acquired resistance mutation to osimertinib in circulating tumor DNA. osimertinib 91-102 epidermal growth factor receptor Homo sapiens 44-48 34117553-1 2021 BACKGROUND: We here applied cancer personalized profiling by deep sequencing (CAPP-seq) to analysis of circulating tumor DNA (ctDNA) to identify resistance mechanisms in osimertinib-treated patients with EGFR T790M-positive non-small cell lung cancer (NSCLC). osimertinib 170-181 epidermal growth factor receptor Homo sapiens 204-208 34117553-8 2021 In addition, one patient who underwent a repeat biopsy was found to harbor the C797S mutation of EGFR after disease progression during osimertinib rechallenge, with this mutation not having been detected at the time of initial progression on osimertinib. osimertinib 135-146 epidermal growth factor receptor Homo sapiens 97-101 34498213-15 2021 The pattern of resistance after exposure to osimertinib/bevacizumab includes known mechanisms in the regulation of EGFR, findings that contribute to the understanding and targeting in a stepwise rational this pathway. osimertinib 44-55 epidermal growth factor receptor Homo sapiens 115-119 34564820-2 2021 Osimertinib (Tagrisso ) is an orally administered, third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) that is widely approved for the first-line treatment of advanced NSCLC with activating EGFR mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 197-201 34720947-3 2021 Our case involves a 63-year-old nonsmoking male who was initially diagnosed with EGFR mutation-positive metastatic nonsquamous, non-small cell lung adenocarcinoma, who subsequently developed HCC and squamous cell carcinoma of the femur despite first-line treatment with EGFR-blocking osimertinib. osimertinib 284-295 epidermal growth factor receptor Homo sapiens 81-85 34720947-3 2021 Our case involves a 63-year-old nonsmoking male who was initially diagnosed with EGFR mutation-positive metastatic nonsquamous, non-small cell lung adenocarcinoma, who subsequently developed HCC and squamous cell carcinoma of the femur despite first-line treatment with EGFR-blocking osimertinib. osimertinib 284-295 epidermal growth factor receptor Homo sapiens 270-274 34471361-0 2021 Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 15-19 34471361-1 2021 The use of epidermal growth factor receptor (EGFR) inhibitors such as osimertinib has improved outcomes and quality of life for patients with EGFR-mutated non-small cell lung cancer (NSCLC). osimertinib 70-81 epidermal growth factor receptor Homo sapiens 11-43 34471361-1 2021 The use of epidermal growth factor receptor (EGFR) inhibitors such as osimertinib has improved outcomes and quality of life for patients with EGFR-mutated non-small cell lung cancer (NSCLC). osimertinib 70-81 epidermal growth factor receptor Homo sapiens 45-49 34471361-1 2021 The use of epidermal growth factor receptor (EGFR) inhibitors such as osimertinib has improved outcomes and quality of life for patients with EGFR-mutated non-small cell lung cancer (NSCLC). osimertinib 70-81 epidermal growth factor receptor Homo sapiens 142-146 34471361-3 2021 More recently osimertinib has also shown to be beneficial in patients with resectable NSCLC harboring EGFR mutations irrespective of whether they received adjuvant chemotherapy or not. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 102-106 34471361-6 2021 The aim of this review is to provide a comprehensive review of the data with osimertinib in EGFR mutation positive NSCLC, potential resistance mechanisms and an overview of key ongoing clinical trials. osimertinib 77-88 epidermal growth factor receptor Homo sapiens 92-96 34424565-1 2021 LESSONS LEARNED: Osimertinib has confirmed effectiveness in this real-world population of patients with EGFR-mutant advanced non-small cell lung cancer population. osimertinib 17-28 epidermal growth factor receptor Homo sapiens 104-108 34424565-4 2021 BACKGROUND: Osimertinib became the standard treatment for patients with untreated EGFR-mutant advanced non-small-cell lung cancer (aNSCLC) following results reported in the phase III randomized FLAURA trial. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 82-86 34490108-2 2021 Erlotinib, afatinib, and osimertinib interacted with GZ17-6.02 to kill NSCLC cells expressing mutant EGFR proteins. osimertinib 25-36 epidermal growth factor receptor Homo sapiens 101-105 34391435-1 2021 BACKGROUND: Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations will inevitably develop drug resistance after being treated with the third-generation EGFR-tyrosine kinase inhibitor (TKI), osimertinib. osimertinib 235-246 epidermal growth factor receptor Homo sapiens 61-93 34391435-1 2021 BACKGROUND: Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations will inevitably develop drug resistance after being treated with the third-generation EGFR-tyrosine kinase inhibitor (TKI), osimertinib. osimertinib 235-246 epidermal growth factor receptor Homo sapiens 95-99 34391435-1 2021 BACKGROUND: Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations will inevitably develop drug resistance after being treated with the third-generation EGFR-tyrosine kinase inhibitor (TKI), osimertinib. osimertinib 235-246 epidermal growth factor receptor Homo sapiens 197-201 34391435-10 2021 In patients with EGFR exon 21 L858R mutation, the increased expression levels of miR-184 and miR-3913-5p derived from serum exosomes indicated osimertinib resistance. osimertinib 143-154 epidermal growth factor receptor Homo sapiens 17-21 34532491-1 2021 Osimertinib has efficacy superior to that of standard epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) for the first-line treatment of patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 174-178 34532491-7 2021 The patient with advanced lung adenocarcinoma harboring EGFR exon 19 deletion initially responded to osimertinib with progression-free survival (PFS) lasting 11 months and then developed resistance with an acquired mutation of MET D1228N. osimertinib 101-112 epidermal growth factor receptor Homo sapiens 56-60 34214933-1 2021 OBJECTIVES: Osimertinib is the main treatment choice for pretreated patients with advanced non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) T790M mutations. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 137-169 34214933-1 2021 OBJECTIVES: Osimertinib is the main treatment choice for pretreated patients with advanced non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) T790M mutations. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 171-175 34233230-9 2021 Osimertinib combined with MET inhibition synergistically induces apoptosis in the MET-amplified EGFR mutant NSCLC cells accompanied with augmented DR4 reduction both in vitro and in vivo. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 96-100 34240806-3 2021 Here, we report the case of a 45-year-old Japanese woman with NSCLC positive for EGFR-KDD (duplication of exons 18-25) who developed carcinomatous meningitis and showed a marked response to the EGFR-TKIs erlotinib and osimertinib. osimertinib 218-229 epidermal growth factor receptor Homo sapiens 194-198 34584858-0 2021 Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study. osimertinib 56-67 epidermal growth factor receptor Homo sapiens 90-94 34584858-1 2021 Background: Osimertinib monotherapy is currently the standard of care as a first-line treatment for patients harboring epidermal growth factor receptor (EGFR) mutations; however, some EGFR-mutated non-small cell lung cancer (NSCLC) patients exhibit primary resistance and an insufficient response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 119-151 34584858-1 2021 Background: Osimertinib monotherapy is currently the standard of care as a first-line treatment for patients harboring epidermal growth factor receptor (EGFR) mutations; however, some EGFR-mutated non-small cell lung cancer (NSCLC) patients exhibit primary resistance and an insufficient response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 153-157 34584858-1 2021 Background: Osimertinib monotherapy is currently the standard of care as a first-line treatment for patients harboring epidermal growth factor receptor (EGFR) mutations; however, some EGFR-mutated non-small cell lung cancer (NSCLC) patients exhibit primary resistance and an insufficient response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 184-188 34584858-1 2021 Background: Osimertinib monotherapy is currently the standard of care as a first-line treatment for patients harboring epidermal growth factor receptor (EGFR) mutations; however, some EGFR-mutated non-small cell lung cancer (NSCLC) patients exhibit primary resistance and an insufficient response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 300-304 34584858-1 2021 Background: Osimertinib monotherapy is currently the standard of care as a first-line treatment for patients harboring epidermal growth factor receptor (EGFR) mutations; however, some EGFR-mutated non-small cell lung cancer (NSCLC) patients exhibit primary resistance and an insufficient response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 333-337 34584858-3 2021 Methods: We prospectively assessed advanced NSCLC patients with EGFR mutations who were treated with osimertinib at 14 institutions in Japan between September 2019 and December 2020. osimertinib 101-112 epidermal growth factor receptor Homo sapiens 64-68 34584858-9 2021 Conclusions: Elevated tumor PD-L1 expression is associated with poor outcomes of osimertinib monotherapy in previously untreated advanced NSCLC patients with EGFR mutation. osimertinib 81-92 epidermal growth factor receptor Homo sapiens 158-162 34331582-1 2022 INTRODUCTION: Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 202-206 34330231-0 2021 Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 87-91 34330231-2 2021 This retrospective study aimed to investigate the potential use of osimertinib for preventing LM in patients with advanced epidermal growth factor receptor (EGFR)-mutated NSCLC. osimertinib 67-78 epidermal growth factor receptor Homo sapiens 123-155 34330231-2 2021 This retrospective study aimed to investigate the potential use of osimertinib for preventing LM in patients with advanced epidermal growth factor receptor (EGFR)-mutated NSCLC. osimertinib 67-78 epidermal growth factor receptor Homo sapiens 157-161 34330231-13 2021 CONCLUSION: Real-world data demonstrate that osimertinib can significantly reduce the incidence of LM in patients with advanced NSCLC harboring common EGFR mutations. osimertinib 45-56 epidermal growth factor receptor Homo sapiens 151-155 34462521-0 2021 Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M. osimertinib 105-116 epidermal growth factor receptor Homo sapiens 57-61 34436667-2 2021 PATIENTS AND METHODS: 417 patients had stage III-IV NSCLC harboring EGFR mutation and 154 out of 417 patients receiving osimertinib as >= second-line EGFR-TKI were identified. osimertinib 120-131 epidermal growth factor receptor Homo sapiens 150-154 34436667-9 2021 CONCLUSIONS: This study demonstrates that osimertinib as second line or subsequent TKI in EGFR-TKI-treated patients without identification of T790M revealed lower risk of death compared to first-line first/second generation TKI without subsequent osimertinib, in real-world practice. osimertinib 42-53 epidermal growth factor receptor Homo sapiens 90-94 34436667-10 2021 Additionally, EGFR-mutant patients with PD-L1 expression >= 50% had a higher risk of treatment failure for osimertinib and worse overall survival than those with PD-L1 expression < 50%. osimertinib 107-118 epidermal growth factor receptor Homo sapiens 14-18 34413682-1 2021 Purpose: Although patients with primary and acquired epidermal growth factor receptor (EGFR) T790M positive non-small-cell lung cancer (NSCLC) respond to osimertinib treatment, the optimal treatment strategy differs for these two groups of patients. osimertinib 154-165 epidermal growth factor receptor Homo sapiens 53-85 34413682-1 2021 Purpose: Although patients with primary and acquired epidermal growth factor receptor (EGFR) T790M positive non-small-cell lung cancer (NSCLC) respond to osimertinib treatment, the optimal treatment strategy differs for these two groups of patients. osimertinib 154-165 epidermal growth factor receptor Homo sapiens 87-91 34445227-0 2021 EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer. osimertinib 72-83 epidermal growth factor receptor Homo sapiens 32-36 34445227-1 2021 Osimertinib is the latest generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor used for patients with EGFR-mutated non-small cell lung cancer (NSCLC). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 37-69 34445227-1 2021 Osimertinib is the latest generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor used for patients with EGFR-mutated non-small cell lung cancer (NSCLC). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 71-75 34445227-1 2021 Osimertinib is the latest generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor used for patients with EGFR-mutated non-small cell lung cancer (NSCLC). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 126-130 34445227-2 2021 We aimed to explore the novel mechanisms of osimertinib by particularly focusing on EGFR-independent effects, which have not been well characterized. osimertinib 44-55 epidermal growth factor receptor Homo sapiens 84-88 34445227-3 2021 We explored the EGFR-independent effects of osimertinib on cell proliferation using NSCLC cell lines, an antibody array analysis, and the association between the action of osimertinib and the ephrin receptor B4 (EphB4). osimertinib 44-55 epidermal growth factor receptor Homo sapiens 16-20 34445227-8 2021 EphB4 is associated with the EGFR-independent suppressive effects of osimertinib on cell cycle and with a poor clinical outcome. osimertinib 69-80 epidermal growth factor receptor Homo sapiens 29-33 34445227-9 2021 Osimertinib can exert significant growth inhibitory effects in EGFR-mutated NSCLC patients with a high EphB4 status. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 63-67 34344199-0 2022 Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC. osimertinib 62-73 epidermal growth factor receptor Homo sapiens 12-16 34344199-0 2022 Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC. osimertinib 62-73 epidermal growth factor receptor Homo sapiens 77-81 34097913-1 2021 Third-generation inhibitors of the epidermal growth factor receptor (EGFR), best exemplified by osimertinib, have been developed to selectively target variants of EGFR bearing activating mutations and the mutation of gatekeeper T790 in patients with EGFR-mutated forms of Non-Small Cell Lung Cancer (NSCLC). osimertinib 96-107 epidermal growth factor receptor Homo sapiens 69-73 34097913-1 2021 Third-generation inhibitors of the epidermal growth factor receptor (EGFR), best exemplified by osimertinib, have been developed to selectively target variants of EGFR bearing activating mutations and the mutation of gatekeeper T790 in patients with EGFR-mutated forms of Non-Small Cell Lung Cancer (NSCLC). osimertinib 96-107 epidermal growth factor receptor Homo sapiens 163-167 34097913-1 2021 Third-generation inhibitors of the epidermal growth factor receptor (EGFR), best exemplified by osimertinib, have been developed to selectively target variants of EGFR bearing activating mutations and the mutation of gatekeeper T790 in patients with EGFR-mutated forms of Non-Small Cell Lung Cancer (NSCLC). osimertinib 96-107 epidermal growth factor receptor Homo sapiens 250-254 34157597-1 2021 The C797S mutation encoded by EGFR exon 20 is classically observed as a tertiary event in EGFR-mutant non-small-cell lung carcinoma (NSCLC) primarily treated by first generation tyrosine kinase inhibitors (TKI) and secondarily treated by third-generation TKI, such as osimertinib, if the EGFR-T790M resistance mutation is detected. osimertinib 268-279 epidermal growth factor receptor Homo sapiens 30-34 34157597-4 2021 We report the case of a 65 year-old female treated by first-line osimertinib for a multimetastatic exon 19-EGFR-mutant NSCLC. osimertinib 65-76 epidermal growth factor receptor Homo sapiens 107-111 34309914-7 2022 RESULTS AND DISCUSSION: Osimertinib was confirmed to have a several-fold higher CNS permeability than other EGFR-TKIs and was recommended as the preferred choice for patients with EGFR-positive LM whether or not they harboured the T790M mutation. osimertinib 24-35 epidermal growth factor receptor Homo sapiens 180-184 34366844-0 2021 Effect of Osimertinib in Combination With Chemotherapy and Bevacizumab for Untreated Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer: Case Report. osimertinib 10-21 epidermal growth factor receptor Homo sapiens 85-117 34366844-1 2021 Introduction: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 170-174 34366844-1 2021 Introduction: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 195-199 34321891-3 2021 Here, we report that a lung adenocarcinoma patient with EGFR L858R mutation who was treated with second-line osimertinib therapy acquired multiple resistance to osimertinib by the non-invasive circulating tumor DNA (ctDNA) genotyping. osimertinib 109-120 epidermal growth factor receptor Homo sapiens 56-60 34321891-3 2021 Here, we report that a lung adenocarcinoma patient with EGFR L858R mutation who was treated with second-line osimertinib therapy acquired multiple resistance to osimertinib by the non-invasive circulating tumor DNA (ctDNA) genotyping. osimertinib 161-172 epidermal growth factor receptor Homo sapiens 56-60 34327032-13 2021 Because the tumor tissue was found to be positive for the EGFR T790M resistance mutation by bronchoscopy, the EGFR-TKI treatment was changed to osimertinib, decreasing the size of the lung cancer lesions. osimertinib 144-155 epidermal growth factor receptor Homo sapiens 110-114 34267282-3 2021 Using spectrometry-based proteomics, we identified increased fibroblast growth factor receptor 1 (FGFR1) expression and Akt activation across erlotinib, gefitinib, and osimertinib EGFR-TKI-resistant cell line models. osimertinib 168-179 epidermal growth factor receptor Homo sapiens 180-184 34298655-2 2021 We generated a new state-of-the-art mouse strain harboring the human EGFRT790M/L858R oncogene and MET overexpression (EGFR/MET strain) that mimics the MET amplification occurring in one out of five patients with EGFR-mutated lung cancer that relapsed after treatment with osimertinib, a third-generation anti-EGFR TKI. osimertinib 272-283 epidermal growth factor receptor Homo sapiens 118-122 34298655-2 2021 We generated a new state-of-the-art mouse strain harboring the human EGFRT790M/L858R oncogene and MET overexpression (EGFR/MET strain) that mimics the MET amplification occurring in one out of five patients with EGFR-mutated lung cancer that relapsed after treatment with osimertinib, a third-generation anti-EGFR TKI. osimertinib 272-283 epidermal growth factor receptor Homo sapiens 212-216 34298655-2 2021 We generated a new state-of-the-art mouse strain harboring the human EGFRT790M/L858R oncogene and MET overexpression (EGFR/MET strain) that mimics the MET amplification occurring in one out of five patients with EGFR-mutated lung cancer that relapsed after treatment with osimertinib, a third-generation anti-EGFR TKI. osimertinib 272-283 epidermal growth factor receptor Homo sapiens 309-313 34298655-4 2021 Moreover, EGFR/MET-driven lung tumors were resistant to osimertinib, recapitulating the phenotype observed in patients. osimertinib 56-67 epidermal growth factor receptor Homo sapiens 10-14 34298655-5 2021 Conversely, as also observed in patients, the crizotinib (anti-MET TKI) and osimertinib combination improved survival and reduced tumor burden in EGFR/MET mice, further validating the model"s value for preclinical studies. osimertinib 76-87 epidermal growth factor receptor Homo sapiens 146-150 34326746-0 2021 Response to a Combination of Full-Dose Osimertinib and Ceritinib in a Non-Small Cell Lung Cancer Patient with EML4-ALK Rearrangement and Epidermal Growth Factor Receptor Co-Mutation. osimertinib 39-50 epidermal growth factor receptor Homo sapiens 137-169 34326746-5 2021 Here, we report a patient with concomitant ALK rearrangement and EGFR mutation treated with a combination of TKIs: osimertinib and ceritinib. osimertinib 115-126 epidermal growth factor receptor Homo sapiens 65-69 34240438-2 2022 We report a case of fingerprint loss secondary to combination therapy using osimertinib (an EGFR TKI that targets mutated EGFR kinases) and anlotinib (a TKI that acts on multiple targets including mutated VEGFR kinases). osimertinib 76-87 epidermal growth factor receptor Homo sapiens 92-96 34240438-2 2022 We report a case of fingerprint loss secondary to combination therapy using osimertinib (an EGFR TKI that targets mutated EGFR kinases) and anlotinib (a TKI that acts on multiple targets including mutated VEGFR kinases). osimertinib 76-87 epidermal growth factor receptor Homo sapiens 122-126 34263613-0 2022 Nasogastric administration of osimertinib suspension for an epidermal growth factor receptor-mutated lung cancer causing an esophageal stricture: case report. osimertinib 30-41 epidermal growth factor receptor Homo sapiens 60-92 34263613-4 2022 Osimertinib is a third-generation EGFR-tyrosine kinase inhibitor that is efficacious against EGFR-sensitizing mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 34-38 34263613-4 2022 Osimertinib is a third-generation EGFR-tyrosine kinase inhibitor that is efficacious against EGFR-sensitizing mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 93-97 34306781-4 2021 However, there is a small percentage of primarily resistant cases to osimertinib, mainly due to histologic transformation, acquired EGFR mutations and off-target genetic resistances that lead to a scenery of poor clinical prognosis in which radiotherapy may have a higher relevance for the management of brain metastases. osimertinib 69-80 epidermal growth factor receptor Homo sapiens 132-136 34430591-7 2021 One patient, with EGFR exon 19 deletion (Ex19del), accepted first-line gefitinib treatment and then received osimertinib treatment due to acquisition of an EGFR-T790M mutation. osimertinib 109-120 epidermal growth factor receptor Homo sapiens 156-160 34564820-2 2021 Osimertinib (Tagrisso ) is an orally administered, third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) that is widely approved for the first-line treatment of advanced NSCLC with activating EGFR mutations. osimertinib 13-21 epidermal growth factor receptor Homo sapiens 197-201 34564820-3 2021 In the pivotal phase III FLAURA trial, osimertinib significantly prolonged progression-free survival (PFS) and overall survival (OS) relative to first-generation EGFR-TKIs in patients with previously untreated, EGFR mutation-positive, advanced NSCLC. osimertinib 39-50 epidermal growth factor receptor Homo sapiens 211-215 34764521-0 2021 Refinement of Covalent EGFR Inhibitor AZD9291 to Eliminate Off-target Activity. osimertinib 38-45 epidermal growth factor receptor Homo sapiens 23-27 34764521-2 2021 Tyrosine kinase inhibitors (TKIs) that target EGFR have been used for the treatment of NSCLC, but often develop drug resistance, and the covalent inhibitor AZD9291 has been developed to tackle the problem of drug resistance mediated by the T790M EGFR mutation; however, there is a side effect of hyperglycemia that may be due to off-target activity. osimertinib 156-163 epidermal growth factor receptor Homo sapiens 246-250 34764521-3 2021 This study examines analogues of AZD9291 by chemical proteomics, identifying analogues that maintain T790M-EGFR engagement while showing reduced cross-reactivity with off-targets. osimertinib 33-40 epidermal growth factor receptor Homo sapiens 107-111 34140482-0 2021 Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer. osimertinib 62-73 epidermal growth factor receptor Homo sapiens 109-113 34397683-0 2021 Dramatic response to osimertinib combined with crizotinib in EGFR T790 M mutation only in blood and Met amplification only in tumor tissue expressive non-small cell lung cancer: A case report. osimertinib 21-32 epidermal growth factor receptor Homo sapiens 61-65 34397683-3 2021 PATIENT CONCERNS: A non-smoking 53-year-old male patient with lung adenocarcinoma underwent gefitinib, afatinib, and osimertinib combined with crizotinib treatment and developed different EGFR resistance mutations. osimertinib 117-128 epidermal growth factor receptor Homo sapiens 188-192 34397683-8 2021 LESSONS: Although osimertinib combined with crizotinib therapy showed dramatic tumor shrinkage in both the primary tumor and bone metastasis to an EGFR T790M-mutant NSCLC patient with MET amplification, the progression-free survival (PFS) was only two months. osimertinib 18-29 epidermal growth factor receptor Homo sapiens 147-151 34140482-1 2021 Despite the clinical success of the third-generation EGFR inhibitor osimertinib as a first-line treatment of EGFR-mutant non-small cell lung cancer (NSCLC), resistance arises due to the acquisition of EGFR second-site mutations and other mechanisms, which necessitates alternative therapies. osimertinib 68-79 epidermal growth factor receptor Homo sapiens 53-57 34140482-1 2021 Despite the clinical success of the third-generation EGFR inhibitor osimertinib as a first-line treatment of EGFR-mutant non-small cell lung cancer (NSCLC), resistance arises due to the acquisition of EGFR second-site mutations and other mechanisms, which necessitates alternative therapies. osimertinib 68-79 epidermal growth factor receptor Homo sapiens 109-113 34140482-1 2021 Despite the clinical success of the third-generation EGFR inhibitor osimertinib as a first-line treatment of EGFR-mutant non-small cell lung cancer (NSCLC), resistance arises due to the acquisition of EGFR second-site mutations and other mechanisms, which necessitates alternative therapies. osimertinib 68-79 epidermal growth factor receptor Homo sapiens 201-205 34601320-6 2021 NCI-H1975 cells which have an EGFR T790M mutation and an EGFR L858R mutation, were sensitive to osimertinib when propagated as spheroids but not when grown in monolayer. osimertinib 96-107 epidermal growth factor receptor Homo sapiens 30-34 34203709-2 2021 Multiple receptor tyrosine kinase (RTK) pathways contribute to the resistance of NSCLC to first- and third-generation EGFR-TKIs, such as erlotinib and osimertinib. osimertinib 151-162 epidermal growth factor receptor Homo sapiens 118-122 34178120-1 2021 Osimertinib is a third-generation tyrosine kinase inhibitor that became the preferred first-line treatment option for metastatic non-small cell lung cancer with sensitizing epidermal growth factor receptor mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 173-205 34103652-0 2021 The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M. osimertinib 83-94 epidermal growth factor receptor Homo sapiens 35-39 34103652-1 2021 The impact of different first-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)s to the clinical efficacy of osimertinib in EGFR-mutant non-small-cell lung cancer (NSCLC) patients with acquired T790M was still unclear. osimertinib 136-147 epidermal growth factor receptor Homo sapiens 35-67 34103652-1 2021 The impact of different first-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)s to the clinical efficacy of osimertinib in EGFR-mutant non-small-cell lung cancer (NSCLC) patients with acquired T790M was still unclear. osimertinib 136-147 epidermal growth factor receptor Homo sapiens 69-73 34103652-1 2021 The impact of different first-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)s to the clinical efficacy of osimertinib in EGFR-mutant non-small-cell lung cancer (NSCLC) patients with acquired T790M was still unclear. osimertinib 136-147 epidermal growth factor receptor Homo sapiens 151-155 34350252-0 2021 Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 33-65 34350265-2 2021 Osimertinib is one of the third-generation EGFR-TKIs and is currently the most advanced in clinical development. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 43-47 34073111-0 2021 Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR. osimertinib 95-106 epidermal growth factor receptor Homo sapiens 13-17 34073111-4 2021 In the present study we detected EGFR mutations in ctDNA and paired CTCs under osimertinib therapy at two time points using crystal dPCR and the naica system (Stilla Technologies). osimertinib 79-90 epidermal growth factor receptor Homo sapiens 33-37 34164239-0 2021 A Rare Case of Small Cell Lung Cancer With an Epidermal Growth Factor Receptor Mutation and Its Response to Osimertinib. osimertinib 108-119 epidermal growth factor receptor Homo sapiens 46-78 34164239-5 2021 We report a case of EGFR-positive metastatic SCLC in a 63-year-old female who was treated with the third-generation TKI, osimertinib. osimertinib 121-132 epidermal growth factor receptor Homo sapiens 20-24 34590033-3 2021 BRAF V600E, as a bypass mechanism on disease progression while receiving osimertinib therapy, has been reported in 3% of EGFR-mutated patients. osimertinib 73-84 epidermal growth factor receptor Homo sapiens 121-125 34070173-4 2021 It was revealed that osimertinib, an ATP-competitive covalent EGFR inhibitor, remarkably enhanced the affinity of a recently developed allosteric inhibitor JBJ-04-125-02 for EGFRL858R/T790M. osimertinib 21-32 epidermal growth factor receptor Homo sapiens 62-66 34070173-5 2021 Here, we utilized extensive large-scale molecular dynamics simulations and the reversed allosteric communication to untangle the detailed molecular underpinning, in which occupation of osimertinib at the orthosteric site altered the overall conformational ensemble of EGFR mutant and reshaped the allosteric site via long-distance signaling. osimertinib 185-196 epidermal growth factor receptor Homo sapiens 268-272 34590035-0 2021 EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma. osimertinib 117-128 epidermal growth factor receptor Homo sapiens 0-4 34590035-12 2021 We also report the first clinical evidence of efficacy generated by osimertinib in patients with lung adenocarcinoma harboring primary or acquired EGFR T790L, shedding light on treatment options for this subset of patients. osimertinib 68-79 epidermal growth factor receptor Homo sapiens 147-151 34150410-5 2021 This likely represents a synergistic relationship between an epidermal growth factor receptor inhibitor, osimertinib, and a vascular endothelial growth factor receptor inhibitor, ramucirumab. osimertinib 105-116 epidermal growth factor receptor Homo sapiens 61-93 34590037-1 2021 Introduction: Although treatment with osimertinib confers survival benefits in patients with lung cancer with the EGFR T790M mutation, the mechanism of acquired resistance to osimertinib remains poorly understood. osimertinib 38-49 epidermal growth factor receptor Homo sapiens 114-118 34068720-2 2021 Osimertinib is a tyrosine kinase approved and effective in treating lung adenocarcinomas that have one of several common activating mutations in epidermal growth factor receptor. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 145-177 34590028-1 2021 Introduction: MET amplification is a frequently observed mechanism of resistance to osimertinib, and coinhibition strategy of MET and EGFR revealed promising results in recent clinical trials. osimertinib 84-95 epidermal growth factor receptor Homo sapiens 134-138 34590028-4 2021 Methods: Whole-exome sequencing was performed in EGFR-mutant, MET-amplified patients who received osimertinib and savolitinib using tissues obtained both before and after therapy. osimertinib 98-109 epidermal growth factor receptor Homo sapiens 49-53 34590027-2 2021 However, despite its high initial response rates, multiple EGFR-independent mechanisms of resistance have been reported in patients receiving osimertinib. osimertinib 142-153 epidermal growth factor receptor Homo sapiens 59-63 34590027-5 2021 In our case report, we present a patient with EGFR-mutant advanced NSCLC who developed an acquired EML4-ALK rearrangement mediating resistance to osimertinib, which was overcome by using a combination of osimertinib with the ALK tyrosine kinase inhibitor alectinib. osimertinib 146-157 epidermal growth factor receptor Homo sapiens 46-50 34590027-5 2021 In our case report, we present a patient with EGFR-mutant advanced NSCLC who developed an acquired EML4-ALK rearrangement mediating resistance to osimertinib, which was overcome by using a combination of osimertinib with the ALK tyrosine kinase inhibitor alectinib. osimertinib 204-215 epidermal growth factor receptor Homo sapiens 46-50 34250398-1 2021 Patients with EGFR-mutant lung cancer have no approved targeted therapies after disease progression on first-line osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). osimertinib 114-125 epidermal growth factor receptor Homo sapiens 146-178 34250398-1 2021 Patients with EGFR-mutant lung cancer have no approved targeted therapies after disease progression on first-line osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). osimertinib 114-125 epidermal growth factor receptor Homo sapiens 180-184 34250398-2 2021 Preclinical studies suggest that tumors with both EGFR-sensitizing alteration and acquired second-site EGFR resistance alterations after treatment with osimertinib retain sensitivity to second-generation EGFR TKIs. osimertinib 152-163 epidermal growth factor receptor Homo sapiens 103-107 34250398-2 2021 Preclinical studies suggest that tumors with both EGFR-sensitizing alteration and acquired second-site EGFR resistance alterations after treatment with osimertinib retain sensitivity to second-generation EGFR TKIs. osimertinib 152-163 epidermal growth factor receptor Homo sapiens 204-208 34557754-4 2021 The first-generation TKIs include erlotinib, gefitinib, lapatinib, and icotinib; the second-generation ErbB family blockers include afatinib, neratinib, and dacomitinib; whereas osimertinib, approved by the FDA on 2015, is a third-generation TKI targeting EGFR harboring specific mutations. osimertinib 178-189 epidermal growth factor receptor Homo sapiens 256-260 34095710-0 2021 Exceptional Response of a Large and Symptomatic EGFR-Mutant Brain Metastasis to Osimertinib: Case Report and Review of the Literature. osimertinib 80-91 epidermal growth factor receptor Homo sapiens 48-52 34590012-0 2021 Intracranial Activity of Osimertinib Plus Capmatinib in a Patient With EGFR and MET-Driven Lung Cancer: Case Report. osimertinib 25-36 epidermal growth factor receptor Homo sapiens 71-75 34590012-1 2021 We previously published in the Journal of Thoracic Oncology the case of a patient with EGFR and MET-driven lung cancer and extracranial response to capmatinib and osimertinib. osimertinib 163-174 epidermal growth factor receptor Homo sapiens 87-91 34601320-6 2021 NCI-H1975 cells which have an EGFR T790M mutation and an EGFR L858R mutation, were sensitive to osimertinib when propagated as spheroids but not when grown in monolayer. osimertinib 96-107 epidermal growth factor receptor Homo sapiens 57-61 34589970-0 2021 Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M-Positive NSCLC. osimertinib 105-116 epidermal growth factor receptor Homo sapiens 138-142 34589970-2 2021 Osimertinib is the standard of care for patients with NSCLC with acquired EGFR T790M mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 74-78 34589970-13 2021 Conclusions: In patients with EGFR-mutated advanced NSCLC, persistent EGFR T790M or increasing activating mutation AF as detected in ctDNA 4 weeks after the start of osimertinib treatment may predict disease progression within 16 weeks. osimertinib 166-177 epidermal growth factor receptor Homo sapiens 30-34 35551303-8 2022 Studies using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs) drugs gefitinib and osimertinib showed clinically relevant responses. osimertinib 107-118 epidermal growth factor receptor Homo sapiens 14-46 35551303-8 2022 Studies using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs) drugs gefitinib and osimertinib showed clinically relevant responses. osimertinib 107-118 epidermal growth factor receptor Homo sapiens 48-52 35473448-2 2022 This is relevant in the context of the recently approved introduction of adjuvant EGFR-targeting therapy, specifically osimertinib in resected stage II-III EGFR-mutated NSCLC. osimertinib 119-130 epidermal growth factor receptor Homo sapiens 82-86 35045945-11 2022 Moreover, EGFR C797S mutation was detected in 1 patient after resistant to osimertinib treatment. osimertinib 75-86 epidermal growth factor receptor Homo sapiens 10-14 35621675-11 2022 Due to EGFR gene mutation, the woman was administered osimertinib, however, the treatment did not succeed, and other therapeutic solutions were undertaken. osimertinib 54-65 epidermal growth factor receptor Homo sapiens 7-11 35621675-13 2022 Patients with advanced ADC harboring EGFR mutation can receive osimertinib, a third-generation tyrosine kinase inhibitor (TKI), however, the use of TKIs in SCC remains controversial. osimertinib 63-74 epidermal growth factor receptor Homo sapiens 37-41 35527328-0 2022 Osimertinib, Surgery, and Radiation Therapy in Treating Patients with Stage IIIB or IV Non-Small Cell Lung Cancer with EGFR Mutations (NORTHSTAR). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 119-123 35378738-5 2022 Likewise, tyrosine kinase inhibitor drugs such as osimertinib used in lung cancer patients with epidermal growth factor receptor (EGFR) mutation are associated with heart failure or prolongation of the QT interval. osimertinib 50-61 epidermal growth factor receptor Homo sapiens 96-128 35378738-5 2022 Likewise, tyrosine kinase inhibitor drugs such as osimertinib used in lung cancer patients with epidermal growth factor receptor (EGFR) mutation are associated with heart failure or prolongation of the QT interval. osimertinib 50-61 epidermal growth factor receptor Homo sapiens 130-134 35378738-6 2022 CASE REPORT: 62-year-old woman diagnosed in September 2019 of lung adenocarcinoma stage IV with bilateral lung and lymph node involvement, carrier of an EGFR mutation (Ex19Del) on treatment with osimertinib. osimertinib 195-206 epidermal growth factor receptor Homo sapiens 153-157 35037771-1 2022 INTRODUCTION: Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR) used for the treatment of non-small cell lung cancer (NSCLC) presenting an EGFR mutation. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 83-115 35037771-1 2022 INTRODUCTION: Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR) used for the treatment of non-small cell lung cancer (NSCLC) presenting an EGFR mutation. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 117-121 35037771-1 2022 INTRODUCTION: Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR) used for the treatment of non-small cell lung cancer (NSCLC) presenting an EGFR mutation. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 198-202 35037771-2 2022 Although Osimertinib has a better safety profile compared to older EGFR-TKIs and although adverse events (AEs) are described in literature, recently the relationship between Osimertinib therapy and cardiotoxicity is gaining attention. osimertinib 174-185 epidermal growth factor receptor Homo sapiens 67-71 35294773-4 2022 These results led to osimertinib"s fast track approval by the US Food and Drug Administration, with this drug thus becoming the first EGFR-TKI approved for the treatment of early-stage disease. osimertinib 21-32 epidermal growth factor receptor Homo sapiens 134-138 35633141-7 2022 Multivariate analysis confirmed that both EGFR-TKI treatment (osimertinib hazard ratio (HR) 0.06, 95% confidence interval (CI) 0.01-0.30; afatinib HR 0.09, 95% CI 0.02-0.39) and a low T790M ratio (HR 0.29, 95% CI 0.12-0.69) were independently favorable prognostic factors for patients with de novo T790M+ NSCLC. osimertinib 62-73 epidermal growth factor receptor Homo sapiens 42-46 35633141-9 2022 In addition, patients treated with first-generation (1G)/second-generation (2G) EGFR-TKIs followed by osimertinib (n = 8) demonstrated the best OS compared with patients treated with frontline osimertinib (n = 5) or 1G/2G EGFR-TKIs without osimertinib (n = 28, p < 0.01). osimertinib 102-113 epidermal growth factor receptor Homo sapiens 222-226 35633141-9 2022 In addition, patients treated with first-generation (1G)/second-generation (2G) EGFR-TKIs followed by osimertinib (n = 8) demonstrated the best OS compared with patients treated with frontline osimertinib (n = 5) or 1G/2G EGFR-TKIs without osimertinib (n = 28, p < 0.01). osimertinib 240-251 epidermal growth factor receptor Homo sapiens 80-84 35596880-7 2022 Finally, for epidermal growth factor receptor (EGFR) mutant NSCLC, a phase III trial of osimertinib compared with SOC revealed an improvement in DFS. osimertinib 88-99 epidermal growth factor receptor Homo sapiens 13-45 35596880-7 2022 Finally, for epidermal growth factor receptor (EGFR) mutant NSCLC, a phase III trial of osimertinib compared with SOC revealed an improvement in DFS. osimertinib 88-99 epidermal growth factor receptor Homo sapiens 47-51 35626421-6 2022 Osimertinib given as a second-line treatment eliminated the EGFR-T790M population and simultaneously consolidated the proliferation of the TP53 + RB1 clone that eventually led to the histologic transformation to small-cell lung cancer (SCLC). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 60-64 35045945-12 2022 CONCLUSION: Presence of EGFR T854A mutation was rare in NSCLC patients and our retrospective study provides clinical evidence that osimertinib may be an effective treatment to improve survival outcomes in patients with EGFR T854A. osimertinib 131-142 epidermal growth factor receptor Homo sapiens 24-28 35045945-12 2022 CONCLUSION: Presence of EGFR T854A mutation was rare in NSCLC patients and our retrospective study provides clinical evidence that osimertinib may be an effective treatment to improve survival outcomes in patients with EGFR T854A. osimertinib 131-142 epidermal growth factor receptor Homo sapiens 219-223 35530643-11 2022 CONCLUSION: EGFR-mutant NSCLC patients with negative tumor PD-L1 expression showed a higher rate of acquisition of the T790M mutation and implementation rate of osimertinib therapy, leading to a longer time on treatment with EGFR-TKI. osimertinib 161-172 epidermal growth factor receptor Homo sapiens 225-229 35534623-4 2022 Both "on-target" mechanisms (largely mediated by acquired resistance mutations in the kinase domains of EGFR or ALK) and "off-target" mechanisms of resistance (mediated by non-target kinase alterations such as bypass signalling activation or phenotypic transformation) have been identified in patients with disease progression on osimertinib or lorlatinib. osimertinib 330-341 epidermal growth factor receptor Homo sapiens 104-108 35499406-0 2022 HJM-561, a potent, selective and orally bioavailable EGFR PROTAC that overcomes osimertinib-resistant EGFR triple mutations. osimertinib 80-91 epidermal growth factor receptor Homo sapiens 102-106 35499406-1 2022 The epidermal growth factor receptor (EGFR) C797S mutation is the most common on-target resistance mechanism to osimertinib in patients with advanced non-small-cell lung cancer (NSCLC). osimertinib 112-123 epidermal growth factor receptor Homo sapiens 4-36 35499406-1 2022 The epidermal growth factor receptor (EGFR) C797S mutation is the most common on-target resistance mechanism to osimertinib in patients with advanced non-small-cell lung cancer (NSCLC). osimertinib 112-123 epidermal growth factor receptor Homo sapiens 38-42 35489768-1 2022 BACKGROUND/AIM: Real-world data on the clinical outcomes of first-line osimertinib treatment for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations is lacking. osimertinib 71-82 epidermal growth factor receptor Homo sapiens 137-169 35489768-1 2022 BACKGROUND/AIM: Real-world data on the clinical outcomes of first-line osimertinib treatment for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations is lacking. osimertinib 71-82 epidermal growth factor receptor Homo sapiens 171-175 35489768-3 2022 PATIENTS AND METHODS: We retrospectively evaluated clinical outcomes of patients with EGFR-mutated NSCLC treated with osimertinib as first-line therapy across 12 institutions in Japan between August 2018 and March 2020. osimertinib 118-129 epidermal growth factor receptor Homo sapiens 86-90 35511414-8 2022 CONCLUSION: Concomitant use of bevacizumab and osimertinib in NSCLC patients with EGFR T790M mutation may have potential therapeutic effect than osimertinib alone. osimertinib 47-58 epidermal growth factor receptor Homo sapiens 82-86 35530643-11 2022 CONCLUSION: EGFR-mutant NSCLC patients with negative tumor PD-L1 expression showed a higher rate of acquisition of the T790M mutation and implementation rate of osimertinib therapy, leading to a longer time on treatment with EGFR-TKI. osimertinib 161-172 epidermal growth factor receptor Homo sapiens 12-16 35468939-8 2022 KLHDC3 shortage significantly increased the sensitivity of lung cancer cells to epidermal growth factor receptor (EGFR)-targeted drugs, providing an alternative explanation for the development of Gefitinib and Osimertinib resistance in NSCLC therapy. osimertinib 210-221 epidermal growth factor receptor Homo sapiens 80-112 35023208-1 2022 WHAT IS KNOWN AND OBJECTIVE: Although osimertinib achieved convincing efficacy for patients with EGFR T790M-positive non-small-cell lung cancer (NSCLC) as second-line treatment in the AURA3 clinical trials, patients developed drug resistance ultimately. osimertinib 38-49 epidermal growth factor receptor Homo sapiens 97-101 35468939-8 2022 KLHDC3 shortage significantly increased the sensitivity of lung cancer cells to epidermal growth factor receptor (EGFR)-targeted drugs, providing an alternative explanation for the development of Gefitinib and Osimertinib resistance in NSCLC therapy. osimertinib 210-221 epidermal growth factor receptor Homo sapiens 114-118 35348294-2 2022 Pigmentary changes caused by EGFR-TKIs are unusual, and to the best of my knowledge, hyperpigmentation with osimertinib has rarely been reported as a skin-related adverse event. osimertinib 108-119 epidermal growth factor receptor Homo sapiens 29-33 35571073-3 2022 Materials and methods: Patients with resectable NSCLC with epidermal growth factor receptor (EGFR) mutation who received osimertinib as neoadjuvant therapy followed by surgery at our center were included. osimertinib 121-132 epidermal growth factor receptor Homo sapiens 59-91 35571073-3 2022 Materials and methods: Patients with resectable NSCLC with epidermal growth factor receptor (EGFR) mutation who received osimertinib as neoadjuvant therapy followed by surgery at our center were included. osimertinib 121-132 epidermal growth factor receptor Homo sapiens 93-97 35571073-15 2022 Conclusion: Neoadjuvant osimertinib therapy seemed to be safe and feasible for resectable EGFR-mutated NSCLC. osimertinib 24-35 epidermal growth factor receptor Homo sapiens 90-94 35445633-1 2022 Osimertinib, almonertinib and furmonertinib are third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) approved for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 126-130 35445633-1 2022 Osimertinib, almonertinib and furmonertinib are third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) approved for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 199-203 35506019-3 2022 The ADAURA trial is a randomized placebo-controlled Phase III trial that demonstrated statistically significant improved disease-free survival (DFS) with the use of 3-years of adjuvant osimertinib in resected stage IB-IIIA NSCLC harboring epidermal growth factor receptor (EGFR) del 19 or L858R mutations. osimertinib 185-196 epidermal growth factor receptor Homo sapiens 239-271 35506019-3 2022 The ADAURA trial is a randomized placebo-controlled Phase III trial that demonstrated statistically significant improved disease-free survival (DFS) with the use of 3-years of adjuvant osimertinib in resected stage IB-IIIA NSCLC harboring epidermal growth factor receptor (EGFR) del 19 or L858R mutations. osimertinib 185-196 epidermal growth factor receptor Homo sapiens 273-277 35467492-0 2022 Osimertinib and chemotherapy combination to treat brain metastasis flare and osimertinib resistance by EGFR C797S. osimertinib 77-88 epidermal growth factor receptor Homo sapiens 103-107 35467492-3 2022 In this case, we describe a young woman who has extracranial progressive disease due to EGFR C797S resistance mutation while being treated with osimertinib, with a rapid neurological deterioration after osimertinib withdrawal due to flare-phenomenon progression in the brain, and a prompt intracranial response with osimertinib reintroduction in addition to chemotherapy to achieve extracranial diseases control. osimertinib 144-155 epidermal growth factor receptor Homo sapiens 88-92 35467492-3 2022 In this case, we describe a young woman who has extracranial progressive disease due to EGFR C797S resistance mutation while being treated with osimertinib, with a rapid neurological deterioration after osimertinib withdrawal due to flare-phenomenon progression in the brain, and a prompt intracranial response with osimertinib reintroduction in addition to chemotherapy to achieve extracranial diseases control. osimertinib 316-327 epidermal growth factor receptor Homo sapiens 88-92 35461372-12 2022 Targeting Hsa-miR-22-3p and Hsa-miR-184 desensitized EGFR-mutated (T790M, L578R) NSCLC cells to Osimertinib. osimertinib 96-107 epidermal growth factor receptor Homo sapiens 53-57 35446957-2 2022 In the FLAURA study, osimertinib, third-generation EGFR-TKI, resulted in significantly longer progression-free survival and overall survival (OS) than first-generation EGFR-TKIs (gefitinib or erlotinib) in patients with previously untreated advanced NSCLC with an EGFR activating mutation. osimertinib 21-32 epidermal growth factor receptor Homo sapiens 51-55 35446957-2 2022 In the FLAURA study, osimertinib, third-generation EGFR-TKI, resulted in significantly longer progression-free survival and overall survival (OS) than first-generation EGFR-TKIs (gefitinib or erlotinib) in patients with previously untreated advanced NSCLC with an EGFR activating mutation. osimertinib 21-32 epidermal growth factor receptor Homo sapiens 264-268 35449204-8 2022 When combined with the third generation EGFR inhibitor, osimertinib (AZD9291), synergistic effects on decreasing the survival of different osimertinib-resistant cell lines were observed with enhanced induction of apoptosis. osimertinib 56-67 epidermal growth factor receptor Homo sapiens 40-44 35449204-8 2022 When combined with the third generation EGFR inhibitor, osimertinib (AZD9291), synergistic effects on decreasing the survival of different osimertinib-resistant cell lines were observed with enhanced induction of apoptosis. osimertinib 69-76 epidermal growth factor receptor Homo sapiens 40-44 35449204-8 2022 When combined with the third generation EGFR inhibitor, osimertinib (AZD9291), synergistic effects on decreasing the survival of different osimertinib-resistant cell lines were observed with enhanced induction of apoptosis. osimertinib 139-150 epidermal growth factor receptor Homo sapiens 40-44 35530305-1 2022 The efficacy of osimertinib is severely limited by the emergence of EGFR C797S, which is detected in either the cis or trans position with T790M when osimertinib is used as a second-line treatment, and which is largely identified in combination with an EGFR 19 deletion. osimertinib 16-27 epidermal growth factor receptor Homo sapiens 68-72 35530305-1 2022 The efficacy of osimertinib is severely limited by the emergence of EGFR C797S, which is detected in either the cis or trans position with T790M when osimertinib is used as a second-line treatment, and which is largely identified in combination with an EGFR 19 deletion. osimertinib 150-161 epidermal growth factor receptor Homo sapiens 68-72 35530305-2 2022 The EGFR T790M-cis-G796S mutation, which also occurs in exon 20 as C797S, participates in osimertinib resistance. osimertinib 90-101 epidermal growth factor receptor Homo sapiens 4-8 35530305-4 2022 Here, we report data for an advanced NSCLC patient who developed EGFR L858R-T790M-cis-G796S and EGFR L718Q resistance co-mutations following progression with osimertinib. osimertinib 158-169 epidermal growth factor receptor Homo sapiens 65-69 35530305-4 2022 Here, we report data for an advanced NSCLC patient who developed EGFR L858R-T790M-cis-G796S and EGFR L718Q resistance co-mutations following progression with osimertinib. osimertinib 158-169 epidermal growth factor receptor Homo sapiens 96-100 35530305-8 2022 Our finding provides clinical evidence that the combined target therapy of brigatinib and cetuximab may potentially be an effective treatment strategy for patients with an acquired EGFR T790M-cis-G796S resistance mutation following osimertinib treatment. osimertinib 232-243 epidermal growth factor receptor Homo sapiens 181-185 35494030-2 2022 For those patients with EGFR mutations, osimertinib, a third-generation tyrosine kinase inhibitor (TKI), is the first choice of treatment. osimertinib 40-51 epidermal growth factor receptor Homo sapiens 24-28 35494030-5 2022 This 55-year-old male patient was found to have a pL858R mutation on EGFR exon 21 combined with TP53 and ERBB2 mutations after developing drug resistance to osimertinib treatment. osimertinib 157-168 epidermal growth factor receptor Homo sapiens 69-73 35494059-0 2022 Osimertinib-Centered Therapy Against Uncommon Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer- A Mini Review. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 46-78 35494059-1 2022 Osimertinib is a third-generation, irreversible mutant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 55-87 35494059-1 2022 Osimertinib is a third-generation, irreversible mutant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 89-93 35494059-2 2022 Osimertinib is currently the first line drug recommended by National Comprehensive Cancer Network (NCCN) guidelines against lung cancer harboring the EGFR TKI-sensitive mutation and acquired EGFR T790M resistance mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 150-154 35494059-2 2022 Osimertinib is currently the first line drug recommended by National Comprehensive Cancer Network (NCCN) guidelines against lung cancer harboring the EGFR TKI-sensitive mutation and acquired EGFR T790M resistance mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 191-195 35494059-3 2022 Osimertinib demonstrated some efficacy in clinical trials and case reports in patients bearing certain uncommon EGFR mutations, but it is not active in patients with other mutations such as C797S. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 112-116 35494059-4 2022 This mini-review presents the mechanisms underlying the variations in patient responses, discusses the use of osimertinib against non-small-cell lung carcinomas with uncommon EGFR mutations, and addresses the future prospects of osimertinib-centered therapy. osimertinib 110-121 epidermal growth factor receptor Homo sapiens 175-179 35463360-2 2022 Third-generation (3rd G) EGFR-TKIs, including osimertinib, offer an effective treatment option for patients with NSCLC resistant 1st and 2nd EGFR-TKIs. osimertinib 46-57 epidermal growth factor receptor Homo sapiens 25-29 35574304-14 2022 Moderate activity was seen against osimertinib resistance EGFR mutations. osimertinib 35-46 epidermal growth factor receptor Homo sapiens 58-62 35431558-1 2022 Background: Osimertinib is an irreversible tyrosine kinase inhibitor approved for the treatment of metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 110-142 35431558-1 2022 Background: Osimertinib is an irreversible tyrosine kinase inhibitor approved for the treatment of metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 144-148 35431558-3 2022 Case Presentation: Herein, we describe the case of a 69-year-old man who received first-line osimertinib for metastatic EGFR-mutated NSCLC. osimertinib 93-104 epidermal growth factor receptor Homo sapiens 120-124 35431558-7 2022 Conclusion: In the current case, first-line treatment with osimertinib at 80 mg daily in a patient with EGFR-mutated NSCLC resulted in severe pancytopenia and a rapid treatment response. osimertinib 59-70 epidermal growth factor receptor Homo sapiens 104-108 35463360-11 2022 This review provides an overview of preclinical studies developed to investigate the mechanisms of acquired resistance to 3rd G EGFR-TKIs, including osimertinib and rociletinib, across all lines of therapy. osimertinib 149-160 epidermal growth factor receptor Homo sapiens 128-132 35462930-6 2022 We here report a patient who acquired EGFR T790M, STRN-ALK fusion, and EGFR amplification after gefitinib progression and subsequent MET amplification acquired from osimertinib. osimertinib 165-176 epidermal growth factor receptor Homo sapiens 38-42 35462930-6 2022 We here report a patient who acquired EGFR T790M, STRN-ALK fusion, and EGFR amplification after gefitinib progression and subsequent MET amplification acquired from osimertinib. osimertinib 165-176 epidermal growth factor receptor Homo sapiens 71-75 35386002-1 2022 PURPOSE: Osimertinib is still essential for the treatment of epidermal growth factor receptor (EGFR)-T790M-positive non-small-cell lung cancer (NSCLC) even in a relapsed setting, which suggests the importance of rebiopsy. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 61-93 35386002-1 2022 PURPOSE: Osimertinib is still essential for the treatment of epidermal growth factor receptor (EGFR)-T790M-positive non-small-cell lung cancer (NSCLC) even in a relapsed setting, which suggests the importance of rebiopsy. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 95-99 35479327-4 2022 Case presentation: A 59-year-old female, diagnosed with relapsed stage IV (cT4N2M1c) NSCLC with T790M mutation of the EGFR gene, received osimertinib treatment. osimertinib 138-149 epidermal growth factor receptor Homo sapiens 118-122 35379563-4 2022 The AURA3 trial (NCT02151981) was a randomized controlled trial comparing osimertinib with platinum-based doublet chemotherapy (standard care) in patients with locally advanced or metastatic epidermal growth factor receptor mutant- and T790M-positive nonsmall cell lung cancer whose disease has progressed with previous epidermal growth factor receptor tyrosine kinase inhibitor therapy. osimertinib 74-85 epidermal growth factor receptor Homo sapiens 191-223 35066105-1 2022 BACKGROUND: The development of targeted agents, such as osimertinib for EGFR-mutated NSCLC, has drastically improved patient outcome, but tumor resistance eventually always occurs. osimertinib 56-67 epidermal growth factor receptor Homo sapiens 72-76 35066105-11 2022 CONCLUSIONS: Distinct molecular driver alterations at osimertinib resistance co-exist with initial EGFR mutations in single cancer cells. osimertinib 54-65 epidermal growth factor receptor Homo sapiens 99-103 35347039-2 2022 Osimertinib can overcome the treatment resistance-associated EGFR T790M mutation, and the sequence of afatinib followed by osimertinib is an effective therapeutic strategy for NSCLC patients. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 61-65 35347039-15 2022 T790M mutation detection and osimertinib availability are important for prolonging survival in patients with NSCLC harboring EGFR mutations. osimertinib 29-40 epidermal growth factor receptor Homo sapiens 125-129 35078784-1 2022 The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib has significantly prolonged progression-free survival (PFS) in EGFR-mutant lung cancer patients, including those with brain metastases. osimertinib 76-87 epidermal growth factor receptor Homo sapiens 4-36 35078784-1 2022 The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib has significantly prolonged progression-free survival (PFS) in EGFR-mutant lung cancer patients, including those with brain metastases. osimertinib 76-87 epidermal growth factor receptor Homo sapiens 38-42 35078784-1 2022 The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib has significantly prolonged progression-free survival (PFS) in EGFR-mutant lung cancer patients, including those with brain metastases. osimertinib 76-87 epidermal growth factor receptor Homo sapiens 151-155 35078784-4 2022 Using metastatic models of EGFR-mutant lung cancer, we show that cancer cells expressing high intracellular S100A9 escape osimertinib and initiate brain relapses. osimertinib 122-133 epidermal growth factor receptor Homo sapiens 27-31 35412115-4 2022 The advent of third-generation EGFR inhibitors (e.g., osimertinib) successfully overcame the T790M resistance mechanism, and osimertinib subsequently became the first-line therapy for EGFR mutant NSCLC. osimertinib 54-65 epidermal growth factor receptor Homo sapiens 31-35 35412115-4 2022 The advent of third-generation EGFR inhibitors (e.g., osimertinib) successfully overcame the T790M resistance mechanism, and osimertinib subsequently became the first-line therapy for EGFR mutant NSCLC. osimertinib 125-136 epidermal growth factor receptor Homo sapiens 31-35 35412115-4 2022 The advent of third-generation EGFR inhibitors (e.g., osimertinib) successfully overcame the T790M resistance mechanism, and osimertinib subsequently became the first-line therapy for EGFR mutant NSCLC. osimertinib 125-136 epidermal growth factor receptor Homo sapiens 184-188 35412115-5 2022 Currently, research in EGFR mutant NSCLC is primarily focused on targeting resistance mechanisms to osimertinib. osimertinib 100-111 epidermal growth factor receptor Homo sapiens 23-27 35412115-8 2022 An important intrinsic resistance mechanism to osimertinib is the EGFR exon 20 insertion mutation, which is sensitive to the newly Food and Drug Administration (FDA)-approved tyrosine kinase inhibitor mobocertinib and the EGFR/MET bispecific antibody amivantamab. osimertinib 47-58 epidermal growth factor receptor Homo sapiens 66-70 35412115-8 2022 An important intrinsic resistance mechanism to osimertinib is the EGFR exon 20 insertion mutation, which is sensitive to the newly Food and Drug Administration (FDA)-approved tyrosine kinase inhibitor mobocertinib and the EGFR/MET bispecific antibody amivantamab. osimertinib 47-58 epidermal growth factor receptor Homo sapiens 222-226 35431966-2 2022 Although third-generation EGFR-TKI osimertinib is demonstrated with superior efficacy compared with first-generation EGFR-TKIs, acquired resistance to EGFR-TKIs remains the bottleneck. osimertinib 35-46 epidermal growth factor receptor Homo sapiens 26-30 35257278-0 2022 Correction to: Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B). osimertinib 15-26 epidermal growth factor receptor Homo sapiens 169-173 35293747-6 2022 Using this strategy, we demonstrated the heterogeneity of TK activity in different non-small cell lung cancer (NSCLC) cell lines and assessed the response of TK activities to the EGFR inhibitor AZD9291 in NSCLC cells. osimertinib 194-201 epidermal growth factor receptor Homo sapiens 179-183 35572898-0 2022 Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). osimertinib 59-70 epidermal growth factor receptor Homo sapiens 184-188 35365042-0 2022 A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report. osimertinib 146-157 epidermal growth factor receptor Homo sapiens 62-94 35245845-0 2022 EGFR-RAD51 fusion in lung adenocarcinoma with systemic and intracranial response to osimertinib: A case report and review of the literature. osimertinib 84-95 epidermal growth factor receptor Homo sapiens 0-4 35245845-3 2022 We report a widely metastatic non-small cell lung cancer in a never-smoker young male patient with sustained near-complete systemic and intracranial response to osimertinib, a third-generation EGFR tyrosine-kinase inhibitor (TKI). osimertinib 161-172 epidermal growth factor receptor Homo sapiens 193-197 35146920-1 2022 Osimertinib is the most efficient first-line drug, with least adverse effects, for metastatic non-small-cell lung carcinoma (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations with exon 19 deletion or exon 21 L858R mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 142-174 35146920-1 2022 Osimertinib is the most efficient first-line drug, with least adverse effects, for metastatic non-small-cell lung carcinoma (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations with exon 19 deletion or exon 21 L858R mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 176-180 35529794-0 2022 Osimertinib as induction therapy for oligometastatic non-small cell lung cancer with EGFR mutation: a case report. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 85-89 35344648-0 2022 Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non-Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 52-56 35344648-0 2022 Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non-Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 194-198 35344648-3 2022 Osimertinib is a third-generation, irreversible, CNS penetrant, oral EGFR TKI that demonstrates promising efficacy in CNS metastases regardless of T790M. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 69-73 35344648-4 2022 Herein, we report four cases of T790M-negative EGFRm NSCLC patients treated with osimertinib combined with systemic chemotherapy, who progressed on prior EGFR TKI and developed LM with extracranial lesions. osimertinib 81-92 epidermal growth factor receptor Homo sapiens 154-158 35347108-7 2022 Thus, by engaging a tumor non-autonomous mechanism involving cGAS-STING and innate immunity, the combination of osimertinib and anti-HER3 antibodies could improve the limited therapeutic and stratification options for advanced stage lung cancer patients with mutant EGFR. osimertinib 112-123 epidermal growth factor receptor Homo sapiens 266-270 35402377-4 2022 In the present research, we found that EGFR-TKIs (such as gefitinib and osimertinib) can induce autophagy in NSCLC cell lines. osimertinib 72-83 epidermal growth factor receptor Homo sapiens 39-43 35402377-6 2022 The use of an autophagy inhibitor could enhance the toxicity of gefitinib and osimertinib, which indicates that the enhancement of protective autophagy might be one of the mechanisms of EGFR-TKI resistance in NSCLC. osimertinib 78-89 epidermal growth factor receptor Homo sapiens 186-190 35323965-1 2022 Osimertinib is active against T790M-positive epidermal growth factor receptor mutant non-small cell lung cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 45-77 35287683-3 2022 This study aimed to compare the efficacy of osimertinib plus bevacizumab with osimertinib in EGFR-mutant NSCLC patients with LM. osimertinib 78-89 epidermal growth factor receptor Homo sapiens 93-97 35287683-10 2022 In the LM xenograft model with H1975 cells, the combined treatment significantly increased the effective intracranial concentration of osimertinib, modulated the level of E-cadherin and downregulated the levels of EGFR and downstream signaling pathways including p-AKT and reduced tumor microvessel density (TMD), indicated that combined osimertinib with bevacizumab may exhibit a synergistic effect in EGFR-mutant LM model possibly by modulating the level of E-cadherin. osimertinib 135-146 epidermal growth factor receptor Homo sapiens 403-407 35462930-3 2022 For patients with secondary T790M-positive after early generation EGFR-TKIs, osimertinib is the standard second-line therapy. osimertinib 77-88 epidermal growth factor receptor Homo sapiens 66-70 35265776-0 2022 Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer. osimertinib 49-60 epidermal growth factor receptor Homo sapiens 91-95 35265776-1 2022 Purpose: Describe the use of osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, as the first-line treatment in a patient with choroidal and central nervous system metastases from EGFR-mutated non-small cell lung cancer. osimertinib 29-40 epidermal growth factor receptor Homo sapiens 61-93 35265776-1 2022 Purpose: Describe the use of osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, as the first-line treatment in a patient with choroidal and central nervous system metastases from EGFR-mutated non-small cell lung cancer. osimertinib 29-40 epidermal growth factor receptor Homo sapiens 95-99 35265776-1 2022 Purpose: Describe the use of osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, as the first-line treatment in a patient with choroidal and central nervous system metastases from EGFR-mutated non-small cell lung cancer. osimertinib 29-40 epidermal growth factor receptor Homo sapiens 227-231 35365043-1 2022 Osimertinib, as a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), targeting EGFR exon 19 deletions, L858R, and T790M, has shown robust clinical efficacy and promising survival advantages in a subset of non-small cell lung cancer (NSCLC) patients. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 69-73 35365043-1 2022 Osimertinib, as a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), targeting EGFR exon 19 deletions, L858R, and T790M, has shown robust clinical efficacy and promising survival advantages in a subset of non-small cell lung cancer (NSCLC) patients. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 118-122 35365043-3 2022 Besides EGFR C797S mutation and EGFR amplification, a rare EGFR mutation, L718V, has been reported to confer osimertinib resistance in the literature, which is developed in about 8.0% of osimertinib-resistant NSCLC patients. osimertinib 109-120 epidermal growth factor receptor Homo sapiens 59-63 35365043-6 2022 Herein, we report that a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib derived durable response to the second-generation EGFR-TKI afatinib with a progression-free survival of 18 months and counting. osimertinib 115-126 epidermal growth factor receptor Homo sapiens 67-71 35365043-6 2022 Herein, we report that a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib derived durable response to the second-generation EGFR-TKI afatinib with a progression-free survival of 18 months and counting. osimertinib 115-126 epidermal growth factor receptor Homo sapiens 177-181 35365042-0 2022 A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report. osimertinib 146-157 epidermal growth factor receptor Homo sapiens 96-100 35105467-2 2022 The Food and Drug Administration and European Medicines Agency have approved several inhibitors for the treatment of non-small cell lung cancer : five tyrosine kinase inhibitors targeting EGFR (erlotinib, gefitinib, afatinib, osimertinib and dacomitinib) and six tyrosine kinase inhibitors targeting ALK (crizotinib, ceritinib, alectinib, brigatinib, lorlatinib and entrectinib). osimertinib 226-237 epidermal growth factor receptor Homo sapiens 188-192 35365042-2 2022 The third-generation EGFR-TKI osimertinib, an irreversible TKI, is approved as a therapy for advanced NSCLC with EGFR sensitive mutations. osimertinib 30-41 epidermal growth factor receptor Homo sapiens 21-25 35365042-2 2022 The third-generation EGFR-TKI osimertinib, an irreversible TKI, is approved as a therapy for advanced NSCLC with EGFR sensitive mutations. osimertinib 30-41 epidermal growth factor receptor Homo sapiens 113-117 35365042-4 2022 Herein, we present a patient diagnosed with stage IV NSCLC with an EGFR L858R/V843I mutation complex who benefited remarkably from osimertinib therapy. osimertinib 131-142 epidermal growth factor receptor Homo sapiens 67-71 35365042-13 2022 To the best of our knowledge, we report here the first known case of an NSCLC patient with a somatic EGFR L858R/V843I mutation complex who responded well to osimertinib. osimertinib 157-168 epidermal growth factor receptor Homo sapiens 101-105 35365043-0 2022 Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review. osimertinib 134-145 epidermal growth factor receptor Homo sapiens 86-90 35365043-1 2022 Osimertinib, as a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), targeting EGFR exon 19 deletions, L858R, and T790M, has shown robust clinical efficacy and promising survival advantages in a subset of non-small cell lung cancer (NSCLC) patients. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 35-67 35081725-11 2022 Osimertinib has certain efficacy in EGFR p.T790M negative NSCLC patients. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 36-40 35343187-0 2022 Safety of osimertinib in adult patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: Results from a Phase IV study in India. osimertinib 10-21 epidermal growth factor receptor Homo sapiens 56-88 35343187-1 2022 Background: A Phase IV, single-arm study was conducted to assess the safety of osimertinib in Indian patients with epidermal growth factor receptor (EGFR) T790M mutation-positive stage IV non-small cell lung cancer (NSCLC). osimertinib 79-90 epidermal growth factor receptor Homo sapiens 115-147 35343187-1 2022 Background: A Phase IV, single-arm study was conducted to assess the safety of osimertinib in Indian patients with epidermal growth factor receptor (EGFR) T790M mutation-positive stage IV non-small cell lung cancer (NSCLC). osimertinib 79-90 epidermal growth factor receptor Homo sapiens 149-153 35399244-0 2022 Potential treatment strategy for the rare osimertinib resistant EGFR L718Q mutation. osimertinib 42-53 epidermal growth factor receptor Homo sapiens 64-68 35266116-13 2022 A combination of MET TKIs with epidermal growth factor receptor (EGFR) TKIs (osimertinib + savolitinib, tepotinib + gefitinib) may be a potential solution for MET-driven EGFR TKI resistance. osimertinib 77-88 epidermal growth factor receptor Homo sapiens 31-63 35266116-13 2022 A combination of MET TKIs with epidermal growth factor receptor (EGFR) TKIs (osimertinib + savolitinib, tepotinib + gefitinib) may be a potential solution for MET-driven EGFR TKI resistance. osimertinib 77-88 epidermal growth factor receptor Homo sapiens 65-69 35266116-13 2022 A combination of MET TKIs with epidermal growth factor receptor (EGFR) TKIs (osimertinib + savolitinib, tepotinib + gefitinib) may be a potential solution for MET-driven EGFR TKI resistance. osimertinib 77-88 epidermal growth factor receptor Homo sapiens 170-174 35102249-1 2022 Treatment of EGFR-mutant non-small cell lung cancer (NSCLC) with mutation-selective third-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib has achieved remarkable success in the clinic. osimertinib 153-164 epidermal growth factor receptor Homo sapiens 13-17 35102249-1 2022 Treatment of EGFR-mutant non-small cell lung cancer (NSCLC) with mutation-selective third-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib has achieved remarkable success in the clinic. osimertinib 153-164 epidermal growth factor receptor Homo sapiens 101-105 35102249-1 2022 Treatment of EGFR-mutant non-small cell lung cancer (NSCLC) with mutation-selective third-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib has achieved remarkable success in the clinic. osimertinib 153-164 epidermal growth factor receptor Homo sapiens 134-138 35102249-3 2022 This study suggests a novel strategy to overcome acquired resistance to osimertinib and other third-generation EGFR-TKIs through directly targeting the intrinsic apoptotic pathway. osimertinib 72-83 epidermal growth factor receptor Homo sapiens 111-115 35102249-7 2022 Hence, this study convincingly demonstrates a novel strategy for overcoming acquired resistance to osimertinib and other 3rd generation EGFR-TKIs by targeting activation of the intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation or both, warranting further clinical validation of this strategy. osimertinib 99-110 epidermal growth factor receptor Homo sapiens 136-140 35076999-0 2022 First-line osimertinib treatment in a patient with lung adenocarcinoma with coexisting epidermal growth factor receptor G719S and de novo T790M mutations. osimertinib 11-22 epidermal growth factor receptor Homo sapiens 87-119 35076999-1 2022 Osimertinib is the standard treatment for non-small cell lung cancer (NSCLC) with an active epidermal growth factor receptor (EGFR) mutation and a T790M mutation-present in cases of acquired resistance. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 92-124 35076999-1 2022 Osimertinib is the standard treatment for non-small cell lung cancer (NSCLC) with an active epidermal growth factor receptor (EGFR) mutation and a T790M mutation-present in cases of acquired resistance. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 126-130 35076999-2 2022 However, there have been no reports on the efficacy of osimertinib in patients with EGFR G719S and de novo T790M mutations. osimertinib 55-66 epidermal growth factor receptor Homo sapiens 84-88 35399574-9 2022 This is, to our knowledge, the first report describing response to the 3rd EGFR TKI osimertinib. osimertinib 84-95 epidermal growth factor receptor Homo sapiens 75-79 35088537-2 2022 We report a case of epidermal growth factor receptor (EGFR) mutation-positive C-SCLC in an 84-year-old patient with metastatic brain lesions who developed intrinsic resistance to osimertinib, a tyrosine kinase inhibitor (TKI). osimertinib 179-190 epidermal growth factor receptor Homo sapiens 20-52 35088537-2 2022 We report a case of epidermal growth factor receptor (EGFR) mutation-positive C-SCLC in an 84-year-old patient with metastatic brain lesions who developed intrinsic resistance to osimertinib, a tyrosine kinase inhibitor (TKI). osimertinib 179-190 epidermal growth factor receptor Homo sapiens 54-58 35197546-1 2022 Osimertinib, a 3rd generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is the first-line standard-of-care for EGFR-mutant non-small cell lung cancer (NSCLC) patients, while acquired drug resistance will inevitably occur. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 90-94 35119858-2 2022 NSP-037 (18), an irreversible inhibitor of the L858R/T790M double-mutant EGFR (EGFRDM) using alpha-chlorofluoroacetamide (CFA) as a novel warhead, has seven times the inhibition selectivity for EGFRDM over the wild type (EGFRWT), as compared to clinically approved osimertinib (7). osimertinib 265-276 epidermal growth factor receptor Homo sapiens 73-77 35119858-2 2022 NSP-037 (18), an irreversible inhibitor of the L858R/T790M double-mutant EGFR (EGFRDM) using alpha-chlorofluoroacetamide (CFA) as a novel warhead, has seven times the inhibition selectivity for EGFRDM over the wild type (EGFRWT), as compared to clinically approved osimertinib (7). osimertinib 265-276 epidermal growth factor receptor Homo sapiens 79-85 35251316-1 2022 Introduction: Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) that is approved for the use of EGFR-mutant non-small cell lung cancer (NSCLC) patients. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 117-121 35189835-8 2022 CONCLUSION: First-line EGFR-TKIs seemed to be less effective in controlling and preventing brain metastasis in patients with uncommon EGFR mutations and Osimertinib was associated with promising efficacy in patients with de novo T790M mutation, which warranted further validation. osimertinib 153-164 epidermal growth factor receptor Homo sapiens 23-27 35197546-3 2022 Here we show that clinically, plasma IL-6 level predicts osimertinib efficacy in EGFR mutant NSCLC patients. osimertinib 57-68 epidermal growth factor receptor Homo sapiens 81-85 35208635-2 2022 Only a few studies have reported the occurrence of heart failure following the administration of osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for EGFR mutation-positive advanced non-small cell lung cancer. osimertinib 97-108 epidermal growth factor receptor Homo sapiens 129-161 34985966-4 2022 Adjuvant osimertinib for patients with EGFR-mutant tumors, preoperative chemoimmunotherapy, and adjuvant immunotherapy could improve outcomes for selected patients with resectable lung cancer, and ongoing or planned studies leveraging biomarkers, immunotherapy, and targeted therapy may further improve survival. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 39-43 35208635-2 2022 Only a few studies have reported the occurrence of heart failure following the administration of osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for EGFR mutation-positive advanced non-small cell lung cancer. osimertinib 97-108 epidermal growth factor receptor Homo sapiens 163-167 35208635-2 2022 Only a few studies have reported the occurrence of heart failure following the administration of osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for EGFR mutation-positive advanced non-small cell lung cancer. osimertinib 97-108 epidermal growth factor receptor Homo sapiens 199-203 35168607-1 2022 BACKGROUND: Osimertinib resistance limits the treatment of epidermal growth factor receptor-(EGFR)-mutated non-small-cell lung carcinoma (NSCLC). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 59-91 35168607-1 2022 BACKGROUND: Osimertinib resistance limits the treatment of epidermal growth factor receptor-(EGFR)-mutated non-small-cell lung carcinoma (NSCLC). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 93-97 35159036-7 2022 The expert panel analysis concluded: (1) osimertinib 80 mg/day is recommended as a first-line treatment for older patients with the EGFR mutation; (2) full-dose first generation TKI, such as erlotinib or gefitinib, is feasible; (3) ALK and ROS1 rearrangement studies including older patients were too scarce to conclude on any definitive recommendations; and (4) given the actual data, TKI should be prescribed as monotherapy. osimertinib 41-52 epidermal growth factor receptor Homo sapiens 132-136 35144338-8 2022 Twenty-four patients developed disease progression on the first-and second EGFR-TKIs treatments, followed by treatment with the third-generation EGFR-TKIs (Osimertinib) in 12 cases, chemotherapy or anti-angiogenesis therapy in 4 cases, and the optimal supportive treatment in 8 cases. osimertinib 156-167 epidermal growth factor receptor Homo sapiens 145-149 35044639-0 2022 Next-Generation Sequencing Liquid Biopsy-Guided Osimertinib Rechallenge in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients. osimertinib 48-59 epidermal growth factor receptor Homo sapiens 75-79 35044639-1 2022 BACKGROUND AND OBJECTIVES: Osimertinib is considered the treatment of choice for patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) who progressed on EGFR tyrosine kinase inhibitors (TKIs). osimertinib 27-38 epidermal growth factor receptor Homo sapiens 95-127 35044639-1 2022 BACKGROUND AND OBJECTIVES: Osimertinib is considered the treatment of choice for patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) who progressed on EGFR tyrosine kinase inhibitors (TKIs). osimertinib 27-38 epidermal growth factor receptor Homo sapiens 129-133 35044639-1 2022 BACKGROUND AND OBJECTIVES: Osimertinib is considered the treatment of choice for patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) who progressed on EGFR tyrosine kinase inhibitors (TKIs). osimertinib 27-38 epidermal growth factor receptor Homo sapiens 205-209 35194503-1 2022 Purpose: To illustrate the regression of a metastatic lesion through ophthalmic imaging and correlating findings with standard chest imaging and treatment with osimertinib, an oral chemotherapy agent specific to Epidermal Growth Factor Receptor + Non-small Cell Lung Cancer (EGFR+ NSCLC). osimertinib 160-171 epidermal growth factor receptor Homo sapiens 212-244 35194503-1 2022 Purpose: To illustrate the regression of a metastatic lesion through ophthalmic imaging and correlating findings with standard chest imaging and treatment with osimertinib, an oral chemotherapy agent specific to Epidermal Growth Factor Receptor + Non-small Cell Lung Cancer (EGFR+ NSCLC). osimertinib 160-171 epidermal growth factor receptor Homo sapiens 275-279 35194503-6 2022 Conclusion: After the initiation of osimertinib, ophthalmic and computed tomography imaging highlighted the regression of the ocular metastatic disease and primary malignancy, respectively.Osimertinib is an effective first-line treatment of EGFR+ NSCLC and corresponding metastatic sites. osimertinib 189-200 epidermal growth factor receptor Homo sapiens 241-245 35127465-5 2021 Patients who received osimertinib after developing LM (n = 35) had a significantly higher rate of LM disease control (p = 0.008) and significantly longer overall survival (15.0 versus 6.0 months; hazard ratio (HR), 2.4292; 95% CI, 1.234-4.779; p = 0.045) than those who received previous generations of EGFR tyrosine kinase inhibitors (TKIs) or other localized therapies (n = 6). osimertinib 22-33 epidermal growth factor receptor Homo sapiens 303-307 35112017-10 2022 Osimertinib can be beneficial for patients with EGFR-positive lung cancer for both ocular and systemic control. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 48-52 35038824-1 2022 Purpose: This study was to evaluate anti-tumor efficacy of osimertinib in patients positive for acquired epidermal growth factor receptor (EGFR) T790M mutation in liquid biopsy using plasma, bronchoalveolar lavage fluid (BALF) or bronchial washing fluid (BWF), and pleural effusion. osimertinib 59-70 epidermal growth factor receptor Homo sapiens 105-137 35038824-1 2022 Purpose: This study was to evaluate anti-tumor efficacy of osimertinib in patients positive for acquired epidermal growth factor receptor (EGFR) T790M mutation in liquid biopsy using plasma, bronchoalveolar lavage fluid (BALF) or bronchial washing fluid (BWF), and pleural effusion. osimertinib 59-70 epidermal growth factor receptor Homo sapiens 139-143 35038824-11 2022 Conclusion: Osimertinib showed favorable efficacy in lung cancer patients with acquired resistance to prior EGFR-TKI therapies, who screened positive for harboring T790M mutation detected from cell free DNA extracted from plasma, BALF/BWF, and pleural effusion. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 108-112 35173881-1 2022 OBJECTIVE: To explore the efficacy and mechanism of osimertinib combined with bevacizumab in treating postoperative epidermal growth factor receptor (EGFR) positive stage II-IIIA lung adenocarcinoma. osimertinib 52-63 epidermal growth factor receptor Homo sapiens 116-148 35173881-1 2022 OBJECTIVE: To explore the efficacy and mechanism of osimertinib combined with bevacizumab in treating postoperative epidermal growth factor receptor (EGFR) positive stage II-IIIA lung adenocarcinoma. osimertinib 52-63 epidermal growth factor receptor Homo sapiens 150-154 35127465-7 2021 Conclusions: Our study provides real-world clinical evidence that patients with EGFR-mutated NSCLC diagnosed with LM who developed LM had better clinical outcomes with osimertinib therapy. osimertinib 168-179 epidermal growth factor receptor Homo sapiens 80-84 34459459-1 2022 Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used to treat non-small cell lung cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 34-66 35106279-0 2022 Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, cis-G796s/cis-C797s by osimertinib, brigatinib, and bevacizumab combination therapy: A case report. osimertinib 120-131 epidermal growth factor receptor Homo sapiens 65-69 35106279-3 2022 Osimertinib, a 3rd EGFR-TKI, commonly was used in patients who were resistant to early-generation EGFR-TKIs carrying T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 19-23 35106279-3 2022 Osimertinib, a 3rd EGFR-TKI, commonly was used in patients who were resistant to early-generation EGFR-TKIs carrying T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 98-102 35106279-5 2022 Herein, we report an effective treatment for a case of advanced pulmonary adenocarcinoma patient with triple EGFR mutations of L858R/T790M/cis-C797S and L858R/T790M/cis-G796S by the combination therapy of osimertinib, brigatinib, and bevacizumab after the combination of brigatinib and cetuximab failed. osimertinib 205-216 epidermal growth factor receptor Homo sapiens 109-113 34983748-1 2022 INTRODUCTION: Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is widely used as the first-line treatment for EGFR mutation-positive non-small cell lung cancer (NSCLC). osimertinib 14-25 epidermal growth factor receptor Homo sapiens 46-78 34983748-1 2022 INTRODUCTION: Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is widely used as the first-line treatment for EGFR mutation-positive non-small cell lung cancer (NSCLC). osimertinib 14-25 epidermal growth factor receptor Homo sapiens 80-84 34983748-1 2022 INTRODUCTION: Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is widely used as the first-line treatment for EGFR mutation-positive non-small cell lung cancer (NSCLC). osimertinib 14-25 epidermal growth factor receptor Homo sapiens 166-170 34261918-0 2022 Osimertinib is an effective epidermal growth factor receptor-tyrosine kinase inhibitor choice for lung cancer with epidermal growth factor receptor exon 18-25 kinase domain duplication: report of two cases. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 28-60 34261918-8 2022 Here, we describe osimertinib as an effective therapy for EGFR-KDD positive lung adenocarcinoma and thereby provide a new alternative for further treatment following resistance to first- and second-generation EGFR-TKIs. osimertinib 18-29 epidermal growth factor receptor Homo sapiens 58-62 34261918-8 2022 Here, we describe osimertinib as an effective therapy for EGFR-KDD positive lung adenocarcinoma and thereby provide a new alternative for further treatment following resistance to first- and second-generation EGFR-TKIs. osimertinib 18-29 epidermal growth factor receptor Homo sapiens 209-213 34459459-1 2022 Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used to treat non-small cell lung cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 68-72 34486539-10 2022 This study presented the first case of NSCLC-LM harboring particular EGFR-SEPT14 fusions, who showed a durable response to osimertinib and intrathecal pemetrexed, providing a potential therapeutic option for NSCLC-LM patients with this particular mutation. osimertinib 123-134 epidermal growth factor receptor Homo sapiens 69-73 34486539-0 2022 Complete remission in leptomeningeal metastasis of NSCLC with rare EGFR-SEPT14 fusion treated with osimertinib combined with intrathecal chemotherapy with pemetrexed. osimertinib 99-110 epidermal growth factor receptor Homo sapiens 67-71 34669648-2 2022 RECENT FINDINGS: Osimertinib has shown favorable efficacy on second-line and first-line treatments in EGFR-mutant advanced nonsmall cell lung cancer (NSCLC). osimertinib 17-28 epidermal growth factor receptor Homo sapiens 102-106 34520433-2 2022 Third-generation EGFR-TKIs, represented by osimertinib, have been approved to overcome the EGFR T790M mutation in patients who are resistant to first- or second-generation TKIs, which brings more survival benefits for patients with advanced NSCLC. osimertinib 43-54 epidermal growth factor receptor Homo sapiens 17-21 34520433-2 2022 Third-generation EGFR-TKIs, represented by osimertinib, have been approved to overcome the EGFR T790M mutation in patients who are resistant to first- or second-generation TKIs, which brings more survival benefits for patients with advanced NSCLC. osimertinib 43-54 epidermal growth factor receptor Homo sapiens 91-95 34074804-7 2022 Recently developed third-generation irreversible EGFR TKIs (osimertinib and lazertinib) are selective toward driving mutations and the T790M mutation, while sparing wildtype EGFR activity. osimertinib 60-71 epidermal growth factor receptor Homo sapiens 174-178 35242623-12 2022 Conclusions: TP53 mt+ have a negative impact on PFS and OS in a group of patients carrying a sensitizing EGFR mt+ and a T790M resistance mutation treated with Osimertinib. osimertinib 159-170 epidermal growth factor receptor Homo sapiens 105-109 35261905-3 2022 Here, we describe a case to report the efficacy of afatinib in an EGFR-mutated NSCLC patient with early progression to first-line osimertinib treatment. osimertinib 130-141 epidermal growth factor receptor Homo sapiens 66-70 35261905-10 2022 NGS revealed no specific gene mutations causing resistance to osimertinib except for the EGFR L858R mutation; however, his tumor had a relatively high tumor mutational burden. osimertinib 62-73 epidermal growth factor receptor Homo sapiens 89-93 35156036-1 2022 Background: Osimertinib is selective for both epidermal growth factor receptor (EGFR)-tyrosine-kinase inhibitor (TKI) sensitizing and Thr790Met mutations. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 46-78 35156036-1 2022 Background: Osimertinib is selective for both epidermal growth factor receptor (EGFR)-tyrosine-kinase inhibitor (TKI) sensitizing and Thr790Met mutations. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 80-84 35005653-1 2022 Osimertinib is the standard of care for the first-line treatment of EGFR-mutated NSCLC. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 68-72 35005656-3 2022 Here, we present a case of spontaneous transformation from EGFR-mutant LUAD with loss of p53 and RB to EGFR expression-positive SCLC and neuroendocrine-differentiated LUAD, which was successfully treated with osimertinib. osimertinib 209-220 epidermal growth factor receptor Homo sapiens 59-63 35005656-3 2022 Here, we present a case of spontaneous transformation from EGFR-mutant LUAD with loss of p53 and RB to EGFR expression-positive SCLC and neuroendocrine-differentiated LUAD, which was successfully treated with osimertinib. osimertinib 209-220 epidermal growth factor receptor Homo sapiens 103-107 31935159-0 2021 Osimertinib in patients with advanced/metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer - the Belgian ASTRIS data. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 49-81 35201951-1 2022 OBJECTIVES: Osimertinib has exhibited promising central nervous system (CNS) efficacy in Epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) patients. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 89-121 35201951-1 2022 OBJECTIVES: Osimertinib has exhibited promising central nervous system (CNS) efficacy in Epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) patients. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 123-127 35201951-11 2022 CONCLUSION: For EGFR-mutated NSCLC patients with only intracranial progressions after previous TKI treatments, osimertinib is a promising treatment option regardless of T790M mutational status from plasma genotyping. osimertinib 111-122 epidermal growth factor receptor Homo sapiens 16-20 35049698-5 2022 Preclinical and clinical data, excluding de novoEGFR exon 20 p.T790M compound mutations, show good responses with EGFR tyrosine kinase inhibitors (TKIs) (combined common mutations: response rate (RR) >= 75% with either first- or second-generation TKIs; combined common plus uncommon: RR 40-80% and 100% with first-generation TKIs and afatinib, respectively; combined uncommon: RR 20-70%, ~80% and ~75% with first-generation TKIs, afatinib and osimertinib, respectively). osimertinib 443-454 epidermal growth factor receptor Homo sapiens 114-118 31935159-1 2021 Objectives: The aim of ASTRIS, a real-world study, was to assess the safety and efficacy of osimertinib in patients with locally advanced or metastatic (stage IIIB-IV) epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC) who had received prior EGFR-tyrosine kinase inhibitor (TKI) therapy. osimertinib 92-103 epidermal growth factor receptor Homo sapiens 168-200 31935159-1 2021 Objectives: The aim of ASTRIS, a real-world study, was to assess the safety and efficacy of osimertinib in patients with locally advanced or metastatic (stage IIIB-IV) epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC) who had received prior EGFR-tyrosine kinase inhibitor (TKI) therapy. osimertinib 92-103 epidermal growth factor receptor Homo sapiens 202-206 33710523-12 2021 Only a third receive osimertinib upon progression on 1G/2G EGFR-TKIs. osimertinib 21-32 epidermal growth factor receptor Homo sapiens 59-63 33855865-4 2021 However, while the third-generation EGFR TKI, osimertinib, confers significant overall survival benefit over erlotinib/gefitinib in non-Asians, this is not apparent in Asians, particularly in countries like Japan with well-resourced healthcare. osimertinib 46-57 epidermal growth factor receptor Homo sapiens 36-40 33939301-1 2021 BACKGROUND: Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) approved for the treatment of patients with EGFR-mutant non-small cell lung cancer (NSCLC). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 106-110 33939301-1 2021 BACKGROUND: Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) approved for the treatment of patients with EGFR-mutant non-small cell lung cancer (NSCLC). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 160-164 33939301-5 2021 We evaluated the profiles of exosomal miRNA associated with resistance to osimertinib in EGFR-mutant NSCLC cells. osimertinib 74-85 epidermal growth factor receptor Homo sapiens 89-93 33939301-10 2021 CONCLUSIONS: Exosomal miR-210-3p may play a crucial role in resistance to osimertinib in the tumor microenvironment of EGFR-mutant NSCLC. osimertinib 74-85 epidermal growth factor receptor Homo sapiens 119-123 34053372-3 2021 Most recently, the FDA granted approval for the adjuvant treatment of patients with early stage mutated EGFR NSCLC after tumor resection.Areas CoveredThis drug discovery case history focuses on the key studies that led to the preclinical discovery and development of osimertinib. osimertinib 267-278 epidermal growth factor receptor Homo sapiens 104-108 34053372-4 2021 The authors focus on published preclinical studies by scientists from AstraZeneca and highlight key events in the clinical development.Expert opinionAlthough eventually compromised by the cellular plasticity of the tumor and the inevitable acquisition of drug resistance through the use of osimertinib, its key role in the treatment of NSCLC with specific EGFR mutations will be maintained in the near future. osimertinib 290-301 epidermal growth factor receptor Homo sapiens 356-360 33829270-0 2021 A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R. osimertinib 8-19 epidermal growth factor receptor Homo sapiens 84-88 33829270-1 2021 OBJECTIVE: A third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimertinib, is the standard treatment for patients with non-small cell lung cancer harbouring mutant EGFR. osimertinib 103-114 epidermal growth factor receptor Homo sapiens 30-62 33829270-1 2021 OBJECTIVE: A third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimertinib, is the standard treatment for patients with non-small cell lung cancer harbouring mutant EGFR. osimertinib 103-114 epidermal growth factor receptor Homo sapiens 64-68 33829270-1 2021 OBJECTIVE: A third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimertinib, is the standard treatment for patients with non-small cell lung cancer harbouring mutant EGFR. osimertinib 103-114 epidermal growth factor receptor Homo sapiens 205-209 33829270-2 2021 Unfortunately, these patients inevitably acquire resistance to EGFR-TKI therapies, including osimertinib. osimertinib 93-104 epidermal growth factor receptor Homo sapiens 63-67 34058255-0 2021 Clinical value of upfront cranial radiotherapy in osimertinib-treated EGFR-mutant non-small-cell lung cancer with brain metastases. osimertinib 50-61 epidermal growth factor receptor Homo sapiens 70-74 34058255-1 2021 BACKGROUND: As a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimertinib has a powerful ability to penetrate the blood-brain barrier and a high potency for controlling brain metastases (BMs) from EGFR-mutant non-small cell lung cancer (NSCLC). osimertinib 107-118 epidermal growth factor receptor Homo sapiens 34-66 34058255-1 2021 BACKGROUND: As a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimertinib has a powerful ability to penetrate the blood-brain barrier and a high potency for controlling brain metastases (BMs) from EGFR-mutant non-small cell lung cancer (NSCLC). osimertinib 107-118 epidermal growth factor receptor Homo sapiens 68-72 34058255-1 2021 BACKGROUND: As a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimertinib has a powerful ability to penetrate the blood-brain barrier and a high potency for controlling brain metastases (BMs) from EGFR-mutant non-small cell lung cancer (NSCLC). osimertinib 107-118 epidermal growth factor receptor Homo sapiens 242-246 34048974-1 2021 Osimertinib (OSI) is the first FDA-approved third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 61-93 34048974-1 2021 Osimertinib (OSI) is the first FDA-approved third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 95-99 34044055-1 2021 Osimertinib is the only third-generation epidermal growth factor receptor tyrosine-kinase inhibitor (EGFR-TKI) approved by Food and Drug Administration (FDA). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 101-105 34001994-8 2021 Osimertinib stimulated dynamic, yet wide-ranging interferon (IFN) program regulation in EGFR mutant cell lines. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 88-92 33988036-0 2021 Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines. osimertinib 99-110 epidermal growth factor receptor Homo sapiens 41-45 33988036-1 2021 Aims: This study describes real-world outcomes of pretreated EGFR T790M-positive (T790M+) advanced non-small-cell lung cancer patients progressing after first- or second-generation tyrosine kinase inhibitors and receiving osimertinib, compared with T790M-negative (T790M-) patients. osimertinib 222-233 epidermal growth factor receptor Homo sapiens 61-65 33975616-0 2021 Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 157-161 33975616-1 2021 BACKGROUND: This study was designed to investigate the difference between brain metastases (BM) and non-brain metastases (non-BM) treated by osimertinib in advanced patients with an acquired EGFR T790M mutation after obtaining first-generation EGFR-TKI resistance. osimertinib 141-152 epidermal growth factor receptor Homo sapiens 191-195 33975616-1 2021 BACKGROUND: This study was designed to investigate the difference between brain metastases (BM) and non-brain metastases (non-BM) treated by osimertinib in advanced patients with an acquired EGFR T790M mutation after obtaining first-generation EGFR-TKI resistance. osimertinib 141-152 epidermal growth factor receptor Homo sapiens 244-248 33975616-14 2021 CONCLUSIONS: In advanced patients with an acquired EGFR T790M mutation after obtaining first-generation EGFR-TKI resistance, osimertinib may be more limited in its control in BM than in non-BM. osimertinib 125-136 epidermal growth factor receptor Homo sapiens 51-55 33975616-14 2021 CONCLUSIONS: In advanced patients with an acquired EGFR T790M mutation after obtaining first-generation EGFR-TKI resistance, osimertinib may be more limited in its control in BM than in non-BM. osimertinib 125-136 epidermal growth factor receptor Homo sapiens 104-108 33977730-0 2021 A non-small cell lung cancer (NSCLC) patient with leptomeningeal metastasis harboring rare epidermal growth factor receptor (EGFR) mutations G719S and L861Q benefited from doubling dosage of osimertinib: a case report. osimertinib 191-202 epidermal growth factor receptor Homo sapiens 91-123 33977730-0 2021 A non-small cell lung cancer (NSCLC) patient with leptomeningeal metastasis harboring rare epidermal growth factor receptor (EGFR) mutations G719S and L861Q benefited from doubling dosage of osimertinib: a case report. osimertinib 191-202 epidermal growth factor receptor Homo sapiens 125-129 33977730-2 2021 Osimertinib, an irreversible tyrosine kinase inhibitor, is approved as a therapy for advanced NSCLC with epidermal growth factor receptor (EGFR) mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 105-137 33977730-2 2021 Osimertinib, an irreversible tyrosine kinase inhibitor, is approved as a therapy for advanced NSCLC with epidermal growth factor receptor (EGFR) mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 139-143 33977730-3 2021 However, the efficacy and optimal dosage of osimertinib in the treatment of NSCLC patients with LM who harbor uncommon EGFR mutations have yet to be fully investigated. osimertinib 44-55 epidermal growth factor receptor Homo sapiens 119-123 33977730-4 2021 Herein, we report a case of an advanced NSCLC patient with LM carrying EGFR G719S and L861Q, who was successfully treated by osimertinib at 160 mg. osimertinib 125-136 epidermal growth factor receptor Homo sapiens 71-75 33977730-12 2021 To our knowledge, this study provides the first clinical evidence that the administration of osimertinib at 160 mg once daily can achieve an encouraging, durable response in an NSCLC patient with LM carrying EGFR G719S and L861Q. osimertinib 93-104 epidermal growth factor receptor Homo sapiens 208-212 34059353-7 2021 A high ratio of Her1 heterodimers to homodimers was associated with poor progression-free survival in NSCLC patients treated with osimertinib. osimertinib 130-141 epidermal growth factor receptor Homo sapiens 16-20 33992097-0 2021 ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition. osimertinib 27-38 epidermal growth factor receptor Homo sapiens 42-46 33992097-2 2021 However, the effect of ID1 expression on osimertinib resistance in EGFR T790M-positive NSCLC is not clear. osimertinib 41-52 epidermal growth factor receptor Homo sapiens 67-71 33992097-14 2021 Our study suggests that ID1 may induce EMT in EGFR T790M-positive NSCLC, which mediates drug resistance of osimertinib. osimertinib 107-118 epidermal growth factor receptor Homo sapiens 46-50 33992097-15 2021 CONCLUSIONS: Our study revealed the mechanism of ID1 mediated resistance to osimertinib in EGFR T790M-positive NSCLC through EMT, which may provide new ideas and methods for the treatment of EGFR mutated NSCLC after osimertinib resistance. osimertinib 76-87 epidermal growth factor receptor Homo sapiens 91-95 33992097-15 2021 CONCLUSIONS: Our study revealed the mechanism of ID1 mediated resistance to osimertinib in EGFR T790M-positive NSCLC through EMT, which may provide new ideas and methods for the treatment of EGFR mutated NSCLC after osimertinib resistance. osimertinib 76-87 epidermal growth factor receptor Homo sapiens 191-195 33992097-15 2021 CONCLUSIONS: Our study revealed the mechanism of ID1 mediated resistance to osimertinib in EGFR T790M-positive NSCLC through EMT, which may provide new ideas and methods for the treatment of EGFR mutated NSCLC after osimertinib resistance. osimertinib 216-227 epidermal growth factor receptor Homo sapiens 91-95 33982444-2 2021 METHODS: Patients with NSCLC who progressed after treatment with EGFR-TKI, and with EGFR T790 M detected by an approved companion diagnostic test (cobas ), were treated with osimertinib. osimertinib 175-186 epidermal growth factor receptor Homo sapiens 84-88 33982444-12 2021 CONCLUSIONS: NGS of ctDNA could be a promising method for predicting osimertinib efficacy in patients with advanced NSCLC harboring EGFR T790 M. osimertinib 69-80 epidermal growth factor receptor Homo sapiens 132-136 34026599-0 2021 Resistance Profile of Osimertinib in Pre-treated Patients With EGFR T790M-Mutated Non-small Cell Lung Cancer. osimertinib 22-33 epidermal growth factor receptor Homo sapiens 63-67 34026599-1 2021 Background: Osimertinib efficacy in pre-treated patients with epidermal growth factor receptor (EGFR) T790M-mutated non-small cell lung cancer (NSCLC) has been demonstrated in clinical trials, but real-world data, particularly regarding resistance profile, remains limited. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 62-94 34026599-1 2021 Background: Osimertinib efficacy in pre-treated patients with epidermal growth factor receptor (EGFR) T790M-mutated non-small cell lung cancer (NSCLC) has been demonstrated in clinical trials, but real-world data, particularly regarding resistance profile, remains limited. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 96-100 34026823-1 2021 Currently, there are limited treatment options for patients who developed resistance to osimertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor. osimertinib 88-99 epidermal growth factor receptor Homo sapiens 120-152 34026823-1 2021 Currently, there are limited treatment options for patients who developed resistance to osimertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor. osimertinib 88-99 epidermal growth factor receptor Homo sapiens 154-158 34026823-3 2021 This multicenter, retrospective study aimed to evaluate the efficacy of the combination treatment with apatinib and osimertinib in 39 patients with EGFR-mutant non-small cell lung carcinoma (NSCLC) who developed osimertinib resistance. osimertinib 116-127 epidermal growth factor receptor Homo sapiens 148-152 34026823-3 2021 This multicenter, retrospective study aimed to evaluate the efficacy of the combination treatment with apatinib and osimertinib in 39 patients with EGFR-mutant non-small cell lung carcinoma (NSCLC) who developed osimertinib resistance. osimertinib 212-223 epidermal growth factor receptor Homo sapiens 148-152 34026823-14 2021 The combination of apatinib and osimertinib improved the ORR and the DCR of patients with osimertinib-refractory EGFR-positive NSCLC, thus making it a reasonable treatment choice after the development of osimertinib resistance. osimertinib 32-43 epidermal growth factor receptor Homo sapiens 113-117 34026823-14 2021 The combination of apatinib and osimertinib improved the ORR and the DCR of patients with osimertinib-refractory EGFR-positive NSCLC, thus making it a reasonable treatment choice after the development of osimertinib resistance. osimertinib 90-101 epidermal growth factor receptor Homo sapiens 113-117 34026823-14 2021 The combination of apatinib and osimertinib improved the ORR and the DCR of patients with osimertinib-refractory EGFR-positive NSCLC, thus making it a reasonable treatment choice after the development of osimertinib resistance. osimertinib 90-101 epidermal growth factor receptor Homo sapiens 113-117 33953280-0 2021 The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC. osimertinib 68-79 epidermal growth factor receptor Homo sapiens 22-26 33953280-0 2021 The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC. osimertinib 68-79 epidermal growth factor receptor Homo sapiens 105-109 33976888-0 2021 Long-term response to osimertinib in elderly patients with lung adenocarcinoma harbouring de novo EGFR T790M: a case report and literature review. osimertinib 22-33 epidermal growth factor receptor Homo sapiens 98-102 33976888-1 2021 Osimertinib is a potent and irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively acts on both EGFR-sensitive and EGFR T790M-resistant mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 41-73 33976888-1 2021 Osimertinib is a potent and irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively acts on both EGFR-sensitive and EGFR T790M-resistant mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 75-79 33976888-1 2021 Osimertinib is a potent and irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively acts on both EGFR-sensitive and EGFR T790M-resistant mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 143-147 33976888-1 2021 Osimertinib is a potent and irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively acts on both EGFR-sensitive and EGFR T790M-resistant mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 143-147 33976888-2 2021 Patients with pre-treatment EGFR T790M mutations (de novo EGFR T790M) respond poorly to existing EGFR-TKIs, whereas osimertinib has positive effects. osimertinib 116-127 epidermal growth factor receptor Homo sapiens 28-32 33976888-4 2021 We treated two elderly patients with de novo EGFR T790M mutations with osimertinib as the first-line therapy. osimertinib 71-82 epidermal growth factor receptor Homo sapiens 45-49 33976888-5 2021 We found that the first-line treatment with osimertinib was safe and resulted in a long-term response in elderly patients with de novo EGFR T790M-mutated lung adenocarcinoma. osimertinib 44-55 epidermal growth factor receptor Homo sapiens 135-139 33730350-8 2021 While further research, including clinical trial data, is needed, real-world data have also demonstrated the feasibility of sequential afatinib followed by the third-generation TKI osimertinib in T790M-positive EGFR mutation-positive patients, which showed longer overall survival. osimertinib 181-192 epidermal growth factor receptor Homo sapiens 211-215 33544933-2 2021 The C797S mutation in the epidermal growth factor receptor (EGFR) confers resistance to osimertinib, a third-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI). osimertinib 88-99 epidermal growth factor receptor Homo sapiens 26-58 33544933-2 2021 The C797S mutation in the epidermal growth factor receptor (EGFR) confers resistance to osimertinib, a third-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI). osimertinib 88-99 epidermal growth factor receptor Homo sapiens 60-64 33544933-2 2021 The C797S mutation in the epidermal growth factor receptor (EGFR) confers resistance to osimertinib, a third-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI). osimertinib 88-99 epidermal growth factor receptor Homo sapiens 120-124 33544933-2 2021 The C797S mutation in the epidermal growth factor receptor (EGFR) confers resistance to osimertinib, a third-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI). osimertinib 88-99 epidermal growth factor receptor Homo sapiens 120-124 33744716-1 2021 INTRODUCTION: Although osimertinib overcomes the T790M mutation acquired after traditional epidermal growth factor receptor (EGFR) gene tyrosine kinase inhibitor (TKI) treatment, resistance to osimertinib eventually occurs. osimertinib 23-34 epidermal growth factor receptor Homo sapiens 91-123 33744716-1 2021 INTRODUCTION: Although osimertinib overcomes the T790M mutation acquired after traditional epidermal growth factor receptor (EGFR) gene tyrosine kinase inhibitor (TKI) treatment, resistance to osimertinib eventually occurs. osimertinib 23-34 epidermal growth factor receptor Homo sapiens 125-129 33831609-1 2021 BACKGROUND: Survival data support the use of first-line osimertinib as the standard of care for epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC). osimertinib 56-67 epidermal growth factor receptor Homo sapiens 96-128 33831609-1 2021 BACKGROUND: Survival data support the use of first-line osimertinib as the standard of care for epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC). osimertinib 56-67 epidermal growth factor receptor Homo sapiens 130-134 33593225-1 2021 INTRODUCTION Osimertinib is a third generation anti epidermal growth factor receptor (EGFR) Tyrosine Kinase Inhibitor (TKI), that irreversibly binds to mutant EGFR, specifically to the T790M mutant EGFR. osimertinib 13-24 epidermal growth factor receptor Homo sapiens 52-84 33593225-1 2021 INTRODUCTION Osimertinib is a third generation anti epidermal growth factor receptor (EGFR) Tyrosine Kinase Inhibitor (TKI), that irreversibly binds to mutant EGFR, specifically to the T790M mutant EGFR. osimertinib 13-24 epidermal growth factor receptor Homo sapiens 86-90 33593225-1 2021 INTRODUCTION Osimertinib is a third generation anti epidermal growth factor receptor (EGFR) Tyrosine Kinase Inhibitor (TKI), that irreversibly binds to mutant EGFR, specifically to the T790M mutant EGFR. osimertinib 13-24 epidermal growth factor receptor Homo sapiens 159-163 33593225-1 2021 INTRODUCTION Osimertinib is a third generation anti epidermal growth factor receptor (EGFR) Tyrosine Kinase Inhibitor (TKI), that irreversibly binds to mutant EGFR, specifically to the T790M mutant EGFR. osimertinib 13-24 epidermal growth factor receptor Homo sapiens 159-163 33593225-5 2021 EXPERT OPINION Osimertinib is a key-player in the treatment of EGFR mutant NSCLC and will probably be used in earlier clinical settings in the future, giving rise to an emerging variety of resistance mechanisms. osimertinib 15-26 epidermal growth factor receptor Homo sapiens 63-67 32276580-1 2021 Third generation EGFR inhibitor osimertinib was approved as the first-line treatment for EGFR T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC) patients in 2017. osimertinib 32-43 epidermal growth factor receptor Homo sapiens 17-21 32276580-1 2021 Third generation EGFR inhibitor osimertinib was approved as the first-line treatment for EGFR T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC) patients in 2017. osimertinib 32-43 epidermal growth factor receptor Homo sapiens 89-93 32276580-2 2021 However, EGFR tertiary Cys797 to Ser797 (C797S) point mutation emanate rapidly after treatment of osimertinib, which is undruggable mutation to the all existing drugs. osimertinib 98-109 epidermal growth factor receptor Homo sapiens 9-13 33333327-1 2021 The first-line treatment of choice for patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) is an EGFR tyrosine kinase inhibitor, of which five are predominantly available in practice: gefitinib, erlotinib, afatinib, dacomitinib and osimertinib. osimertinib 287-298 epidermal growth factor receptor Homo sapiens 53-85 33333327-1 2021 The first-line treatment of choice for patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) is an EGFR tyrosine kinase inhibitor, of which five are predominantly available in practice: gefitinib, erlotinib, afatinib, dacomitinib and osimertinib. osimertinib 287-298 epidermal growth factor receptor Homo sapiens 87-91 33338652-1 2021 Single agent osimertinib is the standard of care for first-line treatment of advanced metastatic EGFR+ non-small cell lung cancer (NSCLC) and remained the only marketed third-generation (third-generation) EGFR tyrosine kinase inhibitor (TKI) until March 2020 when almonertinib (HS-10296) was approved in China for the treatment of advanced EGFR T790M+ NSCLC. osimertinib 13-24 epidermal growth factor receptor Homo sapiens 97-101 33338652-1 2021 Single agent osimertinib is the standard of care for first-line treatment of advanced metastatic EGFR+ non-small cell lung cancer (NSCLC) and remained the only marketed third-generation (third-generation) EGFR tyrosine kinase inhibitor (TKI) until March 2020 when almonertinib (HS-10296) was approved in China for the treatment of advanced EGFR T790M+ NSCLC. osimertinib 13-24 epidermal growth factor receptor Homo sapiens 205-209 33338652-1 2021 Single agent osimertinib is the standard of care for first-line treatment of advanced metastatic EGFR+ non-small cell lung cancer (NSCLC) and remained the only marketed third-generation (third-generation) EGFR tyrosine kinase inhibitor (TKI) until March 2020 when almonertinib (HS-10296) was approved in China for the treatment of advanced EGFR T790M+ NSCLC. osimertinib 13-24 epidermal growth factor receptor Homo sapiens 205-209 33836373-1 2021 OBJECTIVES: Non-small cell lung cancer (NSCLC) tumors harboring common (exon19del, L858R) and uncommon (e.g. G719X, L861Q) activating epidermal growth factor receptor (EGFR) mutations are best treated with EGFR tyrosine kinase inhibitors (TKI) such as the first-generation EGFR TKI erlotinib, second-generation afatinib or third-generation osimertinib. osimertinib 340-351 epidermal growth factor receptor Homo sapiens 134-166 33724860-0 2021 Thermal treatment decreases resistance to osimertinib in non-small cell lung cancer through the EGFR/PI3K/AKT pathway. osimertinib 42-53 epidermal growth factor receptor Homo sapiens 96-100 33682361-0 2021 EGFR-mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib. osimertinib 98-109 epidermal growth factor receptor Homo sapiens 0-4 33682361-1 2021 Here, we report a rare case involving a 66-year-old man with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma and antisynthetase syndrome (ASS) treated with osimertinib. osimertinib 175-186 epidermal growth factor receptor Homo sapiens 61-93 33682361-1 2021 Here, we report a rare case involving a 66-year-old man with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma and antisynthetase syndrome (ASS) treated with osimertinib. osimertinib 175-186 epidermal growth factor receptor Homo sapiens 95-99 33682361-4 2021 Osimertinib could therefore be a treatment option for EGFR-mutant lung cancer with paraneoplastic ILD. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 54-58 33939068-0 2021 Savolitinib +- Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C. BACKGROUND: Preliminary data suggest that combining savolitinib, a potent and highly selective MET-tyrosine kinase inhibitor (TKI), with osimertinib, a third-generation, irreversible, oral epidermal growth factor receptor-TKI (EGFR-TKI), may overcome MET-based resistance to EGFR-TKIs. osimertinib 15-26 epidermal growth factor receptor Homo sapiens 84-88 34048974-12 2021 STATEMENT OF SIGNIFICANCE: : Osimertinib (OSI) is the first FDA-approved third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. osimertinib 29-40 epidermal growth factor receptor Homo sapiens 90-122 34048974-12 2021 STATEMENT OF SIGNIFICANCE: : Osimertinib (OSI) is the first FDA-approved third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. osimertinib 29-40 epidermal growth factor receptor Homo sapiens 124-128 33910930-8 2021 Screening a panel of brain-penetrating EGFR inhibitors identified osimertinib as the most potent inhibitor of the EGFR-TAZ signaling axis. osimertinib 66-77 epidermal growth factor receptor Homo sapiens 39-43 33934994-0 2021 Quantification of BIM mRNA in circulating tumor cells of osimertinib-treated patients with EGFR mutation-positive lung cancer. osimertinib 57-68 epidermal growth factor receptor Homo sapiens 91-95 33934994-1 2021 BACKGROUND: The response rate for osimertinib is high among patients with untreated epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). osimertinib 34-45 epidermal growth factor receptor Homo sapiens 84-116 33934994-1 2021 BACKGROUND: The response rate for osimertinib is high among patients with untreated epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). osimertinib 34-45 epidermal growth factor receptor Homo sapiens 118-122 33934994-9 2021 RESULTS: We enrolled 30 EGFR mutation-positive NSCLC patients treated with osimertinib during the period from April 2018 through December 2019. osimertinib 75-86 epidermal growth factor receptor Homo sapiens 24-28 33934994-14 2021 CONCLUSIONS: BIM-gamma mRNA overexpression in CTCs from EGFR mutation-positive NSCLC patients is a potential a biomarker for poor response to osimertinib. osimertinib 142-153 epidermal growth factor receptor Homo sapiens 56-60 33910930-8 2021 Screening a panel of brain-penetrating EGFR inhibitors identified osimertinib as the most potent inhibitor of the EGFR-TAZ signaling axis. osimertinib 66-77 epidermal growth factor receptor Homo sapiens 114-118 33910930-9 2021 Systemic osimertinib treatment inhibited the EGFR-TAZ axis and in vivo growth of GBM stem-like cell xenografts. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 45-49 33977727-3 2021 However, osimertinib rechallenge following osimertinib resistance in EGFR T790M-negative patient is less explored. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 69-73 33958875-0 2021 Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis EGFR T790M-C797S in NSCLC: A Case Report. osimertinib 15-26 epidermal growth factor receptor Homo sapiens 88-92 33958875-1 2021 The emergence of epidermal growth factor receptor (EGFR) exon 20 p.C797S is one of the major resistance mechanisms for osimertinib. osimertinib 119-130 epidermal growth factor receptor Homo sapiens 17-49 33958875-1 2021 The emergence of epidermal growth factor receptor (EGFR) exon 20 p.C797S is one of the major resistance mechanisms for osimertinib. osimertinib 119-130 epidermal growth factor receptor Homo sapiens 51-55 33958875-2 2021 However, there are no standard of care for non-small cell lung cancer (NSCLC) patients after acquiring EGFR C797S currently, which brings significant challenges to post-osimertinib clinical management. osimertinib 169-180 epidermal growth factor receptor Homo sapiens 103-107 33958875-3 2021 In the present study, we described a 52-year-old female patient with EGFR-mutated stage IV lung adenocarcinoma, who achieved a partial response (PR) to the treatment of gefitinib and osimertinib after acquiring EGFR exon 20 p.T790M-trans-C797S at osimertinib failure. osimertinib 183-194 epidermal growth factor receptor Homo sapiens 69-73 33958875-3 2021 In the present study, we described a 52-year-old female patient with EGFR-mutated stage IV lung adenocarcinoma, who achieved a partial response (PR) to the treatment of gefitinib and osimertinib after acquiring EGFR exon 20 p.T790M-trans-C797S at osimertinib failure. osimertinib 183-194 epidermal growth factor receptor Homo sapiens 211-215 33981604-0 2021 Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review. osimertinib 67-78 epidermal growth factor receptor Homo sapiens 82-114 33981604-1 2021 Introduction: Small cell lung cancer (SCLC) transformation represents a mechanism of resistance to osimertinib in EGFR-mutated lung adenocarcinoma, which dramatically impacts patients" prognosis due to high refractoriness to conventional treatments. osimertinib 99-110 epidermal growth factor receptor Homo sapiens 114-118 33981604-2 2021 Case Description: We present the case of a patient who developed a SCLC phenotypic transformation as resistance mechanism to second-line osimertinib for T790M-positive EGFR-mutated NSCLC. osimertinib 137-148 epidermal growth factor receptor Homo sapiens 168-172 33977727-4 2021 Herein, we describe a metastatic adenocarcinoma NSCLC patient with exon 19 deletion in EGFR (19del) who acquired resistance to initial gefitinib and second-line osimertinib but was successfully rechallenged with osimertinib following treatment failure with chemotherapy. osimertinib 161-172 epidermal growth factor receptor Homo sapiens 87-91 33977727-4 2021 Herein, we describe a metastatic adenocarcinoma NSCLC patient with exon 19 deletion in EGFR (19del) who acquired resistance to initial gefitinib and second-line osimertinib but was successfully rechallenged with osimertinib following treatment failure with chemotherapy. osimertinib 212-223 epidermal growth factor receptor Homo sapiens 87-91 33977727-5 2021 The osimertinib rechallenge, despite the absence of EGFR T790M, was considered after the development of multiple small pulmonary lesions and an increase in EGFR exon 19 deletion. osimertinib 4-15 epidermal growth factor receptor Homo sapiens 156-160 33889629-1 2021 BACKGROUND: Osimertinib is the recommended first-line treatment for adult patients with epidermal growth factor receptor (EGFR) mutation positive advanced or metastatic non-small cell lung cancer (NSCLC). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 88-120 33889629-1 2021 BACKGROUND: Osimertinib is the recommended first-line treatment for adult patients with epidermal growth factor receptor (EGFR) mutation positive advanced or metastatic non-small cell lung cancer (NSCLC). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 122-126 33896827-1 2021 BACKGROUND: Osimertinib is an epidermal growth factor receptor-tyrosine kinase inhibitor that specifically targets the T790M mutation in cancer.Unfortunately, most non-small cell lung cancer (NSCLC) patients develop osimertinib resistance. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 30-62 33937055-1 2021 The acquired EGFR C797X mutation has been identified as the most notable resistance to osimertinib, and novel secondary mutations of EGFR L718 and L792 residues have also been demonstrated to confer osimertinib resistance, making the choice of medication after osimertinib treatment a quandary. osimertinib 87-98 epidermal growth factor receptor Homo sapiens 13-17 33937055-1 2021 The acquired EGFR C797X mutation has been identified as the most notable resistance to osimertinib, and novel secondary mutations of EGFR L718 and L792 residues have also been demonstrated to confer osimertinib resistance, making the choice of medication after osimertinib treatment a quandary. osimertinib 199-210 epidermal growth factor receptor Homo sapiens 133-137 33937055-1 2021 The acquired EGFR C797X mutation has been identified as the most notable resistance to osimertinib, and novel secondary mutations of EGFR L718 and L792 residues have also been demonstrated to confer osimertinib resistance, making the choice of medication after osimertinib treatment a quandary. osimertinib 199-210 epidermal growth factor receptor Homo sapiens 133-137 33937055-3 2021 In five lung adenocarcinoma patients resistant to later-line osimertinib, recurrent mutations at EGFR L792 and/or L718 were identified using targeted next-generation sequencing of tissue or cell-free DNA from plasma or pleural effusion. osimertinib 61-72 epidermal growth factor receptor Homo sapiens 97-101 33848354-6 2021 By demonstrating that VPS34 is the key player controlling autophagy and glycolysis simultaneously, our study may provide a new strategy for overcoming osimertinib resistance for treatment of EGFR-mutant non-small cell lung cancer (NSCLC patients. osimertinib 151-162 epidermal growth factor receptor Homo sapiens 191-195 33896827-1 2021 BACKGROUND: Osimertinib is an epidermal growth factor receptor-tyrosine kinase inhibitor that specifically targets the T790M mutation in cancer.Unfortunately, most non-small cell lung cancer (NSCLC) patients develop osimertinib resistance. osimertinib 216-227 epidermal growth factor receptor Homo sapiens 30-62 31802642-1 2021 BACKGROUND: Osimertinib has been approved by the Food and Drug Administration (FDA) of the United States (US) for the treatment of progressive non-small cell lung cancer (NSCLC) that has acquired T790M mutation during treatment with first-line epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 305-309 33912453-10 2021 Resected EGFR-mutant NSCLC patients treated with osimertinib experienced improved DFS and a lower risk of brain recurrence than those treated with gefitinib or erlotinib. osimertinib 49-60 epidermal growth factor receptor Homo sapiens 9-13 33901930-0 2021 Late recurrence of lung adenocarcinoma harboring EGFR exon 20 insertion (A763_Y764insFQEA) mutation successfully treated with osimertinib. osimertinib 126-137 epidermal growth factor receptor Homo sapiens 49-53 33414509-1 2021 The third-generation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), represented by osimertinib, has achieved remarkable clinical outcomes in the treatment of non-small-cell lung cancer (NSCLC) with EGFR mutation. osimertinib 114-125 epidermal growth factor receptor Homo sapiens 24-56 33414509-1 2021 The third-generation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), represented by osimertinib, has achieved remarkable clinical outcomes in the treatment of non-small-cell lung cancer (NSCLC) with EGFR mutation. osimertinib 114-125 epidermal growth factor receptor Homo sapiens 58-62 33414509-1 2021 The third-generation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), represented by osimertinib, has achieved remarkable clinical outcomes in the treatment of non-small-cell lung cancer (NSCLC) with EGFR mutation. osimertinib 114-125 epidermal growth factor receptor Homo sapiens 229-233 33414509-3 2021 In this study, we generated an osimertinib-acquired resistant lung cancer model from a NSCLC cell line H1975 harboring EGFR L858R and T790M mutations. osimertinib 31-42 epidermal growth factor receptor Homo sapiens 119-123 33732316-0 2021 Cost-effectiveness analysis of different sequences of osimertinib administration for epidermal growth factor receptor-mutated non-small-cell lung cancer. osimertinib 54-65 epidermal growth factor receptor Homo sapiens 85-117 33732316-1 2021 Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that is clinically effective in patients with EGFR-mutated non-small-cell lung cancer (NSCLC). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 94-98 33132329-3 2021 We experienced a case of EGFR mutant lung squamous cell carcinoma in which fifth-line treatment with osimertinib was effective after T790M EGFR mutation turned positive. osimertinib 101-112 epidermal growth factor receptor Homo sapiens 25-29 33132329-3 2021 We experienced a case of EGFR mutant lung squamous cell carcinoma in which fifth-line treatment with osimertinib was effective after T790M EGFR mutation turned positive. osimertinib 101-112 epidermal growth factor receptor Homo sapiens 139-143 33132329-5 2021 Osimertinib may be a promising treatment option for EGFR mutant lung squamous cell carcinoma. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 52-56 32955628-0 2021 Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma. osimertinib 26-37 epidermal growth factor receptor Homo sapiens 120-124 32955628-1 2021 Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has exhibited efficacy in patients with EGFR-mutant non-small cell lung cancer (NSCLC). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 34-66 32955628-1 2021 Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has exhibited efficacy in patients with EGFR-mutant non-small cell lung cancer (NSCLC). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 68-72 32955628-1 2021 Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has exhibited efficacy in patients with EGFR-mutant non-small cell lung cancer (NSCLC). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 151-155 32955628-13 2021 For patients with EGFR-mutant NSCLC who experience grade 1 ILD during osimertinib therapy, osimertinib re-challenge may be suitable when no other treatments are available. osimertinib 91-102 epidermal growth factor receptor Homo sapiens 18-22 34012779-0 2021 Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib. osimertinib 167-178 epidermal growth factor receptor Homo sapiens 80-84 33828979-9 2021 Three patients with EGFR T790M mutations in CSF achieved iPR after second-line osimertinib treatment. osimertinib 79-90 epidermal growth factor receptor Homo sapiens 20-24 33591844-10 2021 New or revised recommendations include the following: Osimertinib is the optimal first-line treatment for patients with activating epidermal growth factor receptor mutations (exon 19 deletion, exon 21 L858R, and exon 20 T790M); alectinib or brigatinib is the optimal first-line treatment for patients with anaplastic lymphoma kinase fusions. osimertinib 54-65 epidermal growth factor receptor Homo sapiens 131-163 33741979-1 2021 Advanced non-small-cell lung cancer (NSCLC) patients with EGFR T790M-positive tumours benefit from osimertinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). osimertinib 99-110 epidermal growth factor receptor Homo sapiens 58-62 33976623-3 2021 This report describes the successful results obtained with the combination of the third-generation TKI osimertinib with the multitargeted TKI and MET inhibitor crizotinib in a patient with EGFR-mutant NSCLC with emerging MET amplification with a tolerable toxicity profile. osimertinib 103-114 epidermal growth factor receptor Homo sapiens 189-193 33376097-0 2021 Phase IB study of osimertinib in combination with navitoclax in EGFR-mutant NSCLC following resistance to initial EGFR therapy (ETCTN 9903). osimertinib 18-29 epidermal growth factor receptor Homo sapiens 64-68 33376097-0 2021 Phase IB study of osimertinib in combination with navitoclax in EGFR-mutant NSCLC following resistance to initial EGFR therapy (ETCTN 9903). osimertinib 18-29 epidermal growth factor receptor Homo sapiens 114-118 33376097-1 2021 INTRODUCTION: Osimertinib is an effective therapy in EGFR mutant NSCLC, but resistance invariably develops. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 53-57 33707235-5 2021 Furthermore, Keap1 inactivation reduced the sensitivity of EGFR-driven tumors to the EGFR inhibitor osimertinib and mutations in the KEAP1 pathway were associated with decreased time on tyrosine kinase inhibitor treatment in patients. osimertinib 100-111 epidermal growth factor receptor Homo sapiens 59-63 33707235-5 2021 Furthermore, Keap1 inactivation reduced the sensitivity of EGFR-driven tumors to the EGFR inhibitor osimertinib and mutations in the KEAP1 pathway were associated with decreased time on tyrosine kinase inhibitor treatment in patients. osimertinib 100-111 epidermal growth factor receptor Homo sapiens 85-89 33676426-0 2021 Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 24-28 33676426-1 2021 BACKGROUND: AURA study reported 61% objective response rate and progression-free survival of 9.6 months with osimertinib in patients with EGFR/T790M+ non-small cell lung cancer. osimertinib 109-120 epidermal growth factor receptor Homo sapiens 138-142 33676426-16 2021 CONCLUSION: This study to assess the real-world clinical impact of osimertinib showed high drug activity in pretreated advanced EGFR/T790M+ non-small cell lung cancer, with manageable adverse events. osimertinib 67-78 epidermal growth factor receptor Homo sapiens 128-132 33675607-0 2021 Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib. osimertinib 76-87 epidermal growth factor receptor Homo sapiens 28-32 33675607-1 2021 Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) used both as the first-line treatment of EGFR-mutated non-small cell lung cancer patients and in second-line after T790M-positive disease progression to first- or second-generation TKIs. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 94-98 33675607-1 2021 Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) used both as the first-line treatment of EGFR-mutated non-small cell lung cancer patients and in second-line after T790M-positive disease progression to first- or second-generation TKIs. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 145-149 33675607-3 2021 We report the case of a patient with advanced EGFR-mutated (exon 19 deletion and T790M-positive) non-small cell lung cancer who developed disease progression to osimertinib characterized by the loss of T790M concurrently with the emergence of G724S EGFR mutation, which was tackled by subsequent afatinib treatment. osimertinib 161-172 epidermal growth factor receptor Homo sapiens 46-50 33675607-3 2021 We report the case of a patient with advanced EGFR-mutated (exon 19 deletion and T790M-positive) non-small cell lung cancer who developed disease progression to osimertinib characterized by the loss of T790M concurrently with the emergence of G724S EGFR mutation, which was tackled by subsequent afatinib treatment. osimertinib 161-172 epidermal growth factor receptor Homo sapiens 249-253 33675607-4 2021 Next-generation sequencing molecular study of rebiopsy at time of progression to osimertinib revealed the persistence of EGFR exon 19 deletion, loss of T790M with a new G724S EGFR mutation; other concomitant mechanisms were excluded. osimertinib 81-92 epidermal growth factor receptor Homo sapiens 121-125 33675607-7 2021 Our case report contributes to increase the knowledge on acquired resistance mechanisms to osimertinib treatment, and it shows, for the first time, the efficacy of afatinib in the case of T790M loss and emergence of G724S EGFR mutation. osimertinib 91-102 epidermal growth factor receptor Homo sapiens 222-226 32678313-1 2021 Osimertinib (AZD9291) has been widely used for the treatment of EGFR mutant non-small cell lung cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 64-68 32678313-1 2021 Osimertinib (AZD9291) has been widely used for the treatment of EGFR mutant non-small cell lung cancer. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 64-68 33040541-2 2021 However, acquired resistance to the third-generation EGFR-TKI osimertinib is an intractable obstacle for many clinical oncologists. osimertinib 62-73 epidermal growth factor receptor Homo sapiens 53-57 33626238-11 2021 Moreover, ACER and net benefit showed that the combination of EGFR-TKI with chemotherapy and osimertinib was of more economic benefit following first-generation EGFR-TKIs. osimertinib 93-104 epidermal growth factor receptor Homo sapiens 62-66 33626238-11 2021 Moreover, ACER and net benefit showed that the combination of EGFR-TKI with chemotherapy and osimertinib was of more economic benefit following first-generation EGFR-TKIs. osimertinib 93-104 epidermal growth factor receptor Homo sapiens 161-165 33199228-9 2021 CONCLUSIONS: This is the first study to explore the efficacy and safety of osimertinib combined with platinum-based chemotherapy in previously untreated NSCLC patients with EGFR-sensitizing mutations. osimertinib 75-86 epidermal growth factor receptor Homo sapiens 173-177 33482349-2 2021 There have been significant advances in the management of metastatic EGFR-mutant NSCLC, from the advent of first and second generation EGFR inhibitors to, more recently, the third-generation inhibitor osimertinib. osimertinib 201-212 epidermal growth factor receptor Homo sapiens 69-73 33741979-1 2021 Advanced non-small-cell lung cancer (NSCLC) patients with EGFR T790M-positive tumours benefit from osimertinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). osimertinib 99-110 epidermal growth factor receptor Homo sapiens 175-179 33741979-2 2021 Here we show that the size of the EGFR T790M-positive clone impacts response to osimertinib. osimertinib 80-91 epidermal growth factor receptor Homo sapiens 34-38 33009209-0 2021 Generation of Osimertinib-Resistant Cells from EGFR L858R/T790M Mutant NSCLC Cell Line. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 47-51 33009209-4 2021 Third generation EGFR-TKI, Osimertinib exhibits high efficacy in patients with exon 19 deletion/L858R/T790M mutation but they experienced acquired resistance thereafter. osimertinib 27-38 epidermal growth factor receptor Homo sapiens 17-21 33641720-0 2021 Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 88-92 33641721-0 2021 Osimertinib Should Not Yet Be Considered the Standard of Care for EGFR-Mutant NSCLC in the Adjuvant Setting. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 66-70 33728415-9 2021 The presence of EGFR-C797S led to >200-fold resistance in proliferation assays probing mobocertinib and osimertinib. osimertinib 104-115 epidermal growth factor receptor Homo sapiens 16-20 33410885-2 2021 Objective: To explore the efficacy and safety of osimertinib plus bevacizumab compared with osimertinib alone in patients with lung adenocarcinoma with EGFR T790M mutation. osimertinib 49-60 epidermal growth factor receptor Homo sapiens 152-156 33486418-1 2021 BACKGROUND: Resistance mechanisms following 1st line therapy with osimertinib in EGFR + NSCLC have become focus of investigation. osimertinib 66-77 epidermal growth factor receptor Homo sapiens 81-85 33434619-5 2021 Furthermore afatinib, dacomitinib, and osimertinib, inhibitors of members of the epidermal growth factor receptor family (ErbB1/2/3/4), are used in the treatment of non-small cell lung cancers. osimertinib 39-50 epidermal growth factor receptor Homo sapiens 122-133 33277055-1 2021 INTRODUCTION: The use of osimertinib is associated with the risk of cancer therapy-related cardiac dysfunction (CTRCD) for EGFR-mutated non-small cell lung cancer (NSCLC) patients. osimertinib 25-36 epidermal growth factor receptor Homo sapiens 123-127 33506568-0 2021 ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non-small cell lung cancer. osimertinib 59-70 epidermal growth factor receptor Homo sapiens 74-78 33506568-5 2021 In our report, a 60-year-old female patient with lung adenocarcinoma with an EGFR mutation was administered multiple treatments, including first-line gefitinib and second-line osimertinib. osimertinib 176-187 epidermal growth factor receptor Homo sapiens 77-81 33544337-1 2021 BACKGROUND: In the global FLAURA study, first-line osimertinib, a third-generation irreversible tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), significantly improved progression-free survival (PFS) and overall survival (OS) versus comparator EGFR TKIs in patients with EGFR mutation-positive (EGFRm) advanced non-small-cell lung cancer (NSCLC). osimertinib 51-62 epidermal growth factor receptor Homo sapiens 131-163 33544337-1 2021 BACKGROUND: In the global FLAURA study, first-line osimertinib, a third-generation irreversible tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), significantly improved progression-free survival (PFS) and overall survival (OS) versus comparator EGFR TKIs in patients with EGFR mutation-positive (EGFRm) advanced non-small-cell lung cancer (NSCLC). osimertinib 51-62 epidermal growth factor receptor Homo sapiens 165-169 33544337-1 2021 BACKGROUND: In the global FLAURA study, first-line osimertinib, a third-generation irreversible tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), significantly improved progression-free survival (PFS) and overall survival (OS) versus comparator EGFR TKIs in patients with EGFR mutation-positive (EGFRm) advanced non-small-cell lung cancer (NSCLC). osimertinib 51-62 epidermal growth factor receptor Homo sapiens 271-275 33544337-1 2021 BACKGROUND: In the global FLAURA study, first-line osimertinib, a third-generation irreversible tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), significantly improved progression-free survival (PFS) and overall survival (OS) versus comparator EGFR TKIs in patients with EGFR mutation-positive (EGFRm) advanced non-small-cell lung cancer (NSCLC). osimertinib 51-62 epidermal growth factor receptor Homo sapiens 271-275 33889509-11 2021 Further analysis revealed that metformin obviously prolonged the median PFS2 of osimertinib treatment among patients who progressed to prior line EGFR-TKIs due to secondary EGFR T790M mutation (cohort B). osimertinib 80-91 epidermal growth factor receptor Homo sapiens 146-150 33679141-0 2021 Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study. osimertinib 19-30 epidermal growth factor receptor Homo sapiens 68-72 33679141-1 2021 Purpose: As a third-generation EGFR TKI has been taken orally, Osimertinib effectively inhibits mutant EGFR, including T790M EGFR resistance mutations. osimertinib 63-74 epidermal growth factor receptor Homo sapiens 31-35 33679141-1 2021 Purpose: As a third-generation EGFR TKI has been taken orally, Osimertinib effectively inhibits mutant EGFR, including T790M EGFR resistance mutations. osimertinib 63-74 epidermal growth factor receptor Homo sapiens 103-107 33679141-1 2021 Purpose: As a third-generation EGFR TKI has been taken orally, Osimertinib effectively inhibits mutant EGFR, including T790M EGFR resistance mutations. osimertinib 63-74 epidermal growth factor receptor Homo sapiens 103-107 33679141-2 2021 Here, we examined real-world efficacy and tolerability of Osimertinib among Chinese patients with advanced EGFR T790M-mutant NSCLC. osimertinib 58-69 epidermal growth factor receptor Homo sapiens 107-111 33658860-3 2021 EGFR C797S and MET amplification are common mechanisms of osimertinib. osimertinib 58-69 epidermal growth factor receptor Homo sapiens 0-4 33658860-10 2021 Conclusion: EGFR C797S mutation and MET amplification are leading mechanisms for osimertinib resistance in lung cancer. osimertinib 81-92 epidermal growth factor receptor Homo sapiens 12-16 33718183-0 2021 Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy. osimertinib 94-105 epidermal growth factor receptor Homo sapiens 29-33 33718183-2 2021 While a large amount of patients with EGFR exon 21 p.Thr790 Met (T790M) benefited from osimertinib treatment, acquired resistance to osimertinb has subsequently become a growing challenge. osimertinib 87-98 epidermal growth factor receptor Homo sapiens 38-42 33596364-0 2021 Osimertinib in EGFR-Mutated Lung Cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 15-19 33596365-0 2021 Osimertinib in EGFR-Mutated Lung Cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 15-19 33334907-1 2021 Both osimertinib and the combination of erlotinib plus ramuciumab are approved for initial therapy of advanced epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC). osimertinib 5-16 epidermal growth factor receptor Homo sapiens 111-143 32999231-1 2021 Osimertinib is the standard treatment for epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 42-74 32999231-1 2021 Osimertinib is the standard treatment for epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 76-80 32999231-5 2021 Treatment with other EGFR-TKIs after osimertinib-induced ILD may be an option for subsequent therapy. osimertinib 37-48 epidermal growth factor receptor Homo sapiens 21-25 33664875-10 2021 Results: EGFR inhibitors (e.g., osimertinib) decreased DR4 levels only in EGFR mutant NSCLC cells and tumors, being tightly associated with induction of apoptosis. osimertinib 32-43 epidermal growth factor receptor Homo sapiens 9-13 33664875-10 2021 Results: EGFR inhibitors (e.g., osimertinib) decreased DR4 levels only in EGFR mutant NSCLC cells and tumors, being tightly associated with induction of apoptosis. osimertinib 32-43 epidermal growth factor receptor Homo sapiens 74-78 33580193-0 2021 Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient. osimertinib 51-62 epidermal growth factor receptor Homo sapiens 79-83 33580193-1 2021 The survival outcomes of the FLAURA trial support osimertinib as the new standard of care for untreated patients harboring activating mutations in the epidermal growth factor receptor (EGFR). osimertinib 50-61 epidermal growth factor receptor Homo sapiens 151-183 33580193-1 2021 The survival outcomes of the FLAURA trial support osimertinib as the new standard of care for untreated patients harboring activating mutations in the epidermal growth factor receptor (EGFR). osimertinib 50-61 epidermal growth factor receptor Homo sapiens 185-189 33580193-4 2021 We report a case of impressive radiological and ctDNA response under dabrafenib, trametinib, and osimertinib in an advanced EGFR-mutant lung adenocarcinoma patient who developed BRAF V600E as one of the acquired resistance mechanisms to second-line osimertinib. osimertinib 97-108 epidermal growth factor receptor Homo sapiens 124-128 33580193-4 2021 We report a case of impressive radiological and ctDNA response under dabrafenib, trametinib, and osimertinib in an advanced EGFR-mutant lung adenocarcinoma patient who developed BRAF V600E as one of the acquired resistance mechanisms to second-line osimertinib. osimertinib 249-260 epidermal growth factor receptor Homo sapiens 124-128 33572269-5 2021 Currently, many oncologists prescribe osimertinib, a third-generation EGFR-TKI that can overcome T790M-mediated resistance, as a first-line TKI. osimertinib 38-49 epidermal growth factor receptor Homo sapiens 70-74 33574724-2 2021 The third-generation EGFR-TKIs, osimertinib and almonertinib, are now approved for the treatment of advanced NSCLC patients harboring activating EGFR mutations (first-line) and/or the resistant T790M mutation (second-line). osimertinib 32-43 epidermal growth factor receptor Homo sapiens 21-25 33471376-6 2021 While EGFR L858R/T90M-mutated cell line was sensitive to osimertinib or TAS-121 in vitro, EGFR-overexpressing cell lines displayed resistance to these EGFR-TKIs. osimertinib 57-68 epidermal growth factor receptor Homo sapiens 6-10 33474947-9 2021 CONCLUSIONS: Osimertinib demonstrated a superior therapeutic benefit with high efficacy and low toxicity for T790M-positive advanced NSCLC patients who were treated with early-generation EGFR-TKIs. osimertinib 13-24 epidermal growth factor receptor Homo sapiens 187-191 33465742-0 2021 Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface. osimertinib 84-95 epidermal growth factor receptor Homo sapiens 24-28 32556898-3 2021 The patient received osimertinib, a third generation EGFR-TKI, as the first-line treatment, but the disease progressed during treatment. osimertinib 21-32 epidermal growth factor receptor Homo sapiens 53-57 33356419-1 2021 PURPOSE: Osimertinib is a third-generation, CNS-active, irreversible, oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that potently and selectively inhibits both EGFR-TKI-sensitizing and T790M resistance mutations. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 135-139 33122107-10 2021 In patients with T790M-negative CSF, EGFR exon 21 L858R mutation, concurrent FGF3 alteration and over 1st line osimertinib showed shortened iPFS. osimertinib 111-122 epidermal growth factor receptor Homo sapiens 37-41 33494928-0 2021 Osimertinib Leads the Way Toward Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 55-59 33494929-0 2021 A Response to the Letter to the Editor: Osimertinib Leads the Way Towards Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases. osimertinib 40-51 epidermal growth factor receptor Homo sapiens 96-100 33976025-0 2021 [Effectiveness of Osimertinib for Postoperative Recurrence of Lung Cancer with L861Q Activating EGFR Mutation:Report of a Case]. osimertinib 18-29 epidermal growth factor receptor Homo sapiens 96-100 33341538-0 2021 Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 87-91 33341538-3 2021 We performed this study to investigate the real efficacy of osimertinib for Chinese advanced NSCLC patients harboring EGFR ex20 ins mutations. osimertinib 60-71 epidermal growth factor receptor Homo sapiens 118-122 33341538-14 2021 Osimertinib either 80 mg or 160 mg once daily showed less activity in Chinese NSCLC patients harboring diverse EGFR ex20 ins mutations. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 111-115 33574724-2 2021 The third-generation EGFR-TKIs, osimertinib and almonertinib, are now approved for the treatment of advanced NSCLC patients harboring activating EGFR mutations (first-line) and/or the resistant T790M mutation (second-line). osimertinib 32-43 epidermal growth factor receptor Homo sapiens 145-149 33475261-0 2021 Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation EGFR-TKIs. osimertinib 7-18 epidermal growth factor receptor Homo sapiens 129-133 33461557-0 2021 Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer. osimertinib 59-70 epidermal growth factor receptor Homo sapiens 45-49 33504904-2 2021 We studied changes in gene expression in CTC-enriched fractions of EGFR-mutant NSCLC patients under osimertinib. osimertinib 100-111 epidermal growth factor receptor Homo sapiens 67-71 33612406-2 2021 However, only about one-half of patients who have received prior treatment with a first- or second-generation EGFR-TKI are eligible for osimertinib therapy because its indication in the second-line setting is limited to metastatic NSCLC positive for the T790M resistance mutation of EGFR. osimertinib 136-147 epidermal growth factor receptor Homo sapiens 110-114 33612406-3 2021 The dose-escalation part of a study in which patients received osimertinib at doses of 20 to 240 mg once daily after the development of resistance to first- or second-generation EGFR-TKIs revealed a response rate of 21% and a median progression-free survival of 2.8 months for individuals whose tumors were negative for EGFR T790M. osimertinib 63-74 epidermal growth factor receptor Homo sapiens 178-182 33612406-3 2021 The dose-escalation part of a study in which patients received osimertinib at doses of 20 to 240 mg once daily after the development of resistance to first- or second-generation EGFR-TKIs revealed a response rate of 21% and a median progression-free survival of 2.8 months for individuals whose tumors were negative for EGFR T790M. osimertinib 63-74 epidermal growth factor receptor Homo sapiens 320-324 33612406-4 2021 We have now designed a phase II study of osimertinib for patients with EGFR mutation-positive NSCLC who develop isolated central nervous system progression (T790M-negative or unknown) after first- or second-generation EGFR-TKI therapy (cohort 1) or who develop systemic disease progression (T790M-negative) after first- or second-generation EGFR-TKI therapy and platinum-based chemotherapy (cohort 2). osimertinib 41-52 epidermal growth factor receptor Homo sapiens 71-75 33612406-4 2021 We have now designed a phase II study of osimertinib for patients with EGFR mutation-positive NSCLC who develop isolated central nervous system progression (T790M-negative or unknown) after first- or second-generation EGFR-TKI therapy (cohort 1) or who develop systemic disease progression (T790M-negative) after first- or second-generation EGFR-TKI therapy and platinum-based chemotherapy (cohort 2). osimertinib 41-52 epidermal growth factor receptor Homo sapiens 218-222 33612406-4 2021 We have now designed a phase II study of osimertinib for patients with EGFR mutation-positive NSCLC who develop isolated central nervous system progression (T790M-negative or unknown) after first- or second-generation EGFR-TKI therapy (cohort 1) or who develop systemic disease progression (T790M-negative) after first- or second-generation EGFR-TKI therapy and platinum-based chemotherapy (cohort 2). osimertinib 41-52 epidermal growth factor receptor Homo sapiens 218-222 33459177-1 2021 ABTRACT The epidermal growth factor receptor (EGFR) kinase inhibitors Gefitinib, Erlotinib, Afatinib and Osimertinib have been approved for the treatments of non-small cell lung cancer patients harboring sensitive EGFR mutations, but resistance arises rapidly. osimertinib 105-116 epidermal growth factor receptor Homo sapiens 12-44 33459177-1 2021 ABTRACT The epidermal growth factor receptor (EGFR) kinase inhibitors Gefitinib, Erlotinib, Afatinib and Osimertinib have been approved for the treatments of non-small cell lung cancer patients harboring sensitive EGFR mutations, but resistance arises rapidly. osimertinib 105-116 epidermal growth factor receptor Homo sapiens 46-50 33459177-1 2021 ABTRACT The epidermal growth factor receptor (EGFR) kinase inhibitors Gefitinib, Erlotinib, Afatinib and Osimertinib have been approved for the treatments of non-small cell lung cancer patients harboring sensitive EGFR mutations, but resistance arises rapidly. osimertinib 105-116 epidermal growth factor receptor Homo sapiens 214-218 33219754-0 2021 Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation. osimertinib 87-98 epidermal growth factor receptor Homo sapiens 28-32 33219754-0 2021 Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation. osimertinib 87-98 epidermal growth factor receptor Homo sapiens 153-157 33219754-1 2021 BACKGROUND: There are few studies that directly compare the effects of osimertinib on patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) T790M mutation between the generation of prior EGFR tyrosine kinase inhibitors (TKIs). osimertinib 71-82 epidermal growth factor receptor Homo sapiens 145-177 33219754-1 2021 BACKGROUND: There are few studies that directly compare the effects of osimertinib on patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) T790M mutation between the generation of prior EGFR tyrosine kinase inhibitors (TKIs). osimertinib 71-82 epidermal growth factor receptor Homo sapiens 179-183 33219754-2 2021 METHODS: We retrospectively reviewed clinical data from the medical records of consecutive patients with advanced NSCLC who had developed resistance to first- or second-generation EGFR-TKIs due to EGFR T790M mutation and were subsequently treated with osimertinib at Juntendo University Hospital. osimertinib 252-263 epidermal growth factor receptor Homo sapiens 197-201 33219754-4 2021 RESULTS: A total of 38 patients with NSCLC harboring EGFR T790M mutation were treated with osimertinib. osimertinib 91-102 epidermal growth factor receptor Homo sapiens 53-57 33219754-10 2021 CONCLUSIONS: PFS of osimertinib was significantly longer in patients with NSCLC harboring EGFR T790M mutation after treatment with afatinib than in patients after treatment with first generation EGFR-TKIs. osimertinib 20-31 epidermal growth factor receptor Homo sapiens 90-94 33219754-10 2021 CONCLUSIONS: PFS of osimertinib was significantly longer in patients with NSCLC harboring EGFR T790M mutation after treatment with afatinib than in patients after treatment with first generation EGFR-TKIs. osimertinib 20-31 epidermal growth factor receptor Homo sapiens 195-199 33219754-11 2021 Additional mutations other than EGFR T790M may affect the efficacy of osimertinib treatment. osimertinib 70-81 epidermal growth factor receptor Homo sapiens 32-36 33219754-12 2021 KEY POINTS: Significant findings of the study: PFS of osimertinib was significantly longer in patients with NSCLC harboring EGFR T790M mutation after treatment with afatinib than in patients after treatment with first generation EGFR-TKIs. osimertinib 54-65 epidermal growth factor receptor Homo sapiens 124-128 33219754-12 2021 KEY POINTS: Significant findings of the study: PFS of osimertinib was significantly longer in patients with NSCLC harboring EGFR T790M mutation after treatment with afatinib than in patients after treatment with first generation EGFR-TKIs. osimertinib 54-65 epidermal growth factor receptor Homo sapiens 229-233 33219754-13 2021 WHAT THIS STUDY ADDS: Additional mutations other than EGFR T790M may affect the efficacy of osimertinib treatment. osimertinib 92-103 epidermal growth factor receptor Homo sapiens 54-58 33459024-1 2021 Osimertinib is a highly potent and selective third-generation epidermal growth factor receptor (EGFR) inhibitor, which provides excellent clinical benefits and is now a standard-of-care therapy for advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 62-94 33459024-1 2021 Osimertinib is a highly potent and selective third-generation epidermal growth factor receptor (EGFR) inhibitor, which provides excellent clinical benefits and is now a standard-of-care therapy for advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 96-100 33459024-1 2021 Osimertinib is a highly potent and selective third-generation epidermal growth factor receptor (EGFR) inhibitor, which provides excellent clinical benefits and is now a standard-of-care therapy for advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 207-211 33610453-0 2021 Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression. osimertinib 10-21 epidermal growth factor receptor Homo sapiens 43-47 33610453-1 2021 BACKGROUND: Osimertinib is a third-generation EGFR tyrosine kinase inhibitor that has improved survival and central nervous system (CNS) outcomes in patients with non-small cell lung cancer (NSCLC) with activating EGFR mutations. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 46-50 33461557-1 2021 BACKGROUND: Epidermal growth factor receptor (EGFR)-mutated lung cancer constitutes a major subgroup of non-small cell lung cancer (NSCLC) and osimertinib is administrated as first-line treatment. osimertinib 143-154 epidermal growth factor receptor Homo sapiens 12-44 33461557-1 2021 BACKGROUND: Epidermal growth factor receptor (EGFR)-mutated lung cancer constitutes a major subgroup of non-small cell lung cancer (NSCLC) and osimertinib is administrated as first-line treatment. osimertinib 143-154 epidermal growth factor receptor Homo sapiens 46-50 33461557-9 2021 RESULTS: Intercellular transfer of exosomal wild type EGFR protein confers osimertinib resistance to EGFR-mutated sensitive cancer cells in vitro and in vivo. osimertinib 75-86 epidermal growth factor receptor Homo sapiens 54-58 33461557-9 2021 RESULTS: Intercellular transfer of exosomal wild type EGFR protein confers osimertinib resistance to EGFR-mutated sensitive cancer cells in vitro and in vivo. osimertinib 75-86 epidermal growth factor receptor Homo sapiens 101-105 33461557-10 2021 Co-culture of EGFR-mutated sensitive cells and EGFR-nonmutated resistant cells promoted osimertinib resistance phenotype in EGFR-mutated cancer cells, while depletion of exosomes from conditioned medium or blockade of exosomal EGFR by neutralizing antibody alleviated this phenotype. osimertinib 88-99 epidermal growth factor receptor Homo sapiens 14-18 33461557-10 2021 Co-culture of EGFR-mutated sensitive cells and EGFR-nonmutated resistant cells promoted osimertinib resistance phenotype in EGFR-mutated cancer cells, while depletion of exosomes from conditioned medium or blockade of exosomal EGFR by neutralizing antibody alleviated this phenotype. osimertinib 88-99 epidermal growth factor receptor Homo sapiens 47-51 33461557-10 2021 Co-culture of EGFR-mutated sensitive cells and EGFR-nonmutated resistant cells promoted osimertinib resistance phenotype in EGFR-mutated cancer cells, while depletion of exosomes from conditioned medium or blockade of exosomal EGFR by neutralizing antibody alleviated this phenotype. osimertinib 88-99 epidermal growth factor receptor Homo sapiens 47-51 33461557-10 2021 Co-culture of EGFR-mutated sensitive cells and EGFR-nonmutated resistant cells promoted osimertinib resistance phenotype in EGFR-mutated cancer cells, while depletion of exosomes from conditioned medium or blockade of exosomal EGFR by neutralizing antibody alleviated this phenotype. osimertinib 88-99 epidermal growth factor receptor Homo sapiens 47-51 33461557-13 2021 Moreover, exosomes could be internalized by EGFR-mutated cancer cells via Clathrin-dependent endocytosis and then the encapsulated exosomal wild type EGFR protein activated downstream PI3K/AKT and MAPK signaling pathways and triggered osimertinib resistance. osimertinib 235-246 epidermal growth factor receptor Homo sapiens 44-48 33461557-13 2021 Moreover, exosomes could be internalized by EGFR-mutated cancer cells via Clathrin-dependent endocytosis and then the encapsulated exosomal wild type EGFR protein activated downstream PI3K/AKT and MAPK signaling pathways and triggered osimertinib resistance. osimertinib 235-246 epidermal growth factor receptor Homo sapiens 150-154 33461557-14 2021 CONCLUSIONS: Intercellular transfer of exosomal wild type EGFR promotes osimertinib resistance in NSCLC, which may represent a novel resistant mechanism of osimertinib and provide a proof of concept for targeting exosomes to prevent and reverse the osimertinib resistance. osimertinib 72-83 epidermal growth factor receptor Homo sapiens 58-62 33461557-14 2021 CONCLUSIONS: Intercellular transfer of exosomal wild type EGFR promotes osimertinib resistance in NSCLC, which may represent a novel resistant mechanism of osimertinib and provide a proof of concept for targeting exosomes to prevent and reverse the osimertinib resistance. osimertinib 156-167 epidermal growth factor receptor Homo sapiens 58-62 33461557-14 2021 CONCLUSIONS: Intercellular transfer of exosomal wild type EGFR promotes osimertinib resistance in NSCLC, which may represent a novel resistant mechanism of osimertinib and provide a proof of concept for targeting exosomes to prevent and reverse the osimertinib resistance. osimertinib 156-167 epidermal growth factor receptor Homo sapiens 58-62 33721431-0 2021 Effect of osimertinib in treating patients with first-generation EGFR-TKI-resistant advanced non-small cell lung cancer and prognostic analysis. osimertinib 10-21 epidermal growth factor receptor Homo sapiens 65-69 33129919-1 2021 The third-generation of EGFR-TKI osimertinib has been approved as a first-line therapy in NSCLC, representing the most successful advance in molecularly targeted therapy. osimertinib 33-44 epidermal growth factor receptor Homo sapiens 24-28 32541922-8 2021 Furthermore, MDL-800 (25, 50 muM) enhanced the antiproliferation of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in osimertinib-resistant HCC827 and PC9 cells as well as in patient-derived primary tumor cells, and suppressed mitogen-activated protein kinase (MAPK) pathway. osimertinib 143-154 epidermal growth factor receptor Homo sapiens 129-133 33500828-3 2021 Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) approved for the treatment of patients with NSCLC with an epithelial growth factor receptor (EGFR) mutation though its role in the treatment of NSCLC-PitM that remains unclear. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 124-157 33500828-3 2021 Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) approved for the treatment of patients with NSCLC with an epithelial growth factor receptor (EGFR) mutation though its role in the treatment of NSCLC-PitM that remains unclear. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 159-163 33500828-9 2021 Conclusion: Osimertinib is a third-generation EGFR-TKI that has demonstrated promising results among patients with metastatic EGFR-mutated NSCLC. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 46-50 33500828-9 2021 Conclusion: Osimertinib is a third-generation EGFR-TKI that has demonstrated promising results among patients with metastatic EGFR-mutated NSCLC. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 126-130 32398685-0 2021 Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 33-37 32398685-4 2021 In this study we investigated the antitumor activity of osimertinib, an FDA-approved epidermal growth factor receptor (EGFR) inhibitor, against patient-derived primary GBM cells. osimertinib 56-67 epidermal growth factor receptor Homo sapiens 85-117 32398685-4 2021 In this study we investigated the antitumor activity of osimertinib, an FDA-approved epidermal growth factor receptor (EGFR) inhibitor, against patient-derived primary GBM cells. osimertinib 56-67 epidermal growth factor receptor Homo sapiens 119-123 32398685-5 2021 Using high-throughput screening approach, we screened the entire panel of FDA-approved drugs against primary cancer cells derived from glioblastoma patients, found that osimertinib (3 muM) suppressed the proliferation of a subset (10/22) of EGFR-negative GBM cells (>50% growth inhibition). osimertinib 169-180 epidermal growth factor receptor Homo sapiens 241-245 33553373-0 2021 The emergence of various genetic alterations mediated the Osimertinib resistance of a patient harboring heterozygous germline EGFR T790M: a case report. osimertinib 58-69 epidermal growth factor receptor Homo sapiens 126-130 33553373-4 2021 This study examined a patient harboring germline EGFR T790M who acquired resistance to Osimertinib therapy. osimertinib 87-98 epidermal growth factor receptor Homo sapiens 49-53 32972042-0 2021 A Phase II Trial of Osimertinib as the First-Line Treatment of Non-small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1. osimertinib 20-31 epidermal growth factor receptor Homo sapiens 111-115 32972042-1 2021 Purpose: Osimertinib is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for both EGFR-activating and T790M resistant mutation. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 64-96 32972042-1 2021 Purpose: Osimertinib is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for both EGFR-activating and T790M resistant mutation. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 98-102 32972042-1 2021 Purpose: Osimertinib is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for both EGFR-activating and T790M resistant mutation. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 139-143 32972042-2 2021 The treatment efficacy of osimertinib was assessed in previously untreated patients with metastatic non-small cell lung carcinoma (NSCLC) harboring activating EGFR mutations in circulating tumor DNA (ctDNA) as well as tumor DNA. osimertinib 26-37 epidermal growth factor receptor Homo sapiens 159-163 32972042-12 2021 Conclusion: Osimertinib had favorable efficacy in the first-line treatment of metastatic NSCLC harboring activating EGFR mutations in ctDNA as well as tumor DNA. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 116-120 33721431-1 2021 PURPOSE: To explore the efficacy and safety of the third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Osimertinib in the treatment of patients with first-generation EGFR-TKI-resistant advanced non-small cell lung cancer (NSCLC). osimertinib 138-149 epidermal growth factor receptor Homo sapiens 128-132 33721431-1 2021 PURPOSE: To explore the efficacy and safety of the third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Osimertinib in the treatment of patients with first-generation EGFR-TKI-resistant advanced non-small cell lung cancer (NSCLC). osimertinib 138-149 epidermal growth factor receptor Homo sapiens 201-205 33721431-17 2021 CONCLUSION: Osimertinib has definite efficacy in the treatment of patients with first-generation EGFR-TKI-resistant advanced NSCLC, with a low incidence rate of tolerable adverse reactions. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 97-101 33276184-3 2021 RESULTS: We report a patient with EGFR-mutated NSCLC who experienced the progression of leptomeningeal metastases as a disease flare shortly after the discontinuation of osimertinib despite the absence of radiological or cytological findings. osimertinib 170-181 epidermal growth factor receptor Homo sapiens 34-38 32467321-1 2021 AIMS: Osimertinib is a third-generation EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor that is effective in non-small cell lung cancer (NSCLC) harbouring the EGFR T790M mutation. osimertinib 6-17 epidermal growth factor receptor Homo sapiens 40-44 32467321-1 2021 AIMS: Osimertinib is a third-generation EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor that is effective in non-small cell lung cancer (NSCLC) harbouring the EGFR T790M mutation. osimertinib 6-17 epidermal growth factor receptor Homo sapiens 46-78 32467321-1 2021 AIMS: Osimertinib is a third-generation EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor that is effective in non-small cell lung cancer (NSCLC) harbouring the EGFR T790M mutation. osimertinib 6-17 epidermal growth factor receptor Homo sapiens 177-181 33296806-14 2021 CONCLUSIONS: BIM-del is associated with poor clinical responses and outcomes, and might be a negative predictive and prognostic biomarker in EGFR T790 M NSCLC patients with osimertinib treatment. osimertinib 173-184 epidermal growth factor receptor Homo sapiens 141-145 33131198-0 2021 Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small-cell lung cancer (WJOG8815L). osimertinib 11-22 epidermal growth factor receptor Homo sapiens 50-54 33131198-0 2021 Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small-cell lung cancer (WJOG8815L). osimertinib 11-22 epidermal growth factor receptor Homo sapiens 114-118 33131198-2 2021 Purpose of this study was to assess the predictive value of monitoring EGFR genomic alterations in circulating tumor DNA (ctDNA) from patients with NSCLC that undergo treatment with the third-generation EGFR-TKI osimertinib. osimertinib 212-223 epidermal growth factor receptor Homo sapiens 71-75 33131198-2 2021 Purpose of this study was to assess the predictive value of monitoring EGFR genomic alterations in circulating tumor DNA (ctDNA) from patients with NSCLC that undergo treatment with the third-generation EGFR-TKI osimertinib. osimertinib 212-223 epidermal growth factor receptor Homo sapiens 203-207 33131198-6 2021 Both MFs were found to decrease during treatment, whereas rebound of the sensitizing EGFR MF was observed at PD/stop, suggesting that osimertinib targeted both T790M mutation-positive tumors and tumors with sensitizing EGFR mutations. osimertinib 134-145 epidermal growth factor receptor Homo sapiens 85-89 33131198-6 2021 Both MFs were found to decrease during treatment, whereas rebound of the sensitizing EGFR MF was observed at PD/stop, suggesting that osimertinib targeted both T790M mutation-positive tumors and tumors with sensitizing EGFR mutations. osimertinib 134-145 epidermal growth factor receptor Homo sapiens 219-223 33131198-8 2021 In conclusion, ctDNA monitoring for sensitizing EGFR mutations at C4 is suitable for predicting the treatment outcomes in NSCLC patients receiving osimertinib. osimertinib 147-158 epidermal growth factor receptor Homo sapiens 48-52 33060857-5 2021 Currently, the field faces an unprecedented number of combinations of activating mutations with distinct resistance mutations in parallel to the approval of osimertinib as a first-line drug for EGFR-mutant lung cancer. osimertinib 157-168 epidermal growth factor receptor Homo sapiens 194-198 33270169-0 2021 The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib. osimertinib 138-149 epidermal growth factor receptor Homo sapiens 24-28 33270169-0 2021 The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib. osimertinib 138-149 epidermal growth factor receptor Homo sapiens 69-73 33270169-1 2021 BACKGROUND: The allele frequency of epidermal growth factor receptor (EGFR) mutations could be a potential molecular biomarker for the outcome of osimertinib therapy. osimertinib 146-157 epidermal growth factor receptor Homo sapiens 36-68 33270169-1 2021 BACKGROUND: The allele frequency of epidermal growth factor receptor (EGFR) mutations could be a potential molecular biomarker for the outcome of osimertinib therapy. osimertinib 146-157 epidermal growth factor receptor Homo sapiens 70-74 33270169-2 2021 OBJECTIVE: The purpose of our study was to assess the clinical relevance of the allele frequency of EGFR mutations in plasma-based circulating tumor DNA (ctDNA) before starting osimertinib therapy in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) who had progressed under treatment with EGFR tyrosine kinase inhibitors (TKIs). osimertinib 177-188 epidermal growth factor receptor Homo sapiens 223-227 33270169-2 2021 OBJECTIVE: The purpose of our study was to assess the clinical relevance of the allele frequency of EGFR mutations in plasma-based circulating tumor DNA (ctDNA) before starting osimertinib therapy in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) who had progressed under treatment with EGFR tyrosine kinase inhibitors (TKIs). osimertinib 177-188 epidermal growth factor receptor Homo sapiens 223-227 33205587-0 2021 Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR-mutation non-small cell lung cancer: A phase II single-arm prospective clinical trial. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 73-77 33569316-2 2021 Herein, we investigated the molecular factors and dynamic changes in ctDNA that can serve as predictors of survival outcomes of patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC) who received osimertinib therapy after progression from prior EGFR inhibitor regimen. osimertinib 247-258 epidermal growth factor receptor Homo sapiens 142-174 33569316-2 2021 Herein, we investigated the molecular factors and dynamic changes in ctDNA that can serve as predictors of survival outcomes of patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC) who received osimertinib therapy after progression from prior EGFR inhibitor regimen. osimertinib 247-258 epidermal growth factor receptor Homo sapiens 176-180 33396393-3 2020 The acquired EGFR C797S mutation is a known mechanism that confers resistance to third-generation EGFR TKIs such as AZD9291. osimertinib 116-123 epidermal growth factor receptor Homo sapiens 13-17 33396393-3 2020 The acquired EGFR C797S mutation is a known mechanism that confers resistance to third-generation EGFR TKIs such as AZD9291. osimertinib 116-123 epidermal growth factor receptor Homo sapiens 98-102 33392076-0 2020 Lung Adenocarcinoma Harboring EGFR Kinase Domain Duplication (EGFR-KDD) Confers Sensitivity to Osimertinib and Nivolumab: A Case Report. osimertinib 95-106 epidermal growth factor receptor Homo sapiens 30-60 33392076-0 2020 Lung Adenocarcinoma Harboring EGFR Kinase Domain Duplication (EGFR-KDD) Confers Sensitivity to Osimertinib and Nivolumab: A Case Report. osimertinib 95-106 epidermal growth factor receptor Homo sapiens 30-34 33392076-10 2020 Conclusions: Our case provided direct evidence to support the role of Osimertinib in the treatment of EGFR-KDD, as well as added valuable insights into application of immune-based therapeutics in the specific subgroups bearing EGFR alteration(s). osimertinib 70-81 epidermal growth factor receptor Homo sapiens 102-110 33392076-10 2020 Conclusions: Our case provided direct evidence to support the role of Osimertinib in the treatment of EGFR-KDD, as well as added valuable insights into application of immune-based therapeutics in the specific subgroups bearing EGFR alteration(s). osimertinib 70-81 epidermal growth factor receptor Homo sapiens 102-106 33489892-2 2020 For instance, the occurrence of EGFR T790M is associated with resistance to gefitinib, erlotinib, and afatinib, while EGFR C797S causes osimertinib to lose activity. osimertinib 136-147 epidermal growth factor receptor Homo sapiens 32-36 33489892-2 2020 For instance, the occurrence of EGFR T790M is associated with resistance to gefitinib, erlotinib, and afatinib, while EGFR C797S causes osimertinib to lose activity. osimertinib 136-147 epidermal growth factor receptor Homo sapiens 118-122 33324104-0 2020 Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 71-75 33324104-7 2020 We then present the most frequent tumor escape mechanisms when osimertinib is prescribed in first line: off-target (MET amplification, HER2 amplification, BRAF mutation, gene fusions, histologic transformation) and on-target mechanisms (EGFR mutation). osimertinib 63-74 epidermal growth factor receptor Homo sapiens 237-241 33280593-3 2022 The USFDA approved osimertinib to treat patients with metastatic T790M EGFR NSCLC on a regular basis in March 2017. osimertinib 19-30 epidermal growth factor receptor Homo sapiens 71-75 33151783-6 2021 Results: Compared with standard EGFR-TKIs, osimertinib was associated with a higher incremental cost of A$118,502, and an incremental benefit of 0.274 QALYs and 0.313 LYs. osimertinib 43-54 epidermal growth factor receptor Homo sapiens 32-36 33280593-6 2022 RESULT: Osimertinib analouge 48, 50, 60, 61, 67, 75, 80, 86, 89, 92, 93, 116 and 124 were the most active and selective compounds against T790M EGFR mutants compared to Osimertinib. osimertinib 8-19 epidermal growth factor receptor Homo sapiens 144-148 33287368-3 2020 We established 3rd generation EGFR-TKI resistant cell lines (H1975/WR and H1975/OR) via repeated exposure to WZ4002 and osimertinib. osimertinib 120-131 epidermal growth factor receptor Homo sapiens 30-34 32424780-0 2020 Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 58-62 32854536-0 2020 Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study. osimertinib 24-35 epidermal growth factor receptor Homo sapiens 53-57 32854536-6 2020 Conclusion: In real-world clinical practice, sequential afatinib and osimertinib was associated with encouraging outcomes in patients with EGFR mutation-positive NSCLC, especially in Del19-positive patients and Asian patients. osimertinib 69-80 epidermal growth factor receptor Homo sapiens 139-143 32542461-1 2020 Background Osimertinib is one of the first-line treatments for advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. osimertinib 11-22 epidermal growth factor receptor Homo sapiens 117-149 32542461-1 2020 Background Osimertinib is one of the first-line treatments for advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. osimertinib 11-22 epidermal growth factor receptor Homo sapiens 151-155 32424780-1 2020 Osimertinib is a molecularly targeted agent used to treat non-small cell lung cancer (NSCLC) patients with an epidermal growth factor receptor (EGFR) T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 110-142 32424780-1 2020 Osimertinib is a molecularly targeted agent used to treat non-small cell lung cancer (NSCLC) patients with an epidermal growth factor receptor (EGFR) T790M mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 144-148 32424780-14 2020 Osimertinib therapy could be beneficial for EGFR T790M mutation-positive advanced NSCLC patients with poor PS. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 44-48 32927121-0 2020 Real-world evaluation of factors for interstitial lung disease incidence and radiologic characteristics in patients with epidermal growth factor receptor T790M-positive non-small cell lung cancer treated with osimertinib in Japan. osimertinib 209-220 epidermal growth factor receptor Homo sapiens 121-153 33035779-0 2020 A rare EGFR mutation L747P conferred therapeutic efficacy to both gefitinib and osimertinib: A case report. osimertinib 80-91 epidermal growth factor receptor Homo sapiens 7-11 33035779-7 2020 This case revealed that EGFR L747 P rendered both gefitinib and osimertinib therapeutically efficacious. osimertinib 64-75 epidermal growth factor receptor Homo sapiens 24-28 33067020-0 2020 Response to Osimertinib in a NSCLC Patient Harboring EGFR V843I Germ-Line Mutation. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 53-57 33186860-0 2020 Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors. osimertinib 158-169 epidermal growth factor receptor Homo sapiens 77-81 33489813-0 2020 Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 47-51 33489825-5 2020 More recently, ADAURA study evaluating adjuvant osimertinib demonstrated a profound reduction of the risk of recurrence in patients with stage I (>4 cm)-IIIA eNSCLC harbouring EGFR sensitizing mutations. osimertinib 48-59 epidermal growth factor receptor Homo sapiens 176-180 33324543-0 2020 Osimertinib Resistance With a Novel EGFR L858R/A859S/Y891D Triple Mutation in a Patient With Non-Small Cell Lung Cancer: A Case Report. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 36-40 33324543-3 2020 Here, we report a novel EGFR L858R/A859S/Y891D triple mutation in plasma-derived circulating tumor DNA (ctDNA) was identified in a 53-year-old male patient with NSCLC resistant to osimertinib treatment, using an ultra-deep (20,000x) 160-gene panel through the NGS platform. osimertinib 180-191 epidermal growth factor receptor Homo sapiens 24-28 33318755-7 2020 Conclusion: In this NMA, we found that osimertinib is the most efficacious and safest EGFR-TKI. osimertinib 39-50 epidermal growth factor receptor Homo sapiens 86-90 33262603-0 2020 Case Report: A Metabolic Complete Response to Upfront Osimertinib in a Smoker Non-Small Cell Lung Cancer Patient Harbouring EGFR G719A/V769M Complex Mutation. osimertinib 54-65 epidermal growth factor receptor Homo sapiens 124-128 33262603-3 2020 Here, we reported the case of a complete metabolic response in a patient with advanced NSCLC carrying the uncommon EGFR G719A/V769M complex mutation treated with the first-line osimertinib. osimertinib 177-188 epidermal growth factor receptor Homo sapiens 115-119 32773008-4 2020 The third-generation EGFR-TKIs, represented by osimertinib, are found to have significant effect on this resistance. osimertinib 47-58 epidermal growth factor receptor Homo sapiens 21-25 33203197-1 2020 BACKGROUND: Osimertinib is approved by Food and Drug Administration for patients with advanced non-small cell lung cancer carrying EGFR-T790M mutations. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 131-135 33174519-2 2022 Osimertinib is the only FDA-approved third-generation inhibitor, which has a good potency against the EGFR-T790M mutant with minimal toxicities and excellent selectivity for wild-type EGFR. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 102-106 33174519-2 2022 Osimertinib is the only FDA-approved third-generation inhibitor, which has a good potency against the EGFR-T790M mutant with minimal toxicities and excellent selectivity for wild-type EGFR. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 184-188 33174519-3 2022 EGFR tertiary Cys797 to Ser797 (C797S) point mutation emanate rapidly after the treatment of osimertinib, which is an undruggable mutation to all three existing generation drugs. osimertinib 93-104 epidermal growth factor receptor Homo sapiens 0-4 32927121-1 2020 INTRODUCTION: Using real-world Japanese post-marketing data, we characterized interstitial lung disease (ILD) development during second- or later-line osimertinib treatment for epidermal growth factor receptor-mutation-positive non-small cell lung cancer. osimertinib 151-162 epidermal growth factor receptor Homo sapiens 177-209 33153414-4 2021 Consequently, osimertinib, a third-generation EGFR TKI, was studied and demonstrated activity against EGFR-sensitizing and resistant mutations. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 46-50 33335671-1 2020 Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) and currently the gold-standard for the treatment of patients suffering from non-small cell lung cancer (NSCLC) harboring T790M-mutated epidermal growth factor receptor (EGFR). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 202-234 33335671-1 2020 Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) and currently the gold-standard for the treatment of patients suffering from non-small cell lung cancer (NSCLC) harboring T790M-mutated epidermal growth factor receptor (EGFR). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 236-240 33153414-4 2021 Consequently, osimertinib, a third-generation EGFR TKI, was studied and demonstrated activity against EGFR-sensitizing and resistant mutations. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 102-106 32861806-0 2020 Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 110-114 33153004-6 2020 In 60% of cases, resistance to these TKIs occurs due to T790M mutation in EGFR, which is overcome 3rd generation drugs (osimertinib). osimertinib 120-131 epidermal growth factor receptor Homo sapiens 74-78 33173309-4 2020 A novel MYH9 (exon41)-RET (exon12) fusion and EGFR exon20 p.T790M loss were identified using plasma circulation tumor DNA (ctDNA) after osimertinib treatment, which led to rapid progression after osimertinib five months and suggested a potential resistance mechanism. osimertinib 136-147 epidermal growth factor receptor Homo sapiens 46-50 33173309-5 2020 Conclusion: Our findings expanded the spectrum of RET arrangement types and provided the basis for this hypothesis: acquired RET rearrangement and EGFR exon20 p.T790M loss potentially serve an additional resistance mechanism to osimertinib in EGFR-mutated non-small-cell lung cancer (NSCLC). osimertinib 228-239 epidermal growth factor receptor Homo sapiens 147-151 33173309-5 2020 Conclusion: Our findings expanded the spectrum of RET arrangement types and provided the basis for this hypothesis: acquired RET rearrangement and EGFR exon20 p.T790M loss potentially serve an additional resistance mechanism to osimertinib in EGFR-mutated non-small-cell lung cancer (NSCLC). osimertinib 228-239 epidermal growth factor receptor Homo sapiens 243-247 32861806-1 2020 BACKGROUND: In AURA3 (NCT02151981), osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), significantly prolonged progression-free survival and improved response in patients with EGFR T790M advanced non-small-cell lung cancer (NSCLC) and progression on prior EGFR-TKI treatment. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 68-100 32861806-1 2020 BACKGROUND: In AURA3 (NCT02151981), osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), significantly prolonged progression-free survival and improved response in patients with EGFR T790M advanced non-small-cell lung cancer (NSCLC) and progression on prior EGFR-TKI treatment. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 230-234 32861806-1 2020 BACKGROUND: In AURA3 (NCT02151981), osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), significantly prolonged progression-free survival and improved response in patients with EGFR T790M advanced non-small-cell lung cancer (NSCLC) and progression on prior EGFR-TKI treatment. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 230-234 33028495-0 2020 Cost-effectiveness of Osimertinib vs Docetaxel-Bevacizumab in Third-Line Treatment in EGFR T790M Resistance Mutation Advanced Non-Small Cell Lung Cancer in China. osimertinib 22-33 epidermal growth factor receptor Homo sapiens 86-90 32798688-0 2020 Osimertinib in CNS-progressive EGFR-mutant lung cancer: Do we need to detect T790M? osimertinib 0-11 epidermal growth factor receptor Homo sapiens 31-35 33294282-1 2020 A growing number of progression on Osimertinib among EGFR-mutated lung cancers represents a great challenge clinically. osimertinib 35-46 epidermal growth factor receptor Homo sapiens 53-57 33294282-5 2020 Compared with the 1st-TKIs-resistant group, EGFR mutations C797S/G, L718Q/V, L792F/H were significantly more enriched in the Osimertinib-resistant cohort, whose sensitivities to Osimertinib were successfully predicted. osimertinib 125-136 epidermal growth factor receptor Homo sapiens 44-48 33294282-5 2020 Compared with the 1st-TKIs-resistant group, EGFR mutations C797S/G, L718Q/V, L792F/H were significantly more enriched in the Osimertinib-resistant cohort, whose sensitivities to Osimertinib were successfully predicted. osimertinib 178-189 epidermal growth factor receptor Homo sapiens 44-48 33294282-6 2020 Importantly, a total of 14 low-frequency EGFR mutations were exclusively or significantly observed in the Osimertinib-resistant group, 7 were predicted to dramatically reduce the binding affinity of EGFR to Osimertinib (G796S, V802F, T725M, Q791L/H, P794S/R). osimertinib 106-117 epidermal growth factor receptor Homo sapiens 41-45 33294282-6 2020 Importantly, a total of 14 low-frequency EGFR mutations were exclusively or significantly observed in the Osimertinib-resistant group, 7 were predicted to dramatically reduce the binding affinity of EGFR to Osimertinib (G796S, V802F, T725M, Q791L/H, P794S/R). osimertinib 106-117 epidermal growth factor receptor Homo sapiens 199-203 33294282-6 2020 Importantly, a total of 14 low-frequency EGFR mutations were exclusively or significantly observed in the Osimertinib-resistant group, 7 were predicted to dramatically reduce the binding affinity of EGFR to Osimertinib (G796S, V802F, T725M, Q791L/H, P794S/R). osimertinib 207-218 epidermal growth factor receptor Homo sapiens 41-45 33294282-6 2020 Importantly, a total of 14 low-frequency EGFR mutations were exclusively or significantly observed in the Osimertinib-resistant group, 7 were predicted to dramatically reduce the binding affinity of EGFR to Osimertinib (G796S, V802F, T725M, Q791L/H, P794S/R). osimertinib 207-218 epidermal growth factor receptor Homo sapiens 199-203 33294282-7 2020 Analysis of pre-Osimertinib treatment samples of two patients supported that EGFR V802F and G796S were acquired during the treatment. osimertinib 16-27 epidermal growth factor receptor Homo sapiens 77-81 33294282-9 2020 This study represented the largest real-world data so far investigating Osimertinib resistance in EGFR-mutated lung cancer. osimertinib 72-83 epidermal growth factor receptor Homo sapiens 98-102 33294282-10 2020 We identified a collection of coexistent EGFR rare mutations and provided possible guidance for those patients who progressed on the first-line treatment of Osimertinib. osimertinib 157-168 epidermal growth factor receptor Homo sapiens 41-45 32928921-0 2020 Allosteric SHP2 inhibitor IACS-13909 overcomes EGFR-dependent and EGFR-independent resistance mechanisms towards osimertinib. osimertinib 113-124 epidermal growth factor receptor Homo sapiens 66-70 32928921-3 2020 The long-term effectiveness of tyrosine kinase inhibitors (TKI) such as the EGFR inhibitor osimertinib in non-small cell lung cancer (NSCLC) is limited by acquired resistance. osimertinib 91-102 epidermal growth factor receptor Homo sapiens 76-80 32928921-4 2020 Multiple clinically identified mechanisms underlie resistance to osimertinib, including mutations in EGFR that preclude drug binding as well as EGFR-independent activation of the MAPK pathway through alternate RTK (RTK-bypass). osimertinib 65-76 epidermal growth factor receptor Homo sapiens 101-105 32928921-4 2020 Multiple clinically identified mechanisms underlie resistance to osimertinib, including mutations in EGFR that preclude drug binding as well as EGFR-independent activation of the MAPK pathway through alternate RTK (RTK-bypass). osimertinib 65-76 epidermal growth factor receptor Homo sapiens 144-148 33028495-1 2020 PURPOSE: This study aimed to evaluate the cost-effectiveness of osimertinib vs docetaxel and bevacizumab in third-line treatment in EGFR T790M resistance mutation advanced non-small cell lung cancer in China from the perspective of the health care system. osimertinib 64-75 epidermal growth factor receptor Homo sapiens 132-136 33028495-4 2020 Efficacy and safety data of osimertinib vs docetaxel and bevacizumab in patients who had acquired EGFR T790M resistance mutation were derived from a key head-to-head clinical trial. osimertinib 28-39 epidermal growth factor receptor Homo sapiens 98-102 33028495-12 2020 IMPLICATIONS: The findings from the present analysis suggest that osimertinib could be cost-effective vs docetaxel and bevacizumab in third-line treatment in EGFR T790M resistance mutation advanced non-small cell lung cancer in China. osimertinib 66-77 epidermal growth factor receptor Homo sapiens 158-162 32845180-4 2020 We describe the methodology for this integration and present a proof-of-concept application to the treatment of non-small cell lung cancer (NSCLC) with EGFR mutation with osimertinib.Materials and methods: For better accuracy in estimating the ADP, we used the prices generated from the six dimensions at scenario levels, not at the dimension-specific price (DSP) level. osimertinib 171-182 epidermal growth factor receptor Homo sapiens 152-156 32845191-3 2020 We describe this dimension"s methodology and present a proof-of-concept application to the treatment of non-small cell lung cancer (NSCLC) with EGFR mutation with osimertinib.Materials and methods: The reference-based pricing dimension utilizes a six-step method: 1) selecting foreign countries based on a set of four criteria (drug is available in the foreign country, price information is available in the foreign country, foreign countries are members within the organization for Economic Co-operation and Development, pricing methods in the foreign countries involve value assessment); 2) adjusting for exchange rates; 3) generating reference price (RP) scenarios; 4) adjusting with the medical inflation rate; 5) pooling all generated RP scenarios and calculating average and standard deviation (SD); 6) and Monte Carlo Simulation (MCS) to estimate the dimension-specific DSPReference. osimertinib 163-174 epidermal growth factor receptor Homo sapiens 144-148 32845201-3 2020 We describe this dimension"s methodology and present a proof-of-concept application to the treatment of non-small cell lung cancer (NSCLC) with EGFR mutation with osimertinib.Materials and methods: Eight WTP scenarios based on four levels of real gross domestic product per capita (<1GDP/capita, 1xGDP/capita, 3xGDP/capita, and >3xGDP/capita) and two market conditions (monopolistic versus competitive) were assumed. osimertinib 163-174 epidermal growth factor receptor Homo sapiens 144-148 32845204-3 2020 We describe this dimension"s methodology and present a proof-of-concept application to the treatment of non-small cell lung cancer (NSCLC) with EGFR mutation with osimertinib.Materials and methods: The risk of efficacy failure pricing dimension utilizes a seven-step method: 1) defining risk; 2) extracting data; 3) predicting models; 4) performing Monte Carlo Simulation (MCS) to estimate risk of efficacy failure; 5) estimating ranges for a payback; 6) adjusting for medical inflation; and 7) performing Monte Carlo Simulation (MCS) to estimate the DSPRisk of efficacy failure. osimertinib 163-174 epidermal growth factor receptor Homo sapiens 144-148 32845205-3 2020 We describe this dimension"s methodology and present a proof-of-concept application to the treatment of non-small cell lung cancer (NSCLC) with EGFR mutation with osimertinib.Materials and methods: The safety-based pricing dimension utilizes a four-step method: 1) pooling adverse events (AE), standardizing, estimating 95%CIs, and adjusting for time; 2) estimating correction factors and corrected probabilities of AEs; 3) estimating the probability of at least one adverse event (AE) occurring and leading to treatment discontinuation; and 4) estimating ranges for payback percentages and performing Monte Carlo Simulation to estimate a DSPSafety. osimertinib 163-174 epidermal growth factor receptor Homo sapiens 144-148 32845209-3 2020 We describe this dimension"s methodology and present a proof-of-concept application to the treatment of non-small cell lung cancer (NSCLC) with EGFR mutation with osimertinib.Materials and methods: We propose two paybacks based on adherence: in-advance (based on clinical trial data) and in-arrear (based on real-world data). osimertinib 163-174 epidermal growth factor receptor Homo sapiens 144-148 32845794-3 2020 We describe this dimension"s methodology and present a proof-of-concept application to the treatment of non-small cell lung cancer (NSCLC) with EGFR mutation with osimertinib.Materials and methods: CEA and CUA were performed using established methods. osimertinib 163-174 epidermal growth factor receptor Homo sapiens 144-148 32886557-0 2020 Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore. osimertinib 31-42 epidermal growth factor receptor Homo sapiens 102-106 33489707-0 2021 First-line osimertinib for leptomeningeal metastasis from lung adenocarcinoma with EGFR mutation as the initial and solitary site of postoperative recurrence. osimertinib 11-22 epidermal growth factor receptor Homo sapiens 83-87 32652216-0 2020 Osimertinib improves overall survival in EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastases regardless of T790M mutational status. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 41-45 32652216-1 2020 INTRODUCTION: Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), efficiently penetrates the blood-brain barrier. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 46-78 32652216-1 2020 INTRODUCTION: Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), efficiently penetrates the blood-brain barrier. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 80-84 32652216-2 2020 Current study explored whether treatment with osimertinib leads to improved overall survival (OS) for EGFR-mutated NSCLC patients with leptomeningeal metastases (LM) compared with those not treated with osimertinib. osimertinib 46-57 epidermal growth factor receptor Homo sapiens 102-106 32652216-10 2020 CONCLUSIONS: Osimertinib is a promising treatment option for EGFR-mutated NSCLC with LM regardless of T790M mutational status. osimertinib 13-24 epidermal growth factor receptor Homo sapiens 61-65 33193830-2 2020 Three reasons are suggested: since rechallenge with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is covered by health insurance in Japan, EGFR-TKI rechallenge rate was higher in SOC than in the osimertinib group, which resulted in a long-term sequential administration of EGFR-TKIs; treatment discontinuation rate was high in the osimertinib group due to adverse events such as interstitial pneumonia among Japanese patients. osimertinib 219-230 epidermal growth factor receptor Homo sapiens 112-116 33193830-2 2020 Three reasons are suggested: since rechallenge with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is covered by health insurance in Japan, EGFR-TKI rechallenge rate was higher in SOC than in the osimertinib group, which resulted in a long-term sequential administration of EGFR-TKIs; treatment discontinuation rate was high in the osimertinib group due to adverse events such as interstitial pneumonia among Japanese patients. osimertinib 219-230 epidermal growth factor receptor Homo sapiens 163-167 33193830-2 2020 Three reasons are suggested: since rechallenge with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is covered by health insurance in Japan, EGFR-TKI rechallenge rate was higher in SOC than in the osimertinib group, which resulted in a long-term sequential administration of EGFR-TKIs; treatment discontinuation rate was high in the osimertinib group due to adverse events such as interstitial pneumonia among Japanese patients. osimertinib 355-366 epidermal growth factor receptor Homo sapiens 112-116 33193830-2 2020 Three reasons are suggested: since rechallenge with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is covered by health insurance in Japan, EGFR-TKI rechallenge rate was higher in SOC than in the osimertinib group, which resulted in a long-term sequential administration of EGFR-TKIs; treatment discontinuation rate was high in the osimertinib group due to adverse events such as interstitial pneumonia among Japanese patients. osimertinib 355-366 epidermal growth factor receptor Homo sapiens 163-167 33193830-6 2020 Methods: The Heat on Beat study is a randomized, open-label, multicenter, phase II study to compare OS between initial treatment with afatinib and osimertinib in treatment-naive patients with advanced or recurrent EGFR-mutant NSCLC. osimertinib 147-158 epidermal growth factor receptor Homo sapiens 214-218 33113300-0 2020 Adjuvant Osimertinib in EGFR-Mutated Non-Small-Cell Lung Cancer. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 24-28 33082305-9 2020 The EGFR-TKI Osimertinib downregulated IPO13 expression level in NSCLC cell lines with EGFR mutations, but not in EGFR wild-type ones. osimertinib 13-24 epidermal growth factor receptor Homo sapiens 4-8 33082305-9 2020 The EGFR-TKI Osimertinib downregulated IPO13 expression level in NSCLC cell lines with EGFR mutations, but not in EGFR wild-type ones. osimertinib 13-24 epidermal growth factor receptor Homo sapiens 87-91 33080698-0 2020 Poor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma: A case report. osimertinib 15-26 epidermal growth factor receptor Homo sapiens 30-34 33080698-1 2020 INTRODUCTION: The clinical efficacy of osimertinib for patients with lung adenocarcinoma harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations is unclear. osimertinib 39-50 epidermal growth factor receptor Homo sapiens 99-131 33080698-1 2020 INTRODUCTION: The clinical efficacy of osimertinib for patients with lung adenocarcinoma harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations is unclear. osimertinib 39-50 epidermal growth factor receptor Homo sapiens 133-137 33080698-8 2020 INTERVENTIONS: Daily oral administration of 80 mg osimertinib was initiated to treat the EGFR exon 20 insertion-positive lung adenocarcinoma. osimertinib 50-61 epidermal growth factor receptor Homo sapiens 89-93 32956986-0 2020 Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. osimertinib 31-42 epidermal growth factor receptor Homo sapiens 92-96 32956986-1 2020 BACKGROUND: Osimertinib is the treatment of choice for advanced EGFR-mutant non-small cell lung cancer (NSCLC). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 64-68 32956986-5 2020 METHODS: MD Anderson Cancer Center GEMINI database was retrospectively queried for EGFR-mutant NSCLC patients who received osimertinib with or without concurrent use of aspirin for progression-free survival (PFS) and overall survival (OS). osimertinib 123-134 epidermal growth factor receptor Homo sapiens 83-87 32956986-11 2020 CONCLUSION: Concurrent aspirin use with osimertinib in EGFR-mutant NSCLC patients was associated with improved survival, regardless of lines of therapy, CNS metastatic status, EGFR mutation type, age, gender, TP53, and PD-L1 status. osimertinib 40-51 epidermal growth factor receptor Homo sapiens 55-59 33489707-2 2021 We present the case of a 54-year-old man with LM from lung adenocarcinoma harboring EGFR L858R point mutation, who received osimertinib as first-line therapy. osimertinib 124-135 epidermal growth factor receptor Homo sapiens 84-88 33489707-8 2021 Osimertinib is considered to be an effective therapeutic option for LM from lung adenocarcinoma harboring EGFR mutation. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 106-110 33163272-2 2020 AZD9291 (osimertinib) represents the first-approved third generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) for the treatment of non-small cell lung cancer (NSCLC) with activating EGFR mutations and resistant T790M mutation, but faces the giant challenge of acquired resistance developed in patients in the clinic. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 69-73 32955177-0 2020 Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 24-28 32955177-1 2020 BACKGROUND: Osimertinib is standard-of-care therapy for previously untreated epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 77-109 32955177-1 2020 BACKGROUND: Osimertinib is standard-of-care therapy for previously untreated epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 111-115 32955177-12 2020 CONCLUSIONS: In patients with stage IB to IIIA EGFR mutation-positive NSCLC, disease-free survival was significantly longer among those who received osimertinib than among those who received placebo. osimertinib 149-160 epidermal growth factor receptor Homo sapiens 47-51 32634610-14 2020 CONCLUSION: Thus, 160 mg osimertinib demonstrated promising ORR and survival benefit with a tolerable safety profile in EGFR T790M-positive NSCLC patients with CNS metastasis who progressed on prior EGFR TKIs. osimertinib 25-36 epidermal growth factor receptor Homo sapiens 120-124 32634610-14 2020 CONCLUSION: Thus, 160 mg osimertinib demonstrated promising ORR and survival benefit with a tolerable safety profile in EGFR T790M-positive NSCLC patients with CNS metastasis who progressed on prior EGFR TKIs. osimertinib 25-36 epidermal growth factor receptor Homo sapiens 199-203 32639668-9 2020 Exploratory analysis showed that OS using the 2G EGFR-TKI was superior to that of the 1G EGFR-TKIs, suggesting the potential of sequential therapy of 2G EGFR-TKI followed by osimertinib. osimertinib 174-185 epidermal growth factor receptor Homo sapiens 49-53 32735723-0 2020 MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib. osimertinib 56-67 epidermal growth factor receptor Homo sapiens 71-75 32735723-1 2020 The third generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib is approved for untreated, or previously EGFR-TKI-treated T790M-positive EGFR-mutated non-small cell lung carcinoma (NSCLC). osimertinib 91-102 epidermal growth factor receptor Homo sapiens 81-85 32735723-1 2020 The third generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib is approved for untreated, or previously EGFR-TKI-treated T790M-positive EGFR-mutated non-small cell lung carcinoma (NSCLC). osimertinib 91-102 epidermal growth factor receptor Homo sapiens 144-148 32735723-13 2020 Hence, MET amplification might induce heterogeneous responses to osimertinib in EGFR-mutated NSCLC. osimertinib 65-76 epidermal growth factor receptor Homo sapiens 80-84 32945365-8 2020 The inhibition of receptor phosphorylation with the 1st, 2nd and 3rd generation TKIs, gefitinib, afatinib, osimertinib, respectively, reduced PLCgamma1 phosphorylation, and reduced the invasive and migratory potential of 293 cells, confirming PLCgamma1 as one of the probable downstream effectors of mutant EGFR signaling. osimertinib 107-118 epidermal growth factor receptor Homo sapiens 307-311 32981603-0 2020 EGFR Exon 20 Insertion (A763_Y764insFQEA) Mutant NSCLC Is Not Identified by Roche Cobas Version 2 Tissue Testing but Has Durable Intracranial and Extracranial Response to Osimertinib. osimertinib 171-182 epidermal growth factor receptor Homo sapiens 0-4 33209443-0 2020 A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 78-82 32586660-0 2020 Comment on: "Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer". osimertinib 13-24 epidermal growth factor receptor Homo sapiens 53-57 32800358-0 2020 A reply to "Comment on: "Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer". osimertinib 25-36 epidermal growth factor receptor Homo sapiens 65-69 32367600-9 2020 CONCLUSION: Osimertinib can be a treatment option for patients with lung ASC harboring germline EGFR T790M mutation. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 96-100 33116624-0 2020 Durable Response to Osimertinib in a Chinese Patient with Metastatic Lung Adenocarcinoma Harboring a Rare EGFR L858R/D761Y Compound Mutation. osimertinib 20-31 epidermal growth factor receptor Homo sapiens 106-110 33116624-3 2020 In the present case, we describe the clinical efficacy of icotinib and osimertinib in a metastatic lung adenocarcinoma patient carrying a highly uncommon EGFR L858R/D761Y compound mutation. osimertinib 71-82 epidermal growth factor receptor Homo sapiens 154-158 33116624-5 2020 To the best of our knowledge, this is the first report of durable osimertinib response in an NSCLC patient with a rare EGFR L858R/D761Y mutation. osimertinib 66-77 epidermal growth factor receptor Homo sapiens 119-123 33163272-2 2020 AZD9291 (osimertinib) represents the first-approved third generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) for the treatment of non-small cell lung cancer (NSCLC) with activating EGFR mutations and resistant T790M mutation, but faces the giant challenge of acquired resistance developed in patients in the clinic. osimertinib 0-7 epidermal growth factor receptor Homo sapiens 101-105 33163272-2 2020 AZD9291 (osimertinib) represents the first-approved third generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) for the treatment of non-small cell lung cancer (NSCLC) with activating EGFR mutations and resistant T790M mutation, but faces the giant challenge of acquired resistance developed in patients in the clinic. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 69-73 33163272-2 2020 AZD9291 (osimertinib) represents the first-approved third generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) for the treatment of non-small cell lung cancer (NSCLC) with activating EGFR mutations and resistant T790M mutation, but faces the giant challenge of acquired resistance developed in patients in the clinic. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 101-105 33209639-0 2020 HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer. osimertinib 43-54 epidermal growth factor receptor Homo sapiens 69-73 32634610-0 2020 A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. osimertinib 52-63 epidermal growth factor receptor Homo sapiens 67-71 33209615-1 2020 Background: T790M relative allele frequency (RAF) in plasma, calculated by the ratio of T790M to epidermal growth factor receptor (EGFR)-sensitizing mutation allele frequencies (AF), is associated with osimertinib response in patients with progressive non-small cell lung cancer (NSCLC) post 1st generation EGFR-tyrosine kinase inhibitor (TKI) treatment. osimertinib 202-213 epidermal growth factor receptor Homo sapiens 97-129 33209615-1 2020 Background: T790M relative allele frequency (RAF) in plasma, calculated by the ratio of T790M to epidermal growth factor receptor (EGFR)-sensitizing mutation allele frequencies (AF), is associated with osimertinib response in patients with progressive non-small cell lung cancer (NSCLC) post 1st generation EGFR-tyrosine kinase inhibitor (TKI) treatment. osimertinib 202-213 epidermal growth factor receptor Homo sapiens 131-135 33209615-1 2020 Background: T790M relative allele frequency (RAF) in plasma, calculated by the ratio of T790M to epidermal growth factor receptor (EGFR)-sensitizing mutation allele frequencies (AF), is associated with osimertinib response in patients with progressive non-small cell lung cancer (NSCLC) post 1st generation EGFR-tyrosine kinase inhibitor (TKI) treatment. osimertinib 202-213 epidermal growth factor receptor Homo sapiens 307-311 33209615-7 2020 Conclusions: In patients with progressive NSCLC post 1st generation EGFR-TKI treatment, plasma T790M RAFs of less than 20% can be used to identify patients who carry concurrent resistance mechanisms, and can predict a poorer response to osimertinib. osimertinib 237-248 epidermal growth factor receptor Homo sapiens 68-72 33008019-1 2020 Osimertinib (OSI, AZD9291), is a third-generation, irreversible tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. osimertinib 13-16 epidermal growth factor receptor Homo sapiens 103-135 33008019-1 2020 Osimertinib (OSI, AZD9291), is a third-generation, irreversible tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. osimertinib 13-16 epidermal growth factor receptor Homo sapiens 137-141 33008019-1 2020 Osimertinib (OSI, AZD9291), is a third-generation, irreversible tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. osimertinib 13-16 epidermal growth factor receptor Homo sapiens 174-178 33008019-1 2020 Osimertinib (OSI, AZD9291), is a third-generation, irreversible tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. osimertinib 13-16 epidermal growth factor receptor Homo sapiens 174-178 33008019-1 2020 Osimertinib (OSI, AZD9291), is a third-generation, irreversible tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. osimertinib 18-25 epidermal growth factor receptor Homo sapiens 103-135 33008019-1 2020 Osimertinib (OSI, AZD9291), is a third-generation, irreversible tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. osimertinib 18-25 epidermal growth factor receptor Homo sapiens 137-141 33008019-1 2020 Osimertinib (OSI, AZD9291), is a third-generation, irreversible tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. osimertinib 18-25 epidermal growth factor receptor Homo sapiens 174-178 33008019-1 2020 Osimertinib (OSI, AZD9291), is a third-generation, irreversible tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. osimertinib 18-25 epidermal growth factor receptor Homo sapiens 174-178 33196042-0 2020 Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases. osimertinib 19-30 epidermal growth factor receptor Homo sapiens 63-67 33196042-1 2020 Background: Osimertinib is a selective irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) with increased penetration across the blood-brain barrier compared with previous EGFR-TKIs, and thus, a 52% reduction in the risk of intracranial disease progression is seen when it is used as a first line of therapy compared with gefitinib and erlotinib. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 112-116 33196042-4 2020 Methods: This is a subcohort analysis from a larger nonrandomized, phase 2, open-label trial, evaluating the efficacy of osimertinib dose escalation from 80 mg to 160 mg in EGFR-mutated advanced non-small-cell lung cancer (NSCLC) patients with intracranial progression in either first- (arm A) or second-line setting (arm B for T790M+ and C for T790M-). osimertinib 121-132 epidermal growth factor receptor Homo sapiens 173-177 32634610-2 2020 Osimertinib (80mg), a third generation, irreversible, oral EGFR TKI, has shown efficacy in active CNS metastases. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 59-63 33209641-0 2020 Meningeal metastasis patients with EGFR G724S who develop resistance to osimertinib benefit from the addition of afatinib. osimertinib 72-83 epidermal growth factor receptor Homo sapiens 35-39 32929081-0 2020 Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. osimertinib 42-53 epidermal growth factor receptor Homo sapiens 84-88 32943544-0 2020 Osimertinib, an EGFR tyrosine kinase inhibitor, exerts anti-tumor activity in preclinical NSCLC models harboring the uncommon EGFR mutations G719X or L861Q or S768I. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 16-20 32943544-1 2020 Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations with lower activity against wild-type EGFR and has demonstrated efficacy in NSCLC CNS metastases. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 115-119 32943544-1 2020 Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations with lower activity against wild-type EGFR and has demonstrated efficacy in NSCLC CNS metastases. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 156-160 32943544-1 2020 Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations with lower activity against wild-type EGFR and has demonstrated efficacy in NSCLC CNS metastases. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 156-160 32943544-8 2020 Together this data supports clinical testing of osimertinib in patients with uncommon EGFR NSCLC. osimertinib 48-59 epidermal growth factor receptor Homo sapiens 86-90 32943545-0 2020 CH7233163 overcomes osimertinib resistant EGFR-Del19/T790M/C797S mutation. osimertinib 20-31 epidermal growth factor receptor Homo sapiens 42-46 32943545-1 2020 Osimertinib is the only EGFR-tyrosine kinase inhibitor (TKI) capable of overcoming EGFR-T790M-mutated NSCLC, but osimertinib-resistant EGFR triple mutations (Del19/T790M/C797S or L858R/T790M/C797S) have been reported. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 24-28 32943545-1 2020 Osimertinib is the only EGFR-tyrosine kinase inhibitor (TKI) capable of overcoming EGFR-T790M-mutated NSCLC, but osimertinib-resistant EGFR triple mutations (Del19/T790M/C797S or L858R/T790M/C797S) have been reported. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 83-87 32943545-1 2020 Osimertinib is the only EGFR-tyrosine kinase inhibitor (TKI) capable of overcoming EGFR-T790M-mutated NSCLC, but osimertinib-resistant EGFR triple mutations (Del19/T790M/C797S or L858R/T790M/C797S) have been reported. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 83-87 32943545-9 2020 Therefore, we conclude that CH7233163 is a potentially effective therapy for osimertinib resistant patients, especially in cases of EGFR-Del19/T790M/C797S. osimertinib 77-88 epidermal growth factor receptor Homo sapiens 132-136 32929081-1 2020 Drug tolerance is the basis for acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) including osimertinib, through mechanisms that still remain unclear. osimertinib 137-148 epidermal growth factor receptor Homo sapiens 116-120 32929081-2 2020 Here, we show that while AXL-low expressing EGFR mutated lung cancer (EGFRmut-LC) cells are more sensitive to osimertinib than AXL-high expressing EGFRmut-LC cells, a small population emerge osimertinib tolerance. osimertinib 110-121 epidermal growth factor receptor Homo sapiens 44-48 32929081-2 2020 Here, we show that while AXL-low expressing EGFR mutated lung cancer (EGFRmut-LC) cells are more sensitive to osimertinib than AXL-high expressing EGFRmut-LC cells, a small population emerge osimertinib tolerance. osimertinib 191-202 epidermal growth factor receptor Homo sapiens 44-48 32929081-4 2020 IGF-1R maintains association with EGFR and adaptor proteins, including Gab1 and IRS1, in the presence of osimertinib and restores the survival signal. osimertinib 105-116 epidermal growth factor receptor Homo sapiens 34-38 32954743-0 2020 Osimertinib for EGFR-mutant lung cancer with central nervous system metastases: a meta-analysis and systematic review. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 16-20 33014788-3 2020 Patients with T790M gain the opportunity of subsequent treatment with third-generation EGFR-TKI, osimertinib. osimertinib 97-108 epidermal growth factor receptor Homo sapiens 87-91 33014788-12 2020 In conclusion, this study showed that patients who progressed from gefitinib treatment, bearing common EGFR mutations, and with longer EGFR-TKI treatment duration had increased incidence of T790M acquisition and, therefore, were suitable for subsequent osimertinib treatment. osimertinib 253-264 epidermal growth factor receptor Homo sapiens 103-107 32954743-1 2020 BACKGROUND: Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), is the only Food and Drug Administration-approved third-generation epidermal growth factor receptor (EGFR)TKI. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 144-176 32954743-1 2020 BACKGROUND: Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), is the only Food and Drug Administration-approved third-generation epidermal growth factor receptor (EGFR)TKI. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 178-182 32954743-4 2020 We review some of the main challenges in targeting EGFR, including lack of central nervous system penetration with most tyrosine kinase inhibitors, activity of osimertinib penetrating blood-brain barrier and the efficacy of osimertinib. osimertinib 160-171 epidermal growth factor receptor Homo sapiens 51-55 32954743-4 2020 We review some of the main challenges in targeting EGFR, including lack of central nervous system penetration with most tyrosine kinase inhibitors, activity of osimertinib penetrating blood-brain barrier and the efficacy of osimertinib. osimertinib 224-235 epidermal growth factor receptor Homo sapiens 51-55 32954743-9 2020 In untreated advanced EGFR-mutated NSCLC with CNS metastases patients, the pooled ORR and DCR of osimertinib were 71% and 93%, respectively. osimertinib 97-108 epidermal growth factor receptor Homo sapiens 22-26 32577785-2 2020 Different mechanisms of acquired resistance to first-generation and second-generation EGFR TKIs have been widely reported, but there were few reports on the resistant mechanism of third-generation EGFR-TKI such as osimertinib (AZD9291). osimertinib 227-234 epidermal growth factor receptor Homo sapiens 197-201 32693293-1 2020 Osimertinib is an irreversible EGFR-tyrosine kinase inhibitor initially approved for treatment of EGFR-positive patients exhibiting a T790 M resistance mutation in the second line setting and now emerging as the new standard of care for all EGFR positive patients as first-line treatment. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 31-35 32389504-0 2020 Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib. osimertinib 132-143 epidermal growth factor receptor Homo sapiens 87-91 32755244-3 2020 AREAS COVERED: We discuss the development of third generation EGFR TKIs, focusing on osimertinib and discuss the most common resistance mechanisms under evaluation. osimertinib 85-96 epidermal growth factor receptor Homo sapiens 62-66 32461525-1 2020 Some patients discontinue receiving osimertinib for non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) Thr790Met (T790M) mutation due to adverse its effects. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 97-129 32461525-1 2020 Some patients discontinue receiving osimertinib for non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) Thr790Met (T790M) mutation due to adverse its effects. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 131-135 32461525-3 2020 An 85-year-old Japanese woman received osimertinib as third-line therapy for NSCLC with the EGFR T790M mutation. osimertinib 39-50 epidermal growth factor receptor Homo sapiens 92-96 33014788-12 2020 In conclusion, this study showed that patients who progressed from gefitinib treatment, bearing common EGFR mutations, and with longer EGFR-TKI treatment duration had increased incidence of T790M acquisition and, therefore, were suitable for subsequent osimertinib treatment. osimertinib 253-264 epidermal growth factor receptor Homo sapiens 135-139 32385709-1 2020 PURPOSE: Osimertinib, a third-generation epidermal growth factor receptor tyrosine-kinase inhibitor (EGFR-TKI), has demonstrated substantial clinical benefit in patients with non-small-cell lung cancer (NSCLC) who were resistant to early-generation EGFR-TKIs and had acquired a T790M mutation. osimertinib 9-20 epidermal growth factor receptor Homo sapiens 101-105 32693293-1 2020 Osimertinib is an irreversible EGFR-tyrosine kinase inhibitor initially approved for treatment of EGFR-positive patients exhibiting a T790 M resistance mutation in the second line setting and now emerging as the new standard of care for all EGFR positive patients as first-line treatment. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 98-102 32693293-1 2020 Osimertinib is an irreversible EGFR-tyrosine kinase inhibitor initially approved for treatment of EGFR-positive patients exhibiting a T790 M resistance mutation in the second line setting and now emerging as the new standard of care for all EGFR positive patients as first-line treatment. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 98-102 32693293-2 2020 Despite its efficacy, resistance to osimertinib inevitably develops and mechanisms of resistance can be grouped broadly in two categories: on-target EGFR-dependent and off-target EGFR-independent mechanisms. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 149-153 32693293-2 2020 Despite its efficacy, resistance to osimertinib inevitably develops and mechanisms of resistance can be grouped broadly in two categories: on-target EGFR-dependent and off-target EGFR-independent mechanisms. osimertinib 36-47 epidermal growth factor receptor Homo sapiens 179-183 32525442-5 2020 The safety and efficacy of osimertinib (a third generation EGFR-TKIs) were confirmed by well-designed clinical trials. osimertinib 27-38 epidermal growth factor receptor Homo sapiens 59-63 32525442-6 2020 Consequently, osimertinib was considered a first-line treatment option, particularly in patients with EGFR mutant NSCLC. osimertinib 14-25 epidermal growth factor receptor Homo sapiens 102-106 32782544-7 2020 In conclusion, the present study analysed the effects of osimertinib in patients with advanced NSCLC with EGFR mutations, particularly T790M mutations. osimertinib 57-68 epidermal growth factor receptor Homo sapiens 106-110 32521387-3 2020 MATERIALS AND METHODS: We generated EGFR TKI-resistant NSCLC cell lines with acquired resistance to erlotinib, gefitinib, and osimertinib (PC9/ER, HCC827/GR and HCC827/OR, respectively). osimertinib 126-137 epidermal growth factor receptor Homo sapiens 36-40 32412152-1 2020 EGFR exon20-insertions (EGFR e20ins) account for up to 10% of EGFR mutations in lung cancer; however, tumors with EGFR e20ins had poor response rates to EGFR tyrosine kinase inhibitors (TKIs) including gefitinib, erlotinib, afatinib and osimertinib, and the heterogeneity of EGFR e20ins further complicate the clinical studies. osimertinib 237-248 epidermal growth factor receptor Homo sapiens 0-4 32412152-1 2020 EGFR exon20-insertions (EGFR e20ins) account for up to 10% of EGFR mutations in lung cancer; however, tumors with EGFR e20ins had poor response rates to EGFR tyrosine kinase inhibitors (TKIs) including gefitinib, erlotinib, afatinib and osimertinib, and the heterogeneity of EGFR e20ins further complicate the clinical studies. osimertinib 237-248 epidermal growth factor receptor Homo sapiens 24-28 32412152-1 2020 EGFR exon20-insertions (EGFR e20ins) account for up to 10% of EGFR mutations in lung cancer; however, tumors with EGFR e20ins had poor response rates to EGFR tyrosine kinase inhibitors (TKIs) including gefitinib, erlotinib, afatinib and osimertinib, and the heterogeneity of EGFR e20ins further complicate the clinical studies. osimertinib 237-248 epidermal growth factor receptor Homo sapiens 24-28 32412152-1 2020 EGFR exon20-insertions (EGFR e20ins) account for up to 10% of EGFR mutations in lung cancer; however, tumors with EGFR e20ins had poor response rates to EGFR tyrosine kinase inhibitors (TKIs) including gefitinib, erlotinib, afatinib and osimertinib, and the heterogeneity of EGFR e20ins further complicate the clinical studies. osimertinib 237-248 epidermal growth factor receptor Homo sapiens 24-28 32412152-1 2020 EGFR exon20-insertions (EGFR e20ins) account for up to 10% of EGFR mutations in lung cancer; however, tumors with EGFR e20ins had poor response rates to EGFR tyrosine kinase inhibitors (TKIs) including gefitinib, erlotinib, afatinib and osimertinib, and the heterogeneity of EGFR e20ins further complicate the clinical studies. osimertinib 237-248 epidermal growth factor receptor Homo sapiens 24-28 32412152-1 2020 EGFR exon20-insertions (EGFR e20ins) account for up to 10% of EGFR mutations in lung cancer; however, tumors with EGFR e20ins had poor response rates to EGFR tyrosine kinase inhibitors (TKIs) including gefitinib, erlotinib, afatinib and osimertinib, and the heterogeneity of EGFR e20ins further complicate the clinical studies. osimertinib 237-248 epidermal growth factor receptor Homo sapiens 24-28 32696212-10 2020 CONCLUSIONS: These data further emphasize that osimertinib should be a standard of care in patients with pretreated EGFR T790M-positive NSCLC. osimertinib 47-58 epidermal growth factor receptor Homo sapiens 116-120 32495514-1 2020 INTRODUCTION: As most patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) develop progressive disease after treatment with osimertinib, it is important to develop more effective treatment options. osimertinib 167-178 epidermal growth factor receptor Homo sapiens 36-68 32495514-1 2020 INTRODUCTION: As most patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) develop progressive disease after treatment with osimertinib, it is important to develop more effective treatment options. osimertinib 167-178 epidermal growth factor receptor Homo sapiens 70-74 32495514-2 2020 Afatinib has been shown to be more effective in in vitro studies than osimertinib when used in cancer cell lines containing some specific EGFR mutations. osimertinib 70-81 epidermal growth factor receptor Homo sapiens 138-142 32495514-6 2020 DISCUSSION: A previous study indicated that afatinib inhibits lung cancer cells with specific EGFR mutations more effectively than other EGFR-TKIs such as osimertinib. osimertinib 155-166 epidermal growth factor receptor Homo sapiens 137-141 32723319-12 2020 Our results suggested that EGFR-mutated advanced NSCLC patients with >=1 risk factors were candidates for PCI or the first-line Osimertinib treatment. osimertinib 128-139 epidermal growth factor receptor Homo sapiens 27-31 32793495-0 2020 Longitudinal Monitoring of EGFR and PIK3CA Mutations by Saliva-Based EFIRM in Advanced NSCLC Patients With Local Ablative Therapy and Osimertinib Treatment: Two Case Reports. osimertinib 134-145 epidermal growth factor receptor Homo sapiens 27-31 32674434-1 2020 The third-generation tyrosine kinase inhibitor (TKI), osimertinib, has revolutionized the treatment of patients with non-small cell lung carcinoma with epidermal growth factor receptor (EGFR)-activating mutation, and resistant to first- and second-generation TKIs. osimertinib 54-65 epidermal growth factor receptor Homo sapiens 152-184 32674434-1 2020 The third-generation tyrosine kinase inhibitor (TKI), osimertinib, has revolutionized the treatment of patients with non-small cell lung carcinoma with epidermal growth factor receptor (EGFR)-activating mutation, and resistant to first- and second-generation TKIs. osimertinib 54-65 epidermal growth factor receptor Homo sapiens 186-190 32782526-7 2020 Several EGFR tyrosine kinase inhibitors (EGFR-TKIs) that target these mutations, including gefitinib, erlotinib, afatinib and osimertinib, have been widely used clinically. osimertinib 126-137 epidermal growth factor receptor Homo sapiens 8-12 32666714-2 2020 Here, we present a report of a patient with adenocarcinoma harboring EGFR exon 19 deletion mutation treated with osimertinib as first-line treatment. osimertinib 113-124 epidermal growth factor receptor Homo sapiens 69-73 32667739-0 2020 Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 25-29 32667739-2 2020 Evidence of the effectiveness of osimertinib in SqCC with EGFR T790M mutation is limited. osimertinib 33-44 epidermal growth factor receptor Homo sapiens 58-62 32667739-6 2020 Osimertinib has shown good efficacy in SqCC harboring a "primary" resistance mechanism (EGFR T790M). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 88-92 32667739-10 2020 Osimertinib has shown good efficacy in SqCC harboring a "primary" resistance mechanism (EGFR T790M). osimertinib 0-11 epidermal growth factor receptor Homo sapiens 88-92 32677256-0 2020 CDK46 inhibitor palbociclib overcomes acquired resistance to third-generation EGFR inhibitor osimertinib in non-small cell lung cancer (NSCLC). osimertinib 93-104 epidermal growth factor receptor Homo sapiens 78-82 32677256-3 2020 METHODS: We established osimertinib-resistant cells (H1975 OR) derived from EGFR-mutant NSCLC cells H1975. osimertinib 24-35 epidermal growth factor receptor Homo sapiens 76-80 32497272-0 2020 MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers. osimertinib 66-77 epidermal growth factor receptor Homo sapiens 109-141 32497272-1 2020 BACKGROUND: The majority of patients with non-small cell lung cancer (NSCLC) harboring activating epidermal growth factor receptor (EGFR) mutations respond well to osimertinib (AZD9291), a third-generation, mutation-selective EGFR inhibitor. osimertinib 164-175 epidermal growth factor receptor Homo sapiens 98-130 32497272-1 2020 BACKGROUND: The majority of patients with non-small cell lung cancer (NSCLC) harboring activating epidermal growth factor receptor (EGFR) mutations respond well to osimertinib (AZD9291), a third-generation, mutation-selective EGFR inhibitor. osimertinib 164-175 epidermal growth factor receptor Homo sapiens 132-136 32497272-1 2020 BACKGROUND: The majority of patients with non-small cell lung cancer (NSCLC) harboring activating epidermal growth factor receptor (EGFR) mutations respond well to osimertinib (AZD9291), a third-generation, mutation-selective EGFR inhibitor. osimertinib 164-175 epidermal growth factor receptor Homo sapiens 226-230 32497272-1 2020 BACKGROUND: The majority of patients with non-small cell lung cancer (NSCLC) harboring activating epidermal growth factor receptor (EGFR) mutations respond well to osimertinib (AZD9291), a third-generation, mutation-selective EGFR inhibitor. osimertinib 177-184 epidermal growth factor receptor Homo sapiens 98-130 32497272-11 2020 From a clinical standpoint, the data support the evaluation of an intermittent treatment schedule of osimertinib in combination with an MEK or ERK inhibitor in patients with EGFR-mutated NSCLC. osimertinib 101-112 epidermal growth factor receptor Homo sapiens 174-178 32982275-0 2020 Three Novel EGFR Mutations (750_758del, I759S, T751_I759delinsS) in One Patient with Metastatic Non-Small Cell Lung Cancer Responding to Osimertinib: A Case Report. osimertinib 137-148 epidermal growth factor receptor Homo sapiens 12-16 32762742-0 2020 An EGFR T790M-mutated lung adenocarcinoma undergoing large-cell neuroendocrine carcinoma transformation after osimertinib therapy: a case report. osimertinib 110-121 epidermal growth factor receptor Homo sapiens 3-7 32762742-3 2020 Epidermal growth factor receptor-dependent resistance mechanisms, bypass pathway activation, and histological transformation have been reported with osimertinib therapy. osimertinib 149-160 epidermal growth factor receptor Homo sapiens 0-32 32762742-4 2020 CASE PRESENTATION: We report a case of a 64-year-old Asian man with epidermal growth factor receptor T790M-positive adenocarcinoma that transformed to epidermal growth factor receptor T790M-negative large-cell neuroendocrine carcinoma after osimertinib therapy. osimertinib 241-252 epidermal growth factor receptor Homo sapiens 68-100 32762742-4 2020 CASE PRESENTATION: We report a case of a 64-year-old Asian man with epidermal growth factor receptor T790M-positive adenocarcinoma that transformed to epidermal growth factor receptor T790M-negative large-cell neuroendocrine carcinoma after osimertinib therapy. osimertinib 241-252 epidermal growth factor receptor Homo sapiens 151-183 32548617-0 2020 Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan. osimertinib 18-29 epidermal growth factor receptor Homo sapiens 34-66 32548617-2 2020 METHODS: Patients with epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer treated with second-line or later oral osimertinib per the Japanese package insert (80 mg once daily) were included. osimertinib 144-155 epidermal growth factor receptor Homo sapiens 57-61 32391625-3 2020 Osimertinib, which is third-generation EGFR-TKI, provides clinical effect even on NSCLC harboring the threonine to methionine change at codon 790 of EGFR (EGFR T790M) mutation that cause TKI resistance. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 39-43 32391625-3 2020 Osimertinib, which is third-generation EGFR-TKI, provides clinical effect even on NSCLC harboring the threonine to methionine change at codon 790 of EGFR (EGFR T790M) mutation that cause TKI resistance. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 149-153 32391625-10 2020 These findings suggest that an immunotherapy targeting a neoantigen derived from EGFR T790M/C797S mutation could be a useful novel therapeutic strategy for NSCLC patients with EGFR-TKI resistance, especially resistant to Osimertinib. osimertinib 221-232 epidermal growth factor receptor Homo sapiens 81-85 32353596-1 2020 BACKGROUND: Acquired resistance to osimertinib mediated by EGFR cis-C797S is now a growing challenge. osimertinib 35-46 epidermal growth factor receptor Homo sapiens 59-63 32353596-3 2020 METHODS: In this retrospective cohort study, 15 patients with advanced lung adenocarcinoma were identified with EGFR-activating mutation/T790M/cis-C797S after osimertinib progression by targeted next-generation sequencing. osimertinib 159-170 epidermal growth factor receptor Homo sapiens 112-116 32534795-1 2020 INTRODUCTION: Previous studies have reported an acquiredBRAF V600E mutation as a potential resistance mechanism to osimertinib treatment in advanced NSCLC patients with an activating mutation in EGFR. osimertinib 115-126 epidermal growth factor receptor Homo sapiens 195-199 32534795-10 2020 CONCLUSION: BRAF V600E may be a resistance mechanism induced by osimertinib in EGFR-mutated advanced NSCLC. osimertinib 64-75 epidermal growth factor receptor Homo sapiens 79-83 32540560-5 2020 Six and five patients received a combination of either first-generation (gefitinib, erlotinib, or icotinib) or third-generation (osimertinib) EGFR-TKI and crizotinib, respectively. osimertinib 129-140 epidermal growth factor receptor Homo sapiens 142-146 32540560-8 2020 Moreover, analysis of acquired resistance mechanisms from nine patients identified EGFR T790 M from three patients who progressed from first-generation EGFR-TKI and crizotinib, while EGFR T790 M/trans-C797S and L718Q, EGFR G724S, and CCDC6-RET fusion were detected from one patient each who progressed from osimertinib and crizotinib regimen. osimertinib 307-318 epidermal growth factor receptor Homo sapiens 83-87 32567817-1 2020 Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR-TKI sensitizing and EGFR T790M and has demonstrated efficacy in non-small cell lung cancer (NSCLC) central nervous system metastases. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 54-86 32567817-1 2020 Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR-TKI sensitizing and EGFR T790M and has demonstrated efficacy in non-small cell lung cancer (NSCLC) central nervous system metastases. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 88-92 32567817-1 2020 Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR-TKI sensitizing and EGFR T790M and has demonstrated efficacy in non-small cell lung cancer (NSCLC) central nervous system metastases. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 170-174 32953518-2 2020 Osimertinib is a third-generation EGFR-TKI, and its efficacy and safety in NSCLC patients with first-generation EGFR-TKI resistance, especially lung adenocarcinoma, are not yet clear. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 34-38 32693293-3 2020 EGFR-dependent resistance typically is associated with additional EGFR-mutations disrupting the osimertinib binding through changes in the binding site by allosteric/ conformational transitions; EGFR-independent mechanisms are related mostly to alternate pathway activation or aberrant downstream signalling but also to lineage plasticity leading to small cell transformation. osimertinib 96-107 epidermal growth factor receptor Homo sapiens 0-4 32693293-3 2020 EGFR-dependent resistance typically is associated with additional EGFR-mutations disrupting the osimertinib binding through changes in the binding site by allosteric/ conformational transitions; EGFR-independent mechanisms are related mostly to alternate pathway activation or aberrant downstream signalling but also to lineage plasticity leading to small cell transformation. osimertinib 96-107 epidermal growth factor receptor Homo sapiens 66-70 32693293-3 2020 EGFR-dependent resistance typically is associated with additional EGFR-mutations disrupting the osimertinib binding through changes in the binding site by allosteric/ conformational transitions; EGFR-independent mechanisms are related mostly to alternate pathway activation or aberrant downstream signalling but also to lineage plasticity leading to small cell transformation. osimertinib 96-107 epidermal growth factor receptor Homo sapiens 66-70 32641854-0 2020 Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations. osimertinib 60-71 epidermal growth factor receptor Homo sapiens 103-107 32498573-1 2021 OBJECTIVE: To estimate the cost-effectiveness of first line tyrosine kinase inhibitors (TKI), afatinib and osimertinib, for the treatment of epidermal growth factor receptor (EGFR) mutation-positive (Exon 19 deletion or L858R) non-small cell lung cancer (NSCLC), stages IIIB - IV in Colombia. osimertinib 107-118 epidermal growth factor receptor Homo sapiens 175-179 32839131-0 2021 Transformations First Into Squamous-Cell Carcinoma and Later Into Sarcomatoid Carcinoma After Acquired Resistance to Osimertinib in a Patient With EGFR-Mutant Lung Adenocarcinoma: Case Report. osimertinib 117-128 epidermal growth factor receptor Homo sapiens 147-151 32692221-8 2020 CONCLUSIONS: The regimens of "Gefitinib + pemetrexed + carboplatin" and "Osimertinib" were associated with the most favorable PFS and OS compared to the other therapies in advanced EGFR-mutant NSCLC patients with stable brain metastases, although the difference between these regimens and the others was not statistically significantly different. osimertinib 73-84 epidermal growth factor receptor Homo sapiens 181-185 32487567-0 2020 Osimertinib Called "Home Run" for EGFR-Mutant NSCLC. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 34-38 32487567-1 2020 Adjuvant treatment with the tyrosine kinase inhibitor osimertinib will likely become a new standard of care in patients with EGFR-mutant non-small cell lung cancer. osimertinib 54-65 epidermal growth factor receptor Homo sapiens 125-129 32391602-0 2020 GSK-3 inhibition overcomes EMT-associated resistance to osimertinib in EGFR mutant lung cancer. osimertinib 56-67 epidermal growth factor receptor Homo sapiens 71-75 32391602-1 2020 A novel EGFR-tyrosine kinase inhibitor (TKI), osimertinib, has marked efficacy in patients with EGFR-mutant lung cancer. osimertinib 46-57 epidermal growth factor receptor Homo sapiens 8-12 32391602-1 2020 A novel EGFR-tyrosine kinase inhibitor (TKI), osimertinib, has marked efficacy in patients with EGFR-mutant lung cancer. osimertinib 46-57 epidermal growth factor receptor Homo sapiens 96-100 32391602-6 2020 These results suggest that GSK-3 inhibition may be useful to circumvent EMT-associated resistance to osimertinib in EGFR mutant lung cancer. osimertinib 101-112 epidermal growth factor receptor Homo sapiens 116-120 32485428-4 2020 Other alterations, such as EGFR T790 M, are responsive to osimertinib, while the EGFR C797S alteration seen in osimertinib resistance demonstrates preclinical sensitivity to combined brigatinib and cetuximab. osimertinib 58-69 epidermal growth factor receptor Homo sapiens 27-31 32485428-4 2020 Other alterations, such as EGFR T790 M, are responsive to osimertinib, while the EGFR C797S alteration seen in osimertinib resistance demonstrates preclinical sensitivity to combined brigatinib and cetuximab. osimertinib 111-122 epidermal growth factor receptor Homo sapiens 81-85 32662665-0 2020 Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutation. osimertinib 11-22 epidermal growth factor receptor Homo sapiens 27-31 32662665-1 2020 Aim: Osimertinib is a key drug for EGFR mutation-positive non-small-cell lung cancer (NSCLC). osimertinib 5-16 epidermal growth factor receptor Homo sapiens 35-39 32662665-3 2020 Patients & methods: We retrospectively analyzed the clinical courses of EGFR mutation-positive NSCLC patients who were potential candidates for salvage osimertinib. osimertinib 152-163 epidermal growth factor receptor Homo sapiens 72-76 32662665-7 2020 Conclusion: Osimertinib is active for T790M-driven acquired resistance in EGFR-mutant NSCLC, but the detection of T790M was unsatisfactory. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 74-78 32387812-0 2020 Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer. osimertinib 68-79 epidermal growth factor receptor Homo sapiens 8-12 32387812-1 2020 OBJECTIVES: Osimertinib is active against epidermal growth factor receptor (EGFR) T790M-mutated non-small cell lung cancer (NSCLC). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 42-74 32387812-1 2020 OBJECTIVES: Osimertinib is active against epidermal growth factor receptor (EGFR) T790M-mutated non-small cell lung cancer (NSCLC). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 76-80 32408132-2 2020 Osimertinib (AZD9291), a third generation EGFR TKI, has replaced earlier generation EGFR TKIs for first line treatment of EGFR mutant lung cancer due to its improved overall survival, longer progression free survival, and better tolerability compared to earlier generation inhibitors. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 42-46 32408132-2 2020 Osimertinib (AZD9291), a third generation EGFR TKI, has replaced earlier generation EGFR TKIs for first line treatment of EGFR mutant lung cancer due to its improved overall survival, longer progression free survival, and better tolerability compared to earlier generation inhibitors. osimertinib 13-20 epidermal growth factor receptor Homo sapiens 42-46 32460198-0 2020 Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment. osimertinib 92-103 epidermal growth factor receptor Homo sapiens 34-38 32397295-10 2020 Currently, osimertinib (which demonstrated to improve efficacy with a better tolerability in comparison with first-generation TKIs) is considered the best treatment option for patients affected by NSCLC harboring a common EGFR mutation. osimertinib 11-22 epidermal growth factor receptor Homo sapiens 222-226 32652816-3 2020 EGFr TKIs (such as afatinib, erlotinib, and osimertinib) reversed the acute inhibitory effect of EGF on chloride secretion induced by carbachol (CCh) across T84 human colonic epithelial cells, which correlated with the diarrhea-inducing effect of each agent clinically. osimertinib 44-55 epidermal growth factor receptor Homo sapiens 0-4 32374485-5 2020 As osimertinib will be used more often in many EGFR-positive NSCLC patients in the future, this potentially life-threatening side effect should receive special attention, especially in first-line treatment. osimertinib 3-14 epidermal growth factor receptor Homo sapiens 47-51 32552277-0 2020 Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review. osimertinib 73-84 epidermal growth factor receptor Homo sapiens 33-37 32552277-1 2020 Since its approval in April 2018, osimertinib has been widely adopted as first-line therapy for patients with advanced EGFR-mutant non -small cell lung cancer (NSCLC). osimertinib 34-45 epidermal growth factor receptor Homo sapiens 119-123 32552277-3 2020 Using data compiled from 6 osimertinib-resistance series, we describe here the heterogeneous profile of EGFR-dependent and independent mechanisms of osimertinib treatment failure. osimertinib 27-38 epidermal growth factor receptor Homo sapiens 104-108 32317208-0 2020 Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide. osimertinib 110-121 epidermal growth factor receptor Homo sapiens 86-90 31538306-0 2020 Efficacy of osimertinib for the treatment of previously EGFR TKI treated NSCLC patients: a meta-analysis. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 56-60 31538306-5 2020 Osimertinib treatment was associated with a PFS of 11.17 months [7.80, 14.55] which was longer in treatment-naive (20.30 [15.37, 25.23]) than in prior EGFR-TKI-treated (10.20 [9.60, 10.80]) patients. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 151-155 31538306-10 2020 CONCLUSION: Osimertinib treatment yields approximately 10 months PFS in prior EGFR-TKI-treated and 20 months in treatment-naive NSCLC patients. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 78-82 32600081-4 2020 However, he switched to osimertinib after repeat biopsy showed EGFR exon 19 deletion and T790M mutation leading to erlotinib resistance. osimertinib 24-35 epidermal growth factor receptor Homo sapiens 63-67 32676311-0 2020 EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients. osimertinib 69-80 epidermal growth factor receptor Homo sapiens 0-4 32676311-1 2020 Background: Osimertinib is a potent third-generation EGFR tyrosine kinase inhibitor (TKI) with robust activity in advanced EGFR-mutant non-small cell lung cancer (NSCLC), including those with T790M resistance mutation. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 53-57 32676311-3 2020 This study aimed to evaluate whether EGFR-mutant genotypes affect the clinical outcomes and resistance mechanisms in T790M-positive NSCLC patients receiving osimertinib therapy. osimertinib 157-168 epidermal growth factor receptor Homo sapiens 37-41 32676311-13 2020 Conclusions: Our findings indicate that the EGFR 19Del subtypes affect the clinical outcomes and resistance mechanisms to osimertinib in T790M-positive patients. osimertinib 122-133 epidermal growth factor receptor Homo sapiens 44-48 32374970-0 2020 Osimertinib in EGFR-Mutated Advanced NSCLC. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 15-19 32374971-0 2020 Osimertinib in EGFR-Mutated Advanced NSCLC. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 15-19 32374972-0 2020 Osimertinib in EGFR-Mutated Advanced NSCLC. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 15-19 32374973-0 2020 Osimertinib in EGFR-Mutated Advanced NSCLC. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 15-19 32483558-0 2020 Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer. osimertinib 38-49 epidermal growth factor receptor Homo sapiens 84-88 32483558-1 2020 Clonal evolution of osimertinib-resistance mechanisms in EGFR mutant lung adenocarcinoma is poorly understood. osimertinib 20-31 epidermal growth factor receptor Homo sapiens 57-61 32498573-1 2021 OBJECTIVE: To estimate the cost-effectiveness of first line tyrosine kinase inhibitors (TKI), afatinib and osimertinib, for the treatment of epidermal growth factor receptor (EGFR) mutation-positive (Exon 19 deletion or L858R) non-small cell lung cancer (NSCLC), stages IIIB - IV in Colombia. osimertinib 107-118 epidermal growth factor receptor Homo sapiens 141-173 32517152-1 2020 Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are used for treating EGFR-mutated lung cancer, and osimertinib is effective in cases that acquired T790M mutations after treatment with the first- and second-generation EGFR-TKIs. osimertinib 124-135 epidermal growth factor receptor Homo sapiens 0-32 32517152-1 2020 Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are used for treating EGFR-mutated lung cancer, and osimertinib is effective in cases that acquired T790M mutations after treatment with the first- and second-generation EGFR-TKIs. osimertinib 124-135 epidermal growth factor receptor Homo sapiens 61-65 32517152-8 2020 These results suggest that osimertinib was relatively safe and effective for non-small cell lung cancer that acquired T790M mutations after previous EGFR-TKI treatment, even among patients who were >=75 years old. osimertinib 27-38 epidermal growth factor receptor Homo sapiens 149-153 31911548-0 2020 Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer. osimertinib 118-129 epidermal growth factor receptor Homo sapiens 133-137 31911548-4 2020 Nineteen percent (5/27) of patients treated with first-line osimertinib had off-target genetic resistance (2 MET amplification, 1 KRAS mutation, 1 RET fusion, and 1 BRAF fusion) whereas 4% (1/27) had an acquired EGFR mutation (EGFR G724S). osimertinib 60-71 epidermal growth factor receptor Homo sapiens 212-216 31911548-4 2020 Nineteen percent (5/27) of patients treated with first-line osimertinib had off-target genetic resistance (2 MET amplification, 1 KRAS mutation, 1 RET fusion, and 1 BRAF fusion) whereas 4% (1/27) had an acquired EGFR mutation (EGFR G724S). osimertinib 60-71 epidermal growth factor receptor Homo sapiens 227-231 32352321-0 2020 Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in EGFR-mutated non-small-cell lung cancer: a real life study. osimertinib 88-99 epidermal growth factor receptor Homo sapiens 103-107 32352321-6 2020 Conclusion: These results, in line with those observed during clinical trials, confirm the effectiveness of the sequence TKI-1G/2G followed by osimertinib in EGFR-mutated non-small-cell lung cancer. osimertinib 143-154 epidermal growth factor receptor Homo sapiens 158-162 32493093-0 2020 Successful treatment of a patient with NSCLC carrying uncommon compound EGFR G719X and S768I mutations using osimertinib: A case report. osimertinib 109-120 epidermal growth factor receptor Homo sapiens 72-76 32495159-1 2020 BACKGROUND: Osimertinib is a standard therapy for advanced non-small cell lung cancer (NSCLC) patients with an acquired epidermal growth factor receptor (EGFR) T790M mutation; however, the exploration of clinical characteristics that may affect prognosis and long-term survival is still lacking. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 120-152 32495159-1 2020 BACKGROUND: Osimertinib is a standard therapy for advanced non-small cell lung cancer (NSCLC) patients with an acquired epidermal growth factor receptor (EGFR) T790M mutation; however, the exploration of clinical characteristics that may affect prognosis and long-term survival is still lacking. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 154-158 32495159-3 2020 PATIENTS AND METHODS: A total of 246 patients with acquired EGFR T790M mutation who were treated with osimertinib were included in this study. osimertinib 102-113 epidermal growth factor receptor Homo sapiens 60-64 32641247-0 2021 Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator). osimertinib 143-154 epidermal growth factor receptor Homo sapiens 134-138 32641247-1 2021 BACKGROUND: Osimertinib is a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that potently and selectively inhibits EGFR activating and EGFR T790M resistance mutations. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 46-78 32641247-1 2021 BACKGROUND: Osimertinib is a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that potently and selectively inhibits EGFR activating and EGFR T790M resistance mutations. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 80-84 32641247-1 2021 BACKGROUND: Osimertinib is a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that potently and selectively inhibits EGFR activating and EGFR T790M resistance mutations. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 157-161 32641247-1 2021 BACKGROUND: Osimertinib is a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that potently and selectively inhibits EGFR activating and EGFR T790M resistance mutations. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 157-161 32641247-2 2021 Osimertinib was found to be more effective than first-generation EGFR-TKIs in patients with previously untreated advanced non-small-cell lung cancer (NSCLC) harboring EGFR-positive mutations in a prior phase III trial. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 167-171 32641247-3 2021 Osimertinib is, therefore, one of the most important standard therapies for EGFR mutation-positive patients. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 76-80 32641247-4 2021 However, there are few reports about osimertinib resistance mechanisms in first-line EGFR-TKI therapy. osimertinib 37-48 epidermal growth factor receptor Homo sapiens 85-89 32641247-5 2021 Understanding first-line osimertinib resistance mechanisms is essential for future therapeutic strategies in patients with NSCLC with EGFR-positive mutations. osimertinib 25-36 epidermal growth factor receptor Homo sapiens 134-138 31953310-1 2020 PURPOSE: Currently, an optimal therapeutic strategy comprising molecularly targeted agents for treating EGFR-mutated non-small cell lung cancer (NSCLC) patients with acquired resistance to osimertinib is not available. osimertinib 189-200 epidermal growth factor receptor Homo sapiens 104-108 31953310-6 2020 We investigated the correlation between AXL expression in tumors and clinical outcomes with osimertinib for EGFR mutated NSCLC patients with acquired resistance to initial EGFR-TKIs. osimertinib 92-103 epidermal growth factor receptor Homo sapiens 108-112 31953310-7 2020 RESULTS: ONO-7475 sensitized AXL-overexpressing EGFR-mutant NSCLC cells to the EGFR-TKIs osimertinib and dacomitinib. osimertinib 89-100 epidermal growth factor receptor Homo sapiens 48-52 31953310-7 2020 RESULTS: ONO-7475 sensitized AXL-overexpressing EGFR-mutant NSCLC cells to the EGFR-TKIs osimertinib and dacomitinib. osimertinib 89-100 epidermal growth factor receptor Homo sapiens 79-83 31953310-9 2020 In the cell line-derived xenograft models of AXL-overexpressing EGFR mutated lung cancer treated with osimertinib, initial combination therapy of ONO-7475 and osimertinib markedly regressed tumors and delayed tumor re-growth compared to osimertinib alone or the combination after acquired resistance to osimertinib. osimertinib 102-113 epidermal growth factor receptor Homo sapiens 64-68 31953310-9 2020 In the cell line-derived xenograft models of AXL-overexpressing EGFR mutated lung cancer treated with osimertinib, initial combination therapy of ONO-7475 and osimertinib markedly regressed tumors and delayed tumor re-growth compared to osimertinib alone or the combination after acquired resistance to osimertinib. osimertinib 159-170 epidermal growth factor receptor Homo sapiens 64-68 31953310-9 2020 In the cell line-derived xenograft models of AXL-overexpressing EGFR mutated lung cancer treated with osimertinib, initial combination therapy of ONO-7475 and osimertinib markedly regressed tumors and delayed tumor re-growth compared to osimertinib alone or the combination after acquired resistance to osimertinib. osimertinib 159-170 epidermal growth factor receptor Homo sapiens 64-68 31953310-9 2020 In the cell line-derived xenograft models of AXL-overexpressing EGFR mutated lung cancer treated with osimertinib, initial combination therapy of ONO-7475 and osimertinib markedly regressed tumors and delayed tumor re-growth compared to osimertinib alone or the combination after acquired resistance to osimertinib. osimertinib 159-170 epidermal growth factor receptor Homo sapiens 64-68 31987959-0 2020 Pattern of recurrence analysis in metastatic EGFR-mutant NSCLC treated with Osimertinib: implications for consolidative stereotactic body radiation therapy. osimertinib 76-87 epidermal growth factor receptor Homo sapiens 45-49 31987959-4 2020 METHODS AND MATERIALS: The serial scans of metastatic EGFR-mutant NSCLC patients treated with osimertinib were retrospectively reviewed. osimertinib 94-105 epidermal growth factor receptor Homo sapiens 54-58 31972351-9 2020 In the LMC model with A925L/AR cells, combined treatment with alectinib and EGFR-TKIs, such as erlotinib and osimertinib, successfully controlled progression of LMC. osimertinib 109-120 epidermal growth factor receptor Homo sapiens 76-80 32642185-0 2020 Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q. osimertinib 42-53 epidermal growth factor receptor Homo sapiens 73-77 32642198-4 2020 The FLAURA study demonstrated that first-line treatment of EGFR mutant patients with osimertinib significantly improved progression free survival (PFS) over first-generation EGFR-TKIs, thus leading to its approval also in this setting. osimertinib 85-96 epidermal growth factor receptor Homo sapiens 59-63 32642198-4 2020 The FLAURA study demonstrated that first-line treatment of EGFR mutant patients with osimertinib significantly improved progression free survival (PFS) over first-generation EGFR-TKIs, thus leading to its approval also in this setting. osimertinib 85-96 epidermal growth factor receptor Homo sapiens 174-178 32207968-1 2020 Osimertinib is a covalent, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for treating non-small cell lung cancer patients with activating EGFR mutations (Exon19del or L858R) or with the T790M resistance mutation following disease progression on first- or second-generation EGFR TKIs. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 44-76 32351892-4 2020 Case Presentation: In this case series, we present three cases of cecal volvulus among patients with EGFR-positive NSCLC patients treated with osimertinib dosed at double the standard 80 mg dose (160 mg daily). osimertinib 143-154 epidermal growth factor receptor Homo sapiens 101-105 32207968-1 2020 Osimertinib is a covalent, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for treating non-small cell lung cancer patients with activating EGFR mutations (Exon19del or L858R) or with the T790M resistance mutation following disease progression on first- or second-generation EGFR TKIs. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 78-82 32207968-1 2020 Osimertinib is a covalent, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for treating non-small cell lung cancer patients with activating EGFR mutations (Exon19del or L858R) or with the T790M resistance mutation following disease progression on first- or second-generation EGFR TKIs. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 190-194 32207968-1 2020 Osimertinib is a covalent, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for treating non-small cell lung cancer patients with activating EGFR mutations (Exon19del or L858R) or with the T790M resistance mutation following disease progression on first- or second-generation EGFR TKIs. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 190-194 32207968-2 2020 The aim of this work is to rationalize and understand how osimertinib achieves mutant EGFR selectivity over the wild-type (WT) by evaluating its kinetic mechanism of action. osimertinib 58-69 epidermal growth factor receptor Homo sapiens 86-90 32207968-3 2020 In doing so, we developed methodologies combining steady-state and pre-steady-state kinetics to determine the covalent inactivation rates (kinact) and reversible binding affinities (Ki) for osimertinib against WT, L858R, and L858R/T790M EGFR and compared these data to the inhibition kinetics of earlier generations of EGFR TKIs. osimertinib 190-201 epidermal growth factor receptor Homo sapiens 237-241 32207968-3 2020 In doing so, we developed methodologies combining steady-state and pre-steady-state kinetics to determine the covalent inactivation rates (kinact) and reversible binding affinities (Ki) for osimertinib against WT, L858R, and L858R/T790M EGFR and compared these data to the inhibition kinetics of earlier generations of EGFR TKIs. osimertinib 190-201 epidermal growth factor receptor Homo sapiens 319-323 32207968-5 2020 The Ki and kinact values reveal that osimertinib binds 3-fold tighter to and reacts 3-fold faster with L858R than WT EGFR and binds 17-fold tighter to and reacts 3-fold faster with L858R/T790M than with the WT EGFR. osimertinib 37-48 epidermal growth factor receptor Homo sapiens 117-121 32207968-5 2020 The Ki and kinact values reveal that osimertinib binds 3-fold tighter to and reacts 3-fold faster with L858R than WT EGFR and binds 17-fold tighter to and reacts 3-fold faster with L858R/T790M than with the WT EGFR. osimertinib 37-48 epidermal growth factor receptor Homo sapiens 210-214 32389962-1 2020 BACKGROUND: In recent years, osimertinib has been increasingly used as a therapeutic drug for epidermal growth factor receptor(EGFR)mutation-positive lung cancer, with heart failure rarely reported as an adverse event. osimertinib 29-40 epidermal growth factor receptor Homo sapiens 94-126 32489263-8 2020 Results: The published overall survival results for osimertinib, combined with its central nervous system activity, have led to osimertinib becoming the preferred first-line treatment for patients with common EGFR mutations, including those with brain metastasis. osimertinib 128-139 epidermal growth factor receptor Homo sapiens 209-213 32389962-1 2020 BACKGROUND: In recent years, osimertinib has been increasingly used as a therapeutic drug for epidermal growth factor receptor(EGFR)mutation-positive lung cancer, with heart failure rarely reported as an adverse event. osimertinib 29-40 epidermal growth factor receptor Homo sapiens 127-131 31941753-5 2020 Recent next-generation sequencing (NGS) of lung cancer samples identified several genetically defined resistance mechanisms to osimertinib, such as EGFR C797S or MET amplification. osimertinib 127-138 epidermal growth factor receptor Homo sapiens 148-152 31887431-0 2020 Osimertinib for patients with leptomeningeal metastases associated with epidermal growth factor receptor T790M positive advanced NSCLC: the AURA LM analysis. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 72-104 31887431-1 2020 BACKGROUND: Osimertinib has shown promising activity in patients with leptomeningeal metastases (LM) from epidermal growth factor receptor (EGFR) positive NSCLC at 160 mg once daily (qd) (BLOOM; NCT02228369). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 106-138 31887431-1 2020 BACKGROUND: Osimertinib has shown promising activity in patients with leptomeningeal metastases (LM) from epidermal growth factor receptor (EGFR) positive NSCLC at 160 mg once daily (qd) (BLOOM; NCT02228369). osimertinib 12-23 epidermal growth factor receptor Homo sapiens 140-144 31887431-12 2020 CONCLUSION: Patients with EGFR T790M-positive NSCLC and radiologically-detected LM derived clinical benefit from osimertinib 80 mg qd. osimertinib 113-124 epidermal growth factor receptor Homo sapiens 26-30 32003107-0 2020 Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol. osimertinib 98-109 epidermal growth factor receptor Homo sapiens 34-38 32003107-0 2020 Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol. osimertinib 98-109 epidermal growth factor receptor Homo sapiens 82-86 32003107-1 2020 The development of acquired resistance to osimertinib (AZD9291 or TAGRISSOTM ), an FDA-approved third generation EGFR inhibitor for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC), limits the long-term benefits for patients. osimertinib 42-53 epidermal growth factor receptor Homo sapiens 113-117 32003107-1 2020 The development of acquired resistance to osimertinib (AZD9291 or TAGRISSOTM ), an FDA-approved third generation EGFR inhibitor for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC), limits the long-term benefits for patients. osimertinib 42-53 epidermal growth factor receptor Homo sapiens 149-153 32003107-1 2020 The development of acquired resistance to osimertinib (AZD9291 or TAGRISSOTM ), an FDA-approved third generation EGFR inhibitor for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC), limits the long-term benefits for patients. osimertinib 55-62 epidermal growth factor receptor Homo sapiens 149-153 32068351-0 2020 Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non-small cell lung cancer harboring EGFR mutation. osimertinib 29-40 epidermal growth factor receptor Homo sapiens 119-123 32420075-0 2020 An advanced non-small cell lung cancer patient with epidermal growth factor receptor sensitizing mutation responded to toripalimab in combination with chemotherapy after resistance to osimertinib: a case report. osimertinib 184-195 epidermal growth factor receptor Homo sapiens 52-84 32420075-1 2020 The clinical activity and favorable toxicity profile of osimertinib has led it to be approved not only for advanced non-small cell lung cancer (NSCLC) patients with T790M-positive tumors when first, or second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment fails, but also for untreated advanced NSCLC patients with EGFR sensitizing mutation, so how to manage patients who get acquired resistance to osimertinib has becoming an emerging clinical challenge. osimertinib 56-67 epidermal growth factor receptor Homo sapiens 280-284 32420075-1 2020 The clinical activity and favorable toxicity profile of osimertinib has led it to be approved not only for advanced non-small cell lung cancer (NSCLC) patients with T790M-positive tumors when first, or second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment fails, but also for untreated advanced NSCLC patients with EGFR sensitizing mutation, so how to manage patients who get acquired resistance to osimertinib has becoming an emerging clinical challenge. osimertinib 56-67 epidermal growth factor receptor Homo sapiens 359-363 32420075-2 2020 This presentation would report a case of an advanced NSCLC patient with EGFR 19DEL who received combination therapy of toripalimab and chemotherapy after resistance to first line osimertinib therapy and achieved a PFS benefit of over 8 months. osimertinib 179-190 epidermal growth factor receptor Homo sapiens 72-76 32420078-11 2020 Up to now, osimertinib treatment was undertaken to base on an EGFR exon 20 T790M mutation using NGS-based genotyping in cerebrospinal fluid (CSF) ctDNA. osimertinib 11-22 epidermal growth factor receptor Homo sapiens 62-66 32420080-2 2020 AURA3 study showed that patients resistant with the first generation of EGFR-TKI and with T790M mutation still received longer progression-free survival (PFS) after treatment with the third generation of EGFR-TKI osimertinib, and osimertinib also had a good effect on brain metastasis. osimertinib 213-224 epidermal growth factor receptor Homo sapiens 72-76 32420080-2 2020 AURA3 study showed that patients resistant with the first generation of EGFR-TKI and with T790M mutation still received longer progression-free survival (PFS) after treatment with the third generation of EGFR-TKI osimertinib, and osimertinib also had a good effect on brain metastasis. osimertinib 213-224 epidermal growth factor receptor Homo sapiens 204-208 32420080-2 2020 AURA3 study showed that patients resistant with the first generation of EGFR-TKI and with T790M mutation still received longer progression-free survival (PFS) after treatment with the third generation of EGFR-TKI osimertinib, and osimertinib also had a good effect on brain metastasis. osimertinib 230-241 epidermal growth factor receptor Homo sapiens 72-76 32420080-2 2020 AURA3 study showed that patients resistant with the first generation of EGFR-TKI and with T790M mutation still received longer progression-free survival (PFS) after treatment with the third generation of EGFR-TKI osimertinib, and osimertinib also had a good effect on brain metastasis. osimertinib 230-241 epidermal growth factor receptor Homo sapiens 204-208 32420080-10 2020 In this case, patient with advanced lung adenocarcinoma and EGFR mutation was resistant with the first generation of EGFR-TKI treatment, and after detection of T790M mutation, we switched to osimertinib for primary disease control, bone metastasis was still obvious, and there was still no obvious effect after pain relief, bone metabolism improvement and local radiotherapy. osimertinib 191-202 epidermal growth factor receptor Homo sapiens 60-64 32420063-0 2020 EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib. osimertinib 115-126 epidermal growth factor receptor Homo sapiens 0-4 32420063-0 2020 EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib. osimertinib 115-126 epidermal growth factor receptor Homo sapiens 53-57 32420063-1 2020 Background: Osimertinib has become standard therapy of advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients and T790M-mediated resistance. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 64-96 32420063-1 2020 Background: Osimertinib has become standard therapy of advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients and T790M-mediated resistance. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 98-102 32068351-1 2020 BACKGROUND: Osimertinib is the most promising treatment option for patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) with acquired T790M resistance. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 81-113 32068351-1 2020 BACKGROUND: Osimertinib is the most promising treatment option for patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) with acquired T790M resistance. osimertinib 12-23 epidermal growth factor receptor Homo sapiens 115-119 32068351-3 2020 METHODS: In this single-institution retrospective study conducted from May 2016 to January 2019, osimertinib was administered to 47 patients with pretreated advanced NSCLC harboring the EGFR mutation. osimertinib 97-108 epidermal growth factor receptor Homo sapiens 186-190 32068351-11 2020 CONCLUSIONS: The use of osimertinib immediately after nivolumab significantly increased the frequency of grade 3 or higher hepatotoxicity in patients with advanced NSCLC harboring EGFR mutation acquired T790M resistance. osimertinib 24-35 epidermal growth factor receptor Homo sapiens 180-184 32252199-15 2020 Osimertinib inhibited the expression of p-EGFR, but did not affect the expressions of PLOD2, p-FAK, p-AKT, p-ERK, vimentin and E-cadherin in HCC827-PLOD2 cells. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 42-46 32346403-0 2020 Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC. osimertinib 54-65 epidermal growth factor receptor Homo sapiens 69-73 32346403-2 2020 Materials & methods: Clinical records were collected from the patients who had received one of two sequential combination strategies of EGFR-TKIs: Salvage use of osimertinib for T790M-mediated acquired resistance to an prior EGFR-TKI or switch use of osimertinib where an EGFR-TKI was switched to osimertinib before disease progression. osimertinib 162-173 epidermal growth factor receptor Homo sapiens 136-140 32346403-4 2020 Conclusion: Switch use of osimertinib seemed to produce improved efficacy for patients with activating EGFR mutations, because of the lack of patient selection via T790M. osimertinib 26-37 epidermal growth factor receptor Homo sapiens 103-107 32257480-0 2020 Complete Remission of Multiple Brain Metastases in a Patient with EGFR-Mutated Non-Small-Cell Lung Cancer Treated with First-Line Osimertinib without Radiotherapy. osimertinib 130-141 epidermal growth factor receptor Homo sapiens 66-70 32257480-1 2020 Osimertinib has demonstrated efficacy against stable or asymptomatic central nervous system (CNS) metastases of epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) in phase 2 and 3 clinical trials that allowed prior CNS radiotherapy. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 112-144 32257480-1 2020 Osimertinib has demonstrated efficacy against stable or asymptomatic central nervous system (CNS) metastases of epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) in phase 2 and 3 clinical trials that allowed prior CNS radiotherapy. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 146-150 32257480-8 2020 This case demonstrated that first-line treatment with osimertinib could even achieve complete remission of multiple brain metastases comprising as many as twenty lesions of EGFR-mutated NSCLC without radiation therapy. osimertinib 54-65 epidermal growth factor receptor Homo sapiens 173-177 31787696-1 2020 Osimertinib is the standard therapy for epidermal-growth-factor-receptor (EGFR)-mutant lung cancers. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 40-72 31787696-1 2020 Osimertinib is the standard therapy for epidermal-growth-factor-receptor (EGFR)-mutant lung cancers. osimertinib 0-11 epidermal growth factor receptor Homo sapiens 74-78 31821539-0 2020 ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib. osimertinib 136-147 epidermal growth factor receptor Homo sapiens 60-92 31821539-1 2020 BACKGROUND: Osimertinib (AZD9291), a third-generation, mutation-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI), is an approved drug for patients who have non-small cell lung cancer (NSCLC) with activating EGFR mutations or those harboring a resistant T790M mutation. osimertinib 25-32 epidermal growth factor receptor Homo sapiens 74-106 31821539-1 2020 BACKGROUND: Osimertinib (AZD9291), a third-generation, mutation-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI), is an approved drug for patients who have non-small cell lung cancer (NSCLC) with activating EGFR mutations or those harboring a resistant T790M mutation. osimertinib 25-32 epidermal growth factor receptor Homo sapiens 108-112 31821539-1 2020 BACKGROUND: Osimertinib (AZD9291), a third-generation, mutation-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI), is an approved drug for patients who have non-small cell lung cancer (NSCLC) with activating EGFR mutations or those harboring a resistant T790M mutation. osimertinib 25-32 epidermal growth factor receptor Homo sapiens 141-145 31821539-1 2020 BACKGROUND: Osimertinib (AZD9291), a third-generation, mutation-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI), is an approved drug for patients who have non-small cell lung cancer (NSCLC) with activating EGFR mutations or those harboring a resistant T790M mutation. osimertinib 25-32 epidermal growth factor receptor Homo sapiens 141-145